ISSN 0378-5173

international journal of pharmaceutics

cumulative author and subject indexes
volumes 41–50

published twice monthly



elsevier

INTERNATIONAL JOURNAL OF PHARMACEUTICS

AIMS AND SCOPE

The INTERNATIONAL JOURNAL OF PHARMACEUTICS provides a medium for the publication of research results dealing with all aspects of Pharmaceutics including physical, chemical, analytical, biological and engineering studies related to drug delivery in its broadest sense. Such areas include:

1. Drug delivery systems
2. Physical pharmacy
3. Biopharmaceutics
4. Pharmacodynamics and pharmacokinetics
5. Membrane function and transport
6. Biotechnology
7. Drug and prodrug design
8. Radiopharmaceuticals
9. Sterility and sterilization
10. Quality control of pharmaceuticals
11. Pharmaceutical analysis
12. Drug stability
13. Pharmaceutical technology
14. Descriptions/reviews of computer programs relating to the above areas
15. Application of cell and molecular biology in drug delivery

EDITORIAL POLICY

The over-riding criteria for publication are originality, high scientific quality and interest to a multidisciplinary audience. Papers not sufficiently substantiated by experimental detail will not be published. Any technical queries will be referred back to the author, although the Editors reserve the right to make alterations in the text without altering the technical content.
Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur with the submission and that a copy of the final manuscript has been approved by all authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out. If accepted, the manuscript shall not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors and Publisher.

EDITORS IN CHIEF

For: Europe, Africa, Near East

P.F. D'ARCY
School of Pharmacy,
University of London,
29/39 Brunswick Square,
London WC1N 1AX,
U.K.

For: The Americas and Australia

W.I. HIGUCHI
Department of
Pharmaceutics,
College of Pharmacy
University of Utah,
Salt Lake City,
UT 84112,
U.S.A.

J.H. RYTTING
(Associate Editor)
Pharmaceutical
Chemistry Dept.,
School of Pharmacy,
University of Kansas,
Lawrence, KS 66045,
U.S.A.

For: Japan

T. NAGAI
Department of
Pharmaceutics, Faculty of
Pharmaceutical Sciences,
Hoshi University,
Ebara 2-4-41,
Shinagawa-ku,
Tokyo 142, Japan.

EDITORIAL BOARD

G. Amidon (Ann Arbor, MI)
B.D. Anderson (Salt Lake City, UT)
G.S. Banker (Minneapolis, MN)
H. Boxenbaum (Cincinnati, OH)
H. Bundgaard (Copenhagen)
J.T. Carstensen (Madison, WI)
D.J.A. Crommelin (Utrecht)
S.S. Davis (Nottingham)
A.T. Florence (London)
J.L. Fox (Salt Lake City, UT)
H.L. Fung (Amherst, NY)
D. Ganderton (London)
J. Hadgraft (Cardiff)
M. Hanano (Tokyo)
E.N. Hiestand (Kalamazoo, MI)
N.F.H. Ho (Kalamazoo, MI)
T.M. Jones (Beckenham)
K. Knutson (Salt Lake City, UT)
G. Levy (Amherst, NY)
A. Li Wan Po (Belfast)
J.A. Mollica (Wilmington, DE)
J.M. Newton (London)
I.H. Pitman (Parkville)
G. Poste (Philadelphia, PA)
B.J. Poulsen (Palo Alto, CA)
A.J. Repta (Lawrence, KS)
J.R. Robinson (Madison, WI)
T.J. Roseman (Round Lake, IL)
R.C. Rowe (Macclesfield)
M.F. Saettone (Pisa)
H. Sezaki (Kyoto)
J.E. Shaw (Palo Alto, CA)
E. Shefter (San Francisco, CA)
D.D. Shen (Seattle, WA)
J. Sjögren (Mölnlycke)
R.S. Summers (Pretoria)
D.J. Temple (Cardiff)
B. Testa (Lausanne)
K. Thoma (Munich)
R.F. Timoney (Dublin)
E. Tomlinson (Cambridge, MA)
J.L. Vila Jato (Santiago de Compostela)
G. Zografi (Madison, WI)

INSTRUCTIONS TO AUTHORS

Submission of a paper to the International Journal of Pharmaceutics implies: (1) that it is not being submitted for publication elsewhere; (2) the transfer of the Copyright from the Author to the Publisher. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur with the submission and that a copy of the final manuscript has been approved by all authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out. If accepted, the manuscript shall not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors and Publisher.
Papers and original figures should be submitted plus **three copies** and accompanied by a letter of transmittal to one of the Editors in Chief. When the paper is to be published as a Rapid Communication, this should be clearly indicated to the Editor in Chief.

TYPES OF PAPERS

(1) Full length papers.
(2) Rapid communications not exceeding 1500 words or equivalent space.
(3) Notes (formerly Short Communications) limited to 1500 words or equivalent, including figures/tables.
(4) Descriptions/reviews of computer programs useful to pharmaceutical scientists.
(5) Suggestions for Review Articles will be considered by the Editors-in-Chief.

INTERNATIONAL JOURNAL OF PHARMACEUTICS

CUMULATIVE AUTHOR AND SUBJECT INDEXES
VOLUMES 41–50

INTERNATIONAL JOURNAL OF PHARMACEUTICS

Editors in Chief

P.F. D'ARCY (London, U.K.), W.I. HIGUCHI (Salt Lake City, UT, U.S.A.)
and T. NAGAI (Tokyo, Japan)
(Associate Editor: J.H. RYTTING, Lawrence, KS, U.S.A.)

Editorial Board

G. AMIDON (Ann Arbor, MI, U.S.A.)
B.D. ANDERSON (Salt Lake City, UT, U.S.A.)
G.S. BANKER (Minneapolis, MN, U.S.A.)
H. BOXENBAUM (Cincinnati, OH, U.S.A.)
H. BUNDGAARD (Copenhagen, Denmark)
J.T. CARSTENSEN (Madison, WI, U.S.A.)
D.J.A. CROMMELIN (Utrecht, The Netherlands)
S.S. DAVIS (Nottingham, U.K.)
A.T. FLORENCE (London, U.K.)
J.L. FOX (Salt Lake City, UT, U.S.A.)
H.L. FUNG (Amherst, NY, U.S.A.)
D. GANDERTON (London, U.K.)
J. HADGRAFT (Cardiff, U.K.)
M. HANANO (Tokyo, Japan)
E.N. HIESTAND (Kalamazoo, MI, U.S.A.)
N.F.H. HO (Kalamazoo, MI, U.S.A.)
T.M. JONES (Beckenham, U.K.)
K. KNUTSON (Salt Lake City, UT, U.S.A.)
G. LEVY (Amherst, NY, U.S.A.)
A. LI WAN PO (Belfast, U.K.)
J.A. MOLLICA (Wilmington, DE, U.S.A.)
J.M. NEWTON (London, U.K.)
I.H. PITMAN (Parkville, Australia)
G. POSTE (Philadelphia, PA, U.S.A.)
B.J. POULSEN (Palo Alto, CA, U.S.A.)
A.J. REPTA (Lawrence, KS, U.S.A.)
J.R. ROBINSON (Madison, WI, U.S.A.)
T.J. ROSEMAN (Round Lake, IL, U.S.A.)
R.C. ROWE (Macclesfield, U.K.)
M.F. SAETTONE (Pisa, Italy)
H. SEZAKI (Kyoto, Japan)
J.E. SHAW (Palo Alto, CA, U.S.A.)
E. SHEFTER (San Francisco, CA, U.S.A.)
D.D. SHEN (Seattle, WA, U.S.A.)
J. SJÖGREN (Mölnlycke, Sweden)
R.S. SUMMERS (Pretoria, South Africa)
B. TESTA (Lausanne, Switzerland)
D.J. TEMPLE (Cardiff, U.K.)
K. THOMA (Munich, F.R.G.)
R.F. TIMONEY (Dublin, Ireland)
E. TOMLINSON (Cambridge, MA, U.S.A.)
J.L. VILA JATO (Santiago de Compostela, Spain)
G. ZOGRAFI (Madison, WI, U.S.A.)

AUTHOR AND SUBJECT INDEXES
VOLUMES 41–50

ELSEVIER SCIENCE PUBLISHERS B.V. – AMSTERDAM

© 1991, Elsevier Science Publishers B.V.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, Elsevier Science Publishers B.V., P.O. Box 1527, 1000 BM Amsterdam, The Netherlands.

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in the medical sciences, the Publisher recommends that independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Special regulations for authors. Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the Publisher. This transfer will ensure the widest possible dissemination of information.

Submission of a paper to this journal entails the author's irrevocable and exclusive authorization of the Publisher to collect any sums or considerations for copying or reproduction payable by third parties (as mentioned in Article 17, Paragraph 2 of the Dutch Copyright Act of 1912, and in the Royal Decree of June 20, 1974 (S. 351) pursuant to Article 16b of the Dutch Copyright Act of 1912) and/or to act in or out of Court in connection therewith.

Special regulations for readers in the U.S.A. This journal has been registered with the Copyright Clearance Center, Inc. Consent is given for copying of articles for personal or internal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per-copy fee stated in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The appropriate fee should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 27 Congress Street, Salem, MA 01970, U.S.A. If no code appears in an article the author has not given broad consent to copy and permission to copy must be obtained directly from the author. All articles published prior to 1980 may be copied for a per-copy fee of US$ 2.25, also payable through the Center. This consent does not extend to other kinds of copying such as for general distribution, resale, advertising and promotion purposes, or for creating new collective works. Special written permission must be obtained from the Publisher for such copying.

Printed in the Netherlands

This journal is printed on acid-free paper.

Announcement from the Publisher

ELSEVIER SCIENCE PUBLISHERS

encourages the submission of electronic manuscripts

The preferred storage medium is a 5¼ or 3½ inch disk in MS-DOS or MS-DOS compatible format, although other systems, e.g. Macintosh, are acceptable.

Please note that it is essential that the disk submitted for publication is the final corrected version of the article and exactly matches the final manuscript. The disk and corresponding manuscript should be forwarded to the Publisher after acceptance of the article.

Please follow the general instructions on style/arrangement and, in particular, the reference style of this journal as given in 'Instructions to Authors'.

Illustrations and tables will be handled conventionally.

Please label the disk with your name, the software & hardware used and the name of the file to be processed.

Contact the Publisher for further information.

ELSEVIER SCIENCE PUBLISHERS B.V.
P.O. Box 1527, 1000 BM Amsterdam
The Netherlands
Fax: (020) 5803454

International Journal of Pharmaceutics, (1991) 1–19
© 1991 Elsevier Science Publishers B.V. 0378-5173/91/$03.50

Author Index

Abdulhameed, M.E., see Suleiman, M.S. (50) 71
Abe, K., see Aramaki, Y. (46) 103
Ackermann, C., see Du Plessis, J. (46) 177
Ackermann, C., see Van der Merwe, E. (44) 71
Ackermann, C., see Van der Merwe, E. (46) 169
Addicks, W.J., see Chiang, C.-M. (49) 109
Ahmed, I. and Chaudhuri, B.
Evaluation of buffer systems in ophthalmic product development (44) 97
Ahmed, I., see Jafari, M.R. (48) 207
Akazawa, M., Itoh, T., Masaki, K., Nghiem, B.T., Tsuzuki, N., Konishi, R. and Higuchi, T.
An automated method for continuously monitoring diffusion cells in skin penetration studies (50) 53
Akbarieh, M., see Kassem, M. (47) 179
Akbarieh, M., see Thibert, R. (47) 171
Akerele, J.O., see Okhamafe, A.O. (50) 83
Akojie, F.O.B. and Folayan, J.O.
Antisickling potential of bat interferon (42) 261
Al-Hassan, M.I., Bawazir, S.A., Matar, K.M. and Tekle, A.
Effect of famotidine on theophylline pharmacokinetics in the rat (50) 35
Al-Shora, H.I., Moustafa, M.A., Niazy, E.M., Gaber, M. and Gouda, M.W.
Interactions of procainamide, verapamil, guanethidine and hydralazine with adsorbent antacids and antidiarrhoeal mixtures (47) 209
Al-Turk, W.A., Majeed, I.A., Murray, W.J., Newton, D.W. and Othman, S.
Some factors affecting the photodecomposition of nifedipine (41) 227
Al-Turk, W.A., see Othman, S. (41) 197
Ali, H.M., Homeida, M.M.A., Ford, J., Truman, C.A., Roberts, C.J.C. and Badwan, A.A.
Paracetamol bioavailability from an elixir, a suspension and a new alcohol-free liquid dosage form in humans (42) 155
Allen, Jr., L.V., see Chen, G. (46) 89
Almog, S., see Touitou, E. (43) 9
Alonso, M.J., Maincent, P., Garcia-Arias, T. and Vila-Jato, J.L.
A comparative biopharmaceutical study of fresh and ageing tolbutamide–polyethyleneglycols solid dispersions (42) 27
Alsina, M.A., see Reig, F. (44) 257
Alsina, M.A., see Reig, F. (44) 269
Altomare, C., Carotti, A., Cellamare, S., Ferappi, M., Cagiano, R. and Renna, G.
QSAR analysis of chemical and serum-catalyzed hydrolysis of phenyl ester prodrugs of nipecotic acid (48) 91
Amagase, H., see Murakami, T. (46) 9
Amagase, H., see Murakami, T. (49) 173
Amidon, G.E. and Middleton, K.R.
Accelerated physical stability testing and long-term predictions of changes in the crushing strength of tablets stored in blister packages (45) 79
Anderberg, E.K., Bisrat, M. and Nyström, C.
Physicochemical aspects of drug release. VII. The effect of surfactant concentration and drug particle size on solubility and dissolution rate of felodipine, a sparingly soluble drug (47) 67
Anders, R. and Merkle, H.P.
Evaluation of laminated muco-adhesive patches for buccal drug delivery (49) 231
Anderson, B.D., Chu, W.W. and Galinsky, R.E.
Reduction of first-pass metabolism of propranolol after oral administration of ester prodrugs (43) 261
Anderson, B.D., Wygant, M.B., Xiang, T.-X., Waugh, W.A. and Stella, V.J.
Preformulation solubility and kinetic studies of 2′,3′-dideoxypurine nucleosides: potential anti-AIDS agents (45) 27
Andrady, A.L., see Pitt, C.G. (45) 1
Aramaki, Y., Inaba, A., Kikuchi, S., Tsuchiya, S., Takagi, H., Abe, K. and Kawakubo, Y.
Reduction of gentamicin-induced enzymuria by dextran sulfate (46) 103
Aramaki, Y., see Hara, T. (42) 69
Aramaki, Y., see Kikuchi, S. (42) 193
Arima, H., see Yoshida, A. (46) 217
Arita, T., see Kohri, N. (49) 213
Armstrong, N.A., Griffiths, H.-A. and James, K.C.
An in vitro model to simulate drug release from oily media (41) 115
Armstrong, N.A., Griffiths, H.-A. and James, K.C.
Migration of ephedrine and salicylic acid from lipid mixtures containing isopropyl myristate (41) 205
Armstrong, N.A., Patel, A.N. and Jones, T.M.
Relationship between porosity and water content of dicalcium phosphate tablets (48) 173
Armstrong, N.A.
Time-dependent factors involved in powder compression and tablet manufacture (49) 1
Arnaud, P., see Zuber, M. (47) 31
Artursson, P., Ericsson, J.L.-E. and Sjöholm, I.

Inflammatory response to polyacryl starch microparticles, role of arachidonic acid metabolites (46) 149
Ashton, P., Hadgraft, J., Brain, K.R., Miller, T.A. and Walters, K.A.
Surfactant effects in topical drug availability (41) 189
Aso, Y., see Yoshioka, S. (46) 121
Asuero, A.G.
Evaluation of partition coefficient and acidity constants of amphoteric substances by graphic differentiation of the distribution ratio against pH curve (45) 157
Attia, M.A., Kassem, M.A. and Safwat, S.M.
In vivo performance of [^{3}H]dexamethasone ophthalmic film delivery systems in the rabbit eye (47) 21
Attwood, D. and Patel, H.K.
Composition of mixed micellar systems of cetrimide and chlorhexidine digluconate (49) 129
Audus, K.L., Shinogle, J.A., Guillot, F.L. and Holthaus, S.R.
Aluminum effects on brain microvessel endothelial cell monolayer permeability (45) 249
Auramo, P., see Laine, E. (43) 241
Awidi, A., see Othman, S. (41) 197

Badwan, A.A., see Ali, H.M. (42) 155
Baichwal, A.R., see Staniforth, J.N. (41) 231
Baillie, A.J., see Mendelow, A.Y. (49) 29
Baker, E., see Hoelgaard, A. (43) 233
Bambagiotti-Alberti, M., see Pinzauti, S. (46) 255
Bambagiotti-Alberti, M., see Vincieri, F.F. (48) 119
Banerjee, P.S. and Ritschel, W.A.
Transdermal permeation of vasopressin.I. Influence of pH, concentration, shaving and surfactant on in vitro permeation (49) 189
Banerjee, P.S. and Ritschel, W.A.
Transdermal permeation of vasopressin.II. Influence of Azone on in vitro and in vivo permeation (49) 199
Banga, A.K. and Chien, Y.W.
Systemic delivery of therapeutic peptides and proteins (48) 15
Bao, Y.T., see Pitt, C.G. (45) 1
Barnes, A.R. and Sugden, J.K.
Detection of photolytically produced hydroxyl radicals by reaction with 2,2,2-trichloroethanol (44) 31
Barone, J.S., see Faulkner, R.D. (43) 53
Barry, B.W., see Bond, J.R. (41) 91
Basu, K., Kildsig, D.O. and Mitra, A.K.
Synthesis and kinetic stability studies of progesterone derivatives (47) 195
Bateman, S.D., Rubinstein, M.H., Rowe, R.C., Roberts, R.J., Drew, P. and Ho, A.Y.K.
A comparative investigation of compression simulators (49) 209
Baveja, S.K., Ranga Rao, K.V. and Devi, K.P.
Relationship between gum content and half-life of soluble β blockers from hydrophilic matrix tablets (47) 133
Baveja, S.K., Rao, K.V.R., Singh, A. and Gombar, V.K.
Release characteristics of some bronchodilators from compressed hydrophilic polymeric matrices and their correlation with molecular geometry (41) 55
Bawazir, S.A., see Al-Hassan, M.I. (50) 35
Beastall, J.C., Hadgraft, J. and Washington, C.
Mechanism of action of Azone as a percutaneous penetration enhancer: lipid bilayer fluidity and transition temperature effects (43) 207
Becker, A., see Gu, L. (41) 95
Becker, A.R., see Powell, M.F. (44) 225
Beckett, A.H., see Kyroudis, A. (43) 145
Beezer, A.E., Fox, G.G., Gooch, C.A., Hunter, W.H., Miles, R.J. and Smith, B.V.
Microcalorimetric studies of the interaction of *m*-hydroxybenzoates with *E. coli* and with *S. aureus* Demonstration of a Collander relationship for biological response (45) 153
Beezer, A.E., see Buckton, G. (41) 139
Beezer, A.E., see Buckton, G. (47) 121
Behl, C., see Masada, T. (49) 57
Beier, W., see Jonkman, J.H.G. (43) 139
Beijnen, J.H., Holthuis, J.J.M., Kerkdijk, H.G., Van der Houwen, O.A.G.J., Paalman, A.C.A., Bult, A. and Underberg, W.J.M.
Degradation kinetics of etoposide in aqueous solution (41) 169
Beijnen, J.H., Van der Houwen, O.A.G.J., Paaij, J.D.F., Paalman, A.C.A. and Underberg, W.J.M.
Degradation kinetics of 7-*N*-(*p*-hydroxyphenyl)mitomycin C (M-83) in aqueous solution (45) 189
Beijnen, J.H., see Underberg, W.J.M. (50) 175
Beijnen, J.H., see Van der Houwen, O.A.G.J. (45) 181
Beijnen, J.H., see Vendrig, D.E.M.M. (43) 131
Beijnen, J.H., see Vendrig, D.E.M.M. (50) 189
Bekers, O., see Underberg, W.J.M. (50) 175
Belaid, K.A., see Irwin, W.J. (46) 57
Belaid, K.A., see Irwin, W.J. (48) 159
Bell, A.E., see Martin, G.P. (44) 57
Benkerrour, L., see Glomot, F. (46) 49
Benoit, J.P., see Ruiz, J.M. (49) 69
Benson, H.A.E., McElnay, J.C. and Harland, R.
Phonophoresis of lignocaine and prilocaine from Emla cream (44) 65
Betageri, G.V. and Rogers, J.A.
The liposome as a distribution model in QSAR studies (46) 95
Bhatt, P.P., Hanna, M.S., Szeptycki, P. and Higuchi, T.
Finite dose transport of drugs in liquid formulations through stratum corneum: analytical solution to a diffusion model (50) 197
Bircher, A.J., Roskos, K.V., Maibach, H.I. and Guy, R.H.
Laser Doppler velocimetric measurements of skin blood flow: a reply (45) 263
Bisrat, M. and Nyström, C.
Physicochemical aspects of drug release. VIII. The relation between particle size and surface specific dissolution rate in agitated suspensions (47) 223
Bisrat, M., see Anderberg, E.K. (47) 67
Björk, E. and Edman, P.

Degradable starch microspheres as a nasal delivery system for insulin (47) 233
Bocci, V., see Paulesu, L. (46) 199
Boddé, H.E., see Le Brun, P.P.H. (49) 141
Bodmeier, R. and McGinity, J.W.
Solvent selection in the preparation of poly(DL-lactide) microspheres prepared by the solvent evaporation method (43) 179
Bolòs, J., see Girona, V. (41) 241
Bond, J.R. and Barry, B.W.
Damaging effect of acetone on the permeability barrier of hairless mouse skin compared with that of human skin (41) 91
Bondi, J.N., see Radebaugh, G.W. (45) 39
Bosanquet, A.G.
Instability of solutions of diaziquone stored at negative temperatures (47) 215
Bottenberg, P., Slop, D., Remon, J.P., De Muynck, C. and Coomans, D.
Influence of viscosity and surfactant on fissure penetration of dental fluoride gels in vitro (49) 147
Boussard, P. and Dony, J.
Influence of protamine on the susceptibility of *Pseudomonas aeruginosa* to cefotaxime, sulphadimethoxine, polymyxin B and some β-lactam antibiotics (46) 45
Bouzon, J., see Liu, H. (45) 217
Boymond, C., see Saleh, S.I. (45) 19
Brain, K.R., see Ashton, P. (41) 189
Bramanti, G., Mura, P., Liguori, A., Ceccarelli, L., Santoni, G., Grossi, G. and Torresi, M.C.
Pharmaceutical availability of digoxin tablets (49) 241
Bridges, J.F., Woodley, J.F., Duncan, R. and Kopeček, J.
Soluble *N*-(2-hydroxypropyl)methacrylamide copolymers as a potential oral, controlled-release, drug delivery system. I. Bioadhesion to the rat intestine in vitro (44) 213
Briggs, C.J., see Washington, C. (48) 133
Buckton, G. and Beezer, A.E.
A microcalorimetric study of powder surface energetics (41) 139
Buckton, G., Choularton, A., Beezer, A.E. and Chatham, S.M.
The effect of the comminution technique on the surface energy of a powder (47) 121
Buckton, G., Ganderton, D. and Shah, R.
In vitro dissolution of some commercially available sustained-release theophylline preparations (42) 35
Buckton, G.
The assessment, and pharmaceutical importance, of the solid/liquid and the solid/vapour interface: a review with respect to powders (44) 1
Bult, A., see Beijnen, J.H. (41) 169
Bult, A., see Van der Houwen, O.A.G.J. (45) 181
Bundgaard, H. and Nielsen, N.M.
Glycolamide esters as a novel biolabile prodrug type for non-steroidal anti-inflammatory carboxylic acid drugs (43) 101
Bundgaard, H., Buur, A., Chang, S.-C. and Lee, V.H.L.
Timolol prodrugs: synthesis, stability and lipophilicity of various alkyl, cycloalkyl and aromatic esters of timolol (46) 77
Bundgaard, H., Buur, A., Hansen, K.T., Larsen, J.D., Møss, J. and Olsen, L.
Prodrugs as drug delivery systems. 77. Phthalidyl derivatives as prodrug forms for amides, sulfonamides, carbamates and other NH-acidic compounds (45) 47
Bundgaard, H., Nørgaard, T. and Nielsen, N.M.
Photodegradation and hydrolysis of furosemide and furosemide esters in aqueous solutions (42) 217
Bundgaard, H., Nielsen, N.M. and Buur, A.
Aspirin prodrugs: synthesis and hydrolysis of 2-acetoxybenzoate esters of various *N*-(hydroxyalkyl)amides (44) 151
Bundgaard, H., see Buur, A. (42) 51
Bundgaard, H., see Buur, A. (46) 159
Bundgaard, H., see Larsen, J.D. (47) 103
Burgess, D.J. and Davis, S.S.
Potential use of albumin microspheres as a drug delivery system. II. In vivo deposition and release of steroids (46) 69
Buri, P., see Nook, T. (43) 119
Burkhanov, S.A., Kosykh, V.A., Repin, V.S., Saatov, T.S. and Torchilin, V.P.
Interaction of liposomes of different phospholipid and ganglioside composition with rat hepatocytes (46) 31
Busquets, M.A., see Reig, F. (44) 257
Buur, A. and Bundgaard, H.
Prodrugs of peptides. III. 5-Oxazolidinones as bioreversible derivatives for the α-amido carboxy moiety in peptides (46) 159
Buur, A., Bundgaard, H. and Lee, V.H.L.
Prodrugs of propranolol: hydrolysis and intramolecular aminolysis of various propranolol esters and an oxazolidin-2-one derivative (42) 51
Buur, A., see Bundgaard, H. (44) 151
Buur, A., see Bundgaard, H. (45) 47
Buur, A., see Bundgaard, H. (46) 77
Buxton, P.C., Lynch, I.R. and Roe, J.M.
Solid-state forms of paroxetine hydrochloride (42) 135
Byron, P.R., see Hickey, A.J. (42) 267

Cagiano, R., see Altomare, C. (48) 91
Campigli, V., see Saettone, M.F. (43) 67
Caramella, C., Colombo, P., Conte, U., Ferrari, F., Gazzaniga, A., LaManna, A. and Peppas, N.A.
A physical analysis of the phenomenon of tablet disintegration (44) 177
Carelli, V., Di Colo, G., Guerrini, C. and Nannipieri, E.
Drug release from silicone elastomer through controlled polymer cracking: an extension to macromolecular drugs (50) 181
Carlucci, G., Mazzeo, P., Quaglia, M.G. and Vetuschi, C.
Determination of 5-methoxy-2-methylindole-3-acetic acid in indomethacin by derivative UV-spectrophotometry (49) 79
Carotti, A., see Altomare, C. (48) 91
Carrupt, P.-A., see Röthlisberger, T. (44) 141
Carstensen, J.T., see Ertel, K.D. (42) 171

Cartwright-Shamoon, J., see McElnay, J.C. (47) 239
Cartwright-Shamoon, J.M., McElnay, J.C. and D'Arcy, P.F.
Examination of sorption and photodegradation of amsacrine during storage in intravenous burette administration sets (42) 41
Casabó, V.G., see Collado, E.F. (44) 187
Ceccarelli, L., see Bramanti, G. (49) 241
Çelebi, N., see Erden, N. (48) 83
Cellamare, S., see Altomare, C. (48) 91
Chafi, N., Montheard, J.P. and Vergnaud, J.M.
Dosage form with drug attached to polymer (polyanhydride) dispersed in a Eudragit matrix: preparation and release of drug in gastric liquid (45) 229
Chan, H.-K. and Gonda, I.
Development of a systematic theory of suspension inhalation aerosols. II. Aggregates of monodisperse particles nebulized in polydisperse droplets (41) 147
Chanal, J.L., see Galleyrand, J.C. (42) 225
Chang, S.-C., see Bundgaard, H. (46) 77
Chang, Y., see Chaudhuri, B. (42) 117
Chatham, S.M., see Buckton, G. (47) 121
Chaudhuri, B., Chang, Y. and Karara, A.H.
Polyether polyurethane delivery systems. I. Evaluation of monolithic systems for N^6-(Δ^2-isopentenyl)adenosine (42) 117
Chaudhuri, B., see Ahmed, I. (44) 97
Chaumeil, J.C., see Zuber, M. (47) 31
Chen, G., Tu, Y.-H., Allen, Jr., L.V. and Wang, D.-P.
Determination of trimethoprim in rat blood, plasma, prostate gland and seminal vesicles by high-performance liquid chromatography (46) 89
Chen, S., see Powell, M.F. (44) 225
Chevin, J.C., Maincent, P., Mougeolle, J.M., Jacque, M. and Martin, J.A.
Nickel II elimination and autoradiographic distribution in normal and nickel-sensitized Guinea pigs (45) 101
Chiang, C.-M., Flynn, G.L., Weiner, N.D. and Szpunar, G.J.
Bioavailability assessment of topical delivery systems: effect of inter-subject variability on relative in vitro deliveries of minoxidil and hydrocortisone from solution and ointment formulations (50) 21
Chiang, C.-M., Flynn, G.L., Weiner, N.D., Addicks, W.J. and Szpunar, G.J.
Bioavailability assessment of topical delivery systems: in vitro delivery of minoxidil from prototypical semi-solid formulations (49) 109
Chiang, H.-S., see Gu, L. (41) 105
Chiang, H.-S., see Gu, L. (41) 95
Chien, Y.W., see Banga, A.K. (48) 15
Chien, Y.W., see Corbo, D.C. (46) 133
Chien, Y.W., see Corbo, D.C. (50) 253
Chien, Y.W., see Humcke-Bogner, R. (42) 199
Chien, Y.W., see Liu, J.-C. (44) 197
Chien, Y.W., see Tan, E.L. (42) 161
Cho, M.J., see Haynes, L.C. (45) 169
Cho, M.J., see Scieszka, J.F. (45) 165
Choularton, A., see Buckton, G. (47) 121
Chow, A.H.-L. and Grant, D.J.W.
Modification of acetaminophen crystals. II. Influence of stirring rate during solution-phase growth on crystal properties in the presence and absence of *p*-acetoxyacetanilide (41) 29
Chow, A.H.L. and Grant, D.J.W.
Modification of acetaminophen crystals. III. Influence of initial supersaturation during solution-phase growth on crystal properties in the presence and absence of *p*-acetoxyacetanilide (42) 123
Chu, W.W., see Anderson, B.D. (43) 261
Collado, E.F., Fabra-Campos, S., Peris-Ribera, J.E., Casabó, V.G., Martín-Villodre, A. and Plá-Delfina, J.M.
Absorption–partition relationships for true homologous series of xenobiotics as a possible approach to study mechanisms of surfactants in absorption. II. Aromatic amines in rat small intestine (44) 187
Colombo, P., see Caramella, C. (44) 177
Concheiro, A., see Martínez-Pacheco, R. (47) 37
Conte, U., see Caramella, C. (44) 177
Conti, B., see Pavanetto, F. (48) 255
Coomans, D., see Bottenberg, P. (49) 147
Coran, S.A., see Vincieri, F.F. (48) 119
Corbo, D.C., Huang, Y.C. and Chien, Y.W.
Nasal delivery of progestational steroids in ovariectomized rabbits. II. Effect of penetrant hydrophilicity (50) 253
Corbo, D.C., Huang, Y.C. and Chien, Y.W.
Nasal delivery of progestational steroids in ovariectomized rabbits.I. Progesterone – comparison of pharmacokinetics with intravenous and oral administration (46) 133
Corradeschi, F., see Paulesu, L. (46) 199
Couvreur, P., see Kubiak, C. (41) 181
Cremieux, A., see Damery, B. (49) 205
Critchley, H., see Illum, L. (46) 261
Crommelin, D.J.A., see Grit, M. (50) 1
Cutler, D.J., see Firmer, S.J. (48) 231
Cutt, T., Fell, J.T., Rue, P.J. and Spring, M.S.
Granulation and compaction of a model system. III. Compaction properties of the granules (49) 157

Daicoviciu, D., see Leucuta, S.E. (41) 213
Dakas, C.J., see Takla, P.G. (43) 225
Dalby, R.N., see Hickey, A.J. (42) 267
Dal Pozzo, A., Donzelli, G., Rodriquez, L. and Tajana, A.
"In vitro" model for the evaluation of drug distribution and plasma protein-binding relationships (50) 97
Damery, B. and Cremieux, A.
Virucidal activity against Herpes and Vaccinia virus of 8 antiseptic formulations (49) 205
Danhof, M., see Verhoeven, J. (45) 65
Danjo, K., see Takeeda, T. (41) 21
Dansereau, R. and Dansereau, R.
Development of a new coated-bead dosage form of sodium iodide I-131 (49) 115
Dansereau, R., see Dansereau, R. (49) 115
Danti, A.G., see Jafari, M.R. (48) 207
Dany, S., see Touitou, E. (43) 9

D'Arcy, P.F., see Cartwright-Shamoon, J.M. (42) 41
D'Arcy, P.F., see McElnay, J.C. (47) 239
Daugherty, A.L., Liggitt, H.D., McCabe, J.G., Moore, J.A. and Patton, J.S.
Absorption of recombinant methionyl-human growth hormone (Met-hGH) from rat nasal mucosa (45) 197
Davis, S.S., Parr, G.D., Feely, L., Leslie, S.T., Malkowska, S. and Lockwood, G.F.
The gastrointestinal transit investigation of a controlled release aminophylline formulation (49) 183
Davis, S.S., see Burgess, D.J. (46) 69
Davis, S.S., see Farraj, N.F. (43) 83
Davis, S.S., see Farraj, N.F. (43) 93
Davis, S.S., see Farraj, N.F. (46) 231
Davis, S.S., see Feely, L.C. (41) 83
Davis, S.S., see Feely, L.C. (44) 131
Davis, S.S., see Hardy, J.G. (48) 79
Davis, S.S., see Illum, L. (46) 261
Davis, S.S., see Washington, C. (44) 169
Davis, S.S., see Washington, C. (46) 25
Deasy, P.B., see O'Neill, C.T. (48) 247
Dellerman, K.M., see Pikal, M.J. (50) 233
Delmonte, G., see Saettone, M.F. (43) 67
De Meere, A.L.J., see Leahy, D.E. (50) 117
De Muynck, C., see Bottenberg, P. (49) 147
De Noord, O.E., see Jonkman, J.H.G. (43) 139
Dent, J., see Matuszewska, B. (46) 111
De Smidt, J.H., see Grit, M. (50) 1
Devi, K.P., see Baveja, S.K. (47) 133
De Vries, M.E., see Le Brun, P.P.H. (49) 141
De Vries-Nijboer, G.W., see Schoonen, A.J.M. (47) 249
De Vries-Nijboer, G.W., see Schoonen, A.J.M. (49) 261
Dey, M., Enever, R., Marino, M., Michelucci, J., Smith, D., Warner, R. and Weierstall, R.
Sustained-release etodolac bioavailability and dose proportionality: correlation between in vivo and in vitro performance (49) 121
De Zeeuw, R.A., see Wiechers, J.W. (47) 43
Dicken, C.M., Rossi, T.M., Rajagopalan, N., Ravin, L.J. and Sternson, L.A.
A study of the chemical stability of amphotericin B in *N,N*-dimethylacetamide (46) 223
Di Colo, G., Giannessi, C., Nannipieri, E., Serafini, M.F. and Vitale, D.
Influence of drug–surfactant and skin–surfactant interactions on percutaneous absorption of two model compounds from ointment bases in vitro (50) 27
Di Colo, G., see Carelli, V. (50) 181
Doelker, E., see Nook, T. (43) 119
Doherty, C. and York, P.
Frusemide crystal forms; solid state and physicochemical analyses (47) 141
Doherty, C. and York, P.
Microenvironmental pH control of drug dissolution (50) 223
Dony, J., see Boussard, P. (46) 45
Donzelli, G., see Dal Pozzo, A. (50) 97
Dorle, A.K., see Labhasetwar, V.D. (47) 261
Dowse, R., see Fassihi, A.R. (50) 79
Drenth, B.F.H., see Wiechers, J.W. (47) 43
Drew, P., see Bateman, S.D. (49) 209
Drieman, J.C., Vervoort-Peters, H.T.M. and Thijssen, H.H.W.
Pharmacokinetic studies on the mechanism of renal selectivity of the vasodilator prodrug CGP 22979 (46) 203
Duchateau, G.S.M.J.E., see Zuidema, J. (47) 1
Duchêne, D., see Glomot, F. (46) 49
Duewell, S., see Schwendener, R.A. (49) 249
Duncan, R., see Bridges, J.F. (44) 213
Du Plessis, J., Tiedt, L.R., Kotze, A.F., Van Wyk, C.J. and Ackermann, C.
A transmission electron microscope method for determination of droplet size in parenteral fat emulsions using negative staining (46) 177

Edman, P., see Björk, E. (47) 233
El-Hinnawi, M.A., see Najib, N.M. (45) 139
Elliott, D.S., see McElnay, J.C. (47) 239
Elmarakby, Z.S., see Owoyale, J.A. (50) 219
Enever, R., see Dey, M. (49) 121
Erden, N. and Çelebi, N.
A study of the inclusion complex of naproxen with β-cyclodextrin (48) 83
Ericsson, J.L.-E., see Artursson, P. (46) 149
Ertel, K.D. and Carstensen, J.T.
An examination of the physical properties of pure magnesium stearate (42) 171
Eshra, A.G., Etman, M.A. and Naggar, V.F.
Effect of milk and food on the bioavailability of ketoprofen in man (44) 9
Espino, C.D., see Fariña, J.B. (45) 123
Estelrich, J., see Girona, V. (41) 241
Etman, M.A., see Eshra, A.G. (44) 9
Etter, J.-C., see Röthlisberger, T. (44) 141
Evans, J.C., see Gay, C.L. (49) 39
Evora, C.M., see Fariña, J.B. (45) 123

Fabin, B., see Touitou, E. (43) 17
Fabin, B., see Touitou, E. (43) 9
Fabra-Campos, S., see Collado, E.F. (44) 187
Fairbrother, J.E., see Queen, D. (44) 25
Fariña, J.B., Evora, C.M., Espino, C.D. and Llabrés, M.
Theoretical model for interpretation of in situ absorption studies (45) 123
Farr, S.J., see Jamshaid, M. (48) 125
Farraj, N., see Illum, L. (46) 261
Farraj, N.F., Davis, S.S., Parr, G.D. and Stevens, H.N.E.
Absorption of progabide from aqueous solutions in a modified recirculating rat intestinal perfusion system (43) 93
Farraj, N.F., Davis, S.S., Parr, G.D. and Stevens, H.N.E.
Dissociation and partitioning of Progabide and its degradation product (46) 231
Farraj, N.F., Davis, S.S., Parr, G.D. and Stevens, H.N.E.
Investigation of progabide absorption from the gastrointestinal tract of the rabbit (43) 83

Fassihi, A.R., Dowse, R. and Robertson, S.S.D.
Effect of dietary cellulose on the absorption and bioavailability of theophylline (50) 79
Fassihi, A.R.
Consolidation behaviour of polymeric substances in non-disintegration solid matrices (44) 249
Faulkner, R.D., Sia, L.L., Look, Z.M., Barone, J.S., Forbes, S.J., Weiss, A.I. and Michael Silber, B.
Bioequivalency of solid oral dosage forms of cefixime (43) 53
Feely, L., see Davis, S.S. (49) 183
Feely, L.C. and Davis, S.S.
Influence of surfactants on drug release from hydroxypropylmethylcellulose matrices (41) 83
Feely, L.C. and Davis, S.S.
The influence of polymeric excipients on drug release from hydroxypropylmethylcellulose matrices (44) 131
Fell, J.T., see Cutt, T. (49) 157
Fell, J.T., see Luangtana-anan, M. (41) 237
Ferappi, M., see Altomare, C. (48) 91
Ferrari, F., see Caramella, C. (44) 177
Firmer, S.J. and Cutler, D.J.
Simulation of gastrointestinal drug absorption I. Longitudinal transport in the small intestine (48) 231
Florence, A.T., see Mendelow, A.Y. (49) 29
Flynn, G.L., see Chiang, C.-M. (49) 109
Flynn, G.L., see Chiang, C.-M. (50) 21
Flynn, G.L., see Neau, S.H. (49) 223
Folayan, J.O., see Akojie, F.O.B. (42) 261
Forbes, S.J., see Faulkner, R.D. (43) 53
Ford, J., see Ali, H.M. (42) 155
Forsyth, A., see Mendelow, A.Y. (49) 29
Fournier, J., see Galleyrand, J.C. (42) 225
Fox, G.G., see Beezer, A.E. (45) 153
Fox, J., see Masada, T. (49) 57
Fox, P.L.A., see Le Brun, P.P.H. (49) 141
Freeman, D.J., Sheth, N.V. and Spruance, S.L.
Preclinical studies of iododeoxuridine in dimethyl sulfoxide for the topical treatment of cutaneous herpes simplex virus infections (48) 141
Friedman, M., Harrari, D., Rimer, A. and Stabholz, A.
Inhibition of plaque formation by a sustained release delivery system for cetylpyridinium chloride (44) 243
Frijlink, H.W., Schoonen, A.J.M. and Lerk, C.F.
The effects of cyclodextrins on drug absorption. I. In vitro observations (49) 91
Fubini, B., Gasco, M.R. and Gallarate, M.
Microcalorimetric study of microemulsions as potential drug delivery systems. I. Evaluation of enthalpy in the absence of any drug (42) 19
Fubini, B., Gasco, M.R. and Gallarate, M.
Microcalorimetric study of microemulsions as potential drug delivery systems. II. Evaluation of enthalpy in the presence of drugs (50) 213
Fujihara, Y., see Kaneo, Y. (44) 265
Fujimoto, T., see Nishihata, T. (42) 251
Funaki, T., Watari, N., Furuta, S. and Kaneniwa, N.
Analysis of the absorption characteristics of cimetidine with the use of the multi-segment absorption model (43) 59
Furuta, S., see Funaki, T. (43) 59
Furuya, Y., see Takada, K. (44) 107
Fuwa, T., see Murakami, T. (46) 9
Fuwa, T., see Murakami, T. (49) 173
Fyhr, P., see Nicklasson, M. (46) 247

Gaber, M., see Al-Shora, H.I. (47) 209
Gachon, M., see Gehenot, A. (45) 13
Galinsky, R.E., see Anderson, B.D. (43) 261
Gallarate, M., see Fubini, B. (42) 19
Gallarate, M., see Fubini, B. (50) 213
Galleyrand, J.C., Fournier, J., Chanal, J.L. and Puozzo, C.
Comparative study of binding of an antiallergic substance to serum albumin and erythrocytes in man, in the dog and in the rat (42) 225
Ganderton, D., see Buckton, G. (42) 35
Garcia-Arias, T., see Alonso, M.J. (42) 27
García Antón, J.M., see Reig, F. (44) 257
García Antón, J.M., see Reig, F. (44) 269
Gard, P.R., see Malhi, J.S. (43) 77
Garren, K.W. and Repta, A.J.
Buccal drug absorption. I. Comparative levels of esterase and peptidase activities in rat and hamster buccal and intestinal homogenates (48) 189
Gasco, M.R., see Fubini, B. (42) 19
Gasco, M.R., see Fubini, B. (50) 213
Gay, C.L., Murphy, T.M., Hadgraft, J., Kellaway, I.W., Evans, J.C. and Rowlands, C.C.
An electron spin resonance study of skin penetration enhancers (49) 39
Gazzaniga, A., see Caramella, C. (44) 177
Gehenot, A., Rao, R.C., Maire, G. and Gachon, M.
Value of thermal analysis in the critical evaluation of classical methods of melting point determination (45) 13
Genta, I., see Pavanetto, F. (48) 255
Georgieva, M., see Simeonova, M. (43) 267
Giannaccini, B., see Saettone, M.F. (43) 67
Giannessi, C., see Di Colo, G. (50) 27
Gibson, S.H.M., Rowe, R.C. and White, E.F.T.
Characterisation of the structure of filled polymer film coatings using ion beam etching (47) 205
Gibson, S.H.M., Rowe, R.C. and White, E.F.T.
Determination of the critical pigment volume concentrations of pigmented film coating formulations using gloss measurement (45) 245
Gibson, S.H.M., Rowe, R.C. and White, E.F.T.
Mechanical properties of pigmented tablet coating formulations and their resistance to cracking. I. Static mechanical measurement (48) 63
Gibson, S.H.M., Rowe, R.C. and White, E.F.T.
Quantitative assessment of additive–polymer interaction in pigmented hydroxypropyl methylcellulose formulations using immersion calorimetry (48) 113
Gibson, S.H.M., Rowe, R.C. and White, E.F.T.
The mechanical properties of pigmented tablet coating

formulations and their resistance to cracking. II. Dynamic mechanical measurement (50) 163
Gilbert, D.L., Okano, T., Miyata, T. and Kim, S.W.
Macromolecular diffusion through collagen membranes (47) 79
Gimenez, F., Postaire, E., Prognon, P., Le Hoang, M.D., Lecomte, J.M., Pradeau, D. and Hazebroucq, G.
Study of thiorphan degradation (43) 23
Girona, V., Estelrich, J., Pujol, M. and Bolòs, J.
Ampicillin polymers: identification by gel-filtration chromatography (41) 241
Glomot, F., Benkerrour, L., Duchêne, D. and Poelman, M.-C.
Improvement in availability and stability of a dermocorticoid by inclusion in β-cyclodextrin (46) 49
Gombar, V.K., see Baveja, S.K. (41) 55
Gonda, I., see Chan, H.-K. (41) 147
Gooch, C.A., see Beezer, A.E. (45) 153
Gorman, S.P., see Woolfson, A.D. (48) 167
Gorman, S.P., see Woolfson, A.D. (49) 135
Gouda, M.W., see Al-Shora, H.I. (47) 209
Gould, P.L., see Thomas, N.W. (44) 261
Grandolfi, G.P., see Zografi, G. (42) 77
Grant, D.J.W., see Chow, A.H.-L. (41) 29
Grant, D.J.W., see Chow, A.H.L. (42) 123
Grasmeyer, G., see Jonkman, J.H.G. (43) 139
Gratteri, P., see Pinzauti, S. (46) 255
Gratteri, P., see Santoni, G. (50) 75
Greaves, J.L., see Wilson, C.G. (46) 241
Greaves, J.L., see Wilson, C.G. (50) 155
Green, P.G. and Hadgraft, J.
The use of second-order derivative UV spectroscopy to monitor the percutaneous absorption of naphazoline and oxprenolol (46) 193
Green, P.G., Guy, R.H. and Hadgraft, J.
In vitro and in vivo enhancement of skin permeation with oleic and lauric acids (48) 103
Griffiths, H.-A., see Armstrong, N.A. (41) 115
Griffiths, H.-A., see Armstrong, N.A. (41) 205
Grijseels, H., see Schoonen, A.J.M. (47) 249
Grislingaas, A.-L., see Tønnesen, H.H. (43) 215
Grit, M., De Smidt, J.H., Struijke, A. and Crommelin, D.J.A.
Hydrolysis of phosphatidylcholine in aqueous liposome dispersions (50) 1
Grossi, G., see Bramanti, G. (49) 241
Gu, L., Chiang, H.-S. and Becker, A.
Kinetics and mechanisms of the autoxidation of ketorolactromethamine in aqueous solution (41) 95
Gu, L., Chiang, H.-S. and Johnson, D.
Light degradation of ketorolac tromethamine (41) 105
Gu, L., Huynh, O., Strickley, R.G., Lin, L.-H. and Visor, G.C.
Parenteral formulation development for the positive inotropic agent RS-82856. Hydrolysis and oxidation kinetics, solubility and i.v. formulation considerations (45) 129
Guentert, T.W., see Øie, S. (48) 223
Guerrini, C., see Carelli, V. (50) 181
Guillot, F.L., see Audus, K.L. (45) 249
Gunnvald, K., see Nicklasson, M. (46) 247
Gupta, P.K. and Robinson, J.R.
Gastric emptying of liquids in the fasted dog (43) 45
Gupta, P.K., Hung, C.T., Lam, F.C. and Perrier, D.G.
Albumin microspheres. III. Synthesis and characterization of microspheres containing adriamycin and magnetite (43) 167
Gupta, R.L., see Singh, S. (42) 263
Gupta, R.L., see Singh, S. (46) 267
Guy, R.H., see Bircher, A.J. (45) 263
Guy, R.H., see Green, P.G. (48) 103

Habib, M.J. and Rogers, J.A.
Kinetics of hydrolysis and stabilization of acetylsalicylic acid in liposome formulations (44) 235
Hadgraft, J. and Ridout, G.
Development of model membranes for percutaneous absorption measurements. II. Dipalmitoyl phosphatidylcholine, linoleic acid and tetradecane (42) 97
Hadgraft, J., see Ashton, P. (41) 189
Hadgraft, J., see Beastall, J.C. (43) 207
Hadgraft, J., see Gay, C.L. (49) 39
Hadgraft, J., see Green, P.G. (46) 193
Hadgraft, J., see Green, P.G. (48) 103
Haigh, J.M., see Meyer, E. (41) 63
Hamada, C., see Kurosaki, Y. (47) 13
Hanlon, G.W., see Malhi, J.S. (43) 77
Hanna, M.S., see Bhatt, P.P. (50) 197
Hannula, A.-M., see Marvola, M. (44) 159
Hansen, K.T., see Bundgaard, H. (45) 47
Happonen, I., see Heinämäki, J. (42) 105
Happonen, I., see Heinämäki, J. (48) 51
Happonen, I., see Marvola, M. (44) 159
Hara, T., Ishihara, H., Aramaki, Y. and Tsuchiya, S.
Specific uptake of asialofetuin-labeled liposomes by isolated hepatocytes (42) 69
Harada, M., see Tashima, T. (42) 61
Hardy, J.G., Davis, S.S., Khosla, R. and Robertson, C.S.
Gastrointestinal transit of small tablets in patients with ulcerative colitis (48) 79
Hardy, J.G., see Pennington, A.K. (43) 221
Harland, R., see Benson, H.A.E. (44) 65
Harrari, D., see Friedman, M. (44) 243
Harrison, P.J., see Willmott, N. (43) 161
Hart, J.P., see Staniforth, J.N. (41) 231
Hatakeyama, Y., see Takeeda, T. (41) 21
Hayashi, T., see Murakami, T. (46) 9
Hayashi, T., see Murakami, T. (49) 173
Haynes, L.C. and Cho, M.J.
Mechanism of Nile red transfer from o/w emulsions as carriers for passive drug targeting to peritoneal macrophages in vitro (45) 169
Haynes, L.C., see Scieszka, J.F. (45) 165
Hazebroucq, G., see Gimenez, F. (43) 23
Heinämäki, J., Marvola, M., Happonen, I. and Westermarck, E.
Formulations releasing the drug proximal to the pylorus in the dog (48) 51

Heinämäki, J., Marvola, M., Happonen, I. and Westermarck, E.
The fate of multiple-unit enteric-coated formulations in the stomach of the dog (42) 105
Heng, P.W.S., see Staniforth, J.N. (41) 231
Herman, J., Remon, J.P., Visavarungroj, N., Schwartz, J.B. and Klinger, G.H.
Formation of theophylline monohydrate during the pelletisation of microcrystalline cellulose–anhydrous theophylline blends (42) 15
Hernández-Borrell, J.
A new confirmation of selective action of liposomes (47) 129
Hickey, A.J., Dalby, R.N. and Byron, P.R.
Effects of surfactants on aerosol powders in suspension. Implications for airborne particle size (42) 267
Higashi, Y., see Murakami, T. (46) 9
Higashi, Y., see Murakami, T. (49) 173
High, A.-J., see Malhi, J.S. (43) 77
Higuchi, F., see Seta, Y. (41) 245
Higuchi, F., see Seta, Y. (41) 255
Higuchi, T., see Akazawa, M. (50) 53
Higuchi, T., see Bhatt, P.P. (50) 197
Higuchi, T., see Nghiem, B.T. (44) 125
Higuchi, T., see Tsuzuki, N. (46) 19
Higuchi, W.I., see Masada, T. (49) 57
Hirayama, F., see Hoshino, T. (50) 45
Hirayama, F., see Yamamoto, M. (49) 163
Hirotani, Y., see Nishihata, T. (42) 257
Hisaichi, S.-i., see Kurosaki, Y. (47) 13
Hisaichi, S.-i., see Kurosaki, Y. (49) 47
Hjorth Tønnesen, H. and Karlsen, J.
Studies on curcumin and curcuminoids. XI. Stabilization of photolabile drugs in serum samples by addition of curcumin (41) 75
Ho, A.Y.K., see Bateman, S.D. (49) 209
Hoelgaard, A., Møllgaard, B. and Baker, E.
Vehicle effect on topical drug delivery. IV. Effect of *N*-methylpyrrolidone and polar lipids on percutaneous drug transport (43) 233
Hollenbeck, R.G.
Bioavailability of phenylpropanolamine HCl from tablet dosage forms containing croscarmellose sodium (47) 89
Holman, L.E. and Leuenberger, H.
The relationship between solid fraction and mechanical properties of compacts – the percolation theory model approach (46) 35
Holthaus, S.R., see Audus, K.L. (45) 249
Holthuis, J.J.M., see Beijnen, J.H. (41) 169
Holthuis, J.J.M., see Vendrig, D.E.M.M. (43) 131
Holthuis, J.J.M., see Vendrig, D.E.M.M. (50) 189
Homeida, M.M.A., see Ali, H.M. (42) 155
Hong, L.-Z., see Kurosaki, Y. (49) 47
Hoshino, T., Hirayama, F., Uekama, K. and Yamasaki, M.
Reduction of protriptyline-photosensitized hemolysis by β-cyclodextrin complexations (50) 45
Huang, Y.C., see Corbo, D.C. (46) 133
Huang, Y.C., see Corbo, D.C. (50) 253
Humcke-Bogner, R., Liu, J.-C. and Chien, Y.W.
Methods for determining partial solubility parameters of potential film-coating polymers (42) 199
Hung, C.T., Lam, F.C., Perrier, D.G. and Souter, A.
A stability study of amphotericin B in aqueous media using factorial design (44) 117
Hung, C.T., see Gupta, P.K. (43) 167
Hunter, W.H., see Beezer, A.E. (45) 153
Hussain, M.S.H., York, P. and Timmins, P.
A study of the formation of magnesium stearate film on sodium chloride using energy-dispersive X-ray analysis (42) 89
Huynh, O., see Gu, L. (45) 129

Ichikawa, T., see Sakiya, Y. (47) 185
Iguchi, S., see Kaneo, Y. (44) 265
IJzerman, A.P.
Ionization constants of sparingly soluble substances from aqueous titration data (46) 173
Illum, L., Farraj, N., Critchley, H. and Davis, S.S.
Nasal administration of gentamicin using a novel microsphere delivery system (46) 261
Inaba, A., see Aramaki, Y. (46) 103
Inaba, A., see Kikuchi, S. (42) 193
Iqbal, M., see Irwin, W.J. (41) 41
Irie, T., Tsunenari, Y., Uekama, K. and Pitha, J.
Effect of bile on the intestinal absorption of α-cyclodextrin in rats (43) 41
Irwin, V.P., Quigley, J.M. and Timoney, R.F.
1-Octanol–water partition coefficients of the anionic and zwitterionic species of diprotic zwitterionic cephalosporin antibiotics (43) 187
Irwin, W.J. and Belaid, K.A.
Drug-delivery by ion-exchange. Hydrolysis and rearrangement of ester pro-drugs of propranolol (46) 57
Irwin, W.J. and Belaid, K.A.
Drug-delivery by ion-exchange. Stability of ester pro-drugs of propranolol in surfactant and enzymatic systems (48) 159
Irwin, W.J. and Iqbal, M.
Thermal stability of bropirimine (41) 41
Ishida, S., see Sakiya, Y. (47) 185
Ishihara, H., see Hara, T. (42) 69
Itoh, T., see Akazawa, M. (50) 53
Ivanova, T., see Simeonova, M. (43) 267
Iwamoto, Y., see Takeeda, T. (41) 21
Iwasa, K., see Kohri, N. (49) 213

Jacque, M., see Chevin, J.C. (45) 101
Jafari, M.R., Danti, A.G. and Ahmed, I.
Comparison of polyethylene glycol, polyvinylpyrrolidone and urea as excipients for solid dispersion systems of miconazole nitrate (48) 207
Jähnchen, E., see Øie, S. (48) 223
Jalal, I., see Najib, N. (44) 43
James, K.C., see Armstrong, N.A. (41) 115

James, K.C., see Armstrong, N.A. (41) 205
Jamoulle, J.C., see Martin, B. (49) 63
Jamshaid, M., Farr, S.J., Kearney, P. and Kellaway, I.W.
Poloxamer sorption on liposomes: comparison with polystyrene latex and influence on solute efflux (48) 125
Johansen, M., see Larsen, C. (41) 121
Johnson, D., see Gu, L. (41) 105
Jones, D.S., see Woolfson, A.D. (48) 167
Jones, D.S., see Woolfson, A.D. (49) 135
Jones, T.M., see Armstrong, N.A. (48) 173
Jonkman, J.H.G., Steinijans, V.W., Beier, W., Yska, J.P., Kerkhof, F.A., De Noord, O.E. and Grasmeyer, G.
Sustained release properties of the once daily theophylline capsule Euphylong as compared with Theo-Dur tablets (43) 139
Jonkman, J.H.G., see Wiechers, J.W. (47) 43
Julian, T.N., see Radebaugh, G.W. (45) 39
Juneskans, O.T., see Karabit, M.S. (46) 141
Junginger, H.E., see Verhoeven, J. (45) 65

Kahela, P., see Laine, E. (43) 241
Kamada, A., see Nishihata, T. (42) 251
Kamada, A., see Nishihata, T. (46) 1
Kamali, F., see Wilson, C.G. (50) 155
Kamide, S., see Nishihata, T. (42) 251
Kaneniwa, N., see Funaki, T. (43) 59
Kaneo, Y., Tanaka, T., Fujihara, Y., Mori, H. and Iguchi, S.
Delivery of glutathione, as a dextran conjugate, into the liver (44) 265
Kanfer, I., see Meyer, E. (41) 63
Karabit, M.S., Juneskans, O.T. and Lundgren, P.
Studies on the evaluation of preservative efficacy. III. The determination of antimicrobial characteristics of benzalkonium chloride (46) 141
Karara, A.H., see Chaudhuri, B. (42) 117
Karjalainen, P., see Vidgren, M. (42) 211
Kärkkäinen, A., see Vidgren, M. (42) 211
Karlsen, J., see Hjorth Tønnesen, H. (41) 75
Karlsen, J., see Tønnesen, H.H. (43) 215
Kassem, M., Akbarieh, M. and Tawashi, R.
Effect of fluid viscosity on the size and morphic features of salicylic acid during ball-mill grinding (47) 179
Kassem, M.A., see Attia, M.A. (47) 21
Katagi, T., see Takahashi, K. (49) 179
Kawahara, Y., see Seta, Y. (41) 245
Kawahara, Y., see Seta, Y. (41) 255
Kawahara, Y., see Seta, Y. (41) 263
Kawakami, U., see Tashima, T. (42) 61
Kawakita, H., see Murakami, T. (46) 9
Kawakubo, Y., see Aramaki, Y. (46) 103
Kearney, P., see Jamshaid, M. (48) 125
Keigami, M., see Nishihata, T. (42) 251
Keigami, M., see Nishihata, T. (46) 1
Kellaway, I.W., see Gay, C.L. (49) 39
Kellaway, I.W., see Jamshaid, M. (48) 125
Kenley, R.A., see Powell, M.F. (44) 225
Kennedy, P.E., Riley, C.M. and Stella, W.J.
Degradation of the antineoplastic drug, clomesone (2-chloroethyl(methylsulfonyl)methanesulfonate, NSC-338947). A kinetic and mechanistic study (48) 179
Kerkdijk, H.G., see Beijnen, J.H. (41) 169
Kerkhof, F.A., see Jonkman, J.H.G. (43) 139
Khosla, R., see Hardy, J.G. (48) 79
Kikuchi, S., Inaba, A., Takahashi, M., Aramaki, Y. and Tsuchiya, S.
Decreased distribution of gentamicin in rat kidney by complexation with dextran sulfate (42) 193
Kikuchi, S., see Aramaki, Y. (46) 103
Kildsig, D.O., see Basu, K. (47) 195
Kim, C.-K. and Oh, Y.-K.
Development of hydrophilic human serum albumin microspheres using a drug–albumin conjugate (47) 163
Kim, S.-K., see Young, C.-S. (45) 59
Kim, S.W., see Gilbert, D.L. (47) 79
Kim, W.B., see Lee, K.C. (44) 49
Kimura, T., see Kurosaki, Y. (47) 13
Kimura, T., see Kurosaki, Y. (49) 47
Kinget, R., see Provost, C. (44) 75
Kishimoto, M., see Murakami, T. (46) 9
Kishimoto, M., see Murakami, T. (49) 173
Kitaura, I., see Takeeda, T. (41) 21
Klier, J. and Peppas, N.A.
Use of energy dispersive X-ray analysis to determine solute concentration profiles (46) 179
Klinger, G.H., see Herman, J. (42) 15
Kogure, T., see Sugito, K. (47) 157
Koh, I.B., see Lee, K.C. (44) 49
Kohri, N., Iwasa, K., Kurihara, J., Miyazaki, K. and Arita, T.
Inter-subject variation in oral absorption of ketoprofen from controlled-release granules in rabbits (49) 213
Koike, H., see Seta, Y. (41) 255
Kojima, M., see Sasaki, H. (44) 15
Konishi, R., see Akazawa, M. (50) 53
Kontny, M.J., see Zografi, G. (42) 77
Kopeček, J., see Bridges, J.F. (44) 213
Kopra, T., see Marvola, M. (44) 159
Kosykh, V.A., see Burkhanov, S.A. (46) 31
Kotze, A.F., see Du Plessis, J. (46) 177
Kreuter, J., see Tröster, S.D. (45) 91
Kristjansson, F., Sternson, L.A. and Lindenbaum, S.
An investigation on possible oligomer formation in pharmaceutical formulations of cisplatin (41) 67
Kubiak, C., Manil, L. and Couvreur, P.
Sorptive properties of antibodies onto cyanoacrylic nanoparticles (41) 181
Kurihara, J., see Kohri, N. (49) 213
Kurosaki, Y., Hisaichi, S.-i., Hamada, C., Nakayama, T. and Kimura, T.
Effects of surfactants on the absorption of salicylic acid from hamster cheek pouch as a model of keratinized oral mucosa (47) 13
Kurosaki, Y., Hisaichi, S.-i., Hong, L.-Z., Nakayama, T. and Kimura, T.
Enhanced permeability of keratinized oral-mucosa to sali-

cylic acid with 1-dodecylazacycloheptan-2-one (Azone). In vitro studies in hamster cheek pouch (49) 47
Kurtzhals, P., see Larsen, C. (41) 121
Kyroudis, A., Markantonis, S.L. and Beckett, A.H.
Relationship between plasma concentration, saliva concentration and urinary excretion rate of lithium in man (43) 145

Labhasetwar, V.D. and Dorle, A.K.
A study on the dielectric constant of salicylic acid and aspirin compacts during aging (47) 261
Lack, L.J., see Thomas, N.W. (44) 261
Lacy, J.E., Parfitt, R.T. and Rowan, M.G.
The effects of column packing material and inorganic cations on the separation of fluorescent *o*-phthalaldehyde derivatives of gentamicin by high-performance liquid chromatography (43) 111
Lafleuril, M.T., see Vincent-Ballereau, F. (50) 87
Laghoueg, N., Paulet, J., Taverdet, J.L. and Vergnaud, J.M.
Oral polymer–drug devices with a core and an erodible shell for constant drug delivery (50) 133
Laine, E., Auramo, P. and Kahela, P.
On the structural behaviour of triglycerides with time (43) 241
Lam, F.C., see Gupta, P.K. (43) 167
Lam, F.C., see Hung, C.T. (44) 117
LaManna, A., see Caramella, C. (44) 177
La Marca, F., see Saettone, M.F. (43) 67
Lampard, J.F., see Wilson, C.G. (50) 155
La Porta, E., see Pinzauti, S. (46) 255
La Porta, E., see Santoni, G. (50) 75
Larsen, C., Kurtzhals, P. and Johansen, M.
Kinetics of regeneration of metronidazole from hemiesters of maleic acid, succinic acid and glutaric acid in aqueous buffer, human plasma and pig liver homogenate (41) 121
Larsen, J.D., Bundgaard, H. and Lee, V.H.L.
Prodrug forms for the sulfonamide group. II. Water-soluble amino acid derivatives of *N*-methylsulfonamides as possible prodrugs (47) 103
Larsen, J.D., see Bundgaard, H. (45) 47
Law, S.L., Lo, W.Y., Pai, S.H. and Teh, G.W.
The electrokinetic behavior of liposomes adsorbed with bovine serum albumin (43) 257
Leahy, D.E., De Meere, A.L.J., Wait, A.R., Taylor, P.J., Tomenson, J.A. and Tomlinson, E.
A general description of water–oil partitioning rates using the rotating diffusion cell (50) 117
Le Brun, P.P.H., Fox, P.L.A., De Vries, M.E. and Boddé, H.E.
In vitro penetration of some β-adrenoreceptor blocking drugs through porcine buccal mucosa (49) 141
Lecomte, J.M., see Gimenez, F. (43) 23
Lee, K.C., Koh, I.B., Kim, W.B. and Lee, Y.J.
Size and morphological analysis of albumin microspheres in the lungs and liver of mice (44) 49
Lee, K.C.
The use of magnetite for estimation of microspheres in mice (47) 265
Lee, M.-H., see Young, C.-S. (45) 59
Lee, V.H.L., see Bundgaard, H. (46) 77
Lee, V.H.L., see Buur, A. (42) 51
Lee, V.H.L., see Larsen, J.D. (47) 103
Lee, Y.J., see Lee, K.C. (44) 49
Le Hoang, M.D., see Gimenez, F. (43) 23
Lerk, C.F., see Frijlink, H.W. (49) 91
Lerk, C.F., see Vromans, H. (46) 183
Leslie, S.T., see Davis, S.S. (49) 183
Leucuta, S.E., Risca, R., Daicoviciu, D. and Porutiu, D.
Albumin microspheres as a drug delivery system for epirubicin: pharmaceutical, pharmacokinetic and biological aspects (41) 213
Leuenberger, H., see Holman, L.E. (46) 35
Leuverman, A., see Moolenaar, F. (45) 161
Li, J., see Liu, J.-C. (44) 197
Liggitt, H.D., see Daugherty, A.L. (45) 197
Liguori, A., see Bramanti, G. (49) 241
Lin, L.-H., see Gu, L. (45) 129
Lindenbaum, S., see Kristjansson, F. (41) 67
Liu, H., Magron, P., Bouzon, J. and Vergnaud, J.M.
Spherical dosage form with a core and shell. Experiments and modelling (45) 217
Liu, J.-C., Sun, Y., Siddiqui, O., Chien, Y.W., Shi, W.-m. and Li, J.
Blood glucose control in diabetic rats by transdermal iontophoretic delivery of insulin (44) 197
Liu, J.-C., see Humcke-Bogner, R. (42) 199
Liu, J.C., see Tan, E.L. (42) 161
Liversidge, G.G., see Matuszewska, B. (46) 111
Llabrés, M., see Fariña, J.B. (45) 123
Lo, W.Y., see Law, S.L. (43) 257
Lockwood, G.F., see Davis, S.S. (49) 183
Look, Z.M., see Faulkner, R.D. (43) 53
Losa, C.M., see Martínez-Pacheco, R. (47) 37
Lostritto, R.T., see Silvestri, S.L. (50) 141
Lowther, N., see Matthews, G.P. (50) 111
Luangtana-anan, M. and Fell, J.T.
Surface energetics of powders before and after compaction (41) 237
Lundgren, P., see Karabit, M.S. (46) 141
Lynch, I.R., see Buxton, P.C. (42) 135

Machida, Y., see Maitani, Y. (49) 23
Magill, A., see Powell, M.F. (44) 225
Magnus, A.D., see Meyer, E. (41) 63
Magnusson, A.-B., see Nicklasson, M. (46) 247
Magron, P., see Liu, H. (45) 217
Maibach, H.I., see Bircher, A.J. (45) 263
Maincent, P., see Alonso, M.J. (42) 27
Maincent, P., see Chevin, J.C. (45) 101
Maire, G., see Gehenot, A. (45) 13
Maitani, Y., Machida, Y. and Nagai, T.
Influence of molecular weight and charge on nasal absorption of dextran and DEAE–dextran in rabbits (49) 23

Majeed, I.A., see Al-Turk, W.A. (41) 227
Malhi, J.S., High, A.-J., Hanlon, G.W., Gard, P.R. and Marriott, C.
Potentiation of oxytetracycline antimicrobial activity in vivo by concurrent administration of bromhexine (43) 77
Malkowska, S., see Davis, S.S. (49) 183
Manil, L., see Kubiak, C. (41) 181
Marino, M., see Dey, M. (49) 121
Markantonis, S.L., see Kyroudis, A. (43) 145
Marriott, C., see Malhi, J.S. (43) 77
Marriott, C., see Martin, G.P. (44) 57
Marriott, C., see Queen, D. (44) 25
Martin, B., Watts, O., Shroot, B. and Jamoulle, J.C.
A new diffusion cell – an automated method for measuring the pharmaceutical availability of topical dosage forms (49) 63
Martin, G.P., Bell, A.E. and Marriott, C.
An in vitro method for assessing particle deposition from metered pressurised aerosols and dry powder inhalers (44) 57
Martin, G.P., see Queen, D. (44) 25
Martin, J.A., see Chevin, J.C. (45) 101
Martín-Villodre, A., see Collado, E.F. (44) 187
Martínez-Pacheco, R., Vila-Jato, J.L., Concheiro, A., Souto, C., Losa, C.M. and Ramos, T.
Effect of compression force on biopharmaceutical characteristics of Eudragit RS-based cephalexin tablets (47) 37
Maruyama, Y., see Sugito, K. (47) 157
Marvola, M., Hannula, A.-M., Westermarck, E., Happonen, I. and Kopra, T.
Disintegration of hard gelatin capsule formulations in the dog stomach — a radiological study (44) 159
Marvola, M., see Heinämäki, J. (42) 105
Marvola, M., see Heinämäki, J. (48) 51
Marwaha, S.B. and Rubinstein, M.H.
Structure–lubricity evaluation of magnesium stearate (43) 249
Masada, T., Higuchi, W.I., Srinivasan, V., Rohr, U., Fox, J., Behl, C. and Pons, S.
Examination of iontophoretic transport of ionic drugs across skin: baseline studies with the four-electrode system (49) 57
Masaki, K., see Akazawa, M. (50) 53
Matar, K.M., see Al-Hassan, M.I. (50) 35
Matsumoto, K., see Nishihata, T. (46) 1
Matthews, G.P., Lowther, N. and Shott, M.J.
Crystallisation of carbamazepine in tablets stored at elevated temperatures (50) 111
Matuszewska, B., Liversidge, G.G., Ryan, F., Dent, J. and Smith, P.L.
In vitro study of intestinal absorption and metabolism of 8-L-arginine vasopressin and its analogues (46) 111
Mayer, J.M., see Röthlisberger, T. (44) 141
Mazzeo, P., see Carlucci, G. (49) 79
Mazzi, G., see Vincieri, F.F. (48) 119
McCabe, J.G., see Daugherty, A.L. (45) 197
McCafferty, D.F., see Woolfson, A.D. (48) 167
McCafferty, D.F., see Woolfson, A.D. (49) 135
McElnay, J.C., Elliott, D.S., Cartwright-Shamoon, J. and D'Arcy, P.F.
Stability of methotrexate and vinblastine in burette administration sets (47) 239
McElnay, J.C., see Benson, H.A.E. (44) 65
McElnay, J.C., see Cartwright-Shamoon, J.M. (42) 41
McGinity, J.W., see Bodmeier, R. (43) 179
McTiernan, R.G., see Sloan, K.B. (44) 87
Meenhorst, P.L., see Underberg, W.J.M. (50) 175
Mendelow, A.Y., Forsyth, A., Baillie, A.J. and Florence, A.T.
In vitro release of nickel sulphate of varying particle size from paraffin bases (49) 29
Mendenhall, D.W., see Zografi, G. (42) 77
Merkle, H.P., see Anders, R. (49) 231
Merville, C., see Vincent-Ballereau, F. (50) 87
Mestres, C., see Reig, F. (44) 269
Meyer, E., Magnus, A.D., Haigh, J.M. and Kanfer, I.
Comparison of the blanching activities of Dermovate, Betnovate and Eumovate creams and ointments (41) 63
Michael Silber, B., see Faulkner, R.D. (43) 53
Michelucci, J., see Dey, M. (49) 121
Middleton, K.R., see Amidon, G.E. (45) 79
Miglani, B.D., see Mukherji, G. (50) 15
Miles, R.J., see Beezer, A.E. (45) 153
Miller, L.L. and Smith, G.A.
Iontophoretic transport of acetate and carboxylate ions through hairless mouse skin. A cation exchange membrane model (49) 15
Miller, T.A. and York, P.
Pharmaceutical tablet lubrication (41) 1
Miller, T.A., see Ashton, P. (41) 189
Mitra, A.K., see Basu, K. (47) 195
Miyagi, T., see Nishihata, T. (46) 1
Miyata, T., see Gilbert, D.L. (47) 79
Miyazaki, K., see Kohri, N. (49) 213
Modena, T., see Pavanetto, F. (48) 255
Møllgaard, B., see Hoelgaard, A. (43) 233
Montheard, J.P., see Chafi, N. (45) 229
Moolenaar, F., Visser, J., Leuverman, A. and Schoonen, B.J.M.
Bioavailability of morphine from suppositories (45) 161
Moore, J.A., see Daugherty, A.L. (45) 197
Mori, H., see Kaneo, Y. (44) 265
Mori, Y., see Sasaki, H. (44) 15
Morimoto, K., see Takeeda, T. (41) 21
Morimoto, Y., see Sato, K. (43) 31
Morisaka, K., see Takeeda, T. (41) 21
Morton, D.J., see Solanki, P. (42) 47
Mosberg, H., see Øie, S. (48) 223
Møss, J., see Bundgaard, H. (45) 47
Mougeolle, J.M., see Chevin, J.C. (45) 101
Moustafa, M.A., see Al-Shora, H.I. (47) 209
Mukherji, G., Murthy, R.S.R. and Miglani, B.D.
Preparation and evaluation of polyglutaraldehyde nanoparticles containing 5-fluorouracil (50) 15
Mulinacci, N., see Vincieri, F.F. (48) 119
Müller, U. and Munz, K.

Distribution of [^{14}C]diazepam associated with two different types of small unilamellar liposomes in mice (47) 111
Mulski, M.J., see Wood, R.W. (50) 61
Munz, K., see Müller, U. (47) 111
Mura, P., see Bramanti, G. (49) 241
Mura, P., see Santoni, G. (50) 75
Murakami, T., Kawakita, H., Kishimoto, M., Higashi, Y., Amagase, H., Hayashi, T., Nojima, N., Fuwa, T. and Yata, N.
Intravenous and subcutaneous pharmacokinetics and rectal bioavailability of human epidermal growth factor in the presence of absorption promoter in rats (46) 9
Murakami, T., Kishimoto, M., Higashi, Y., Amagase, H., Hayashi, T., Fuwa, T. and Yata, N.
Biliary and urinary excretions of immunoreactive human epidermal growth factor after intravenous administration in rats (49) 173
Muranishi, S., see Takada, K. (44) 107
Murphy, T.M., see Gay, C.L. (49) 39
Murray, W.J., see Al-Turk, W.A. (41) 227
Murtha, J.L., see Radebaugh, G.W. (45) 39
Murthy, R.S.R., see Mukherji, G. (50) 15
Muti, H., see Othman, S. (41) 197
Muti, H.Y., see Suleiman, M.S. (50) 71

Nagai, T., see Maitani, Y. (49) 23
Naganuma, H., see Seta, Y. (41) 263
Naggar, V.F., see Eshra, A.G. (44) 9
Naggar, V.F., see Samaha, M.W. (42) 1
Najib, N. and Jalal, I.
Correlation between dissolution and disintegration rate constants for acetaminophen tablets (44) 43
Najib, N.M., El-Hinnawi, M.A. and Suleiman, M.S.
Physicochemical characterization of ibuprofen–polyvinylpyrrolidone dispersions (45) 139
Najib, N.M., see Suleiman, M.S. (50) 103
Najib, N.M., see Suleiman, M.S. (50) 71
Nakagawa, T., see Tashima, T. (42) 61
Nakamoto, Y., see Takeeda, T. (41) 21
Nakamura, J., see Sasaki, H. (44) 15
Nakayama, T., see Kurosaki, Y. (47) 13
Nakayama, T., see Kurosaki, Y. (49) 47
Nannipieri, E., see Carelli, V. (50) 181
Nannipieri, E., see Di Colo, G. (50) 27
Neau, S.H., Flynn, G.L. and Yalkowsky, S.H.
The influence of heat capacity assumptions on the estimation of solubility parameters from solubility data (49) 223
Newton, D.W., see Al-Turk, W.A. (41) 227
Newton, J.M., see Wright, M.P. (45) 237
Nghiem, B.T. and Higuchi, T.
Esterase activity in snake skin (44) 125
Nghiem, B.T., see Akazawa, M. (50) 53
Niazy, E.M., see Al-Shora, H.I. (47) 209
Nicklasson, M., Fyhr, P., Magnusson, A.-B. and Gunnvald, K.
A preformulation study on the in vitro dissolution characteristics of the organophosphorus poisoning antidote HI-6 (46) 247
Nicoletti, C., see Paulesu, L. (46) 199
Nielsen, N.M., see Bundgaard, H. (42) 217
Nielsen, N.M., see Bundgaard, H. (43) 101
Nielsen, N.M., see Bundgaard, H. (44) 151
Nilsson, P., Westerberg, M. and Nyström, C.
Physicochemical aspects of drug release. V. The importance of surface coverage and compaction on drug dissolution from ordered mixtures (45) 111
Nishihata, T., Hirotani, Y., Yamazi, A., Takahashi, K. and Yoshitomi, H.
Preliminary study on sustained-release particles prepared with hydrogenated soya phospholipid and cholesterol (42) 257
Nishihata, T., Kamada, A., Sakai, K., Takahashi, K., Matsumoto, K., Shinozaki, K., Tabata, Y., Keigami, M., Miyagi, T. and Tatsumi, N.
Percutaneous absorption of diclofenac in rats and humans: aqueous gel formulation (46) 1
Nishihata, T., Keigami, M., Kamada, A., Fujimoto, T., Kamide, S. and Tatsumi, N.
Clinical investigation of sodium diclofenac sustained-release suppositories (42) 251
Nishihatal, T., see Takahashi, K. (49) 179
Nishimura, K., see Seta, Y. (41) 245
Nishimura, K., see Seta, Y. (41) 255
Nishimura, K., see Seta, Y. (41) 263
Nixon, J.R. and Wong, K.T.
Evaluation of permeation through polymeric membranes as a model for the release of drugs from gelatin–acacia walled microcapsules (50) 205
Noguchi, M., see Sugito, K. (47) 157
Nojima, N., see Murakami, T. (46) 9
Nook, T., Doelker, E. and Buri, P.
Intestinal absorption kinetics of various model drugs in relation to partition coefficients (43) 119
Nørgaard, T., see Bundgaard, H. (42) 217
Norman, S., see Wilson, C.G. (46) 241
Nuutinen, J., see Vidgren, M. (42) 211
Nyström, C., see Anderberg, E.K. (47) 67
Nyström, C., see Bisrat, M. (47) 223
Nyström, C., see Nilsson, P. (45) 111
Nyström, C., see Sjökvist, E. (47) 51

Ogata, H., see Sugito, K. (47) 157
Oh, Y.-K., see Kim, C.-K. (47) 163
Ohnishi, N., see Toyoshima, K. (46) 211
Øie, S., Trenk, D., Guentert, T.W., Mosberg, H. and Jähnchen, E.
Disposition of vitamin K_1 after intravenous and oral administration to subjects on phenprocoumon therapy (48) 223
Oka, T., see Takada, K. (44) 107
Okada, R., see Seta, Y. (41) 245
Okada, R., see Seta, Y. (41) 255
Okada, R., see Seta, Y. (41) 263
Okano, T., see Gilbert, D.L. (47) 79
Okhamafe, A.O. and Akerele, J.O.

Some aspects of the bioavailability of orally administered ofloxacin in healthy human volunteers (50) 83
Okor, R.S.
Enhanced dissolution rate of aspirin from aspirin–methacrylic acid, methyl methacrylate coacervates in a simulated intestinal fluid (47) 263
Olsen, L., see Bundgaard, H. (45) 47
O'Neill, C.T. and Deasy, P.B.
Development and evaluation using hairless mouse skin of a transdermal timolol product (48) 247
On Woo, S., see Tønnesen, H.H. (43) 215
Orbe, A. and Sundelöf, L.-O.
A new in vitro model for quantitative study of cream permeability (41) 49
Othman, S., Muti, H., Shaheen, O., Awidi, A. and Al-Turk, W.A.
Studies on the adsorption and solubility of nalidixic acid (41) 197
Othman, S., see Al-Turk, W.A. (41) 227
Otsuka, A., see Takeeda, T. (41) 21
Otsuka, T., see Seta, Y. (41) 255
Otsuka, T., see Seta, Y. (41) 263
Owoyale, J.A. and Elmarakby, Z.S.
Effect of sunlight, ultraviolet irradiation and heat on proguanil (50) 219
Ozil, P. and Rochat, M.H.
Experimental design, an efficient tool for studying the stability of parenteral nutrition (42) 11

Paaij, J.D.F., see Beijnen, J.H. (45) 189
Paalman, A.C.A., see Beijnen, J.H. (41) 169
Paalman, A.C.A., see Beijnen, J.H. (45) 189
Paborji, M., Riley, C.M. and Stella, V.J.
A novel use of Intralipid for the parenteral delivery of perilla ketone (NSC-348407), an investigational cytotoxic drug with a high affinity for plastic (42) 243
Padmalatha Devi, K., see Ranga Rao, K.V. (48) 1
Pai, S.H., see Law, S.L. (43) 257
Palin, K.J., see Thomas, N.W. (44) 261
Pandit, N.K., Strykowski, J.M. and Shtohryn, L.
The effect of salts on the distribution and solubility of an acidic drug (50) 7
Papeschi, G., see Pinzauti, S. (46) 255
Parfitt, R.T., see Lacy, J.E. (43) 111
Paronen, P., see Vidgren, M. (42) 211
Parr, G.D., see Davis, S.S. (49) 183
Parr, G.D., see Farraj, N.F. (43) 83
Parr, G.D., see Farraj, N.F. (43) 93
Parr, G.D., see Farraj, N.F. (46) 231
Patel, A.N., see Armstrong, N.A. (48) 173
Patel, H.K., see Attwood, D. (49) 129
Patton, J.S., see Daugherty, A.L. (45) 197
Paulesu, L., Corradeschi, F., Nicoletti, C. and Bocci, V.
Oral administration of human recombinant interferon-α_2 in rats (46) 199
Paulet, J., see Laghoueg, N. (50) 133
Pavanetto, F., Conti, B., Modena, T., Genta, I. and Ponci, R.
Particulate contamination in parenteral type medical devices (48) 255
Peach, J.M., see Wilson, C.G. (46) 241
Pellion, B., see Zuber, M. (47) 31
Pennington, A.K., Ratcliffe, J.H., Wilson, C.G. and Hardy, J.G.
The influence of solution viscosity on nasal spray deposition and clearance (43) 221
Peppas, N.A., see Caramella, C. (44) 177
Peppas, N.A., see Klier, J. (46) 179
Peris-Ribera, J.E., see Collado, E.F. (44) 187
Perrier, D.G., see Gupta, P.K. (43) 167
Perrier, D.G., see Hung, C.T. (44) 117
Peschier, L.J.C., see Verhoeven, J. (45) 65
Pieters, F.A.J.M., see Zuidema, J. (47) 1
Pikal, M.J. and Dellerman, K.M.
Stability testing of pharmaceuticals by high-sensitivity isothermal calorimetry at 25°C: cephalosporins in the solid and aqueous solution states (50) 233
Pinzauti, S., La Porta, E., Vincieri, F.F., Gratteri, P., Papeschi, G. and Bambagiotti-Alberti, M.
Differential pulse polarographic determination of total benzophenantridinium alkaloids in *Sanguinaria* extract-based oral rinses (46) 255
Pinzauti, S., see Santoni, G. (50) 75
Pitha, J., see Irie, T. (43) 41
Pitha, J., see Yoshida, A. (46) 217
Pitt, C.G., Bao, Y.T., Andrady, A.L. and Samuel, P.N.K.
The correlation of polymer–water and octanol–water partition coefficients: estimation of drug solubilities in polymers (45) 1
Plá-Delfina, J.M., see Collado, E.F. (44) 187
Poelman, M.-C., see Glomot, F. (46) 49
Polli, G.P., see Williams, N.A. (44) 205
Ponci, R., see Pavanetto, F. (48) 255
Pons, S., see Masada, T. (49) 57
Porutiu, D., see Leucuta, S.E. (41) 213
Postaire, E., see Gimenez, F. (43) 23
Powell, M.F., Magill, A., Becker, A.R., Kenley, R.A., Chen, S. and Visor, G.C.
Non-steroidal anti-psoriatic prodrugs. II. Citric acid stabilization of lonapalene in various alcohol media and an ointment formulation (44) 225
Pradeau, D., see Gimenez, F. (43) 23
Prapaitrakul, W., see Sprockel, O.L. (48) 217
Prasad, K.P.P., see Wan, L.S.C. (41) 159
Prasad, K.P.P., see Wan, L.S.C. (50) 147
Prognon, P., see Gimenez, F. (43) 23
Provost, C. and Kinget, R.
Transparent oil–water gels: a study of some physicochemical and biopharmaceutical characteristics. Part I. Formation of transparent oil–water gels in the 4-component-system of Eumulgin B3, Cetiol HE, isopropyl palmitate, and water (44) 75
Pugh, K., see Wilson, C.G. (46) 241
Pujol, M., see Girona, V. (41) 241
Puozzo, C., see Galleyrand, J.C. (42) 225

Quaglia, M.G., see Carlucci, G. (49) 79
Queen, D., Martin, G.P., Marriott, C. and Fairbrother, J.E.
Assessment of the potential of a new hydrocolloid dermatological patch (Actiderm) in the treatment of steroid-responsive dermatoses (44) 25
Quigley, J.M., see Irwin, V.P. (43) 187

Radebaugh, G.W., Murtha, J.L., Julian, T.N. and Bondi, J.N.
Methods for evaluating the puncture and shear properties of pharmaceutical polymeric films (45) 39
Raikov, Z., see Simeonova, M. (43) 267
Raikova, E., see Simeonova, M. (43) 267
Rajagopalan, N., see Dicken, C.M. (46) 223
Ramos, T., see Martínez-Pacheco, R. (47) 37
Ranga Rao, K.V. and Padmalatha Devi, K.
Swelling controlled-release systems: recent developments and applications (48) 1
Ranga Rao, K.V., see Baveja, S.K. (47) 133
Rao, K.P., see Vasantha, R. (47) 95
Rao, K.V.R., see Baveja, S.K. (41) 55
Rao, R.C., see Gehenot, A. (45) 13
Ratcliffe, J.H., see Pennington, A.K. (43) 221
Ravin, L.J., see Dicken, C.M. (46) 223
Rees, J.A., see Wilson, C.G. (50) 155
Reig, F., Busquets, M.A., García Antón, J.M., Valencia, G. and Alsina, M.A.
Interaction of analgesics with lecithin and ganglioside monolayers (44) 257
Reig, F., Mestres, C., García Antón, J.M., Valencia, G. and Alsina, M.A.
Penetration of morphine and naloxone in phosphatidylserine monolayers (44) 269
Remon, J.P., see Bottenberg, P. (49) 147
Remon, J.P., see Herman, J. (42) 15
Remon, J.P., see Van Aerde, P. (45) 145
Renna, G., see Altomare, C. (48) 91
Repin, V.S., see Burkhanov, S.A. (46) 31
Repta, A.J., see Garren, K.W. (48) 189
Ridout, G., see Hadgraft, J. (42) 97
Riley, C.M., see Kennedy, P.E. (48) 179
Riley, C.M., see Paborji, M. (42) 243
Riley, C.M., see Sendo, F. (45) 207
Rimer, A., see Friedman, M. (44) 243
Risca, R., see Leucuta, S.E. (41) 213
Ritschel, W.A., see Banerjee, P.S. (49) 189
Ritschel, W.A., see Banerjee, P.S. (49) 199
Roberts, C.J.C., see Ali, H.M. (42) 155
Roberts, R.J., see Bateman, S.D. (49) 209
Robertson, C.S., see Hardy, J.G. (48) 79
Robertson, S.S.D., see Fassihi, A.R. (50) 79
Robinson, J.R., see Gupta, P.K. (43) 45
Rochat, M.H., see Ozil, P. (42) 11
Rodriquez, L., see Dal Pozzo, A. (50) 97
Roe, J.M., see Buxton, P.C. (42) 135
Rogers, J.A., see Betageri, G.V. (46) 95
Rogers, J.A., see Habib, M.J. (44) 235
Rohr, U., see Masada, T. (49) 57
Rolland, A.
Pharmacokinetics and tissue distribution of doxorubicin-loaded polymethacrylic nanoparticles in rabbits (42) 145
Roskos, K.V., see Bircher, A.J. (45) 263
Rossi, T.M., see Dicken, C.M. (46) 223
Röthlisberger, T., Testa, B., Carrupt, P.-A., Mayer, J.M. and Etter, J.-C.
The influence of hydration and structure-promoting effects on the viscosity of binary solvent mixtures (44) 141
Rowan, M.G., see Lacy, J.E. (43) 111
Rowe, R.C.
Adhesion of film coatings to tablet surfaces — a theoretical approach based on solubility parameters (41) 219
Rowe, R.C.
Interaction of lubricants with microcrystalline cellulose and anhydrous lactose — a solubility parameter approach (41) 223
Rowe, R.C.
Interactions in the ternary powder system microcrystalline cellulose, magnesium stearate and colloidal silica — a solubility parameter approach (45) 259
Rowe, R.C.
Tablet–tablet contact and mutual rubbing within a coating drum — an important factor governing the properties and appearance of tablet film coatings (43) 155
Rowe, R.C., see Bateman, S.D. (49) 209
Rowe, R.C., see Gibson, S.H.M. (45) 245
Rowe, R.C., see Gibson, S.H.M. (47) 205
Rowe, R.C., see Gibson, S.H.M. (48) 113
Rowe, R.C., see Gibson, S.H.M. (48) 63
Rowe, R.C., see Gibson, S.H.M. (50) 163
Rowlands, C.C., see Gay, C.L. (49) 39
Rubino, J.T.
Electrostatic and non-electrostatic free energy contributions to acid dissociation constants in cosolvent–water mixtures (42) 181
Rubinstein, M.H., see Bateman, S.D. (49) 209
Rubinstein, M.H., see Marwaha, S.B. (43) 249
Rue, P.J., see Cutt, T. (49) 157
Ruiz, J.M., Tissier, B. and Benoit, J.P.
Microencapsulation of peptide: a study of the phase separation of poly(D,L-lactic acid–co-glycolic acid) copolymers 50/50 by silicone oil (49) 69
Ryan, F., see Matuszewska, B. (46) 111

Saatov, T.S., see Burkhanov, S.A. (46) 31
Saettone, M.F., Giannaccini, B., Delmonte, G., Campigli, V., Tota, G. and La Marca, F.
Solubilization of tropicamide by poloxamers: physicochemical data and activity data in rabbits and humans (43) 67
Safwat, S.M., see Attia, M.A. (47) 21
Sakai, K., see Nishihata, T. (46) 1
Sakiya, Y., Ishida, S. and Ichikawa, T.
Absorption of benzene derivatives through the body surface and gill membranes of goldfish: substituent and intramolecular interaction effects (47) 185

Saleh, S.I., Boymond, C. and Stamm, A.
Preparation of direct compressible effervescent components: spray-dried sodium bicarbonate (45) 19
Saleh, S.I., Wehrlé, P. and Stamm, A.
Improvement of lubrication capacity of sodium benzoate; effects of milling and spray drying (48) 149
Samaha, M.W. and Naggar, V.F.
Micellar properties of non-ionic surfactants in relation to their solubility parameters (42) 1
Samuel, P.N.K., see Pitt, C.G. (45) 1
Santoni, G., Mura, P., Pinzauti, S., Gratteri, P. and La Porta, E.
Simultaneous determination of naphazoline and diphenhydramine hydrochlorides in nasal drops by second-order derivative UV spectroscopy (50) 75
Santoni, G., see Bramanti, G. (49) 241
Sasaki, H., Kojima, M., Mori, Y., Nakamura, J. and Shibasaki, J.
Enhancing effect of pyrrolidone derivatives on transdermal drug delivery. I. (44) 15
Sasaki, Y., see Sugito, K. (47) 157
Sato, K., Sugibayashi, K. and Morimoto, Y.
Effect and mode of action of aliphatic esters on the in vitro skin permeation of nicorandil (43) 31
Satoh, N., see Tashima, T. (42) 61
Schoonen, A.J.M. and De Vries-Nijboer, G.W.
Dissolution of acetaminophen in a single pore and its relevance for dissolution of tablets (49) 261
Schoonen, A.J.M., Grijseels, H. and De Vries-Nijboer, G.W.
Dissolution of a particle system at the fluid/fluid interface (47) 249
Schoonen, A.J.M., see Frijlink, H.W. (49) 91
Schoonen, B.J.M., see Moolenaar, F. (45) 161
Schwartz, J.B., see Herman, J. (42) 15
Schwendener, R.A., Wüthrich, R., Duewell, S., Westera, G. and Von Schulthess, G.K.
Small unilamellar liposomes as magnetic resonance contrast agents loaded with paramagnetic Mn-, Gd- and Fe-DTPA–stearate complexes (49) 249
Scieszka, J.F., Vidmar, T.J., Haynes, L.C. and Cho, M.J.
Biochemical stability in serum of a lipid-soluble probe molecule entrapped in an o/w emulsion as a carrier for passive drug targeting (45) 165
Sehgal, P.K., see Vasantha, R. (47) 95
Selkämaa, R. and Tammilehto, S.
Photochemical decomposition of midazolam. I. Isolation and identification of products (49) 83
Sempik, A.K., see Wilson, C.G. (50) 155
Sendo, F., Riley, C.M. and Stella, V.J.
Kinetics of hydrolysis of fetindomide (NSC-373965), bis-*N*,*N*′-phenylalanyloxymethyl prodrug of mitindomide (NSC-284356); an unexpected catalytic effect of generated formaldehyde (45) 207
Serafini, M.F., see Di Colo, G. (50) 27
Seta, Y., Higuchi, F., Kawahara, Y., Nishimura, K. and Okada, R.
Design and preparation of captopril sustained-release dosage forms and their biopharmaceutical properties (41) 245
Seta, Y., Higuchi, F., Otsuka, T., Kawahara, Y., Nishimura, K., Okada, R. and Koike, H.
Preparation and pharmacological evaluation of captopril sustained-release dosage forms using oily semisolid matrix (41) 255
Seta, Y., Otsuka, T., Tokiwa, H., Naganuma, H., Kawahara, Y., Nishimura, K. and Okada, R.
Design of captopril sustained-release preparation with oily semisolid matrix intended for use in human subjects (41) 263
Shah, R., see Buckton, G. (42) 35
Shaheen, O., see Othman, S. (41) 197
Sherertz, E.F., see Sloan, K.B. (44) 87
Sheth, N.V., see Freeman, D.J. (48) 141
Shi, W.-m., see Liu, J.-C. (44) 197
Shibasaki, J., see Sasaki, H. (44) 15
Shim, C.-K., see Young, C.-S. (45) 59
Shinogle, J.A., see Audus, K.L. (45) 249
Shinozaki, K., see Nishihata, T. (46) 1
Shively, M.L. and Simonelli, A.P.
The investigation of dual-wavelength spectroscopy for the analysis of dissolved drug in microcapsule suspensions (50) 39
Shott, M.J., see Matthews, G.P. (50) 111
Shroot, B., see Martin, B. (49) 63
Shtohryn, L., see Pandit, N.K. (50) 7
Sia, L.L., see Faulkner, R.D. (43) 53
Siddiqui, O., see Liu, J.-C. (44) 197
Silvestri, S.L. and Lostritto, R.T.
Theoretical evaluation of dispersed droplet radii in submicron oil-in-water emulsions (50) 141
Simeonova, M., Ivanova, T., Raikova, E., Georgieva, M. and Raikov, Z.
Tissue distribution of polybutylcyanoacrylate nanoparticles carrying spin-labelled nitrosourea (43) 267
Simonelli, A.P., see Shively, M.L. (50) 39
Singh, A., see Baveja, S.K. (41) 55
Singh, S. and Gupta, R.L.
A critical study on degradation of azathioprine in aqueous solutions (42) 263
Singh, S. and Gupta, R.L.
Dielectric constant effects on degradation of azathioprine in solution (46) 267
Siver, K.G. and Sloan, K.B.
The effect of structure of Mannich base prodrugs of 6-mercaptopurine on their ability to deliver 6-mercaptopurine through hairless mouse skin (48) 195
Sjöholm, I., see Artursson, P. (46) 149
Sjökvist, E. and Nyström, C.
Physicochemical aspects of drug release. VI. Drug dissolution rate from solid particulate dispersions and the importance of carrier and drug particle properties (47) 51
Sjökvist, R., see Wirbrant, A. (41) 131
Sloan, K.B., Sherertz, E.F. and McTiernan, R.G.
The effect of structure of Mannich base prodrugs on their

ability to deliver theophylline and 5-fluorouracil through hairless mouse skin (44) 87
Sloan, K.B., see Siver, K.G. (48) 195
Slop, D., see Bottenberg, P. (49) 147
Smeets, B.P.G.M., see Vendrig, D.E.M.M. (43) 131
Smith, B.V., see Beezer, A.E. (45) 153
Smith, D., see Dey, M. (49) 121
Smith, G.A., see Miller, L.L. (49) 15
Smith, P.L., see Matuszewska, B. (46) 111
Smyth, W.F. and Yarnitzky, C.
An analytical study of drug adsorption at mercury electrodes using square wave polarography (42) 235
Solanki, P. and Morton, D.J.
Comparative bioavailability of adrenaline-containing ophthalmic solutions: use of an in vitro method of evaluation (42) 47
Souter, A., see Hung, C.T. (44) 117
Souto, C., see Martínez-Pacheco, R. (47) 37
Spring, M.S., see Cutt, T. (49) 157
Sprockel, O.L. and Prapaitrakul, W.
Effect of eluant properties on drug release from cellulose acetate butyrate-coated drug resin complexes (48) 217
Spruance, S.L., see Freeman, D.J. (48) 141
Srinivasan, V., see Masada, T. (49) 57
Stabholz, A., see Friedman, M. (44) 243
Stamm, A., see Saleh, S.I. (45) 19
Stamm, A., see Saleh, S.I. (48) 149
Staniforth, J.N., Baichwal, A.R., Hart, J.P. and Heng, P.W.S.
Effect of addition of water on the rheological and mechanical properties of microcrystalline celluloses (41) 231
Steinijans, V.W., see Jonkman, J.H.G. (43) 139
Stella, V.J., Umprayn, K. and Waugh, W.N.
Development of parenteral formulations of experimental cytotoxic agents. I. Rhizoxin (NSC-332598) (43) 191
Stella, V.J., see Anderson, B.D. (45) 27
Stella, V.J., see Paborji, M. (42) 243
Stella, V.J., see Sendo, F. (45) 207
Stella, W.J., see Kennedy, P.E. (48) 179
Sternson, L.A., see Dicken, C.M. (46) 223
Sternson, L.A., see Kristjansson, F. (41) 67
Stevens, H.N.E., see Farraj, N.F. (43) 83
Stevens, H.N.E., see Farraj, N.F. (43) 93
Stevens, H.N.E., see Farraj, N.F. (46) 231
Strickley, R.G., see Gu, L. (45) 129
Struijke, A., see Grit, M. (50) 1
Strykowski, J.M., see Pandit, N.K. (50) 7
Sugden, J.K., see Barnes, A.R. (44) 31
Sugibayashi, K., see Sato, K. (43) 31
Sugito, K., Ogata, H., Noguchi, M., Kogure, T., Takano, M., Maruyama, Y. and Sasaki, Y.
The spreading of radiolabelled fatty suppository bases in the human rectum (47) 157
Suleiman, M.S. and Najib, N.M.
Isolation and physicochemical characterization of solid forms of glibenclamide (50) 103
Suleiman, M.S., Abdulhameed, M.E., Najib, N.M. and Muti, H.Y.
Effect of ultraviolet radiation on the stability of diltiazem (50) 71
Suleiman, M.S., see Najib, N.M. (45) 139
Sun, Y., see Liu, J.-C. (44) 197
Sundelöf, L.-O., see Orbe, A. (41) 49
Szeptycki, P., see Bhatt, P.P. (50) 197
Szpunar, G.J., see Chiang, C.-M. (49) 109
Szpunar, G.J., see Chiang, C.-M. (50) 21

Tabata, Y., see Nishihata, T. (46) 1
Tajana, A., see Dal Pozzo, A. (50) 97
Takada, K., Furuya, Y., Yoshikawa, H., Muranishi, S., Yasumura, T. and Oka, T.
Increased systemic availability of cyclosporin A by formulation design: pharmacokinetic consideration on its transport (44) 107
Takagi, H., see Aramaki, Y. (46) 103
Takahashi, K., Katagi, T., Tamagawa, S. and Nishihatal, T.
Effect of pH on the dissolution of drug particle dispersed in solid matrix of hydrogenated soya phospholipid (49) 179
Takahashi, K., see Nishihata, T. (42) 257
Takahashi, K., see Nishihata, T. (46) 1
Takahashi, M., see Kikuchi, S. (42) 193
Takano, M., see Sugito, K. (47) 157
Takeeda, T., Hatakeyama, Y., Kitaura, I., Iwamoto, Y., Morimoto, K., Yasuda, M., Nakamoto, Y., Morisaka, K., Danjo, K. and Otsuka, A.
Lymphatic and plasma transport of 1-(2-tetrahydrofuryl)-5-fluorouracil by polyacrylic acid aqueous gel after rectal administration and its antitumor effect on Yoshida sarcoma implanted in rats (41) 21
Takla, P.G. and Dakas, C.J.
A study of interactions of chloroquine with ethanol, sugars and glycerol using ultraviolet spectrophotometry (43) 225
Tamagawa, S., see Takahashi, K. (49) 179
Tammilehto, S., see Selkämaa, R. (49) 83
Tan, E.L., Liu, J.C. and Chien, Y.W.
Controlled drug release from silicone coated tablets: preliminary evaluation of coating techniques and characterization of membrane permeation kinetics (42) 161
Tanaka, H., see Tashima, T. (42) 61
Tanaka, T., see Kaneo, Y. (44) 265
Tashima, T., Kawakami, U., Harada, M., Satoh, N., Nakagawa, T. and Tanaka, H.
Relationship between precipitation in aqueous solution of glutaraldehyde for chemosterilization and impurities detected by gas chromatography (42) 61
Tatsumi, N., see Nishihata, T. (42) 251
Tatsumi, N., see Nishihata, T. (46) 1
Taverdet, J.L., see Laghoueg, N. (50) 133
Tawashi, R., see Kassem, M. (47) 179
Tawashi, R., see Thibert, R. (47) 171
Taylor, P.J., see Leahy, D.E. (50) 117
Taylor, S.J., see Washington, C. (46) 25
Teh, G.W., see Law, S.L. (43) 257
Tekle, A., see Al-Hassan, M.I. (50) 35

Testa, B., see Röthlisberger, T. (44) 141
Thibert, R., Akbarieh, M. and Tawashi, R.
Morphic features variation of solid particles after size reduction: sonification compared to jetmill grinding (47) 171
Thijssen, H.H.W., see Drieman, J.C. (46) 203
Thomas, N.W., Lack, L.J., Woodhouse, B.A., Palin, K.J. and Gould, P.L.
Formulation of Fenbufen suppositories. III. Histology of the rectal mucosa of rats following repeat dosing of Fenbufen in Witepsol H12 and PEG vehicles (44) 261
Tiedt, L.R., see Du Plessis, J. (46) 177
Timmins, P., see Hussain, M.S.H. (42) 89
Timoney, R.F., see Irwin, V.P. (43) 187
Tissier, B., see Ruiz, J.M. (49) 69
Tojo, K.
Concentration profile in plasma after transdermal drug delivery (43) 201
Tokiwa, H., see Seta, Y. (41) 263
Tomenson, J.A., see Leahy, D.E. (50) 117
Tomlinson, E., see Leahy, D.E. (50) 117
Tønnesen, H.H., Grislingaas, A.-L., On Woo, S. and Karlsen, J.
Photochemical stability of antimalarials. I. Hydroxychloroquine (43) 215
Tønnesen, H.H.
Studies on curcumin and curcuminoids. XIII. Catalytic effect of curcumin on the peroxidation of linoleic acid by 15-lipoxygenase (50) 67
Tønnesen, H.H.
Studies on curcumin and curcuminoids. XIV. Effect of curcumin on hyaluronic acid degradation in vitro (50) 91
Torchilin, V.P., see Burkhanov, S.A. (46) 31
Torresi, M.C., see Bramanti, G. (49) 241
Tota, G., see Saettone, M.F. (43) 67
Touitou, E. and Fabin, B.
Altered skin permeation of a highly lipophilic molecule: tetrahydrocannabinol (43) 17
Touitou, E., Fabin, B., Dany, S. and Almog, S.
Transdermal delivery of tetrahydrocannabinol (43) 9
Touitou, E.
Skin permeation enhancement by *n*-decyl methyl sulfoxide: effect of solvent systems and insights on mechanism of action (43) 1
Toyoshima, K., Yasumura, M., Ohnishi, N. and Ueda, Y.
Quantitative evaluation of tablet sticking by surface roughness measurement (46) 211
Trenk, D., see Øie, S. (48) 223
Tröster, S.D. and Kreuter, J.
Contact angles of surfactants with a potential to alter the body distribution of colloidal drug carriers on poly(methyl methacrylate) surfaces (45) 91
Truman, C.A., see Ali, H.M. (42) 155
Tsuchiya, S., see Aramaki, Y. (46) 103
Tsuchiya, S., see Hara, T. (42) 69
Tsuchiya, S., see Kikuchi, S. (42) 193
Tsunenari, Y., see Irie, T. (43) 41
Tsuzuki, N., Wong, O. and Higuchi, T.
Effect of primary alcohols on percutaneous absorption (46) 19
Tsuzuki, N., see Akazawa, M. (50) 53
Tu, Y.-H., see Chen, G. (46) 89

Uchiyama, M., see Yoshioka, S. (46) 121
Ueda, Y., see Toyoshima, K. (46) 211
Uekama, K., see Hoshino, T. (50) 45
Uekama, K., see Irie, T. (43) 41
Uekama, K., see Yamamoto, M. (49) 163
Uekama, K., see Yoshida, A. (46) 217
Umprayn, K., see Stella, V.J. (43) 191
Underberg-Chitoe, U.K., see Underberg, W.J.M. (50) 175
Underberg, W.J.M., Underberg-Chitoe, U.K., Bekers, O., Meenhorst, P.L. and Beijnen, J.H.
A rapid, simple and accurate method for the bioanalysis of zidovudine (50) 175
Underberg, W.J.M., see Beijnen, J.H. (41) 169
Underberg, W.J.M., see Beijnen, J.H. (45) 189
Underberg, W.J.M., see Van der Houwen, O.A.G.J. (45) 181
Upadrashta, S.M. and Wurster, D.E.
Equilibrium binding studies of the interaction between anthralin and bovine serum albumin (49) 103

Valencia, G., see Reig, F. (44) 257
Valencia, G., see Reig, F. (44) 269
Van Aerde, P. and Remon, J.P.
In vitro evaluation of modified starches as matrices for sustained release dosage forms (45) 145
Van der Houwen, O.A.G.J., Beijnen, J.H., Bult, A. and Underberg, W.J.M.
A general approach to the interpretation of pH degradation profiles (45) 181
Van der Houwen, O.A.G.J., see Beijnen, J.H. (41) 169
Van der Houwen, O.A.G.J., see Beijnen, J.H. (45) 189
Van der Houwen, O.A.G.J., see Vendrig, D.E.M.M. (43) 131
Van der Houwen, O.A.G.J., see Vendrig, D.E.M.M. (50) 189
Van der Merwe, E., Ackermann, C. and Van Wyk, C.J.
Factors affecting the permeability of urea and water through nude mouse skin in vitro. I. Temperature and time of hydration (44) 71
Van der Merwe, E., Ackermann, C. and Van Wyk, C.J.
Factors affecting the permeability of water through nude mouse skin in vitro. II. Antibiotics in diffusion media (46) 169
Van Wyk, C.J., see Du Plessis, J. (46) 177
Van Wyk, C.J., see Van der Merwe, E. (44) 71
Van Wyk, C.J., see Van der Merwe, E. (46) 169
Vasantha, R., Sehgal, P.K. and Rao, K.P.
Collagen ophthalmic inserts for pilocarpine drug delivery system (47) 95
Vendrig, D.E.M.M., Beijnen, J.H., Van der Houwen, O.A.G.J. and Holthuis, J.J.M.
Degradation kinetics of vincristine sulphate and vindesine sulphate in aqueous solutions (50) 189
Vendrig, D.E.M.M., Smeets, B.P.G.M., Beijnen, J.H., Van der Houwen, O.A.G.J. and Holthuis, J.J.M.

Degradation kinetics of vinblastine sulphate in aqueous solutions (43) 131
Vergnaud, J.M., see Chafi, N. (45) 229
Vergnaud, J.M., see Laghoueg, N. (50) 133
Vergnaud, J.M., see Liu, H. (45) 217
Verhoeven, J., Peschier, L.J.C., Danhof, M. and Junginger, H.E.
A controlled-release matrix tablet of furosemide: design, in vitro evaluation, pharmacological and pharmacodynamic evaluation (45) 65
Vervoort-Peters, H.T.M., see Drieman, J.C. (46) 203
Vetuschi, C., see Carlucci, G. (49) 79
Vidgren, M., Kärkkäinen, A., Karjalainen, P., Paronen, P. and Nuutinen, J.
Effect of powder inhaler design on drug deposition in the respiratory tract (42) 211
Vidmar, T.J., see Scieszka, J.F. (45) 165
Vila-Jato, J.L., see Alonso, M.J. (42) 27
Vila-Jato, J.L., see Martínez-Pacheco, R. (47) 37
Vincent-Ballereau, F., Merville, C. and Lafleuril, M.T.
Sodium hypochlorite as a disinfectant for injection materials in third world rural dispensaries (50) 87
Vincieri, F.F., Mulinacci, N., Mazzi, G., Coran, S.A. and Bambagiotti-Alberti, M.
Stabilization of tinctures with cyclodextrins: a tincture from the fruits of *Oenanthe aquatica* L. (48) 119
Vincieri, F.F., see Pinzauti, S. (46) 255
Visavarungroj, N., see Herman, J. (42) 15
Visor, G.C., see Gu, L. (45) 129
Visor, G.C., see Powell, M.F. (44) 225
Visser, J., see Moolenaar, F. (45) 161
Vitale, D., see Di Colo, G. (50) 27
Von Schulthess, G.K., see Schwendener, R.A. (49) 249
Vromans, H. and Lerk, C.F.
Densification properties and compactibility of mixtures of pharmaceutical excipients with and without magnesium stearate (46) 183

Wait, A.R., see Leahy, D.E. (50) 117
Walters, K.A., see Ashton, P. (41) 189
Wan, L.S.C. and Prasad, K.P.P.
Effect of microcrystalline cellulose and cross-linked sodium carboxymethylcellulose on the properties of tablets with methylcellulose as a binder (41) 159
Wan, L.S.C. and Prasad, K.P.P.
Uptake of water by excipients in tablets (50) 147
Wang, D.-P., see Chen, G. (46) 89
Warner, R., see Dey, M. (49) 121
Washington, C. and Briggs, C.J.
Reduction of absorption of drugs into TPN plastic containers by phospholipids and fat emulsions (48) 133
Washington, C. and Davis, S.S.
The production of parenteral feeding emulsions by Microfluidizer (44) 169
Washington, C., Taylor, S.J. and Davis, S.S.
The structure of colloidal formulations of amphotericin B (46) 25
Washington, C., see Beastall, J.C. (43) 207
Washington, N., see Wilson, C.G. (46) 241
Washington, N., see Wilson, C.G. (50) 155
Watari, N., see Funaki, T. (43) 59
Watts, O., see Martin, B. (49) 63
Waugh, W.A., see Anderson, B.D. (45) 27
Waugh, W.N., see Stella, V.J. (43) 191
Wehrlé, P., see Saleh, S.I. (48) 149
Weierstall, R., see Dey, M. (49) 121
Weiner, N.D., see Chiang, C.-M. (49) 109
Weiner, N.D., see Chiang, C.-M. (50) 21
Weiner, N.D., see Williams, N.A. (50) 261
Weiss, A.I., see Faulkner, R.D. (43) 53
Westera, G., see Schwendener, R.A. (49) 249
Westerberg, M., see Nilsson, P. (45) 111
Westermarck, E., see Heinämäki, J. (42) 105
Westermarck, E., see Heinämäki, J. (48) 51
Westermarck, E., see Marvola, M. (44) 159
White, E.F.T., see Gibson, S.H.M. (45) 245
White, E.F.T., see Gibson, S.H.M. (47) 205
White, E.F.T., see Gibson, S.H.M. (48) 113
White, E.F.T., see Gibson, S.H.M. (48) 63
White, E.F.T., see Gibson, S.H.M. (50) 163
Wiechers, J.W., Drenth, B.F.H., Jonkman, J.H.G. and De Zeeuw, R.A.
Percutaneous absorption, metabolism, and elimination of the penetration enhancer Azone in humans after prolonged application under occlusion (47) 43
Williams, N.A. and Polli, G.P.
Differential scanning calorimetric studies on frozen cephalosporin solutions (44) 205
Williams, N.A. and Weiner, N.D.
Interactions of small polypeptides with dimyristoylphosphatidylcholine monolayers: effect of size and hydrophobicity (50) 261
Willmott, N. and Harrison, P.J.
Characterisation of freeze-dried albumin microspheres containing the anti-cancer drug adriamycin (43) 161
Wilson, C.G., Washington, N., Greaves, J.L., Kamali, F., Rees, J.A., Sempik, A.K. and Lampard, J.F.
Bimodal release of ibuprofen in a sustained-release formulation: a scintigraphic and pharmacokinetic open study in healthy volunteers under different conditions of food intake (50) 155
Wilson, C.G., Washington, N., Norman, S., Greaves, J.L., Peach, J.M. and Pugh, K.
A gamma scintigraphic study to compare oesophageal clearance of "Expidet" formulations, tablets and capsules in supine volunteers (46) 241
Wilson, C.G., see Pennington, A.K. (43) 221
Wirbrant, A. and Sjökvist, R.
Regulatory aspects of permeation through ordinary and modified nylon films (41) 131
Wong, K.T., see Nixon, J.R. (50) 205
Wong, O., see Tsuzuki, N. (46) 19

Wood, R.W. and Mulski, M.J.
Methodology for the determination of water vapor transport across plastic films (50) 61
Woodhouse, B.A., see Thomas, N.W. (44) 261
Woodley, J.F., see Bridges, J.F. (44) 213
Woolfson, A.D., Gorman, S.P., McCafferty, D.F. and Jones, D.S.
Assay procedures for Taurolin solutions using pre-column derivatisation and high-performance liquid chromatography with fluorescence detection (49) 135
Woolfson, A.D., McCafferty, D.F., Gorman, S.P. and Jones, D.S.
Polarographic analysis of taurolidine, a non-antibiotic antimicrobial agent (48) 167
Wright, M.P. and Newton, J.M.
Stability of methotrexate injection in prefilled, plastic disposable syringes (45) 237
Wurster, D.E., see Upadrashta, S.M. (49) 103
Wüthrich, R., see Schwendener, R.A. (49) 249
Wygant, M.B., see Anderson, B.D. (45) 27

Xiang, T.-X., see Anderson, B.D. (45) 27

Yalkowsky, S.H., see Neau, S.H. (49) 223
Yamamoto, M., Yoshida, A., Hirayama, F. and Uekama, K.
Some physicochemical properties of branched β-cyclodextrins and their inclusion characteristics (49) 163
Yamasaki, M., see Hoshino, T. (50) 45
Yamazi, A., see Nishihata, T. (42) 257
Yarnitzky, C., see Smyth, W.F. (42) 235
Yasuda, M., see Takeeda, T. (41) 21
Yasumura, M., see Toyoshima, K. (46) 211
Yasumura, T., see Takada, K. (44) 107
Yata, N., see Murakami, T. (46) 9
Yata, N., see Murakami, T. (49) 173
York, P., see Doherty, C. (47) 141
York, P., see Doherty, C. (50) 223
York, P., see Hussain, M.S.H. (42) 89
York, P., see Miller, T.A. (41) 1
Yoshida, A., Arima, H., Uekama, K. and Pitha, J.
Pharmaceutical evaluation of hydroxyalkyl ethers of β-cyclodextrins (46) 217
Yoshida, A., see Yamamoto, M. (49) 163
Yoshikawa, H., see Takada, K. (44) 107
Yoshioka, S., Aso, Y. and Uchiyama, M.
Statistical evaluation of non-isothermal prediction of drug stability. II. Experimental design for practical drug products (46) 121
Yoshitomi, H., see Nishihata, T. (42) 257
Young, C.-S., Shim, C.-K., Lee, M.-H. and Kim, S.-K.
Effect of sodium salicylate on in vitro percutaneous penetration of isopropamide iodide through mouse skin (45) 59
Yska, J.P., see Jonkman, J.H.G. (43) 139

Zografi, G., Grandolfi, G.P., Kontny, M.J. and Mendenhall, D.W.
Prediction of moisture transfer in mixtures of solids: transfer via the vapor phase (42) 77
Zuber, M., Pellion, B., Arnaud, P. and Chaumeil, J.C.
Kinetics of theophylline release from suppositories in vitro: influence of physicochemical parameters (47) 31
Zuidema, J., Pieters, F.A.J.M. and Duchateau, G.S.M.J.E.
Release and absorption rate aspects of intramuscularly injected pharmaceuticals (47) 1

International Journal of Pharmaceutics, 41 (1991) 21–33
© 1991 Elsevier Science Publishers B.V. 0378-5173/91/$03.50

Subject Index

Absorption, (43) 93; (47) 13; (48) 133
Absorption enhancer, (45) 197
Absorption kinetics, (43) 119
Absorption–partition correlation, (44) 187
Absorption promoter, (46) 9
Absorption rate, (47) 1
Absorption rate constant, (43) 59
Accelerated stability testing, (50) 233
Accelerated testing, (45) 79
Accessible surface area, (41) 55
Acetaminophen, (41) 29; (42) 123; (44) 265; (47) 249; (50) 197
Acetaminophen (paracetamol), (44) 43
Acetaminophen (paracetamol) crystals, (49) 261
Acetone, (41) 91
p-Acetoxyacetanilide, (41) 29; (42) 123
Acetylsalicylic acid, (44) 151; (44) 235
Acid-catalyzed hydrolysis, (49) 163
Acidity constant, (45) 157
Acrylic resin, (47) 37
Activation energy, (46) 141
Active transport, (43) 145
N-Acyl derivatives, (47) 103
N-(Acyloxyalkyl)amide derivative, (44) 151
N-Acyloxyalkyl derivative, (45) 47; (46) 159
O-n-Acyl propranolol, (46) 57; (48) 159
Additive–polymer interaction, (48) 113
Adherence to the mucosa, (44) 159
Adhesion, (41) 219; (46) 241
Adhesive polymer, (49) 231
Administrations set, (48) 255
Adrenaline, (42) 47
β-Adrenoreceptor blocking drug, (49) 141
Adriamycin, (43) 161
Adriamycin release, (43) 167
Adsorbed 5-fluorouracil, (50) 15
Adsorption, (41) 197; (43) 257; (44) 1; (47) 121; (48) 125; (48) 133
Adsorption kinetics, (44) 257; (44) 269
Adsorptive endocytosis, (42) 69
Aerosol, (42) 267; (44) 57
Aerosolization of suspensions, (41) 147
Aerosol particle size, (41) 147
Ageing of triglycerides, (43) 241
Aggregate size distribution, (41) 147
Aggregation, (42) 267
AIDS, (45) 27
Albino rat, (50) 15
Albumin, (41) 213; (48) 133
Albumin microsphere, (44) 49; (46) 69; (47) 265
Alcohol effect on mixed micelle, (49) 129
Alcohol-free elixir formulation, (42) 155
Aliphatic ester, (43) 31
Alprenolol-HCl, (47) 133
Aluminum chloride, (45) 249
Amberset, (42) 41
γ-Aminobutyric acid, (48) 91
Amino end group, (41) 131
Aminoglycoside, (42) 193
Aminophylline, (49) 183
Amphotericin B, (44) 117; (46) 25; (46) 169; (46) 223
Amphoteric substance, (45) 157
Ampicillin, (41) 241
Amsacrine, (42) 41
Angiotensin-converting enzyme activity, (41) 255
Anhydrous lactose, (41) 223
Anhydrous theophylline, (42) 15
Anthralin, (49) 63; (49) 103
Antiarrhythmic drug, (47) 209
Antibiotic, (41) 241; (43) 77; (46) 169
Anticonvulsant activity, (48) 91
Antiemetic, (43) 9
Antihypertensive drug, (47) 209
Antimalarial, (43) 215
Antimicrobial characteristic, (46) 141
Antineoplastic drug, (48) 179
Antiseptic, (49) 205
Antisickling, (42) 261
Antitumor effect, (41) 21
Antiviral drug, (50) 175
Apparent partition coefficient (APC)/percutaneous permeability correlation, (45) 59
Appearance, (43) 155
Application in drug delivery, (48) 1
Aqueous diffusion layer removal, (44) 187
Aqueous gel, (46) 1
Aqueous solubility, (49) 163
Aqueous solution, (45) 181; (46) 1; (50) 71
Arachidonic acid metabolite, (46) 149
Arginine vasopressin, (46) 111
Artificial lipid membrane, (42) 97
Ascorbic acid, (41) 255; (41) 263
Asialofetuin, (42) 69
Aspirin, (44) 151; (47) 261
Aspirin ester, (44) 151

Aspirin–methacrylic acid-methyl methacrylate coacervates, (47) 263
Atropine, (43) 59
Automated system, (50) 53
Autoradiography, (45) 101; (47) 111; (47) 157
Autoxidation, (41) 95; (41) 105
Availability, (46) 49; (47) 31
Azathioprine, (42) 263; (46) 267
Azone, (43) 1; (43) 207; (47) 43; (49) 199

Barrier cream, (41) 49
Bat, (42) 261
Batch variation process and formulation effect, (41) 1
Beagle dog, (41) 245; (41) 255
Benzalkonium chloride, (46) 141
Benzocaine, (50) 27
Benzodiazepine, (49) 83
Benzophenantridinium alkaloid determination, (46) 255
Benzophenone, (49) 83
Betnovate, (41) 63
Bile, (43) 41; (49) 179
Bile salt, (45) 197
Biliary excretion, (49) 173
Binding, (42) 193; (49) 189
Binding isotherm, (49) 103
Binding property, (46) 183
Bioadhesion, (49) 231
Bioadhesion to rat intestine, (44) 213
Bioadhesive microsphere, (46) 261
Bioadhesive polymer, (44) 213
Bioanalysis, (50) 175
Bioavailability, (42) 35; (43) 83; (43) 139; (43) 261; (44) 9; (44) 25; (45) 65; (45) 197; (47) 21; (47) 37; (47) 89; (47) 209; (47) 233; (48) 223; (49) 183; (50) 83
Bioavailability in vivo, (42) 155
Bioavailability of theophylline in the presence of cellulose, (50) 79
Biodegradation, (43) 179; (44) 49
Biodistribution, (44) 49; (47) 265
Biopharmaceutical study, (42) 27
Biotechnology, (48) 15
Biphasic hydrolysis profile, (45) 165
Blanching, (41) 63
Blister packaging, (45) 79
β-Blocker, (46) 95; (47) 133
Blood, (46) 89
Blood–brain barrier, (45) 249
Body distribution, (45) 91
Born equation, (42) 181
Bovine serum albumin, (43) 257; (49) 103; (50) 181
Brain microvessel endothelium, (45) 249
Branched β-cyclodextrin, (49) 163
Branching effect, (42) 1
Brattleboro rat, (49) 199
Break, puncture or shear strength, (45) 39
Brittle and plastic behaviour, (46) 35
Bromhexine, (43) 77
Bronchodilator, (41) 55; (43) 139
Buccal delivery, (49) 231
Buccal drug absorption, (48) 189
Buccal metabolism, (48) 189
Buccal patch, (49) 231
Buccal transport, (49) 141
Buffer, (47) 195
Buffer capacity, (44) 97
Buffered formulation, (50) 223
Buffer system, (44) 97
Burette administration set, (47) 239
t-Butanol, (43) 191
Buthionine sulfoximine, (44) 265

Caffeine, (48) 103
Calorimetry, (44) 1; (48) 113; (50) 233
Capsule, (46) 241; (49) 79
Captopril, (41) 245; (41) 255; (41) 263
Carbamazepine, (45) 13; (50) 111
Carbon dioxide source, (45) 19
Carboxyfluorescein, (48) 125
Carrier, (47) 129
Cascade impactor, (44) 57
Catalytic effect, (50) 67; (50) 91
Cation, (43) 111
Cefixime, (43) 53
Cefotaxime, (46) 45
Cellulose acetate phthalate, (42) 105
Cellulose ether, (48) 1
Cephalexin, (47) 37
Cephalosporin, (43) 53; (43) 187; (44) 205; (50) 233
Cetrimide, (49) 129
Cetylpyridinium chloride, (44) 243
Characterisation, (50) 205
Chelerythrine, (46) 255
Chemical kinetics, (45) 207
Chemosterilization, (42) 61
Chemotherapy, (47) 129
[^{3}H]Cholesteryl hexadecyl ether, (47) 111
Chloramphenicol, (46) 169
Chlorhexidine digluconate, (49) 129
Chloroquine, (43) 225
Chlorpheniramine maleate, (41) 83
Cholesterol, (42) 257
Cimetidine, (43) 59
Circadian variation, (43) 145
Cisplatin, (41) 67
Citrate, (47) 215
Citric acid, (45) 13
Clinical correlation, (41) 63
Clinical study, (43) 139
Clomesone, (48) 179
Clonidine, (43) 201
Coated slow-release granule, (41) 245
Coating, (48) 63

Coating technique, (42) 161
Collagen, (47) 79; (47) 95
Collision complex, (45) 169
Colloidal silicon dioxide, (50) 147
Compactibility, (46) 183
Compactibility of polymers in solid matrices, (44) 249
Comparative enzyme activity, (48) 189
Comparison, (49) 209
Competition kinetics, (44) 31
Complex, (49) 91
Complexation, (41) 83; (41) 205; (44) 131
Compound CGP 18137, (46) 203
Compound HI-6, (46) 247
Compressed disc, (44) 1
Compressed tablet, (44) 43; (44) 177; (45) 79; (45) 111
Compressibility, (45) 19
Compression, (49) 157
Compression of a model granule system, (49) 157
Compression of polymeric substances, (44) 249
Compression pressure, (46) 211
Computer simulation, (50) 197
Computer simulation model, (48) 231
Concentration exponent, (46) 141
Conjugated drug, (47) 163
Constant drug delivery, (50) 133
Contact angle, (41) 237; (44) 1
Contact angle measurement, (45) 91
Controlled drug delivery, (45) 229; (46) 133; (50) 253
Controlled release, (41) 83; (44) 131; (45) 65; (47) 37; (48) 51; (49) 15
Controlled release system, (49) 183
Core and shell, (50) 133
Corneal penetration, (46) 95
Cosolvent, (42) 181
Co-solvent, (43) 191
Coulter Counter method, (47) 67
Critical micelle concentration, (49) 129
Critical micelle concentration (CMC), (42) 1
Critical pigment volume concentration, (45) 245
Croscarmellose, (47) 89
Crospovidone, (50) 147
Cross-linked sodium carboxymethylcellulose, (41) 159
Crystal defect, (41) 29; (42) 123
Crystal growth, (50) 111
Crystal habit, (41) 29; (42) 123
Crystallisation, (50) 111
Crystallization of triglycerides, (43) 241
Crystal properties, (47) 141
Crystal transition, (42) 15
Culture cells, (47) 129
Curcumin, (41) 75; (50) 67; (50) 91
Cyanoacrylic nanoparticle, (41) 181
Cyclodextrin, (46) 77; (48) 119; (49) 91
α-Cyclodextrin, (43) 41
β-Cyclodextrin, (43) 93; (46) 49; (48) 83; (50) 45
Cyclosporin A, (44) 107
Cytotoxic, (42) 243
Damage to muscle tissue, (46) 217
DEAE-dextran, (49) 23
Debromination, (41) 41
Decreased radiation hazard, (49) 115
Decylmethylsulfoxide, (43) 17
n-Decyl methyl sulfoxide, (43) 1
Defect, (48) 63
Degradation, (43) 23
Degradation kinetics, (41) 169; (43) 131; (44) 225; (45) 181; (45) 189; (47) 195; (50) 189
Degradation product, (41) 95
Degree of substitution, (46) 217
Degree of supercooling, (44) 205
Delivery route, (48) 15
Densification behavior, (46) 183
Density distribution in polymeric matrices, (44) 249
Deoxyribonucleic acid, (49) 103
Derivative spectroscopy, (46) 193; (49) 79
Dermal delivery, (44) 87; (48) 195
Dermal form, (46) 49
Dermatological patch, (44) 25
Dermatose, (44) 25
Dermocorticoid, (46) 49
Dermovate, (41) 63
N-Desalkylflurazepam, (49) 83
Desamino-8-D-arginine vasopressin, (46) 111
Determination, (43) 23
Device with core and shell (empty), (45) 217
[^{3}H]Dexamethasone, (47) 21
Dextran, (44) 265; (49) 23
Dextran conjugate of glutathione, (44) 265
Dextran sulfate, (42) 193; (46) 103
Dialysis equipment, (48) 255
cis-Diamminemonochloromonoaquoplatinum(II), (41) 67
Diastereoisomer, (43) 23
[^{14}C]Diazepam, (47) 111
Diaziquone, (47) 215
Dicalcium phosphate dihydrate, (48) 173
cis-Dichlorodiammineplatinum(II), (41) 67
2′,3′-Dideoxyadenosine, (45) 27
2′,3′-Dideoxyinosine, (45) 27
Dielectric constant, (47) 261
Dielectric constant effect, (46) 267
Dielectrics, (41) 139
Diethylenetriamine pentaacetic acid–stearate, (49) 249
Differential pulse polarography, (46) 255; (48) 167
Differential scanning calorimetry, (41) 41; (44) 205; (45) 13; (45) 139; (47) 141; (48) 83
Diffusion, (49) 109; (50) 21
Diffusion cell, (41) 49; (44) 87; (46) 193; (49) 63; (50) 53
Diffusion cell experiment, (48) 195
Diffusion layer thickness, (47) 223
Diffusion model, (50) 197
Digoxin, (47) 223
Digoxin dissolution rate, (49) 241
Digoxin tablet, (49) 241
Di-μ-hydroxo-bis(cis-diammineplatinum(II)), (41) 67

Dilazep, (46) 173
Diltiazem, (50) 71
Diluents in gelatin capsules, (44) 159
Di-maltosyl-β-cyclodextrin, (49) 163
N, *N*-Dimethylacetamide, (46) 223
Di-*O*-methyl-β-cyclodextrin, (50) 45
Dimethyl sulfoxide, (48) 141
Dimyristoylphosphatidylcholine monolayer, (50) 261
Dipalmitoyl phosphatidylcholine, (42) 97
Diphenhydramine hydrochloride, (50) 75
Direct compression, (45) 19
Discharge, (43) 45
Disinfectant, (42) 61
Disintegrant, (44) 177; (48) 51
Disintegration, (41) 159; (44) 177; (50) 147
Disintegration force, (44) 177
Disodium cromoglycate, (42) 211
Dissociation, (46) 231
Dissociation constant, (42) 181
Dissolution, (41) 159; (42) 35; (46) 247; (47) 31; (47) 141; (47) 249; (48) 207; (49) 179; (49) 261; (50) 103; (50) 223
Dissolution and disintegration rate constant, (44) 43
Dissolution medium, (44) 43
Dissolution profile, (48) 83
Dissolution rate, (41) 29; (41) 49; (42) 123; (45) 111; (47) 51; (47) 223; (47) 263
Distribution coefficient, (50) 7
Distribution pattern, (50) 15
1-Dodecylazacycloheptan-2-one (Azone), (49) 47
Dog, (42) 105; (44) 159; (48) 51
Dorsal skin, (46) 1
Dose proportionality, (49) 121
Double bond contribution, (42) 1
Doxorubicin on methacrylic copolymer nanoparticle, blood clearance and distribution patterns in rabbit, (42) 145
Droplet size, (46) 177; (50) 141
Drug adsorption at mercury surface, (42) 235
Drug binding parameter, (42) 225
Drug delivery, (45) 1
Drug delivery system, (42) 19; (43) 179
Drug distribution, (50) 97
Drug–excipient interaction, (47) 89
Drug plastics interaction, (47) 239
Drug release, (41) 55; (45) 111; (47) 163; (48) 217; (49) 63; (49) 69
Drug release rate, (42) 15
Drug–resin complex, (48) 217
Drug solubility, (45) 1
Drug sorption, (47) 239
Drug targeting, (42) 145; (44) 49; (47) 129
Dry powder inhaler, (42) 211; (44) 57
Dual-wavelength, (50) 39
Duration time, (41) 263
D-value, (46) 141

Effect of cellulose on theophylline absorption, (50) 79
Effervescent component, (45) 19
Efflux, (48) 125
Ehrlich ascites carcinoma, (41) 213
Electrokinetic behavior, (43) 257
Electron microscopic level, (47) 111
Electron spin resonance, (49) 39
Elimination, (47) 43
Elongation to break or puncture, (45) 39
Eluant property, (48) 217
Embolisation, (43) 161
Empirical modelling, (42) 11
Emulsification, (44) 169
Emulsion, (42) 243; (45) 165
Emulsion drug carrier, (45) 169
Emulsion theory, (50) 141
Energy-dispersive X-ray analysis, (42) 89
Energy dispersive X-ray analysis, (46) 179
Energy to break, puncture or shear, (45) 39
Enhanced permeability, (43) 1
Enhanced skin permeation, (43) 17
Enhancer, (46) 19; (49) 47
Enteric coated granule, (41) 245
Enteric granule, (42) 105
Enteric material, (48) 51
Enthalpy variation, (42) 19; (50) 213
Enzymatic hydrolysis, (43) 101; (45) 47
Enzyme-catalyzed hydrolysis, (49) 163
Enzyme induction, (50) 35
Enzymuria, (46) 103
Ephedrine, (41) 205
Epirubicin, (41) 213
EPR spectroscopy, (43) 267
Equilibrium solubility, (50) 103
Erythrocyte, (42) 225
Escherichia coli, (45) 153
Esophageal transit, (46) 241
Esophagus, (46) 241
Ester, (43) 261
Esterase activity, (44) 125
Esterase hydrolysis, (48) 159
Estimation, (42) 181
Ethanol, (43) 225
Ethylene vinyl alcohol, (48) 1
2-Ethylhexyl *p*-dimethylaminobenzoate, (50) 27
Etodolac, (49) 121
Etoposide, (41) 169
Eudragit, (45) 229; (50) 133
Eumovate, (41) 63
Euphylong, (43) 139
Eutectic, (44) 205
Excipient surface coverage, (42) 89
Excised skin, (43) 233
Excretion, (44) 9
Experimental design, (42) 11
Expidet, (46) 241
Eye ointment, (41) 115

Factorial design, (44) 117
Famotidine, (50) 35

Fasted state, (43) 45
Fat emulsion, (44) 169; (46) 25
Fatty acid, (48) 103
Fatty suppository base, (47) 157
Fenbufen, (44) 261
Fetindomide, (45) 207
Filler, (47) 205
Film, (41) 131; (48) 63
Film-coated tablet, (48) 51
Film coating, (41) 219; (42) 199; (45) 245; (50) 163
Film coating, aqueous, (49) 115
Film coating, HPMC, (49) 115
Film penetration, (50) 261
Filter-probe extraction, (46) 231
First-pass metabolism, (43) 261
Flaking, (48) 255
Flow-through, (46) 193
Fluorescence, (45) 249
Fluorescence detection, (43) 111; (49) 135
Fluorescence polarization, (49) 47
Fluorescence quenching, (46) 25; (49) 103
Fluoride gel, (49) 147
5-Fluorouracil, (41) 91; (43) 1; (44) 87
Fluorouracyl-selective skin permeation, (43) 17
Flurbiprofen ethyl ester, (45) 165
Flux, (50) 21
Food, (44) 9; (50) 83; (50) 155
Food intake, (41) 245
Formaldehyde, (45) 207
Formulation, (45) 129; (49) 29
Formulation design, (44) 107
Formulation effect, (41) 147
Four-component gel, (44) 75
Fourier descriptor, (47) 179
Fourier shape descriptor, (47) 171
Free radical, (44) 31
Free volume, (47) 79
Freeze drying, (43) 191
Freeze-drying, (44) 205
Frictional theory, (41) 1
Frusemide, (47) 141; (50) 223
FT-207, (41) 21
Furosemide, (45) 65
Furosemide ester, (42) 217
Furosemide (frusemide), (42) 217
Fusion energetics, (41) 29; (42) 123

Galactose-binding protein, (42) 69
Galenics, (49) 147
Gamma scintigraphy, (50) 155
Ganglioside, (46) 31
Gas chromatography, (42) 61
Gastric-acidity-controlled rabbit, (49) 213
Gastric liquid, (45) 229
Gastric pH, (49) 213
Gastrointestinal absorption, (43) 225
Gastrointestinal transit, (42) 105; (48) 79; (49) 183
Gelatin–acacia coacervate, (50) 205
Gel filtration chromatography, (41) 241
Gelucire, (50) 133
Gender, (50) 83
Gentamicin, (46) 103; (46) 261
Gentamicin component, (43) 111
Glass transition, (44) 205
Glaucoma, (47) 95
Glibenclamide, (50) 103
Gloss measurement, (45) 245
Glucosyl-β-cyclodextrin, (49) 163
Glutaraldehyde, (42) 61
Glutathione, (44) 265
Glutathione delivery, (44) 265
Glycerol, (43) 225
Glycolamide ester, (43) 101
Glycoprotein, (42) 261
Granulation, (49) 157
Granule, (42) 257; (49) 179
Griseofulvin, (45) 111; (47) 51
Guinea pig, (45) 101
Gum-to-drug ratio, (47) 133

Hairless mouse skin, (41) 91; (48) 247
Hairless rat, (43) 31
Halogeno pyrimidinone, (41) 41
Hamster cheek pouch, (47) 13; (49) 47
Hardening of fatty suppositories, (43) 241
Hard gelatin capsule, (44) 159
Healthy human, (46) 1
Heat denaturation, (46) 69
Heckel plot of polymeric materials, (44) 249
Hemimaleinate, hemisuccinate and hemiglutarate esters of metronidazole, (41) 121
Hemolysis activity, (46) 217
Hemolytic activity, (49) 163
Hepatocyte, (42) 69; (46) 31
Herpes simplex virus, (48) 141
Herpes virus, (49) 205
Hexobendine, (46) 173
High-performance liquid chromatography, (46) 89; (49) 135
High-performance liquid chromatography assay, (49) 213
High-pressure liquid chromatography (HPLC), (43) 131; (50) 189
Histology, (44) 261
HPLC assay, (41) 169
HPLC, bonded phase, (43) 111
Human, (46) 199; (47) 43
Human abdominal skin, (41) 91
Human epidermal growth factor, (46) 9; (49) 173
Human growth hormone, (45) 197
Human rectum, (47) 157
Human skin, (44) 65
Human subject, (41) 263
Humidity, (44) 57
Hyaluronic acid degradation, (50) 91
Hydrate, (42) 171

Hydration, (44) 71
Hydration number, (44) 141
3-Hydrazone derivatives, (47) 195
Hydrocolloid, (44) 25
Hydrogel, (48) 1
Hydrogenated phospholipid, (49) 179
Hydrogen bond, (44) 141
Hydrolysed gelatin binder, (49) 157
Hydrolysis, (42) 51; (42) 217; (43) 261; (44) 151; (45) 27; (45) 47; (45) 207; (46) 57; (46) 159; (47) 103; (50) 1
Hydrolysis by rat serum, (45) 165
Hydrolytic product, (42) 263
Hydrophilic albumin microsphere, (47) 163
Hydrophilic matrix, (41) 83; (44) 131; (45) 145; (47) 133
Hydrophilic polymeric matrix, (41) 55
Hydrophobic interaction, (44) 141
Hydrophobicity, (50) 261
Hydroxyalkylated β-cyclodextrin, (46) 217
m-Hydroxybenzoate, (45) 153
Hydroxychloroquine, (43) 215
Hydroxyethylcellulose, (49) 147
Hydroxyl radical, (44) 31; (50) 91
7-*N*-(*p*-Hydroxyphenyl)mitomycin C, (45) 189
N-(2-Hydroxypropyl)methacrylamide copolymers, (44) 213
Hydroxypropylmethylcellulose, (41) 83; (44) 131; (47) 133; (49) 157
Hydroxypropyl methyl cellulose, (48) 63
Hydroxypropyl methylcellulose, (48) 113; (50) 163
Hydroxypropyl methylcellulose phthalate, (42) 105
Hysteresis, (44) 1

Ibuprofen, (45) 139; (50) 155
Ibuprofen–polyvinylpyrrolidone interaction, (45) 139
Idoxuridine, (43) 1
Imidazole, (41) 241
Immersion, (44) 1
Immunonanoparticle, (41) 181
Immunoradiometric assay, (41) 181
Immunoreactive hEGF, (49) 173
Impurity, (42) 61
Impurity in drugs, (49) 79
Inclusion, (46) 49
Inclusion ability, (49) 163
Inclusion complexation, (48) 83; (50) 45
Incorporation efficiency, (47) 163
Indentation hardness, (46) 35
Indentation test, (46) 35
Indomethacin, (42) 257; (49) 79
Inflammatory response in mice, (46) 149
Influence of specific surface area on film formation, (42) 89
Infrared spectroscopy, (48) 83; (50) 103
Inhalation, (42) 267
Injectable doxorubicin-loaded nanosphere, (42) 145
In situ absorption study, (45) 123
In situ perfusion, (43) 119
In situ recirculating perfusion, (43) 41
Insulin, (47) 233
Interaction, (45) 259
Interface, (47) 249; (49) 91
Interferon, (42) 261
Interferon-α_2, (46) 199
Intermolecular interaction, (44) 141
Intersubject variation, (43) 145
Inter-subject variation, (49) 213
Intestinal absorption, (43) 41; (43) 119; (44) 187
Intestinal absorption rate, (47) 185
Intestinal metabolism, (46) 111; (48) 189
Intestinal transport, (46) 111
Intra-adipose injection, (47) 1
Intralipid, (42) 243; (43) 191; (44) 169
Intramolecular aminolysis, (42) 51
Intramolecular interaction constant, (47) 185
Intramuscular injection, (47) 1
Intranasal absorption, (45) 197
Intravenous administration, (46) 9; (49) 173
Inulin, (44) 97
In vitro, (41) 115
In vitro buccal absorption model, (49) 141
In vitro dissolution/bioavailability, (49) 121
In vitro intestinal degradation, (48) 159
In vitro pharmacokinetic model, (50) 97
In vitro release, (41) 205; (49) 29
In vitro skin model, (42) 97
In vivo disintegration, (44) 159
In vivo release, (46) 69
In vivo study, (47) 43
Iododeoxyuridine, (48) 141
Ion beam etching, (47) 205
Ion-exchange chromatography, (41) 241
Ion-exchange resin, (44) 131
Ionizable drug, (43) 187
Ionization constant, (46) 173
Ion pair, (48) 103
Ion-pair, (50) 7
Ion-pair complex, (45) 59
Ion-pair HPLC, (44) 117
Iontophoretic delivery, (49) 15
Ipomeanol, (42) 243
N^6-(Δ^2-Isopentenyl)adenosine, (42) 117
Isopropamide iodide, (45) 59
Isopropyl myristate, (41) 205; (42) 97; (43) 31
I.v. administration set, (42) 243

Jet-mill grinding, (47) 171

Keratinized oral mucosa, (47) 13
Keratinized oral-mucosa, (49) 47
Ketoprofen, (44) 9; (49) 213
Ketorolac tromethamine, (41) 95; (41) 105
Kinetics, (41) 67; (41) 95; (43) 23; (46) 57; (47) 121; (50) 71
Kinetics, Mechanism, (48) 179
Kinetics of degradation, (46) 223
Kinetics of hydrolysis, (41) 121

Lacrimation, (44) 97
β-Lactam antibiotic, (41) 241; (46) 45
Lactose, (45) 161
Laminate, (49) 231
L1210 cell culture, (42) 117
Lead-glass ballotini, (49) 157
Light, (44) 31
Light degradation, (41) 105
Lignocaine, (44) 65
Linear free energy approach, (42) 181
Linoleic acid peroxidation, (50) 67
Lipid bilayer, (43) 207
Lipid mixture, (41) 205
Lipid transfer, (45) 169
Lipophilic drug, (47) 1
Lipophilicity, (42) 243; (47) 103
Liposomal contrast agent, (49) 249
Liposome, (42) 69; (43) 257; (46) 25; (46) 31; (46) 95; (47) 129; (48) 125; (50) 1
Liposome formulation, (44) 235
Liquid chromatography, (43) 23
Liquid chromatography/mass spectrometry, (50) 45
Liquid penetration, (44) 1
Lithium, (43) 145
Liver, (44) 265
Localization, (47) 111
Longitudinal transport, (48) 231
Lubricant, (41) 223; (42) 171; (43) 249; (46) 211
Lubricant assessment, (41) 1
Lubricant characterisation, (41) 1
Lubricant film formation, (42) 89
Lubricant selection and optimisation, (41) 1
Lubricant surface area, (43) 249
Lubrication, (46) 183
Lubrication property, (48) 149
Lubricity, (43) 249
Luteinizing hormone releasing hormone analogue, (49) 69
Lymphatic absorption, (44) 107
Lymph concentration, (41) 21

Macromolecular diffusion, (47) 79
Macrophage, (46) 149
Macroscopic level, (47) 111
Magnesium palmitate, (43) 249
Magnesium stearate, (42) 171; (43) 249; (46) 183; (46) 211
Magnetic albumin microsphere, (43) 167
Magnetic microsphere, (47) 265
Magnetic resonance imaging, (49) 249
Magnetite, (44) 49; (47) 265
Magnetite distribution, (43) 167
Maltosyl-β-cyclodextrin, (49) 163
Mannich base, (44) 87
Mass spectrometry, (43) 23
Mathematical model, (43) 201
Matrix degradation, (47) 163
Matrix tablet, (45) 65
Mean transit time, (43) 59
Mechanical, (48) 63
Mechanical property, (50) 163
Mechanism, (41) 95; (41) 105
Medical device, (48) 255
Melting-point, (45) 13
Membrane, (41) 49; (47) 31
Membrane permeability modification, (44) 187
Menadione, (50) 213
6-Mercaptopurine, (48) 195
Metabolism, (47) 43
Metastable state, (44) 205
Method, (50) 61
Methotrexate, (47) 239
Methotrexate–albumin conjugate, (47) 163
Methotrexate injection, (45) 237
5-Methoxy-2-methylindole-3-acetic acid, (49) 79
Methylcellulose, (41) 159; (50) 147
N-Methyl-2-pyrrolidone, (43) 233
Metoclopramide, (43) 59
Metoprolol tartrate, (47) 133
Metronidazole, (43) 233
Micellar complex formation, (47) 13
Micellar solubilization, (44) 187
Micellar solution, (47) 67
Miconazole nitrate, (48) 207
Microcalorimetric study, (45) 153
Microcalorimetry, (41) 139; (47) 121; (50) 233
Microcapsule, (48) 217; (50) 39; (50) 205
Microcrystalline cellulose, (41) 159; (41) 223; (41) 231
Microemulsion, (42) 19
Microencapsulation, (43) 179; (49) 69
Microenvironmental pH control, (50) 223
Microfluidization, (50) 141
Microfluidizer, (44) 169
Microparticle, (46) 149
Microporous polypropylene, (45) 65
Microsphere, (41) 213; (43) 161; (43) 179; (47) 233
Microsphere size, (44) 49
Midazolam [8-chloro-6-(2′-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]-benzodiazepine], (49) 83
Milk, (44) 9
Milling, (47) 121; (48) 149
Mitindomide, Degradation, (45) 207
Mitomycin derivative, (45) 189
Mixed micelle, (48) 223; (49) 129
Mixed tank model, (45) 123
Mixing time, (46) 211
Model film, (50) 205
Modelling of drug delivery, (45) 217
Model membrane, (44) 125
Modified release tablet, (41) 245
Modified starch, (45) 145
Moisture sensitivity, (45) 79
Moisture sorption, (46) 217
Molecular conformation, (47) 141
Monitoring kinetics of drug decomposition in acidic solution, (42) 235

Monoclonal antibody, (41) 181; (47) 129
Monolayer, (44) 257; (44) 269
Monte Carlo method, (46) 121
Morphine, (45) 161
Morphology, (44) 49
Motility, (43) 45
Mouse liver, (47) 111
Mouse skin in vitro, (44) 71; (46) 169
Mucolytic, (43) 77
Mucosal adhesion, (49) 231
Multisegment absorption model, (43) 59

Nalidixic acid, (41) 197
Nanoparticle, (45) 91
Naphazoline, (46) 193; (48) 103
Naphazoline hydrochloride, (50) 75
Naphthyl ester hydrolysis, (44) 225
Napp Continus system, (49) 183
Naproxen, (48) 83
Nasal absorption, (46) 133; (50) 253
Nasal administration, (49) 23
Nasal delivery, (46) 261; (47) 233
Nasal drops, (50) 75
Nasal spray, (43) 221
Natural convection, (47) 249
Nephrotoxicity, (42) 193; (46) 103
New drug-carrier, (42) 145
Nickel, (45) 101
Nickel absorption, (45) 101
Nickel distribution, (45) 101
Nickel elimination, (45) 101
Nickel sensitization, (45) 101
Nickel sulphate, (49) 29
Nicorandil, (43) 31
Nifedipine, (41) 227
Nipecotic acid esters, (48) 91
Nitrite, (44) 31
Nitroglycerin, (43) 201
Non-isothermal method, (46) 121
Non-linear estimation, (46) 121
Non-linear regression, (45) 123
Non-polar media, (41) 115
Non-steroidal anti-inflammatory drug, (43) 101
Normalized solid fraction, (46) 35
Nucleophile effect, (48) 179
Nucleoside, (45) 27
Numerical deconvolution, (45) 65
Nutrient mixture, (42) 11
Nylon, (41) 131

Occlusal fissure, (49) 147
Occlusion, (47) 43
n-Octanol, (46) 95
1-Octanol–water partition coefficient, (43) 187
Octanol–water partition coefficient, (45) 1
Ocular absorption, (44) 97
Ocular insert, (47) 21
Oenanthe aquatica L., (48) 119
Ofloxacin, (50) 83
Oil-in-water microemulsion, (50) 213
Oily semisolid matrix, (41) 245; (41) 255; (41) 263
Ointment formulation, (44) 225
Oleaginous ointment, (50) 27
Oleic acid, (43) 17
Ophthalmic, (44) 97
Ophthalmic bioavailability, (42) 47
Ophthalmic drug-delivery system, (47) 95
Ophthalmic insert, (47) 95
Ophthalmic solution, (42) 47
Ophthalmic vehicle, (43) 67
Opiate–phospholipid interaction, (44) 257; (44) 269
Optimisation method, (48) 149
Oral administration, (49) 213
Oral drug delivery, (44) 213
Oral rinse, (46) 255
Ordered mixture, (45) 111
Organophosphorus antidote, (46) 247
Orthogonal design, (42) 11
Oscillating relative humidity, (45) 79
Oxazepam, (45) 111; (47) 223
Oxazolidin-2-one, (42) 51
5-Oxazolidinone, (46) 159
Oxidation, (46) 223
2-Oxo-imidazo[2,1-b]quinazoline, (45) 129
Oxprenolol, (46) 193
Oxprenolol-HCl, (47) 133
Oxytetracycline, (43) 77

Pancreatic insufficiency, (42) 105; (48) 51
Papaverine, (46) 173
Paracellular pathway, (43) 41
Paracetamol (acetaminophen), (42) 155
Parameters influence, (41) 147
Parenteral fat emulsion, (46) 177
Parenteral nutrition, (42) 11; (44) 169
Paroxetine hydrochloride, (42) 135
Partial solubility parameter, (42) 199
Particle deposition, (42) 211; (44) 57
Particle size, (42) 267; (47) 67; (47) 171; (47) 223
Particle size distribution, (47) 51
Particle system, (47) 249
Particulate drug carrier, Passive drug targeting, (45) 165
Particulate matter, (48) 255
Partition, (46) 231
Partition coefficient, (43) 119; (43) 187; (45) 157; (46) 77; (49) 91; (49) 141; (49) 189; (50) 7; (50) 117
Partitioning, (46) 95
Patch testing, (49) 29
Pathway of degradation, (42) 263
Patient, (42) 251
Pelletisation process, (42) 15
Penetration enhancement, (41) 189; (44) 15
Penetration enhancer, (43) 207; (47) 43
Penetration measurement, (49) 147

Penticainide, (45) 13
Peptide, (48) 15
Peptide derivative, (46) 159
Peptides, (46) 261
Percolation theory, (46) 35
Percolation threshold, (46) 35
Percutaneous absorption, (41) 91; (41) 189; (42) 97; (44) 15; (44) 65; (46) 1; (46) 19; (46) 193; (47) 43
Percutaneous absorption enhancement, (50) 27
Percutaneous absorption enhancer, (43) 31
Percutaneous penetration, (43) 207
Perfusion, (43) 93
Perilla ketone, (42) 243
Permeability, (44) 71; (45) 249; (46) 169; (49) 47; (49) 189; (50) 21
Permeability coefficient, (49) 141
Permeability determination, (41) 49
Permeation, (41) 131; (50) 205
Permeation enhancer, (43) 233
Permeation kinetics, (42) 161
pH, (43) 45; (44) 97; (49) 179; (49) 189
pH dependence, (41) 131
pH effect, (45) 207
pH effects on partition coefficient, (43) 187
pH-independent controlled-release granule, (49) 213
pH–rate profile, (43) 191; (48) 179
Phagocytosis, (45) 169; (46) 69
Pharmaceutical availability, (49) 63; (49) 241
Pharmaceutical excipient, (41) 197
Pharmaceutical film, (45) 39
Pharmaceutical powder lubricant, (42) 89
Pharmacodynamics, (45) 65
Pharmacokinetic correlation, (46) 95
Pharmacokinetic interaction, (50) 35
Pharmacokinetic model, (43) 201
Pharmacokinetics, (41) 213; (42) 155; (44) 107; (46) 9; (46) 133; (48) 223
Pharmacokinetics and organ distribution in rabbits, after intravenous injection, (42) 145
Pharmacologic activity, (48) 223
Phase diagram, (44) 75
Phase solubility method, (49) 91
Phenol red, (44) 15
Phenolsulfonphthalein, (44) 15
Phenylpropanolamine, (48) 217
4-Phenylquinazoline, (49) 83
Phonophoresis, (44) 65
Phosphate, (47) 215
Phosphatidylcholine, (50) 1
Phospholipid, (46) 31
Phospholipid bilayer, (49) 39
Phospholipid, Fat emulsion, (48) 133
Phospholipid liposome, (47) 111
Photochemical decomposition, (49) 83
Photochemical oxidation, (41) 227
Photochemical stability, (43) 215
Photodecomposition, (41) 227
Photodegradation, (42) 41; (42) 217; (47) 239; (50) 45
Photohemolysis, (50) 45
Photolabile drug, (41) 75
Photon correlation spectroscopy, (48) 125
Photostabilization, (41) 75
o-Phthalaldehyde derivative, (43) 111
Phthalidyl derivative, (45) 47
Physical model, (45) 79
Physical property, (44) 25; (50) 117
Physical stability, (45) 79
Physicochemical parameter, (47) 31
Pigment, (47) 205; (48) 63; (48) 113; (50) 163
Pilocarpine, (47) 95
Pilocarpine nitrate, (44) 97
pK_a, (45) 27; (46) 231
pK_a value, (46) 173
Plaque prevention, (44) 243
Plasma, (46) 89
Plasma concentration, (41) 245; (41) 255; (46) 1
Plasma concentration–time course, (43) 201
Plasma concentration–time profile, (50) 155
Plasma level, (44) 107; (49) 213
Plastic, (50) 61
Plastic disposable syringe, (45) 237
Plastics intravenous administration set, (42) 41
Plastic uptake, (42) 243
Podophyllotoxin, (41) 169
Polar lipid, (43) 233
Poloxamer, (43) 67; (48) 125
Polyacetylene, (48) 119
Polyacrylic acid, (41) 21
Polyacryl starch, (46) 149
Polyanhydride polymer, (45) 229
Poly A: Poly Br^5U, (42) 261
Polybutylcyanoacrylate nanoparticles, (43) 267
Poly-ε-caprolactone, (45) 1
Polydimethylsiloxane, (45) 1
Poly(D,L-lactic acid–co-glycolic acid), (49) 69
Poly(DL-lactide), (43) 179
Polyether–polyurethane, (42) 117
Polyethylene, (45) 1
Polyethylene-co-vinyl acetate, (45) 1
Polyethylene glycol, (42) 27
Polyethylene glycol 6000, (48) 207
Polyethylene glycol (PEG), (44) 261
Poly(ethylene oxide), (48) 1
Polyglutaraldehyde nanoparticle, (50) 15
Poly(hydroxyalkyl-methacrylate), (48) 1
Poly-2-hydroxyethyl methacrylate, (45) 1
Poly(2-hydroxyethyl methacrylate) (PHEMA), (46) 179
Polymer, (41) 241
Polymer film, (47) 205
Polymeric delivery system, (42) 117
Polymeric device, (45) 217
Polymer matrix, (50) 181
Polymer-pigment interaction, (48) 63
Polymer–polymer incompatibility, (49) 69

Polymer–water partition coefficient, (45) 1
Polymethacrylic nanoparticle, (42) 145
Polymethacrylic nanosphere, effect of non-ionic surfactant on blood clearance, (42) 145
Poly(methyl methacrylate), (45) 91
Polymorph, (47) 141
Polymorphism, (42) 135; (42) 171; (50) 103
Polymyxin B, (46) 45
Polyoxyethylated non-ionic surfactant, (42) 1
Polyoxyethylene ether, (45) 197
Polyoxyethylene–polyoxypropylene block copolymer, (43) 67
Polypeptide, (50) 261
Polypeptide drug, (45) 197
Polysorbate 80, (47) 67
Poly(vinyl alcohol, (48) 1
Polyvinylpyrollidone, (49) 157
Polyvinylpyrrolidone, (45) 139; (48) 207; (50) 223
Porcine buccal mucosa, (49) 141
Pore mechanism, (47) 79
Porosity, (48) 173
Portal absorption, (44) 107
Powder compression, (49) 1
Powder mixture, (46) 183
Precipitation, (42) 61
Precorneal disposition, (44) 97
Prednisolone, (46) 69
Prednisone, (50) 213
Preservative, (46) 141
Preservative efficacy, (46) 141
Pressor response, (41) 255
Preventive dentistry, (49) 147
Prilocaine, (44) 65
Primary alcohol, (46) 19
Prodrug, (42) 51; (43) 101; (43) 261; (44) 151; (45) 47; (45) 207; (46) 77; (46) 159; (47) 103; (48) 91
Pro-drug, (46) 57; (48) 159
Prodrug CGP 22979, (46) 203
Prodrug, Mannich base, (48) 195
Product analysis, (48) 179
Progabide, (43) 83; (43) 93; (46) 231
Progabide–ranitidine interaction in vivo, (43) 83
Progesterone, (46) 133; (47) 195; (50) 253
Propranolol, (42) 51; (43) 261
Propranolol ester, (42) 51
Propranolol-HCl, (47) 133
Prostate gland, (46) 89
Protamine, (46) 45
Protein, (46) 261; (48) 15
Protein analysis, (48) 15
Protein binding, (50) 97
Protein delivery system, (50) 181
Protein formulation, (48) 15
Protriptyline, (50) 45
Pseudomonas aeruginosa, (46) 45
Pseudo-polymorphism, (42) 171; (50) 103
Psoriasis treatment, (44) 225
Pulsed profile, (43) 201
Puncture test, (45) 39
Purification index, (42) 61
2-Pyrrolidone derivative, (44) 15

QSAR, (48) 91
Quality control, (49) 63
Quantitative infrared spectroscopy, (42) 135
Quantitative structure—property relationship, (41) 55
Quaternary ammonium compound, (41) 131
Quinidine sulfate, (43) 179

Rabbit, (43) 83; (46) 133; (50) 253
Ranitidine, (43) 83
Rat, (44) 107; (44) 261; (46) 1; (47) 233
Rate-controlled release, (50) 181
Rat intestinal loop, (43) 93
Reaction mechanism, (46) 267
Rearrangement, (46) 57; (48) 159
Recirculation model, (45) 123
Recombinant interferon, (46) 199
Rectal absorption, (45) 161; (46) 9
Rectal administration, (41) 21
Rectal dosage, (41) 115
Regulation, (41) 131
Rehydration, (42) 171
Relative bioavailability, (43) 53
Relative humidity, (45) 79
Relaxed complex Young's modulus, (46) 35
Release, (41) 115
Release kinetics, (47) 31; (50) 205
Release mechanism, (41) 213
Release of cholesterol, (49) 163
Release rate, (41) 189
Release-rate, (43) 161
Release rate in human plasma, (41) 121
Release rate in pig liver homogenate, (41) 121
Renal vasodilator, (46) 203
Respiratory tract, (42) 211
Reticuloendothelial system, (49) 249
Rheology, (49) 147
Rheumatoid arthritis, (42) 251
Rhizoxin, (43) 191
Roentgenography, (42) 105
Rotating diffusion cell, (42) 97; (50) 117
Rotating disc technique, (46) 247

Salbutamol, (44) 57; (47) 171
Salicylic acid, (41) 205; (47) 13; (47) 261; (49) 47
Saliva, (50) 83
Saliva concentration, (43) 145
Sanguinaria canadensis extract, (46) 255
Sanguinarine, (46) 255
Saran Wrap, (44) 25
Saturable biliary excretion, (49) 173
Scanning electron microscopy, (47) 205
γ-Scintigraphy, (47) 157
Second-derivative UV spectroscopy, (50) 75

Seminal vesicle, (46) 89
Separation of eye tissues, (47) 21
Serum albumin, (42) 225
Serum-catalyzed hydrolysis, (48) 91
Serum sample, (41) 75
Shape parameter, (47) 179
Shaving, (49) 189
Shear, (43) 155
Shear test, (45) 39
Shed snake skin, (50) 53
Shelf-life, (46) 121
Sialic acid, (42) 261
Sickle cell anemia, (42) 261
Silanophilic interaction, (43) 111
Silicone, (42) 199
Silicone-coated tablet, (42) 161
Silicone rubber, (50) 181
Simulated intestinal fluid, (47) 263
Simulator, (49) 209
Simultaneous determination, (50) 75
Single and binary component compacts, (46) 35
Single pores, (49) 261
Size reduction, (47) 179
Skin, (49) 189
Skin autoradiograph, (43) 9
Skin penetration, (48) 141; (50) 53
Skin penetration enhancer, (49) 39
Skin permeability, (43) 233
Skin permeation, (43) 1; (43) 9; (43) 31; (48) 103; (49) 199
Skin–surfactant interaction, (50) 27
SL79.182, (46) 231
Small intestinal transit time, (48) 231
Small intestine, (48) 231
Small tablet, (48) 79
Snake skin, (44) 125; (46) 19; (50) 197
Sodium benzoate, (48) 149
Sodium bicarbonate, (45) 19
Sodium caprate, (46) 9
Sodium carboxymethyl cellulose, (46) 9
Sodium carboxymethylcellulose, (47) 133
Sodium chloride, (47) 215
Sodium cholate, (43) 41
Sodium deoxycholate, (46) 223
Sodium diclofenac, (42) 251; (46) 1
Sodium glycocholate, (49) 23
Sodium iodide I-131: Coated bead dosage form, (49) 115
Sodium laurylsulphate, (49) 147
Sodium salicylate, (45) 59; (45) 217; (48) 103
Sodium starch glycolate, (50) 147
Solid, (50) 233
Solid dispersion, (41) 41; (42) 27; (47) 51; (48) 207; (50) 223
Solid dosage form, (45) 229
Solid oral formulation, (43) 53
Solid state, (50) 71
Solid-state form, (42) 135
Solid-state kinetics, (42) 135
Solid state NMR, (47) 141
Solubilities, (47) 195
Solubility, (41) 197; (43) 191; (45) 27; (45) 129; (47) 103; (47) 141
Solubility measurement, (42) 135
Solubility parameter, (41) 219; (41) 223; (42) 1; (44) 87; (45) 259
Solubility product, (50) 7
Solubilization, (46) 217
Solubilization data analysis, (42) 1
Soluflazine, (46) 173
Solute concentration profile, (46) 179
Solution formulation, (50) 197
Solution viscosity, (43) 221
Solvent acidity and basicity, (44) 141
Solvent damage, (41) 91
Solvent evaporation method, (43) 179
Solvent isotope effect, (48) 179
Sonification, (47) 171
Sorption, (42) 41
Soya phospholipid, (42) 257
Sparingly soluble substance, (46) 173
Spectral displacement method, (49) 91
Spherical oral dosage device, (45) 217; (50) 133
Spin-labelled nitrosourea, (43) 267
Spray-dried lactose, (49) 209
Spray-drying, (45) 19
Spray drying, (48) 149
Square wave polarography (SWP) and voltammetry (SWV), (42) 235
Stability, (41) 67; (41) 95; (41) 105; (42) 27; (43) 191; (45) 129; (46) 49; (46) 57; (46) 77; (47) 215; (48) 179; (50) 1; (50) 71; (50) 233
Stability constant, (49) 91
Stability constants of generalized species, (46) 173
Stability control, (42) 11
Stability in gastrointestinal tract, (41) 255
Stability of drugs in liposomes, (44) 235
Stability on storage, (45) 237
Stability prediction, (46) 121
Stability study, (44) 117
Stabilization, (48) 119
Staphylococcus aureus, (45) 153
Statistical estimation, (45) 123
Statistical moment analysis, (45) 65
Statistics of aggregation, (41) 147
Steady-state, (43) 139
Stearic acid, (50) 111
Steroid treatment, (44) 25
Sticking, (46) 211
Stirring speed, (41) 29
Stomach, (43) 45
Storage, (43) 23; (43) 161
Storage frozen, (47) 215
Stratum corneum, (49) 39; (49) 47
Stratum corneum diffusion, (50) 197
Streptomycin, (46) 169
Stress relaxation, (50) 163

Structure, (47) 205
Structure–activity relationship, (42) 97; (45) 153
Structure-promoting effect, (44) 141
Subcutaneous adipose layer, (47) 1
Subcutaneous administration, (46) 9
Submicron emulsion, (50) 141
Substituent constant, (47) 185
Sugar, (43) 225
Sulfanilamide, (50) 133
Sulfonamide, (47) 103
Sulphadimethoxine, (46) 45
Sulphanilamide, (45) 123
Supersaturation, (42) 123
Suppository, (42) 251; (44) 261; (45) 161; (47) 31; (49) 79
Suppository spreading, (47) 157
Sureset, (42) 41
Surface activity, (46) 217
Surface charge, (45) 249
Surface Energetics, (41) 139
Surface energetics, (47) 121
Surface energy, (44) 1
Surface energy of powders and compacts, (41) 237
Surface roughness, (43) 155; (46) 211
Surface specific dissolution rate, (47) 67
Surfactant, (41) 83; (42) 267; (47) 13; (47) 67; (49) 189
Surfactant coating, (45) 91
Surfactant–drug interaction, (50) 27
Surfactant effects on absorption, (44) 187
Surfactant–skin interaction, (50) 27
Suspension, (47) 21; (49) 29; (50) 39
Suspension formulation, (42) 267
Suspension stability, (47) 163
Sustained/controlled release, (42) 35
Sustained release, (42) 251; (43) 139; (45) 145; (48) 217; (49) 121; (50) 155
Sustained-release dosage form, (41) 263
Sustained release preparation, (50) 181
Sustained-release varnish, (44) 243
Swelling, (42) 199
Swelling controlled-release system, (48) 1
Systemic availability, (44) 107

Tablet, (41) 219; (48) 173; (50) 111
Tablet aging, (47) 261
Tablet coating, (47) 205
Tablet compression, (42) 135; (49) 209
Tablet crushing strength, (45) 79
Tablet film coating, (43) 155
Tablet hardness, (44) 43
Tablet holder, (42) 161
Tablet lubricant, (43) 249
Tablet lubrication, (41) 1
Tablet manufacture, (49) 1
Tablets, (46) 241
Targeting, (41) 181
Targetting, (42) 69
Taurinamide, (49) 135
Taurolidine, (48) 167; (49) 135
Taurolin, (49) 135
Taurultam, (48) 167; (49) 135
^{99m}Tc-labelling, (42) 211
Technetium, (47) 157
Temperature, (44) 71
Temperature coefficient, (46) 141
Temperature effect, (47) 195
Temperature of complete solidification, (44) 205
Temperature of incipient melting, (44) 205
Tensile strength, (48) 63
Tensile test, (45) 39
Ternary diagram, (49) 69
Ternary powder mix, (45) 259
Terpene, (48) 119
Tetradecane, (42) 97
Tetrahydrocannabinol, (43) 9; (43) 17
Theo-Dur, (43) 139
Theophylline, (42) 35; (43) 139; (44) 87; (45) 145; (49) 179; (50) 35
Theophylline absorption, (50) 79
Theory stability profiles, (45) 181
Therapeutic aerosol, (41) 147
Therapeutic drug monitoring, (43) 145
Thermal analysis, (50) 103
Thermal degradation, (41) 41
Thermodynamic activity, (41) 189
Thermodynamics, (44) 1; (47) 121; (49) 103
Thermogravimetry, (45) 13
Thin Application, (49) 109
Thin application, (50) 21
Thiorphan, (43) 23
Three-phase ($w_1/o/w_2$) partition apparatus, (50) 97
Timolol, (46) 77
Timolol base, (48) 247
Timolol ester, (46) 77
Tincture, (48) 119
Tissue distribution, (47) 111
Tissue distribution in mice, (43) 267
Tolbutamide, (42) 27
Topical, (41) 205; (50) 21
Topical availability, (41) 189
Topical corticosteroid, (41) 63
Topical delivery, (49) 109
Topical dosage, (41) 115
Topical formulation, (49) 63
Topical ophthalmic drug, (43) 67
Topical therapy, (48) 141
TPN, (48) 133
Trace analysis, (42) 235
Tracer, (47) 265
Transdermal delivery, (43) 9; (43) 207; (48) 247; (49) 15
Transdermal drug delivery, (43) 201; (44) 15
Transdermal transport, (50) 197
Transesterification, (44) 225
Transmission electron microscope, (46) 177
Transparent oil–water gel, (44) 75

Transport, (50) 61
Transport rate, (49) 91
Triamcinolone, (46) 69
2,2,2-Trichloroethanol, (44) 31
Trimethoprim, (46) 89
Tri-μ-hydroxo-tris(*cis*-diammineplatinum(II)), (41) 67
Tritiated water, (50) 61
Tropicamide, (43) 67
Turbidity, (42) 199
Turbid solution, (50) 39
Tween 80, Tween 80–progabide interaction, (43) 93
Two-phase transfer system, (49) 91

Ulcerative colitis, (48) 79
Ultrasound, (44) 65
Ultraviolet absorption, (42) 61
Ultraviolet radiation, (50) 71
Ultraviolet spectrometry, (43) 23
Ultraviolet spectrophotometric determination, (43) 225
Ultra-violet spectroscopy, (50) 39
Uracil, (41) 21
Urea, (44) 71; (48) 207
Urinary excretion, (45) 65; (49) 173
Urinary excretion rate, (43) 145
Urine, (50) 83
UV-spectrophotometry, (49) 79

Vaccinia virus, (49) 205
Vacuum microbalance, (41) 139; (44) 1; (47) 121
Vaginal microflora, (43) 77
Vasopressin, (49) 189; (49) 199
Vehicle, (47) 31; (49) 109; (50) 21
Vehicle effect, (43) 233
Vinblastine, (47) 239
Vinblastine (sulphate), (43) 131
Vincristine (sulphate), (50) 189
Vindesine (sulphate), (50) 189
Virucidal activity, (49) 205
Viscosity, (42) 199; (44) 141
Viscosity of grinding medium, (47) 179
Vitamin K_1, (48) 223
Vitamin K_1 disposition, (48) 223
Vitamin K_1-epoxide, (48) 223

Walker carcinoma, (41) 213
Water, (43) 45; (44) 71; (46) 169
Water content, (41) 29; (42) 123; (48) 173
Water–oil partitioning rate, (50) 117
Water penetration, (41) 159; (50) 147
Water–solid interaction, (42) 77
Water-soluble lubricant, (48) 149
Water-soluble prodrug, (41) 121
Water–solvent binary mixture, (44) 141
Water vapor, (50) 61
Wet granulation, (41) 231
Wettability, (44) 1
Wetting, (41) 139; (41) 237
Witepsol H12, (44) 261

X-ray, (48) 51
X-ray diffraction, (47) 141; (48) 83; (50) 103
X-ray powder diffraction, (45) 139

Yield force, (48) 173
Yoshida sarcoma, (41) 21
Young's modulus, (45) 39; (48) 63

Zero-order release, (50) 181
Zidovudine (azidothymidine), (50) 175

INTERNATIONAL JOURNAL OF PHARMACEUTICS

CONTENTS

Announcement from the Publisher v

Author Index 1

Subject Index 21

© 1991 Elsevier Science Publishers B.V. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher, Elsevier Science Publishers B.V., P.O. Box 1527, 1000 BM Amsterdam, The Netherlands.

Submission of a paper to this journal entails the author's irrevocable and exclusive authorization of the publisher to collect any sums or considerations for copying or reproduction payable by third parties (as mentioned in article 17 paragraph 2 of the Dutch Copyright Act of 1912 and in the Royal Decree of June 20, 1974 (S. 351) pursuant to article 16b of the Dutch Copyright Act of 1912) and/or to act in or out of Court in connection therewith.

Special regulations for readers in the U.S.A. This journal has been registered with the copyright Clearance Center, Inc. Consent is given for copying of articles for personal or internal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per-copy fee stated in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The appropriate fee should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 27 Congress Street, Salem, MA 01970, U.S.A. If no code appears in an article, the author has not given broad consent to copy and permission to copy must be obtained directly from the author. All articles published prior to 1980 may be copied for a per-copy fee of US $2.25, also payable through the Center. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotion purposes, or for creating new collective works. Special written permission must be obtained from the publisher for such copying.

Special regulations for authors. Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the publisher. This transfer will ensure the widest possible dissemination of information.

Cited in: Current Contents (Life Sciences; Clinical Practice); International Pharmaceutical Abstracts; Biological Abstracts; Chemical Abstracts; Excerpta Medica EMBASE; PASCAL M; Science Citation Index

Printed in The Netherlands

MANUSCRIPTS should be submitted **in quadruplicate** in English and be accompanied by a list of **6–8 key words**. All data that would help referees to evaluate the paper should also be supplied.

Full length papers should be typewritten with double spacing on one side of the sheet only, should be divided into **Summary** (including **key words**), Introduction, Materials and Methods, Results and Discussion,
should be accompanied by a separate sheet bearing Title, Author's names and their affiliations.
should not **normally** exceed 10 printed pages (18 typescript pages) in length.

Rapid communications should not exceed 4 printed pages (9 typescript pages) and should not be divided into sections i.e. Introduction etc. They preferably should have a 20–50 word Summary and a full reference list should be provided. Preferably **no figures** should be included; otherwise a delay in publication time will occur.

Descriptions / reviews of computer programs should include in the manuscript information on hardware compatibility and software availability (including costs, ordering address, etc.). All manuscripts must be accompanied by a manual describing software validation; operating instructions (in greater detail than in the manuscript) and illustrations of input and output data sets. In order that reviewers can appropriately evaluate the package, three copies of the manual and software (diskettes, tapes, etc.) should accompany submission. Software and manuals will be returned only upon request by the authors.

Tables should be compiled on separate sheets with a short descriptive title, a legend and / or footnotes identified by a, b, c, etc.

Figures Line drawings (including graphs) should be drawn in black ink on white paper. Lettering should be in proportion to the figure to allow for reduction to page format.
Half-tone figures should be sharp, high-contrast original prints on glossy paper.
The magnification of micrographs should be indicated by **a scale bar in the figure**.
If figures are not to be reduced their format should not exceed 16 × 20 cm. All legends should be typed double spaced on separate sheets.

References

Should be assembled alphabetically on a separate sheet. In the text they should be referred to by name and year (Harvard System). More than one paper from the same author in the same year must be identified by the letters a, b, c, etc. placed after the year of publication. In the text, when referring to a work by more than two authors, the name of the first author should be given followed by et al. Literature references must consist of names and initials of all authors, title of paper referred to, abbreviated title of periodicals and the volume, year and first **and last** page numbers of the paper. Periodicals, books and multi-author books should accord with the following examples:

Kaplan, S.A., Weinfeld, R.E. and Lee, T.L., Semiautomated spectrophotofluorometric determination of trimethoprim in biological fluids. J. Pharm. Sci., 62 (1973) 1865–1870.
D'Arcy, P.F. and Griffin, J.P., Iatrogenic Diseases, Oxford University Press, London, 1972, p. 11.
Johnson, C.A., International problems in the control of medicines. In Deasy, P.B. and Timoney, R.F. (Eds.), The Quality Control of Medicines, Elsevier, Amsterdam, 1976, pp. 83–95.

Abbreviations of journal titles should follow the system used by the ISDS List of Serial Title Word Abbreviations, 1985 (available from 20 rue Bachaumont, 75002 Paris, France – ISBN 2-904938-02-8), but beginning each word with a capital

Proofreading will be undertaken by the Publisher. *Correspondence and queries relating to proofs* should be directed to the publishers: IJP, Elsevier Science Publishers B.V., P.O. Box 1527, 1014 AG Amsterdam, The Netherlands. Telephone: (20) 5803465. Proofs will not be sent out unless specifically requested by the author(s) when the paper is submitted and so indicated on the title page. No alteration of substance to the text, tables or legends will be accepted.

Page Charge There will be no page charge.

Reprints Fifty reprints of each paper will be provided free of charge. Additional copies may be ordered at prices shown on the reprint order form which will be sent to the author.

Subscriptions
1991: Volumes 67–77 (11 volumes in 33 issues). Volume 67 is published in advance in order to decrease publication time. It remains part of the 1991 subscription year. Dfl. 3740.00 (US$ 2101.00) including postage, packaging and handling.
The Dutch guilder price is definitive. The US$ price is subject to exchange rate fluctuations and is therefore only given as a guide

Journals are sent by surface delivery to all countries, except the following countries where SAL air delivery (Surface Airlifted Mail) is ensured: U.S.A., Canada, Japan, Australia, New Zealand, P.R. China, India, Israel, South Africa, Malaysia, Singapore, South Korea, Taiwan, Pakistan, Hong Kong, Brazil, Argentina, Mexico and Thailand. Airmail rates for other countries are available on request.

Subscription orders can be entered only by calendar year (January–December) and should be sent to: **Elsevier Science Publishers B.V., Journals Department, P.O. Box 211, 1000 AE Amsterdam, The Netherlands, Telex 18582 ESPA NL**, or to your usual subscription agent. Claims for missing issues should be made within three months of publication, otherwise they cannot be honored free of charge.

In the U.S.A. and Canada: All questions arising **after acceptance** of a manuscript by the editor, especially those relating to proofs, publication and reprints, should be directed to the publishers, **Elsevier Science Publishers B.V. P.O. Box 1527, 1000 BM Amsterdam, The Netherlands**. For further information and personal subscriptions, contact: **Elsevier Science Publishing Co., Inc., Attn.: Journal Information Center, 655 Avenue of the Americas, New York, NY 10010, U.S.A. Tel.: (212) 633-3750; Telefax: (212) 633-3990; Telex: 420-643 AEP UI.**

Advertising. Apply to W.J. van Cattenburch (Advertising Manager), P.O. Box 211, 1000 AE Amsterdam, The Netherlands. (Tel. (20) 5803714.)

This journal is printed on acid-free paper.

ISSN 0378-5173

international journal of pharmaceutics

cumulative author and subject indexes
volumes 51–60

published twice monthly



elsevier

INTERNATIONAL JOURNAL OF PHARMACEUTICS

AIMS AND SCOPE

The INTERNATIONAL JOURNAL OF PHARMACEUTICS provides a medium for the publication of research results dealing with all aspects of Pharmaceutics including physical, chemical, analytical, biological and engineering studies related to drug delivery in its broadest sense. Such areas include:

1. Drug delivery systems
2. Physical pharmacy
3. Biopharmaceutics
4. Pharmacodynamics and pharmacokinetics
5. Membrane function and transport
6. Biotechnology
7. Drug and prodrug design
8. Radiopharmaceuticals
9. Sterility and sterilization
10. Quality control of pharmaceuticals
11. Pharmaceutical analysis
12. Drug stability
13. Pharmaceutical technology
14. Descriptions/reviews of computer programs relating to the above areas
15. Application of cell and molecular biology in drug delivery

EDITORIAL POLICY

The over-riding criteria for publication are originality, high scientific quality and interest to a multidisciplinary audience. Papers not sufficiently substantiated by experimental detail will not be published. Any technical queries will be referred back to the author, although the Editors reserve the right to make alterations in the text without altering the technical content.
Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur with the submission and that a copy of the final manuscript has been approved by all authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out. If accepted, the manuscript shall not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors and Publisher.

EDITORS IN CHIEF

For: Europe, Africa, Near East

P.F. D'ARCY
School of Pharmacy,
University of London,
29/39 Brunswick Square,
London WC1N 1AX,
U.K.

For: The Americas and Australia

W.I. HIGUCHI
Department of Pharmaceutics,
College of Pharmacy
University of Utah,
Salt Lake City,
UT 84112,
U.S.A.

J.H. RYTTING
(Associate Editor)
Pharmaceutical Chemistry Dept.,
School of Pharmacy,
University of Kansas,
Lawrence, KS 66045,
U.S.A.

For: Japan

T. NAGAI
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences,
Hoshi University,
Ebara 2-4-41,
Shinagawa-ku,
Tokyo 142, Japan.

EDITORIAL BOARD

G. Amidon (Ann Arbor, MI)
B.D. Anderson (Salt Lake City, UT)
G.S. Banker (Minneapolis, MN)
H. Boxenbaum (Cincinnati, OH)
H. Bundgaard (Copenhagen)
J.T. Carstensen (Madison, WI)
D.J.A. Crommelin (Utrecht)
S.S. Davis (Nottingham)
A.T. Florence (London)
J.L. Fox (Salt Lake City, UT)
H.L. Fung (Amherst, NY)
D. Ganderton (London)
J. Hadgraft (Cardiff)
M. Hanano (Tokyo)
E.N. Hiestand (Kalamazoo, MI)
N.F.H. Ho (Kalamazoo, MI)
T.M. Jones (Beckenham)
K. Knutson (Salt Lake City, UT)
G. Levy (Amherst, NY)
A. Li Wan Po (Belfast)
J.A. Mollica (Wilmington, DE)
J.M. Newton (London)
I.H. Pitman (Parkville)
G. Poste (Philadelphia, PA)
B.J. Poulsen (Palo Alto, CA)
A.J. Repta (Lawrence, KS)
J.R. Robinson (Madison, WI)
T.J. Roseman (Round Lake, IL)
R.C. Rowe (Macclesfield)
M.F. Saettone (Pisa)
H. Sezaki (Kyoto)
J.E. Shaw (Palo Alto, CA)
E. Shefter (San Francisco, CA)
D.D. Shen (Seattle, WA)
J. Sjögren (Mölnlycke)
R.S. Summers (Pretoria)
D.J. Temple (Cardiff)
B. Testa (Lausanne)
K. Thoma (Munich)
R.F. Timoney (Dublin)
E. Tomlinson (Cambridge, MA)
J.L. Vila Jato (Santiago de Compostela)
G. Zografi (Madison, WI)

INSTRUCTIONS TO AUTHORS

Submission of a paper to the International Journal of Pharmaceutics implies: (1) that it is not being submitted for publication elsewhere; (2) the transfer of the Copyright from the Author to the Publisher. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur with the submission and that a copy of the final manuscript has been approved by all authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out. If accepted, the manuscript shall not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors and Publisher.
Papers and original figures should be submitted plus **three copies** and accompanied by a letter of transmittal to one of the Editors in Chief. When the paper is to be published as a Rapid Communication, this should be clearly indicated to the Editor in Chief.

TYPES OF PAPERS

(1) Full length papers.
(2) Rapid communications not exceeding 1500 words or equivalent space.
(3) Notes (formerly Short Communications) limited to 1500 words or equivalent, including figures/tables.
(4) Descriptions/reviews of computer programs useful to pharmaceutical scientists.
(5) Suggestions for Review Articles will be considered by the Editors-in-Chief.

INTERNATIONAL JOURNAL OF PHARMACEUTICS

CUMULATIVE AUTHOR AND SUBJECT INDEXES
VOLUMES 51–60

INTERNATIONAL JOURNAL OF PHARMACEUTICS

Editors in Chief

P.F. D'ARCY (London, U.K.), W.I. HIGUCHI (Salt Lake City, UT, U.S.A.)
and T. NAGAI (Tokyo, Japan)
(Associate Editor: J.H. RYTTING, Lawrence, KS, U.S.A.)

Editorial Board

G. AMIDON (Ann Arbor, MI, U.S.A.)
B.D. ANDERSON (Salt Lake City, UT, U.S.A.)
G.S. BANKER (Minneapolis, MN, U.S.A.)
H. BOXENBAUM (Cincinnati, OH, U.S.A.)
H. BUNDGAARD (Copenhagen, Denmark)
J.T. CARSTENSEN (Madison, WI, U.S.A.)
D.J.A. CROMMELIN (Utrecht, The Netherlands)
S.S. DAVIS (Nottingham, U.K.)
A.T. FLORENCE (London, U.K.)
J.L. FOX (Salt Lake City, UT, U.S.A.)
H.L. FUNG (Amherst, NY, U.S.A.)
D. GANDERTON (London, U.K.)
J. HADGRAFT (Cardiff, U.K.)
M. HANANO (Tokyo, Japan)
E.N. HIESTAND (Kalamazoo, MI, U.S.A.)
N.F.H. HO (Kalamazoo, MI, U.S.A.)
T.M. JONES (Beckenham, U.K.)
K. KNUTSON (Salt Lake City, UT, U.S.A.)
G. LEVY (Amherst, NY, U.S.A.)
A. LI WAN PO (Belfast, U.K.)
J.A. MOLLICA (Wilmington, DE, U.S.A.)
J.M. NEWTON (London, U.K.)
I.H. PITMAN (Parkville, Australia)
G. POSTE (Philadelphia, PA, U.S.A.)
B.J. POULSEN (Palo Alto, CA, U.S.A.)
A.J. REPTA (Lawrence, KS, U.S.A.)
J.R. ROBINSON (Madison, WI, U.S.A.)
T.J. ROSEMAN (Round Lake, IL, U.S.A.)
R.C. ROWE (Macclesfield, U.K.)
M.F. SAETTONE (Pisa, Italy)
H. SEZAKI (Kyoto, Japan)
J.E. SHAW (Palo Alto, CA, U.S.A.)
E. SHEFTER (San Francisco, CA, U.S.A.)
D.D. SHEN (Seattle, WA, U.S.A.)
J. SJÖGREN (Mölnlycke, Sweden)
R.S. SUMMERS (Pretoria, South Africa)
B. TESTA (Lausanne, Switzerland)
D.J. TEMPLE (Cardiff, U.K.)
K. THOMA (Munich, F.R.G.)
R.F. TIMONEY (Dublin, Ireland)
E. TOMLINSON (Cambridge, MA, U.S.A.)
J.L. VILA JATO (Santiago de Compostela, Spain)
G. ZOGRAFI (Madison, WI, U.S.A.)

AUTHOR AND SUBJECT INDEXES
VOLUMES 51–60

ELSEVIER SCIENCE PUBLISHERS B.V. – AMSTERDAM

© 1991, Elsevier Science Publishers B.V.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, Elsevier Science Publishers B.V., P.O. Box 1527, 1000 BM Amsterdam, The Netherlands.

No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in the medical sciences, the Publisher recommends that independent verification of diagnoses and drug dosages should be made.

Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.

Special regulations for authors. Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the Publisher. This transfer will ensure the widest possible dissemination of information.

Submission of a paper to this journal entails the author's irrevocable and exclusive authorization of the Publisher to collect any sums or considerations for copying or reproduction payable by third parties (as mentioned in Article 17, Paragraph 2 of the Dutch Copyright Act of 1912, and in the Royal Decree of June 20, 1974 (S. 351) pursuant to Article 16b of the Dutch Copyright Act of 1912) and/or to act in or out of Court in connection therewith.

Special regulations for readers in the U.S.A. This journal has been registered with the Copyright Clearance Center, Inc. Consent is given for copying of articles for personal or internal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per-copy fee stated in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The appropriate fee should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 27 Congress Street, Salem, MA 01970, U.S.A. If no code appears in an article the author has not given broad consent to copy and permission to copy must be obtained directly from the author. All articles published prior to 1980 may be copied for a per-copy fee of US$ 2.25, also payable through the Center. This consent does not extend to other kinds of copying such as for general distribution, resale, advertising and promotion purposes, or for creating new collective works. Special written permission must be obtained from the Publisher for such copying.

Printed in the Netherlands

This journal is printed on acid-free paper.

Announcement from the Publisher

ELSEVIER SCIENCE PUBLISHERS

encourages the submission of electronic manuscripts

The preferred storage medium is a 5¼ or 3½ inch disk in MS-DOS or MS-DOS compatible format, although other systems, e.g. Macintosh, are acceptable.

Please note that it is essential that the disk submitted for publication is the final corrected version of the article and exactly matches the final manuscript. The disk and corresponding manuscript should be forwarded to the Publisher after acceptance of the article.

Please follow the general instructions on style/arrangement and, in particular, the reference style of this journal as given in 'Instructions to Authors'.

Illustrations and tables will be handled conventionally.

Please label the disk with your name, the software & hardware used and the name of the file to be processed.

Contact the Publisher for further information.

ELSEVIER SCIENCE PUBLISHERS B.V.
P.O. Box 1527, 1000 BM Amsterdam
The Netherlands
Fax: (020) 5803454

International Journal of Pharmaceutics, (1991) 1–19
© 1991 Elsevier Science Publishers B.V. 0378-5173/91/$03.50

Author Index

Abdel-Hamid, M.E., see Suleiman, M.S. (54) 65
Abdel-Hamid, M.E., see Tabba, H.D. (54) 57
Abrahamsson, B., see Wingstrand, K. (60) 151
Abu-Lafi, S., see Tabba, H.D. (54) 57
Addicks, W.J., Flynn, G., Weiner, N. and Curl, R.
A mathematical model to describe drug release from thin topical applications (56) 243
Adesanya, K.I., see Eboka, C.J. (51) 161
Adesanya, K.I., see Eboka, C.J. (51) 263
Aeed, P.A., see Scieszka, J.F. (53) 167
Ahlgren, R., see Wennergren, B. (53) 35
Ahlneck, C. and Alderborn, G.
Moisture adsorption and tabletting. I. Effect on volume reduction properties and tablet strength for some crystalline materials (54) 131
Ahlneck, C. and Alderborn, G.
Moisture adsorption and tabletting. II. The effect on tensile strength and air permeability of the relative humidity during storage of tablets of 3 crystalline materials (56) 143
Aiache, J.-M., Cardot, J.-M. and Aiache, S.
A comparative study of the release kinetics of trinitrine from transdermic therapeutic systems (55) 147
Aiache, S., see Aiache, J.-M. (55) 147
Aito, H., see Marvola, M. (53) 145
Akbarieh, M., see El-Ridy, M. (56) 23
Akbuğa, J.
Preparation and evaluation of controlled release furosemide microspheres by spherical crystallization (53) 99
Al-Arab, M.M., see Tabba, H.D. (54) 57
Al-Assadi, H., see Baillie, A.J. (53) 241
Al-Gamal, S.S., see Al-Gohary, O.M. (55) 47
Al-Gohary, O.M., Al-Gamal, S.S., Hammad, A. and Molokhia, A.M.
Effect of storage on tabletted microencapsulated aspirin granules (55) 47
Al-Meshal, M.A., see Turkistani, A.A.A. (59) R1
Al-Razzak, L.A. and Stella, V.J.
Stability and solubility of 2-chloro-2′,3′-dideoxyadenosine (60) 53
Al-Shora, H.I., see Turkistani, A.A.A. (59) R1
Aldén, M., see Sjökvist, E. (54) 161
Alderborn, G., see Ahlneck, C. (54) 131
Alderborn, G., see Ahlneck, C. (56) 143
Alexander, J., see Baillie, A.J. (57) 23
Alexander, J., see Carter, K.C. (53) 129
Allen, Jr., L.V., see Kale, N.J. (57) 87
Allen, Jr., L.V., see Tu, Y.-H. (51) 157
Alonso, M.J., see Torres, D. (59) 9
Altomare, C., Carotti, A., Cellamare, S. and Ferappi, M.
Lipophilicity measurements of benzenesulfonamide inhibitors of carbonic anhydrase by reversed-phase HPLC (56) 273
Amagase, H., see Murakami, T. (54) 259
Amdidouche, D., Darrouzet, H., Duchêne, D. and Poelman, M.-C.
Inclusion of retinoic acid in β-cyclodextrin (54) 175
Amidon, G., see Johnston, T.P. (59) 95
Amidon, G.L., see Johnston, T.P. (52) 139
Amidon, G.L., see Sinko, C.M. (55) 247
Ammoury, N., see Fessi, H. (55) R1
Andersin, R. and Tammilehto, S.
Photochemical decomposition of midazolam. II. Kinetics in ethanol (56) 175
Anderson, B.D., see Darrington, R.T. (59) 35
Anderson, B.D., see Xiang, T.-x. (59) 45
Anglade, P., see Postaire, E. (55) 99
Antal, E.J., Dick, C.F., Wright III, C.E., Welshman, I.R. and Block, E.M.
Comparative bioavailability of two medroxyprogesterone acetate suspensions (54) 33
Antimisiaris, S., see Macheras, P. (54) 123
Apichartpichean, R., see Hasegawa, T. (56) 235
Apichartpichean, R., see Hasegawa, T. (58) 129
Araki, Y., see Gomita, Y. (54) 89
Archondikis, A. and Papaioannou, G.
Comparative study of two dissolution methods for indomethacin suppositories from fatty and water-soluble bases (55) 217
Arima, H., Irie, T. and Uekama, K.
Differences in the enhancing effects of water soluble β-cyclodextrins on the release of ethyl 4-biphenylyl acetate, an anti-inflammatory agent from an oleaginous suppository base (57) 107
Artursson, P., Berg, A. and Edman, P.
Biochemical and cellular effects of degraded starch microspheres on macrophages (52) 183
Arwidsson, H. and Nicklasson, M.
Application of intrinsic viscosity and interaction constant as a formulation tool for film coating. I. Studies on ethyl cellulose 10 cps in organic solvents (56) 187
Arwidsson, H. and Nicklasson, M.
Application of intrinsic viscosity and interaction constant

as a formulation tool for film coating. II. Studies on different grades of ethyl cellulose in organic solvent systems (58) 73
Ashby, L.J., Beezer, A.E. and Buckton, G.
In vitro dissolution testing of oral controlled release preparations in the presence of artificial foodstuffs. I. Exploration of alternative methodology: microcalorimetry (51) 245
Asuero, A.G.
A bilogarithmic method for the evaluation of acidity constants of amphoteric substances from solubility measurements (52) 129
Attwood, D. and Ktistis, G.
A light scattering study on oil-in-water microemulsions (52) 165
Audus, K.L., see Tavakoli-Saberi, M.R. (56) 135
Aungst, B.J. and Rogers, N.J.
Comparison of the effects of various transmucosal absorption promoters on buccal insulin delivery (53) 227
Ayres, J.W., see Borin, M.T. (54) 199

Babu, S.R., see Radebaugh, G.W. (57) 95
Baillie, A.J., Al-Assadi, H. and Florence, A.T.
Influence of non-ionic surfactant structure on motility inhibition of *Tetrahymena elliotti*: a model for surfactant–membrane interactions (53) 241
Baillie, A.J., Dolan, T.F., Alexander, J. and Carter, K.C.
Visceral leishmaniasis in the BALB/c mouse: sodium stibogluconate treatment during acute and chronic stages of infection (57) 23
Baillie, A.J., see Carter, K.C. (53) 129
Baker, N.D., Griffin, R.J., Irwin, W.J. and Slack, J.A.
The reduction of aryl azides by dithiothreitol: a model for bioreduction of aromatic azido-substituted drugs (52) 231
Barber, R.F. and Shek, P.N.
Tear-induced release of liposome-entrapped agents (60) 219
Barry, B.W., see Goodman, M. (57) 29
Barry, B.W., see Kadir, R. (60) 139
Barry, B.W., see Williams, A.C. (36) 43
Barry, B.W., see Williams, A.C. (57) R7
Barry, M.D. and Rowe, R.C.
The characterisation by small-angle X-ray scattering of a pharmaceutical gel with a lamellar structure (53) 139
Beckett, A.H., Behrendt, W.A. and Hadzija, B.W.
Some aspects on the bioavailability of a controlled release clonidine formulation in man (52) 37
Beezer, A.E., see Ashby, L.J. (51) 245
Beezer, A.E., see Buckton, G. (56) 151
Bégué, J.-M., see Rolland, A. (53) 67
Behrendt, W.A., see Beckett, A.H. (52) 37
Beijnen, J.H., see Bekers, O. (52) 239
Beijnen, J.H., see Bekers, O. (56) 103
Beijnen, J.H., see Suenaga, A. (59) 121
Bekers, O., Beijnen, J.H., Groot Bramel, E.H., Otagiri, M., Bult, A. and Underberg, W.J.M.
Stabilization of mitomycins on complexation with cyclodextrins in aqueous acidic media (52) 239
Bekers, O., Beijnen, J.H., Storm, G., Bult, A. and Underberg, W.J.M.
Chemical stability of *N*-trifluoroacetyldoxorubicin-14-valerate (AD-32) in aqueous media and after liposome encapsulation (56) 103
Bekers, O., see Suenaga, A. (59) 121
Bellotti, A., see Catellani, P.L. (51) 63
Beltrami, V., see Gander, B. (58) 63
Benita, S., see Fessi, H. (55) R1
Benita, S., see Levy, M.Y. (54) 103
Berg, A., see Artursson, P. (52) 183
Bernabei, M.T., see Forni, F. (60) 83
Betteridge, R.F., Culverwell, A.L. and Bosanquet, A.G.
Stability of tauromustine (TCNU) in aqueous solutions during preparation and storage (56) 37
Bidah, D. and Vergnaud, J.M.
Kinetics of in vitro release of sodium salicylate dispersed in Gelucire (58) 215
Biddiscombe, M., see Zainudin, B.M.Z. (51) 67
Bilbao-Revoredo, O., see Sutinen, R. (57) 155
Björnsdóttir, S., see Loftsson, T. (57) 63
Blake, J.M., see Quigley, J.M. (54) 155
Block, E.M., see Antal, E.J. (54) 33
Boddé, H.E., Kruithof, M.A.M., Brussee, J. and Koerten, H.K.
Visualisation of normal and enhanced $HgCl_2$ transport through human skin in vitro (53) 13
Boddé, H.E., see Bouwstra, J.A. (52) 47
Boddé, H.E., see Tiemessen, H.L.G.M. (53) 119
Boddé, H.E., see De Haan, F.H.N. (56) 75
Boddé, H.E., see Tiemessen, H.L.G.M. (56) 87
Bodmeier, R. and Paeratakul, O.
Propranolol HCl release from acrylic films prepared from aqueous latexes (59) 197
Bodmeier, R., Oh, K.H. and Chen, H.
The effect of the addition of low molecular weight poly(DL-lactide) on drug release from biodegradable poly(DL-lactide) drug delivery systems (51) 1
Bodor, N., Venkatraghavan, V., Winwood, D., Estes, K. and Brewster, M.E.
Improved delivery through biological membranes. XLI. Brain-enhanced delivery of chlorambucil (53) 195
Bodor, N., see Brewster, M.E. (59) 231
Bodor, N., see El-Koussi, A.A. (53) 189
Bodor, N., see Loftsson, T. (57) 63
Bodor, N.S., see Dietzel, K. (59) 225
Bolling, S.F., see Johnston, T.P. (52) 139
Bondi, J.N., see Radebaugh, G.W. (57) 95
Bonfils, A., see Fortier, M. (52) 27
Bonner, F.J., see Quigley, J.M. (54) 155
Bonny, J.D., see Leuenberger, H. (52) 91
Bootsma, H.P.R., Frijlink, H.W., Eissens, A., Proost, J.H., Van Doorne, H. and Lerk, C.F.
β-Cyclodextrin as an excipient in solid oral dosage forms: in vitro and in vivo evaluation of spray-dried diazepam-β-cyclodextrin products (51) 213
Borin, M.T. and Ayres, J.W.
Single dose bioavailability of acetaminophen following oral administration (54) 199
Bos, C.E., Van Doorne, H. and Lerk, C.F.

Microbiological stability of tablets stored under tropical conditions (55) 175
Bosanquet, A.G., see Betteridge, R.F. (56) 37
Boston, V., see Woolfson, A.D. (51) 183
Bottenberg, P., Slop, D., Remon, J.P., De Muynck, C. and Coomans, D.
Penetration of some commercially available fluoride gels into occlusal fissures in vitro (58) 203
Boussard, P., Devleeschouwer, M.J. and Dony, J.
Prevention of the adhesion of *Pseudomonas aeruginosa* to human buccal epithelial cells (53) 253
Bouwstra, J.A., Peschier, L.J.C., Brussee, J. and Boddé, H.E.
Effect of *N*-alkyl-azocycloheptan-2-ones including azone on the thermal behaviour of human stratum corneum (52) 47
Bove, E.L., see Johnston, T.P. (52) 139
Boyd, J.A., see Johnston, T.P. (52) 139
Boyd, J.A., see Johnston, T.P. (59) 95
Brewster, M.E., Estes, K.S. and Bodor, N.
An intravenous toxicity study of 2-hydroxypropyl-β-cyclodextrin, a useful drug solubilizer, in rats and monkeys (59) 231
Brewster, M.E., see Bodor, N. (53) 195
Brewster, M.E., see Dietzel, K. (59) 225
Brion, F., see Postaire, E. (55) 99
Brussee, J., see Boddé, H.E. (53) 13
Brussee, J., see Bouwstra, J.A. (52) 47
Buckton, G., Beezer, A.E., Chatham, S.M. and Patel, K.K.
In vitro dissolution testing of oral controlled release preparations in the presence of artificial foodstuffs. II. Probing drug/food interactions using microcalorimetry (56) 151
Buckton, G., see Ashby, L.J. (51) 245
Buckton, G., see Efentakis, M. (60) 229
Buckton, G., see Young, S.A. (60) 235
Buckton, G., see Zajic, L. (59) 155
Bult, A., see Bekers, O. (52) 239
Bult, A., see Bekers, O. (56) 103
Bundgaard, H., Mørk, N. and Hoelgaard, A.
Enhanced delivery of nalidixic acid through human skin via acyloxymethyl ester prodrugs (55) 91
Bundgaard, H., see Drustrup Larsen, J. (51) 27
Bundgaard, H., see Jensen, E. (58) 143
Bundgaard, H., see Mørk, N. (60) 163
Bundgaard, H., see Møss, J. (52) 255
Bundgaard, H., see Steffansen, B. (56) 159
Burgalassi, S., see Saettone, M.F. (51) 203
Buri, P., see Ranga Rao, K.V. (52) 265
Burke, M., see Harron, D.W.G. (57) 9
Burton, P.S., see Cho, M.J. (52) 79
Butterworth, P., see Thomas, N.W. (53) 261

Cachet, T., Van den Mooter, G., Hauchecorne, R., Vinckier, C. and Hoogmartens, J.
Decomposition kinetics of erythromycin A in acidic aqueous solutions (55) 59
Cachet, T., see Vinckier, C. (55) 67
Caramella, C., see Peppas, N.A. (51) 77
Cardot, J.-M., see Aiache, J.-M. (55) 147
Carelli, V., Di Colo, G., Nannipieri, E. and Serafini, M.F.
Evaluation of the solution impregnation method for loading drugs into suspension-type polymer matrices: a study of factors determining the patterns of solid drug distribution in matrix and drug release from matrix (55) 199
Carlisi, B., see Castelli, F. (59) 19
Carlisi, B., see Giammona, G. (57) 55
Carlucci, G., Colanzi, A., Mazzeo, P. and Quaglia, M.G.
Determination of 2-aminopyridine in piroxicam by derivative UV-spectrophotometry (53) 257
Carman-Meakin, B., see Farr, S.J. (51) 39
Carotti, A., see Altomare, C. (56) 273
Carrupt, P.-A., see Gryllaki, M. (51) 95
Carrupt, P.-A., see Röthlisberger, T. (51) 73
Carruthers, K.M., see Smith, A. (59) 115
Carstensen, J.T., see Van Scoik, K.G. (58) 185
Carter, K.C., O'Grady, J., Dolan, T.F., Baillie, A.J., Alexander, J. and Keys, J.
A direct comparison of sodium stibogluconate treatment in two animal models of human visceral leishmaniasis, mouse and hamster (53) 129
Carter, K.C., see Baillie, A.J. (57) 23
Caruso, A., see Giammona, G. (57) 55
Casabó, V.G., see Pérez-Buendía, M.D. (55) 165
Castelli, F., Giammona, G., Puglisi, G., Carlisi, B. and Gurrieri, S.
Interaction of macromolecular pro-drugs with lipid model membrane: calorimetric study of 4-biphenylacetic acid linked to α,β-poly(*N*-hydroxyethyl)-DL-aspartamide interacting with phosphatidylcholine vesicles (59) 19
Castelli, F., Puglisi, G., Pignatello, R. and Gurrieri, S.
Calorimetric studies of the interaction of 4-biphenylacetic acid and its β-cyclodextrin inclusion compound with lipid model membrane (52) 115
Catellani, P.L., Predella, P., Bellotti, A. and Colombo, P.
Tablet water uptake and disintegration force measurements (51) 63
Catz, P. and Friend, D.R.
Alkyl esters as skin permeation enhancers for indomethacin (55) 17
Catz, P. and Friend, D.R.
Transdermal delivery of levonorgestrel. VIII. Effect of enhancers on rat skin, hairless mouse skin, hairless guinea pig skin, and human skin (58) 93
Cellamare, S., see Altomare, C. (56) 273
Cha, C.Y., see Lee, K.C. (59) 27
Chafi, N., Montheard, J.P. and Vergnaud, J.M.
Dosage form with salicylic acid attached to a polyanhydride polymer dispersed in an Eudragit matrix (52) 203
Chan, H.-K. and Grant, D.J.W.
Influence of compaction on the intrinsic dissolution rate of modified acetaminophen and adipic acid crystals (57) 117
Chan, S.Y. and Li Wan Po, A.
Prodrugs for dermal delivery (55) 1
Chang, R.-K., Iturrioz, G. and Luo, C.-W.
Preparation and evaluation of shellac pseudolatex as an aqueous enteric coating system for pellets (60) 171

Chast, F., see Dumortier, G. (59) 1
Chatham, S.M., see Buckton, G. (56) 151
Chaumeil, J.C., see Dumortier, G. (59) 1
Chawla, A., see Washington, C. (54) 191
Chawner, J.A. and Gilbert, P.
Adsorption of alexidine and chlorhexidine to *Escherichia coli* and membrane components (55) 209
Chen, H., see Bodmeier, R. (51) 1
Chen, T.K., Thornton, D. and Ho, M.Y.K.
Reduction of dimethyl sulfoxide by dihydrohalide salts of pharmaceuticals (59) 211
Chetoni, P., see Saettone, M.F. (51) 203
Chiam, S.-F., see Hu, O.Y.-P. (53) 85
Chiang, C.-M., Flynn, G.L., Weiner, N.D. and Szpunar, G.J.
Bioavailability assessment of topical delivery systems: Effect of vehicle evaporation upon in vitro delivery of minoxidil from solution formulations (55) 229
Chien, Y.W., see Lelawongs, P. (56) 13
Chien, Y.W., see Wearley, L.L. (59) 87
Cho, M.J., Scieszka, J.F. and Burton, P.S.
Citric acid as an adjuvant for transepithelial transport (52) 79
Cho, M.J., see Scieszka, J.F. (53) 167
Chow, H.-L.A. and Grant, D.J.W.
Influence of crystallization conditions on the physical properties of acetaminophen crystals: evaluation by multiple linear regression (51) 115
Chow, A.H.-L. and Grant, D.J.W.
Physical factors influencing the aqueous dissolution rate of acetaminophen crystals doped with *p*-acetoxyacetanilide: evaluation by multiple linear regression (51) 129
Chowhan, Z.T., see Wang, L.-H. (60) 61
Christensen, S., see Mørk, N. (60) 163
Christy, N., see Washington, C. (54) 191
Chu, M.-L., see Hu, O.Y.-P. (53) 85
Chung, P.-H., see Hu, O.Y.-P. (53) 85
Ciesliga, B.L., see Johnston, T.P. (52) 139
Ciesliga, B.L., see Johnston, T.P. (59) 95
Colanzi, A., see Carlucci, G. (53) 257
Collado, E.F., see Garrigues, T.M. (57) 189
Collier, P.S., see Grainger-Rousseau, T.-J. (54) 1
Collier, P.S., see McClean, E. (60) 35
Collins, A.E.M., Deasy, P.B., MacCarthy, D.J. and Shanley, D.B.
Evaluation of a controlled-release compact containing tetracycline hydrochloride bonded to tooth for the treatment of periodontal disease (51) 103
Colombo, P., see Catellani, P.L. (51) 63
Colombo, P., see Peppas, N.A. (51) 77
Conklin, J.D., see Wagner, D.L. (57) 177
Conrath, G., see Couarraze, G. (56) 197
Conte, U., see Peppas, N.A. (51) 77
Conti, B., see Pavanetto, F. (51) 55
Conti, B., see Pavanetto, F. (54) 143
Cook, C.S., Hauswald, C.L., Grahn, A.Y., Kowalski, K., Karim, A., Koch, R., Schoenhard, G.L. and Oppermann, J.A.
Suitability of the dog as an animal model for evaluating theophylline absorption and food effects from different formulations (60) 125
Coomans, D., see Bottenberg, P. (58) 203
Coppi, G., see Forni, F. (60) 83
Corrigan, O.I., see Quigley, J.M. (58) 107
Cots, J., see Pujol, M. (58) 103
Couarraze, G., Leclerc, B., Conrath, G., Falson-Rieg, F. and Puisieux, F.
Diffusion of a dispersed solute in a polymeric matrix (56) 197
Couvreur, P., see Marchal-Heussler, L. (58) 115
Critchley, H., see Illum, L. (57) 49
Cucala, J., see Fábregas, J.L. (52) 173
Culverwell, A.L., see Betteridge, R.F. (56) 37
Curl, R., see Addicks, W.J. (56) 243

Daniel, P.T., see Müller, C.E. (57) 41
Darrington, R.T., Xiang, T.-x. and Anderson, B.D.
Inclusion complexes of purine nucleosides with cyclodextrins. I. Complexation and stabilization of a dideoxypurine nucleoside with 2-hydroxypropyl-β-cyclodextrin (59) 35
Darrouzet, H., see Amdidouche, D. (54) 175
Davies, M.C., Wilding, I.R., Short, R.D., Khan, M.A., Watts, J.F. and Melia, C.D.
An analysis of the surface chemical structure of polymethacrylate (Eudragit) film coating polymers by XPS (57) 183
Davis, S.S., Khosla, R., Wilson, C.G., Washington, N., Leslie, S.T. and Malkowska, S.
The gastrointestinal transit of a controlled release formulation of indomethacin (60) 191
Davis, S.S., see Farraj, N.F. (52) 11
Davis, S.S., see Farraj, N.F. (52) 19
Davis, S.S., see Illum, L. (52) 221
Davis, S.S., see Illum, L. (54) 41
Davis, S.S., see Illum, L. (57) 49
Davis, S.S., see Johnson, O.L. (53) 237
Davis, S.S., see Johnson, O.L. (59) 131
Davis, S.S., see Khosla, R. (52) 1
Davis, S.S., see Khosla, R. (53) 107
Davis, S.S., see Torrado, J.J. (51) 85
Davis, S.S., see Washington, C. (54) 191
Deasy, P.B., see Collins, A.E.M. (51) 103
De Bruijn, W.C., see De Haan, F.H.N. (56) 75
Deering, A., see Harron, D.W.G. (57) 9
De Haan, F.H.N., Boddé, H.E., De Bruijn, W.C., Ginsel, L.A. and Junginger, H.E.
Visualizing drug transport across stratum corneum: cryotechniques, vapour fixation, autoradiography (56) 75
De Muynck, C., see Bottenberg, P. (58) 203
Derendorf, H., see Dietzel, K. (59) 225
De Vilder, J., see Herman, J. (56) 51
Devine, S., see Harron, D.W.G. (57) 9
Devissaguet, J.-P., see Gürsoy, A. (52) 101
Devissaguet, J.P., see Fessi, H. (55) R1
Devleeschouwer, M.J., see Boussard, P. (53) 253

Devleeschouwer, M.J., see Ibwala, N. (59) 205
Dick, C.F., see Antal, E.J. (54) 33
Di Colo, G., see Carelli, V. (55) 199
Diepold, R., Kreuter, J., Guggenbuhl, P. and Robinson, J.R.
Distribution of poly-hexyl-2-cyano-[3-^{14}C]acrylate nanoparticles in healthy and chronically inflamed rabbit eyes (54) 149
Dietzel, K., Estes, K.S., Brewster, M.E., Bodor, N.S. and Derendorf, H.
The use of 2-hydroxypropyl-β-cyclodextrin as a vehicle for intravenous administration of dexamethasone in dogs (59) 225
Doelker, E., see Gander, B. (58) 63
Dolan, T.F., see Baillie, A.J. (57) 23
Dolan, T.F., see Carter, K.C. (53) 129
Dony, J., see Boussard, P. (53) 253
Dony, J., see Ibwala, N. (59) 205
Drustrup Larsen, J. and Bundgaard, H.
Prodrug forms for the sulfonamide group. III. Chemical and enzymatic hydrolysis of various *N*-sulfonyl imidates — a novel prodrug form for a sulfonamide group or an ester function (51) 27
Duchêne, D., see Amdidouche, D. (54) 175
Dumortier, G., Zuber, M., Chast, F., Sandouk, P. and Chaumeil, J.C.
Systemic absorption of morphine after ocular administration: evaluation of morphine salt insert in vitro and in vivo (59) 1

Ebian, A.R., see Nada, A.H. (53) 175
Eboka, C.J. and Adesanya, K.I.
Assay of drugs in the presence of spectral interferants in tablets (51) 161
Eboka, C.J. and Adesanya, K.I.
Spectrophotometric assay of drugs in the presence of spectral interferants in suspensions and syrups (51) 263
Economou, P.T., see Issopoulos, P.B. (57) 235
Edgar, B., see Wingstrand, K. (60) 151
Edman, P., see Artursson, P. (52) 183
Efentakis, M. and Buckton, G.
Modelling drug release from hydrophobic matrices by use of thermodynamic activation parameters (60) 229
Eickhoff, W.M., see Fong, G.W. (53) 91
Eissens, A., see Bootsma, H.P.R. (51) 213
El-Arini, S.K., Shiu, G.K. and Skelly, J.P.
An in vitro study of possible food–drug interactions of the controlled-release propranolol products (55) 25
El-Gorashi, A.S., see Niazy, E.M. (56) 181
El-Khordagui, L.K., see Saleh, A.M. (57) 205
El-Koussi, A.A. and Bodor, N.
Formation of propranolol in the iris-ciliary body from its propranolol ketoxime precursor – a potential antiglaucoma drug (53) 189
El-Ridy, M., Akbarieh, M., Kassem, M., Sharkawi, M. and Tawashi, R.
Chemoprophylaxis of schistosomiasis using liposome-encapsulated tartar emetic (56) 23
El Eini, D.I.D., see Vincké, B.J. (54) 181
Elkins, J., see Shah, V.P. (53) 53
El Sirag, O., see El Turabi, H. (53) 249
El Tayar, N., see Gryllaki, M. (51) 95
El Turabi, H., El Sirag, O., Homeida, M.M.A., Harron, D.W.G. and Leahey, W.J.
Paracetamol pharmacokinetics in patients with hepatosplenic schistosomiasis (53) 249
Eroğlu, L., see Gürsoy, A. (52) 101
Esezobo, S.
Disintegrants: effects of interacting variables on the tensile strengths and disintegration times of sulphaguanidine tablets (56) 207
Estelrich, J., see Hernández, J. (57) 211
Estes, K., see Bodor, N. (53) 195
Estes, K.S., see Brewster, M.E. (59) 231
Estes, K.S., see Dietzel, K. (59) 225
Etman, M.A. and Naggar, V.F.
Thermodynamics of paracetamol solubility in sugar-water cosolvent systems (58) 177
Etman, M.A., see Nada, A.H. (53) 175
Eto, K., see Gomita, Y. (54) 89
Ezzedeen, F.W., Majeed, S.H., Shihab, F.A., Mahmoud, M.J., Robinson, D.H., Tahseen, Y.H. and Stohs, S.J.
In vitro and in vivo evaluation of four co-trimoxazole oral suspensions (59) 255

Fabra-Campos, S., see Garrigues, T.M. (57) 189
Fábregas, J.L. and Cucala, J.
Influence of microphysical structure on in vitro activity of new synthetic antacids (52) 173
Fahelelbom, K.M.S., see Quigley, J.M. (58) 107
Fairbrother, J.E., see Kadir, R. (60) 139
Falch, E., see Jensen, E. (58) 143
Falson-Rieg, F., see Couarraze, G. (56) 197
Farr, S.J., Kellaway, I.W. and Carman-Meakin, B.
Comparison of solute partitioning and efflux in liposomes formed by a conventional and an aerosolised method (51) 39
Farraj, N.F., Davis, S.S., Parr, G.D. and Stevens, H.N.E.
Modification of the aqueous solubility and stability of progabide (52) 11
Farraj, N.F., Davis, S.S., Parr, G.D. and Stevens, H.N.E.
Studies on the simultaneous dissolution and degradation of progabide powders (52) 19
Farraj, N.F., see Illum, L. (57) 49
Fassihi, A.R., see Munday, D.L. (52) 109
Fawzi, M.B., see Mahjour, M. (56) 1
Fee, J.P.H., see McClean, E. (60) 35
Feely, L.C., see Khosla, R. (53) 107
Fell, J.T., see Harris, D. (56) 97
Fell, J.T., see Luangtana-Anan, M. (60) 197
Ferappi, M., see Altomare, C. (56) 273
Ferrari, F., see Peppas, N.A. (51) 77
Fessi, H., Puisieux, F., Devissaguet, J.P., Ammoury, N. and Benita, S.
Nanocapsule formation by interfacial polymer deposition following solvent displacement (55) R1
Fessi, H., see Gürsoy, A. (52) 101

Field, W.N., Gamble, M.D. and Lewis, D.A.
A comparison of the treatment of thyroidectomized rats with free thyroxine and thyroxine encapsulated in erythrocytes (51) 175
Fisch, A., see Vincent-Ballereau, F. (58) 25
Florence, A.T., see Baillie, A.J. (53) 241
Florence, A.T., see Saleh, A.M. (57) 205
Flynn, G., see Addicks, W.J. (56) 243
Flynn, G.L., see Chiang, C.-M. (55) 229
Fong, G.W. and Eickhoff, W.M.
Liquid chromatographic determination of amines in complex cough-cold formulations (53) 91
Ford, J.L., see Vulovic, N. (55) 123
Forni, F., Coppi, G., Vandelli, M.A. and Bernabei, M.T.
An interpretation of the diffusion-type mechanism of drug release from microcapsules (60) 83
Fort, J.J. and Mitra, A.K.
Solubility and stability characteristics of a series of methotrexate dialkyl esters (59) 271
Fortier, M., Bonfils, A., Zalisz, R., Heyman, M. and Smets, P.
Pharmacokinetic profile of RU 41740, a bacterial immunomodulator, in mice, rats, and monkeys (52) 27
Friend, D.R., see Catz, P. (55) 17
Friend, D.R., see Catz, P. (58) 93
Frijlink, H.W., see Bootsma, H.P.R. (51) 213
Fujihara, Y., see Kaneo, Y. (57) 263
Fujimoto, S., see Morimoto, Y. (54) 27
Fujimoto, S., see Natsume, H. (58) 79
Fujita, K., see Kaneo, Y. (57) 263
Fujita, Y., see Katsu, T. (53) 61
Furuno, K., see Gomita, Y. (54) 89
Fuwa, T., see Murakami, T. (54) 259

Gaber, M., see Turkistani, A.A.A. (59) R1
Gamble, M.D., see Field, W.N. (51) 175
Gander, B., Beltrami, V., Gurny, R. and Doelker, E.
Effects of the method of drug incorporation and the size of the monolith on drug release from cross-linked polymers (58) 63
García-Encina, G., see Torres, D. (59) 9
Garrigues, T.M., Collado, E.F., Fabra-Campos, S., Pérez-Buendía, M.D., Martín-Villodre, A. and Plá-Delfina, J.M.
Absorption-partition relationships for true homologous series of xenobiotics as a possible approach to study mechanisms of surfactants in absorption. III. Aromatic amines and cationic surfactants (57) 189
Garrigues, T.M., see Pérez-Buendía, M.D. (55) 165
Gazzaniga, A., see Peppas, N.A. (51) 77
Genta, I., see Pavanetto, F. (51) 55
Genta, I., see Pavanetto, F. (54) 143
Georgiacodis, M., see Macheras, P. (52) 249
Ghebre-Sellassie, I., see Yang, S.T. (60) 109
Ghodbane, S. and McCauley, J.A.
Study of the polymorphism of 3-(((3-(2-(7-chloro-2-quinolinyl)- (*E*)-ethenyl)phenyl)((3-(dimethylamino-3-oxopropyl)thio)methyl)- thio)propanoic acid (MK571) by DSC, TG, XRPD and solubility measurements (59) 281
Giammona, G., Puglisi, G., Carlisi, B., Pignatello, R., Spadaro, A. and Caruso, A.
Polymeric prodrugs: α,β-poly (*N*-hydroxyethyl)-DL-aspartamide as a macromolecular carrier for some non-steroidal anti-inflammatory agents (57) 55
Giammona, G., see Castelli, F. (59) 19
Giannaccini, B., see Saettone, M.F. (51) 203
Gilbert, P., see Chawner, J.A. (55) 209
Ginsel, L.A., see De Haan, F.H.N. (56) 75
Girona, V., see Pujol, M. (58) 103
Gleeson, J.M., see Seminoff, L.A. (54) 251
Goethals, F., see Tasset, C. (58) 41
Gomita, Y., Nanba, M., Furuno, K., Eto, K. and Araki, Y.
Microdetermination of cimetidine in rat plasma by high-performance liquid chromatography (54) 89
Goodman, M. and Barry, B.W.
Lipid-protein-partitioning (LPP) theory of skin enhancer activity: finite dose technique (57) 29
Goto, H., see Sugito, K. (60) 89
Gouda, M.W., see Turkistani, A.A.A. (59) R1
Gould, P.L., Howard, J.R. and Oldershaw, G.A.
The effect of hydrate formation on the solubility of theophylline in binary aqueous cosolvent systems (51) 195
Gould, P.L., see Thomas, N.W. (53) 261
Graf, E., see März, F. (58) 155
Grahn, A.Y., see Cook, C.S. (60) 125
Grainger-Rousseau, T.-J., McElnay, J.C. and Collier, P.S.
The influence of disease on plasma protein binding of drugs (54) 1
Grant, D.J.W., see Albert, (51) 115
Grant, D.J.W., see Chan, H.-K. (57) 117
Grant, D.J.W., see Chow, A.H.-L. (51) 129
Gratteri, P., see Orzalesi, G. (52) 225
Greaves, J.L., see Washington, N. (57) 17
Green, P.G., Hadgraft, J. and Wolff, M.
Physicochemical aspects of the transdermal delivery of Bupranolol (55) 265
Greenway, M.J., see Jones, S.P. (53) 43
Griffin, R.J., see Baker, N.D. (52) 231
Grislingaas, A.-L., see Tønnesen, H.H. (60) 157
Gröning, R. and Heun, G.
Dosage forms with controlled gastrointestinal passage – studies on the absorption of nitrofurantoin (56) 111
Groot Bramel, E.H., see Bekers, O. (52) 239
Grove, J., see Rozier, A. (57) 163
Gryllaki, M., Van de Waterbeemd, H., Testa, B., El Tayar, N., Mayer, J.M. and Carrupt, P.-A.
Solvent-dependent lipophilicity and hydrogen-bonding capacity of 2-pyridylalkanols (51) 95
Gu, L. and Strickley, R.G.
A profound solvent effect on the diketopiperazine formation of the new dipeptide angiotensin-converting enzyme inhibitor, Moexipril (60) 99
Guggenbuhl, P., see Diepold, R. (54) 149
Guillouzo, A., see Rolland, A. (53) 67
Gupta, P.K. and Hung, C.-T.
Albumin microspheres. V. Evaluation of parameters con-

trolling the efficacy of magnetic microspheres in the targeted delivery of adriamycin in rats (59) 57
Gupta, P.K. and Hung, C.T.
Quantitative evaluation of targeted drug delivery systems (56) 217
Gupta, P.K., Lam, F.C. and Hung, C.T.
Albumin microspheres. IV. Effect of protein concentration and stabilization time on the release rate of adriamycin (51) 253
Gupta, P.K.
Magnetite as a tracer for the estimation of biodistribution of microspheres: a critical consideration (52) 87
Gurny, R., see Gander, B. (58) 63
Gurrieri, S., see Castelli, F. (52) 115
Gurrieri, S., see Castelli, F. (59) 19
Gürsoy, A., Eroğlu, L., Ulutin, Ş., Taşyürek, M., Fessi, H., Puisieux, F. and Devissaguet, J.-P.
Evaluation of indomethacin nanocapsules for their physical stability and inhibitory activity on inflammation and platelet aggregation (52) 101
Guy, R.H. and Hadgraft, J.
On the determination of drug release rates from topical dosage forms (60) R1

Hadgraft, J., see Green, P.G. (55) 265
Hadgraft, J., see Guy, R.H. (60) R1
Hadzija, B.W., see Beckett, A.H. (52) 37
Hailey, F.J., see Wagner, D.L. (57) 177
Hamaguchi, N., see Iga, K. (57) 241
Hammad, A., see Al-Gohary, O.M. (55) 47
Hanlon, G.W., see Wilkins, K.M. (57) 1
Hanlon, G.W., see Wilkins, K.M. (58) 165
Harboe, E., Larsen, C., Johansen, M. and Olesen, H.P.
Macromolecular prodrugs. XIV. Absorption characteristics of naproxen after oral administration of a dextran T-70-naproxen ester prodrug in pigs (53) 157
Harper, M.I.A., see Taylor, R.B. (60) 185
Harris, D., Fell, J.T., Taylor, D.C., Lynch, J. and Sharma, H.L.
Oral availability of a poorly absorbed drug, hydrochlorothiazide, from a bioadhesive formulation in the rat (56) 97
Harron, D.W.G., Liddle, J., Devine, S., Scott, M.G., Deering, A., Burke, M. and Shanks, R.G.
Pharmacokinetics and dynamics of a new formulation of slow release oxprenolol combined with triamterene and hydrochlorothiazide in healthy man (57) 9
Harron, D.W.G.
Digoxin pharmacokinetic modelling – 10 years later (53) 181
Harron, D.W.G., see El Turabi, H. (53) 249
Hasan, M.M., see Tabba, H.D. (54) 57
Hasegawa, T., Apichartpichean, R., Kuzuya, T., Nadai, M., Tsunekawa, Y., Horiuchi, T. and Miyamoto, K.
Protein binding characteristics of new bronchodilators, 1-methyl-3-propylxanthine (MPX) and 3-propylxanthine (enprofylline) (56) 235
Hasegawa, T., Miyamoto, K., Wakusawa, S., Takagi, K., Apichartpichean, R., Kuzuya, T., Nadai, M. and Horiuchi, T.
Relationship between hydrophobicity and biological activities of xanthine derivatives in guinea pig tracheal smooth muscle (58) 129
Hasegawa, T., see Kawaguchi, T. (58) R1
Hashida, M., see Sakane, T. (57) 77
Hashida, M., see Yamamoto, A. (51) 137
Haslam, J.L., Merfeld, A.E. and Rork, G.S.
Surface wetting effects in the lipid osmotic pump (56) 227
Hassan, M.A., Suleiman, M.S. and Najib, N.M.
Improvement of the in vitro dissolution characteristics of famotidine by inclusion in β-cyclodextrin (58) 19
Hassan, M.A., see Suleiman, M.S. (54) 65
Hauchecorne, R., see Cachet, T. (55) 59
Hauchecorne, R., see Vinckier, C. (55) 67
Hauswald, C.L., see Cook, C.S. (60) 125
Hayward, D.S., Kenley, R.A. and Jenke, D.R.
Interactions between polymer containers and parenteral solutions: the correlation of equilibrium constants for polymer-water partitioning with octanol-water partition coefficients (59) 245
Hedin, L., see Lundin, S. (59) 263
Hendriksen, B.A.
Characterization of calcium fenoprofen. 1. Powder dissolution rate and degree of crystallinity (60) 243
Herman, J. and Remon, J.P.
Modified starches as hydrophilic matrices for controlled oral delivery. II. In vitro drug release evaluation of thermally modified starches (56) 65
Herman, J., Remon, J.P. and De Vilder, J.
Modified starches as hydrophilic matrices for controlled oral delivery. I. Production and characterisation of thermally modified starches (56) 51
Herman, J., Visavarungroj, N. and Remon, J.P.
Instability of drug release from anhydrous theophylline–microcrystalline cellulose formulations (55) 143
Herman, J., see Visavarungroj, N. (59) 73
Hernández, J., Estelrich, J., Montero, M.T. and Valls, O.
Interaction between human serum albumin and liposomes: a monolayer and liposome study (57) 211
Hessell, P.G., Lloyd-Jones, J.G., Muir, N.C., Parr, G.D. and Sugden, K.
A comparison of the availability of prochlorperazine following i.m. buccal and oral administration (52) 159
Heun, G., see Gröning, R. (56) 111
Heya, T., see Okada, H. (54) 231
Heyman, M., see Fortier, M. (52) 27
Higashi, Y., see Murakami, T. (54) 259
Higuchi, T., see Wong, O. (52) 191
Higuchi, W.I., see Srinivasan, V. (60) 133
Hintz, R.J. and Johnson, K.C.
The effect of particle size distribution on dissolution rate and oral absorption (51) 9
Hisaichi, S.-i., see Kurosaki, Y. (51) 47
Hjärtstam, J., see Lindstedt, B. (56) 261
Ho, M.Y.K., see Chen, T.K. (59) 211
Hoelgaard, A., see Bundgaard, H. (55) 91
Hoffman, M., see Kedzierewicz, F. (58) 221
Hoffman, M., see Marchal-Heussler, L. (58) 115

Hollingsbee, D.A., see Kadir, R. (60) 139
Holman, L.E. and Leuenberger, H.
Effect of compression speed on the relationship between normalised solid fraction and mechanical properties of compacts (57) R1
Holmberg, D., see Seminoff, L.A. (54) 251
Holzschuh, J., see Müller, C.E. (57) 41
Homeida, M.M.A., see El Turabi, H. (53) 249
Hoogmartens, J., see Cachet, T. (55) 59
Hoogmartens, J., see Vinckier, C. (55) 67
Horiuchi, T., see Hasegawa, T. (56) 235
Horiuchi, T., see Hasegawa, T. (58) 129
Howard, J.R., see Gould, P.L. (51) 195
Hu, O.Y.-P., Liou, W.-S., Su, T.-J., Chiam, S.-F., Lai, J.-S., Chu, M.-L. and Chung, P.-H.
Pharmacokinetic properties of intramuscular gentamicin in Chinese subjects (53) 85
Hung, C.-T., see Gupta, P.K. (59) 57
Hung, C.T., see Gupta, P.K. (51) 253
Hung, C.T., see Gupta, P.K. (56) 217
Huntington, J., see Wong, O. (52) 191

Ibwala, N., Devleeschouwer, M.J. and Dony, J.
Inhibition of the adhesion of *Escherichia coli* to human urinary epithelial cells (59) 205
Iga, K., Hamaguchi, N., Igari, Y., Ogawa, Y., Toguchi, H. and Shimamoto, T.
Heat-specific drug release of large unilamellar vesicle as hyperthermia-mediated targeting delivery (57) 241
Igari, Y., see Iga, K. (57) 241
Igari, Y., see Okada, H. (54) 231
Iguchi, S., see Kaneo, Y. (57) 263
Illum, L., Farraj, N.F., Critchley, H., Johansen, B.R. and Davis, S.S.
Enhanced nasal absorption of insulin in rats using lysophosphatidylcholine (57) 49
Illum, L., West, P., Washington, C. and Davis, S.S.
The effect of stabilising agents on the organ distribution of lipid emulsions (54) 41
Illum, L., Wright, J. and Davis, S.S.
Targeting of microspheres to sites of inflammation (52) 221
Illum, L., see Richardson, J.L. (56) 29
Illum, L., see Richardson, J.L. (56) R1
Illum, L., see Torrado, J.J. (51) 85
Imai, T., Saito, Y., Matsumoto, H., Satoh, T. and Otagiri, M.
Influence of egg albumin on dissolution of several drugs (53) 7
Irie, T., see Arima, H. (57) 107
Irwin, W.J., see Baker, N.D. (52) 231
Issopoulos, P.B. and Economou, P.T.
A sensitive colorimetric determination of microquantities of isonicotinic acid hydrazide (isoniazid) (57) 235
Itoh, T., see Wong, O. (52) 191
Iturrioz, G., see Chang, R.-K. (60) 171

Jalal, I., Zmaily, E. and Najib, N.
Dissolution kinetics of commercially available controlled-release theophylline preparations (52) 63
Jaroszewsi, J.W., Schaumberg, K. and Kofod, H.
NMR Spectroscopy in Drug Research. Alfred Benzon Symposium 26 (53) 265
Jenke, D.R., see Hayward, D.S. (59) 245
Jensen, E., Bundgaard, H. and Falch, E.
Design of a water-soluble, solution-stable and biolabile prodrug of metronidazole for parenteral administration: *N*-substituted aminomethylbenzoate esters (58) 143
Jeyanthi, R. and Panduranga Rao, K.
Release characteristics of bleomycin mitomycin C and 5-fluorouracil from gelatin microspheres (55) 31
Johansen, B.R., see Illum, L. (57) 49
Johansen, M., see Harboe, E. (53) 157
Johnson,, T.S., see Monnot, E.A. (60) 41
Johnson, K.C., see Hintz, R.J. (51) 9
Johnson, O.L., Washington, C. and Davis, S.S.
Thermal stability of fluorocarbon emulsions that transport oxygen (59) 131
Johnson, O.L., Washington, C., Davis, S.S. and Schaupp, K.
The destabilization of parenteral feeding emulsions by heparin (53) 237
Johnston, T.P., Bove, E.L., Bolling, S.F., Boyd, J.A., Ciesliga, B.L., Amidon, G.L., Schoen, F.J. and Levy, R.J.
Controlled release of 1-hydroxyethylidene diphosphonate: in vitro assessment and effects on bioprosthetic calcification in sheep tricuspid valve replacements (52) 139
Johnston, T.P., Boyd, J.A., Ciesliga, B.L., Schoen, F.J., Amidon, G. and Levy, R.J.
Controlled release of ethanehydroxy diphosphonate from polyurethane reservoirs to inhibit calcification of bovine pericardium used in bioprosthetic heart valves (59) 95
Jones, S.P., Greenway, M.J. and Orr, N.A.
The influence of receptor fluid on in vitro percutaneous penetration (53) 43
Joshi, H.N., Kral, M.A. and Topp, E.M.
Microwave drying of aqueous tablet film coatings: a study on free films (51) 19
Juneskans, O.T., see Karabit, M.S. (54) 51
Juneskans, O.T., see Karabit, M.S. (56) 169
Junginger, H.E., see De Haan, F.H.N. (56) 75
Junginger, H.E., see Tiemessen, H.L.G.M. (53) 119
Junginger, H.E., see Tiemessen, H.L.G.M. (56) 87
Juni, K., see Kawaguchi, T. (58) R1
Juni, K., see Natsume, H. (58) 79
Juni, K., see Seki, T. (57) 73

Kadir, R., Barry, B.W., Fairbrother, J.E. and Hollingsbee, D.A.
Delivery of triamcinolone acetonide through human epidermis:. Effect of Actiderm, a new hydrocolloid dermatological patch (60) 139
Kale, N.J. and Allen, Jr., L.V.
Studies on microemulsions using Brij 96 as surfactant and glycerin, ethylene glycol and propylene glycol as cosurfactants (57) 87
Kaneo, Y., Fujihara, Y., Tanaka, T., Ogawa, K., Fujita, K. and Iguchi, S.
Preparation and characterization of a soluble glutathione-dextran conjugate (57) 263

Kannikoski, A., see Marvola, M. (53) 145
Kao, Y.-H., see Lin, S.-Y. (56) 249
Karabit, M.S., Juneskans, O.T. and Lundgren, P.
Factorial designs in the evaluation of preservative efficacy (56) 169
Karabit, M.S., Juneskans, O.T. and Lundgren, P.
Studies on the evaluation of preservative efficacy. IV. The determination of antimicrobial characteristics of some pharmaceutical compounds in aqueous solutions (54) 51
Karabit, M.S.
Studies on the evaluation of preservative efficacy. V. Effect of concentration of micro-organisms on the antimicrobial activity of phenol (60) 147
Karim, A., see Cook, C.S. (60) 125
Karim, E.F.I.A., Millership, J.S., Temple, D.J. and Woolfson, A.D.
The influence of diet on drug metabolism studies of *S*-carboxymethyl-L-cysteine (52) 155
Karlsen, J., see Sande, S.A. (55) 193
Kassem, M., see El-Ridy, M. (56) 23
Katsu, T., Kuroko, M., Sanchika, K., Morikawa, T., Kurosaki, Y., Nakayama, T., Kimura, T. and Fujita, Y.
Interaction of 1-dodecylazacycloheptan-2-one (Azone) with erythrocyte membrane (53) 61
Kawaguchi, T., Hasegawa, T., Seki, T., Juni, K. and Saneyoshi, M.
Ester prodrugs of 2′,3′-dideoxy-2′,3′-didehydrothymidine (D4T) (58) R1
Kawaguchi, T., see Seki, T. (57) 73
Kawaratani, T., see Yamamoto, A. (51) 137
Kedzierewicz, F., Hoffman, M. and Maincent, P.
Comparison of tolbutamide β-cyclodextrin inclusion compounds and solid dispersions. Physicochemical characteristics and dissolution studies (58) 221
Kellaway, I.W., see Farr, S.J. (51) 39
Kellaway, I.W., see Khan, Z.U. (55) 129
Kellaway, I.W., see Smart, J.D. (53) 79
Kellaway, I.W., see Taylor, K.M.G. (58) 49
Kellaway, I.W., see Taylor, K.M.G. (58) 57
Kendall, A.T., Stark, E. and Sugden, J.K.
Effect of hydroxyl radicals on the stability of metronidazole in buffer solution at pH 9.2 (57) 217
Kenley, R.A., see Hayward, D.S. (59) 245
Ketolainen, J., see Pesonen, T. (57) 139
Keys, J., see Carter, K.C. (53) 129
Khan, M.A., see Davies, M.C. (57) 183
Khan, Z.U. and Kellaway, I.W.
Differential scanning calorimetry of dimethylsulphoxide-treated human stratum corneum (55) 129
Khosla, R. and Davis, S.S.
Gastric emptying and small and large bowel transit of non-disintegrating tablets in fasted subjects (52) 1
Khosla, R., Feely, L.C. and Davis, S.S.
Gastrointestinal transit of non-disintegrating tablets in fed subjects (53) 107
Khosla, R., see Davis, S.S. (60) 191
Kim, S.-K., see Shim, C.-K. (56) 269
Kim, S.W., see Seminoff, L.A. (54) 241
Kim, S.W., see Seminoff, L.A. (54) 251
Kim, W.B., see Lee, K.C. (59) 27
Kimura, T., see Katsu, T. (53) 61
Kimura, T., see Kurosaki, Y. (51) 47
Kindberg, C.G., see Monnot, E.A. (60) 41
Kishimoto, M., see Murakami, T. (54) 259
Kitamura, S., Koda, S., Miyamae, A., Yasuda, T. and Morimoto, Y.
Dehydration effect on the stability of cefixime trihydrate (59) 217
Kitamura, S., Miyamae, A., Koda, S. and Morimoto, Y.
Effect of grinding on the solid-state stability of cefixime trihydrate (56) 125
Kobe, J., see Kristl, A. (57) 229
Koch, R., see Cook, C.S. (60) 125
Koda, S., see Kitamura, S. (56) 125
Koda, S., see Kitamura, S. (59) 217
Koerten, H.K., see Boddé, H.E. (53) 13
Kofod, H., see Jaroszewsi, J.W. (53) 265
Kogure, T., see Sugito, K. (60) 89
Koizumi, K., see Suenaga, A. (59) 121
Kojima, M., see Sasaki, H. (60) 177
Konishi, R., see Wong, O. (52) 191
Kontny, M.J. and Mulski, C.A.
Gelatin capsule brittleness as a function of relative humidity at room temperature (54) 79
Koosha, F., see Washington, C. (59) 79
Kosykh, V.A., Podres, E.A., Novikov, D.K., Volgushev, S.A., Victorov, A.V., Repin, V.S. and Smirnov, V.N.
Effects of khellin and timefurone on secretion and catabolism of lipoproteins by cultured rabbit and human hepatocytes (57) 223
Koupparis, M., see Macheras, P. (54) 123
Koupparis, M., see Parissi-Poulou, M. (51) 169
Kovanen, A., see Sutinen, R. (57) 149
Kowalski, K., see Cook, C.S. (60) 125
Kozjek, F., see Kristl, A. (57) 229
Krahn, F.U. and Mielck, J.B.
Effect of type and extent of crystalline order on chemical and physical stability of carbamazepine (53) 25
Kral, M.A., see Joshi, H.N. (51) 19
Kreuter, J., Müller, U. and Munz, K.
Quantitative and microautoradiographic study on mouse intestinal distribution of polycyanoacrylate nanoparticles (55) 39
Kreuter, J., see Diepold, R. (54) 149
Kristl, A., Mrhar, A., Kozjek, F. and Kobe, J.
Lipophilicity of guanine derivatives (57) 229
Kruithof, M.A.M., see Boddé, H.E. (53) 13
Ktistis, G., see Attwood, D. (52) 165
Kuehnhoff, J., see Wong, O. (52) 191
Kunchandy, E. and Rao, M.N.A.
Effect of curcumin on hydroxyl radical generation through Fenton reaction (57) 173
Kunchandy, E. and Rao, M.N.A.
Oxygen radical scavenging activity of curcumin (58) 237

Kuroko, M., see Katsu, T. (53) 61
Kurosaki, Y., Hisaichi, S.-i., Nakayama, T. and Kimura, T.
Enhancing effect of 1-dodecylazacycloheptan-2-one (Azone) on the absorption of salicylic acid from keratinized oral mucosa and the duration of enhancement in vivo (51) 47
Kurosaki, Y., see Katsu, T. (53) 61
Kuu, W.-Y., Prisco, M.R., Wood, R.W. and Roseman, T.J.
Studies of dissolution behavior of highly soluble drugs using a rotating disk (55) 77
Kuzuya, T., see Hasegawa, T. (56) 235
Kuzuya, T., see Hasegawa, T. (58) 129

Lai, J.-S., see Hu, O.Y.-P. (53) 85
Lam, F.C., see Gupta, P.K. (51) 253
Lam, S.-Y., see Shah, V.P. (53) 53
Lampard, J.F., see Smith, A. (59) 115
Larsen, C.
Macromolecular prodrugs. XII. Kinetics of release of naproxen from various polysaccharide ester prodrugs in neutral and alkaline solution (51) 233
Larsen, C.
Macromolecular prodrugs. XIII. Determination of the ionization constant of dextran by potentiometric titration and from kinetic analysis of the hydrolysis of dextran indomethacin ester conjugates (52) 55
Larsen, C., see Harboe, E. (53) 157
Lau, S.W.J. and Slattery, J.T.
Absorption of diazepam and lorazepam following intranasal administration (54) 171
Leahey, W.J., see El Turabi, H. (53) 249
Leclerc, B., see Couarraze, G. (56) 197
Lee, K.C., Lee, Y.J., Kim, W.B. and Cha, C.Y.
Monoclonal antibody-based targeting of methotrexate-loaded microspheres (59) 27
Lee, M.-H., see Shim, C.-K. (56) 269
Lee, Y.J., see Lee, K.C. (59) 27
Le Hoang, M.D., see Postaire, E. (55) 99
Lelawongs, P., Liu, J.-C., Siddiqui, O. and Chien, Y.W.
Transdermal iontophoretic delivery of arginine-vasopressin (I): Physicochemical considerations (56) 13
Lerk, C.F., see Bootsma, H.P.R. (51) 213
Lerk, C.F., see Bos, C.E. (55) 175
Lerk, C.F., see Leuenberger, H. (52) 91
Leslie, S.T., see Davis, S.S. (60) 191
Leucuţa, S.E.
The kinetics of in vitro release and the pharmacokinetics of miotic response in rabbits of gelatin and albumin microspheres with pilocarpine (54) 71
Leuenberger, H., Bonny, J.D., Lerk, C.F. and Vromans, H.
Relation between crushing strength and internal specific surface area of lactose compacts (52) 91
Leuenberger, H., see Holman, L.E. (57) R1
Leuenberger, H., see Usteri, M. (55) 135
Le Verge, R., see Rolland, A. (53) 67
Levy, M.Y. and Benita, S.
Design and characterization of a submicronized o/w emulsion of diazepam for parenteral use (54) 103
Levy, R.J., see Johnston, T.P. (52) 139
Levy, R.J., see Johnston, T.P. (59) 95
Lewis, D.A., see Field, W.N. (51) 175
Li, V.H.-K. and Robinson, J.R.
Solution viscosity effects on the ocular disposition of cromolyn sodium in the albino rabbit (53) 219
Liaw, J., Rubinstein, A. and Robinson, J.R.
Bioavailability study of Theo-dur tablets in the fasted cannulated dog (59) 105
Liddle, J., see Harron, D.W.G. (57) 9
Lin, S.-Y. and Kao, Y.-H.
Solid particulates of drug–β-cyclodextrin inclusion complexes directly prepared by a spray-drying technique (56) 249
Lindberg, J., see Wennergren, B. (53) 35
Lindstedt, B., Ragnarsson, G. and Hjärtstam, J.
Osmotic pumping as a release mechanism for membrane-coated drug formulations (56) 261
Liou, W.-S., see Hu, O.Y.-P. (53) 85
Lippold, B.C., see Lippold, B.H. (54) 15
Lippold, B.H., Sutter, B.K. and Lippold, B.C.
Parameters controlling drug release from pellets coated with aqueous ethyl cellulose dispersion (54) 15
Liu, J.-C., see Lelawongs, P. (56) 13
Li Wan Po, A., see Chan, S.Y. (55) 1
Li Wan Po, A., see Mhando, J.R. (59) 165
Lloyd-Jones, J.G., see Hessell, P.G. (52) 159
Loftsson, T., Björnsdóttir, S., Pálsdóttir, G. and Bodor, N.
The effects of 2-hydroxypropyl-β-cyclodextrin on the solubility and stability of chlorambucil and melphalan in aqueous solution (57) 63
Lopez-Berestein, G., see Vadiei, K. (57) 125
Lopez-Berestein, G., see Vadiei, K. (57) 133
Low, A.S., see Taylor, R.B. (60) 185
Luangtana-Anan, M. and Fell, J.T.
Bonding mechanisms in tabletting (60) 197
Lucks, J.S., Müller, B.W. and Müller, R.H.
Inorganic suspensions–interaction with salts and ionic surfactants (58) 229
Ludwig, A. and Van Ooteghem, M.
The evaluation of viscous ophthalmic vehicles by slit lamp fluorophotometry in humans (54) 95
Luke, D.R., see Vadiei, K. (57) 125
Luke, D.R., see Vadiei, K. (57) 133
Lundgren, P., see Karabit, M.S. (54) 51
Lundgren, P., see Karabit, M.S. (56) 169
Lundin, S., Pantzar, N., Hedin, L. and Weström, B.R.
Intestinal absorption enhancement by sodium taurodihydrofusidate of a peptide hormone analogue (dDAVP) and a macromolecule (BSA) in vitro and in vivo (59) 263
Luo, C.-W., see Chang, R.-K. (60) 171
Lynch, J., see Harris, D. (56) 97

MacCarthy, D.J., see Collins, A.E.M. (51) 103
Macheras, P., Koupparis, M. and Antimisiaris, S.
An in vitro model for exploring CR theophylline– milk fat interactions (54) 123

Macheras, P., Symillides, M. and Georgiacodis, M.
A new approach for the in vivo evaluation of sustained release dosage forms (52) 249
Macheras, P., see Parissi-Poulou, M. (51) 169
Magdassi, S. and Siman-Tov, A.
Formation and stabilization of perfluorocarbon emulsions (59) 69
Mahjour, M., Mauser, B.E. and Fawzi, M.B.
Skin permeation enhancement effects of linoleic acid and Azone on narcotic analgesics (56) 1
Mahmoud, M.J., see Ezzedeen, F.W. (59) 255
Maincent, P., see Kedzierewicz, F. (58) 221
Maincent, P., see Marchal-Heussler, L. (58) 115
Majeed, S.H., see Ezzedeen, F.W. (59) 255
Malkin, J.E., see Vincent-Ballereau, F. (58) 25
Malkowska, S., see Davis, S.S. (60) 191
Marchal-Heussler, L., Maincent, P., Hoffman, M., Spittler, J. and Couvreur, P.
Antiglaucomatous activity of betaxolol chlorhydrate sorbed onto different isobutylcyanoacrylate nanoparticle preparations (58) 115
Marriott, C., see Wilkins, K.M. (57) 1
Marriott, C., see Wilkins, K.M. (58) 165
Marshall, P.V. and York, P.
Crystallisation solvent induced solid-state and particulate modifications of nitrofurantoin (55) 257
Martin, G.P., see Wilkins, K.M. (57) 1
Martin, G.P., see Wilkins, K.M. (58) 165
Martín-Villodre, A., see Garrigues, T.M. (57) 189
Martinez, D., see Postaire, E. (55) 99
Maruyama, T., Otagiri, M. and Schulman, S.G.
Binding characteristics of coumarin anticoagulants to human α_1-acid glycoprotein and human serum albumin (59) 137
Maruyama, Y., see Sugito, K. (60) 89
Marvola, M., Kannikoski, A., Aito, H. and Nykänen, S.
The effect of food on gastrointestinal transit and drug absorption of a multiparticular sustained-release verapamil formulation (53) 145
März, F., Scheer, R. and Graf, E.
Microbiological aspects in the production of water for injection by reverse osmosis (58) 155
Masaki, K., see Wong, O. (52) 191
Matsuda, Y. and Tatsumi, E.
Physicochemical characterization of furosemide modifications (60) 11
Matsuda, Y., Teraoka, R. and Sugimoto, I.
Comparative evaluation of photostability of solid-state nifedipine under ordinary and intensive light irradiation conditions (54) 211
Matsumoto, H., see Imai, T. (53) 7
Mauser, B.E., see Mahjour, M. (56) 1
Mayer, J.M., see Gryllaki, M. (51) 95
Mazuel, C., see Rozier, A. (57) 163
Mazzeo, P., see Carlucci, G. (53) 257
McCafferty, D.F., see Woolfson, A.D. (51) 183
McCarthy, T.M., see Vincké, B.J. (54) 181
McCauley, J.A., see Ghodbane, S. (59) 281
McClean, E., Collier, P.S. and Fee, J.P.H.
The effect of formulation on the plasma binding and blood/plasma concentration ratio of diazepam (60) 35
McElnay, J.C., see Grainger-Rousseau, T.-J. (54) 1
McGowan, K.E., see Woolfson, A.D. (51) 183
Mediratta, D.K., see Singla, A.K. (60) 27
Meisner, D., Pringle, J. and Mezei, M.
Liposomal ophthalmic drug delivery. III. Pharmacodynamic and biodisposition studies of atropine (55) 105
Melia, C.D., see Davies, M.C. (57) 183
Merfeld, A.E., see Haslam, J.L. (56) 227
Mezei, M., see Meisner, D. (55) 105
Mhando, J.R. and Li Wan Po, A.
Two-stage release of benzocaine from sunflower oil/gelatin emulsion films (59) 165
Mielck, J.B., see Krahn, F.U. (53) 25
Mikos, A.G. and Peppas, N.A.
Measurement of the surface tension of mucin solutions (53) 1
Millership, J.S., see Karim, E.F.I.A. (52) 155
Minhas, P.S., see Richardson, J.L. (56) 29
Minhas, P.S., see Richardson, J.L. (56) R1
Mitra, A.K., see Fort, J.J. (59) 271
Miyamae, A., see Kitamura, S. (56) 125
Miyamae, A., see Kitamura, S. (59) 217
Miyamoto, K., see Hasegawa, T. (56) 235
Miyamoto, K., see Hasegawa, T. (58) 129
Modena, T., see Pavanetto, F. (54) 143
Moës, A.J., see Oth, M.P. (55) 157
Mohammad, S.F., see Seminoff, L.A. (54) 251
Mollee, H., see Tiemessen, H.L.G.M. (53) 119
Molokhia, A.M., see Al-Gohary, O.M. (55) 47
Molokhia, A.M., see Niazy, E.M. (56) 181
Monnot, E.A., Kindberg, C.G., Johnson,, T.S., Riley, C.M., Stobaugh, J.F. and Slavik, M.
Stability of intravenous admixtures of 5-fluorouracil and spirogermanium, a novel combination of cytotoxic agents (60) 41
Montanari, L., see Pavanetto, F. (51) 55
Montanari, L., see Pavanetto, F. (54) 143
Montero, M.T., see Hernández, J. (57) 211
Montheard, J.P., see Chafi, N. (52) 203
Moody, R.R., see Taylor, R.B. (60) 185
Mori, Y., see Sasaki, H. (60) 1
Mori, Y., see Sasaki, H. (60) 177
Morikawa, T., see Katsu, T. (53) 61
Morimoto, Y., Natsume, H., Sugibayashi, K. and Fujimoto, S.
Effect of chemoembolization of albumin microspheres containing mitomycin C on AH 272 liver metastasis in rats (54) 27
Morimoto, Y., see Kitamura, S. (56) 125
Morimoto, Y., see Kitamura, S. (59) 217
Morimoto, Y., see Natsume, H. (58) 79
Morimoto, Y., see Seki, T. (57) 73
Morimoto, Y., see Urushizaki, F. (58) 135
Mørk, N., Bundgaard, H., Shalmi, M. and Christensen, S.
Furosemide prodrugs: synthesis, enzymatic hydrolysis and solubility of various furosemide esters (60) 163

Mørk, N., see Bundgaard, H. (55) 91
Møss, J. and Bundgaard, H.
Prodrugs of peptides. 5. Protection of the pyroglutamyl residue against pyroglutamyl aminopeptidase by bioreversible derivatization with glyoxylic acid derivatives (52) 255
Mrhar, A., see Kristl, A. (57) 229
Muir, N.C., see Hessell, P.G. (52) 159
Müller, B.W., see Lucks, J.S. (58) 229
Müller, C.E., Daniel, P.T., Holzschuh, J. and Roth, H.J.
Lipophilic disulfide prodrugs – syntheses and disulfide bond cleavage (57) 41
Müller, R.H., see Lucks, J.S. (58) 229
Müller, U., see Kreuter, J. (55) 39
Mulski, C.A., see Kontny, M.J. (54) 79
Munday, D.L. and Fassihi, A.R.
Controlled release delivery: effect of coating composition on release characteristics of mini-tablets (52) 109
Munz, K., see Kreuter, J. (55) 39
Murakami, T., Kishimoto, M., Higashi, Y., Amagase, H., Fuwa, T. and Yata, N.
Down-regulation and its effect of epidermal growth factor receptors on the pharmacokinetics of human epidermal growth factor after i.v. administration in rats (54) 259

Nada, A.H., Etman, M.A. and Ebian, A.R.
In vitro adsorption of mepyramine maleate onto some adsorbents and antacids (53) 175
Nadai, M., see Hasegawa, T. (56) 235
Nadai, M., see Hasegawa, T. (58) 129
Naggar, V.F., see Etman, M.A. (58) 177
Naidoo, N.T.
Encapsulation and in vitro release of indomethacin from semi-solid matrix capsules (55) 53
Najib, N., see Jalal, I. (52) 63
Najib, N.M. and Suleiman, M.S.
Characterization of a diflunisal polyethylene glycol solid dispersion system (51) 225
Najib, N.M. and Suleiman, M.S.
The kinetics of dissolution of diflunisal and diflunisal-polyethylene glycol solid dispersion (57) 197
Najib, N.M., see Hassan, M.A. (58) 19
Najib, N.M., see Suleiman, M.S. (54) 65
Najib, N.M., see Tabba, H.D. (54) 57
Nakamura, J., see Sasaki, H. (60) 1
Nakamura, J., see Sasaki, H. (60) 177
Nakamura, K., see Urushizaki, F. (58) 135
Nakayama, T., see Katsu, T. (53) 61
Nakayama, T., see Kurosaki, Y. (51) 47
Nanba, M., see Gomita, Y. (54) 89
Nannipieri, E., see Carelli, V. (55) 199
Natsume, H., Sugibayashi, K., Juni, K., Morimoto, Y., Shibata, T. and Fujimoto, S.
Preparation and evaluation of biodegradable albumin microspheres containing mitomycin C (58) 79
Natsume, H., see Morimoto, Y. (54) 27
Navarro, J., see Postaire, E. (55) 99
Nesbitt, J.D., see Wagner, D.L. (57) 177
Nghiem, B., see Wong, O. (52) 191
Niazy, E.M., Molokhia, A.M. and El-Gorashi, A.S.
Effect of Azone and other penetration enhancers on the percutaneous absorption of dihydroergotamine (56) 181
Nicklasson, M., see Arwidsson, H. (56) 187
Nicklasson, M., see Arwidsson, H. (58) 73
Nicklasson, M., see Wennergren, B. (53) 35
Nilsson, G., see Wennergren, B. (53) 35
Nixon, J.R. and Wong, K.T.
Evaluation of drug permeation through polymeric membranes as a model for release (II) ethylcellulose-walled microcapsules (58) 31
Noguchi, M., see Sugito, K. (60) 89
Norman, S., see Washington, N. (57) 17
Novikov, D.K., see Kosykh, V.A. (57) 223
Numajiri, S., see Urushizaki, F. (58) 135
Nyberg, G., see Wennergren, B. (53) 35
Nykänen, S., see Marvola, M. (53) 145
Nyström, C., see Sjökvist, E. (54) 161

Obi, C.E., see Okor, R.S. (58) 89
Ochekpe, N.A., see Taylor, R.B. (60) 185
Ogata, H., see Sugito, K. (60) 89
Ogawa, K., see Kaneo, Y. (57) 263
Ogawa, Y., see Iga, K. (57) 241
Ogawa, Y., see Okada, H. (54) 231
O'Grady, J., see Carter, K.C. (53) 129
Oh, K.H., see Bodmeier, R. (51) 1
Okada, H., Heya, T., Igari, Y., Ogawa, Y., Toguchi, H. and Shimamoto, T.
One-month release injectable microspheres of leuprolide acetate inhibit steroidogenesis and genital organ growth in rats (54) 231
Okor, R.S. and Obi, C.E.
Drug release through aqueous-based film coatings of acrylate-methacrylate, a water-insoluble copolymer (58) 89
Oldershaw, G.A., see Gould, P.L. (51) 195
Olesen, H.P., see Harboe, E. (53) 157
Olsen, G.B., see Seminoff, L.A. (54) 241
Olsen, G.B., see Seminoff, L.A. (54) 251
Oppermann, J.A., see Cook, C.S. (60) 125
Orr, N.A., see Jones, S.P. (53) 43
Orzalesi, G., Selleri, S., Gratteri, P. and Pinzauti, S.
Chromatographic analysis of picotamide and its impurities (52) 225
Otagiri, M., see Bekers, O. (52) 239
Otagiri, M., see Imai, T. (53) 7
Otagiri, M., see Maruyama, T. (59) 137
Otagiri, M., see Suenaga, A. (59) 121
Oth, M.P. and Moës, A.J.
Sustained release solid dispersions of indomethacin with Eudragit RS and RL (55) 157
Owoyale, J.A.
Amodiaquine less sensitive than chloroquine to photochemical reactions (56) 213
Owoyale, J.A.
Decomposition profile of ultraviolet-irradiated chloroquine (52) 179

Ozer, A.Y. and Talsma, H.
Preparation and stability of liposomes containing 5-fluorouracil (55) 185

Paeratakul, O., see Bodmeier, R. (59) 197
Palm, B., see Wennergren, B. (53) 35
Pálsdóttir, G., see Loftsson, T. (57) 63
Panduranga Rao, K., see Jeyanthi, R. (55) 31
Pantzar, N., see Lundin, S. (59) 263
Papaioannou, G., see Archondikis, A. (55) 217
Papaioannou, G., see Velissaratou, A.S. (52) 83
Parissi-Poulou, M., Reizopoulou, V., Koupparis, M. and Macheras, P.
Second derivative UV spectrophotometric determination of hydrochlorothiazide and hydrochlorothiazide–amiloride combination in tablets (51) 169
Park, K.
A new approach to study mucoadhesion: colloidal gold staining (53) 209
Parkinson, H., Stanford, J.B. and Sugden, J.K.
The influence of sonic energy on the hydrolysis of procaine hydrochloride in aqueous buffer at pH 9.15 (51) 189
Paronen, P., see Pesonen, T. (57) 139
Paronen, P., see Sutinen, R. (57) 149
Paronen, P., see Sutinen, R. (57) 155
Parr, G.D., see Farraj, N.F. (52) 11
Parr, G.D., see Farraj, N.F. (52) 19
Parr, G.D., see Hessell, P.G. (52) 159
Patel, K.K., see Buckton, G. (56) 151
Pathak, K., see Singla, A.K. (60) 27
Pavanetto, F., Conti, B., Genta, I., Ponci, R., Montanari, L. and Vianello, S.
Particulate matter contamination of small volume parenterals (51) 55
Pavanetto, F., Genta, I., Conti, B., Modena, T. and Montanari, L.
Aluminium, cadmium and lead in large volume parenterals: contamination levels and sources (54) 143
Peach, J.M., see Washington, N. (57) 17
Peppas, N.A. and Sahlin, J.J.
A simple equation for the description of solute release. III. Coupling of diffusion and relaxation (57) 169
Peppas, N.A., Colombo, P., Conte, U., Gazzaniga, A., Caramella, C. and Ferrari, F.
Energetics of tablet disintegration (51) 77
Peppas, N.A., see Mikos, A.G. (53) 1
Pérez-Buendía, M.D., Garrigues, T.M., Peris-Ribera, J.E., Casabó, V.G. and Plá-Delfina, J.M.
Correlation between in situ absorption and in vitro dialysis data found in the presence of surfactants (55) 165
Pérez-Buendía, M.D., see Garrigues, T.M. (57) 189
Perez-Soler, R., see Vadiei, K. (57) 125
Perez-Soler, R., see Vadiei, K. (57) 133
Peris-Ribera, J.E., see Pérez-Buendía, M.D. (55) 165
Permentier, D., see Vermeersch, H. (60) 253
Persson, C., see Wennergren, B. (53) 35
Peschier, L.J.C., see Bouwstra, J.A. (52) 47
Pesonen, T., Paronen, P. and Ketolainen, J.
Disintegrant properties of an agglomerated cellulose powder (57) 139
Pignatello, R., see Castelli, F. (52) 115
Pignatello, R., see Giammona, G. (57) 55
Pikal, M.J., Shah, S., Roy, M.L. and Putman, R.
The secondary drying stage of freeze drying: drying kinetics as a function of temperature and chamber pressure (60) 203
Pilpel, N., see Wong, L.W. (59) 145
Pinzauti, S., see Orzalesi, G. (52) 225
Pitt, C.G.
The controlled parenteral delivery of polypeptides and proteins (59) 173
Plá-Delfina, J.M., see Garrigues, T.M. (57) 189
Plá-Delfina, J.M., see Pérez-Buendía, M.D. (55) 165
Plazonnet, B., see Rozier, A. (57) 163
Podres, E.A., see Kosykh, V.A. (57) 223
Poelman, M.-C., see Amdidouche, D. (54) 175
Ponci, R., see Pavanetto, F. (51) 55
Postaire, E., Le Hoang, M.D., Anglade, P., Martinez, D., Brion, F., Navarro, J., Prognon, P. and Pradeau, D.
Stability and behaviour of selenium in total parenteral nutrition solutions (55) 99
Pradeau, D., see Postaire, E. (55) 99
Prankerd, R.J. and Stella, V.J.
Equilibria and kinetics of hydrolysis of ebifuramin (NSC-201047), an azomethine-containing structure exhibiting a reversible degradation step in acidic solutions (52) 71
Prapaitrakul, W., see Sprockel, O.L. (58) 123
Prasad, K.P.P., see Wan, L.S.C. (55) 115
Prat, J., see Pujol, M. (58) 103
Préat, V., see Tasset, C. (58) 41
Predella, P., see Catellani, P.L. (51) 63
Primorac, M., see Vulovic, N. (55) 123
Pringle, J., see Meisner, D. (55) 105
Prisco, M.R., see Kuu, W.-Y. (55) 77
Prognon, P., see Postaire, E. (55) 99
Proost, J.H., see Bootsma, H.P.R. (51) 213
Pugh, K., see Washington, N. (57) 17
Puglisi, G., see Castelli, F. (52) 115
Puglisi, G., see Castelli, F. (59) 19
Puglisi, G., see Giammona, G. (57) 55
Puisieux, F., see Couarraze, G. (56) 197
Puisieux, F., see Fessi, H. (55) R1
Puisieux, F., see Gürsoy, A. (52) 101
Pujol, M., Girona, V., Prat, J. and Cots, J.
HPLC determination of azlocillin sodium for stability studies (58) 103
Putman, R., see Pikal, M.J. (60) 203

Quaglia, M.G., see Carlucci, G. (53) 257
Quigley, J.M., Blake, J.M. and Bonner, F.J.
The effect of ionization on the partitioning of clofazimine in the 2,2,4-trimethylpentane–water system (54) 155
Quigley, J.M., Fahelelbom, K.M.S., Timoney, R.F. and Corrigan, O.I.

Temperature dependence and thermodynamics of partitioning of clofazimine analogues in the *n*-octanol/water system (58) 107

Radebaugh, G.W., Babu, S.R. and Bondi, J.N.
Characterization of the viscoelastic properties of compacted pharmaceutical powders by a novel nondestructive technique (57) 95
Ragnarsson, G., see Lindstedt, B. (56) 261
Ranga Rao, K.V. and Buri, P.
A novel in situ method to test polymers and coated microparticles for bioadhesion (52) 265
Rao, M.N.A., see Kunchandy, E. (57) 173
Rao, M.N.A., see Kunchandy, E. (58) 237
Regan, P., see Smith, A. (59) 115
Reizopoulou, V., see Parissi-Poulou, M. (51) 169
Remon, J.P., see Bottenberg, P. (58) 203
Remon, J.P., see Herman, J. (55) 143
Remon, J.P., see Herman, J. (56) 51
Remon, J.P., see Herman, J. (56) 65
Remon, J.P., see Vermeersch, H. (60) 253
Remon, J.P., see Visavarungroj, N. (59) 73
Repin, V.S., see Kosykh, V.A. (57) 223
Richardson, J.L., Minhas, P.S., Thomas, N.W. and Illum, L.
Vaginal administration of gentamicin to rats. Pharmaceutical and morphological studies using absorption enhancers (56) 29
Richardson, J.L., Minhas, P.S., Thomas, N.W. and Illum, L.
Vaginal administration of propranolol to rats: Absorption and histological effects on the vaginal epithelium (56) R1
Riley, C.M., see Monnot, E.A. (60) 41
Robb, D.A., see Saleh, A.M. (57) 205
Roberts, R.J. and Rowe, R.C.
Determination of the critical stress intensity factor (K_{IC}) of microcrystalline cellulose using radially edge-cracked tablets (52) 213
Robinson, D.H., see Ezzedeen, F.W. (59) 255
Robinson, J.R., see Diepold, R. (54) 149
Robinson, J.R., see Li, V.H.-K. (53) 219
Robinson, J.R., see Liaw, J. (59) 105
Robinson, J.R., see Rojanasakul, Y. (55) 237
Rodriguez-Hornedo, N., see Zipp, G.L. (51) 147
Rogers, N.J., see Aungst, B.J. (53) 227
Rojanasakul, Y. and Robinson, J.R.
Transport mechanisms of the cornea: characterization of barrier permselectivity (55) 237
Roland, M., see Tasset, C. (58) 41
Rolland, A., Bégué, J.-M., Le Verge, R. and Guillouzo, A.
Increase of doxorubicin penetration in cultured rat hepatocytes by its binding to polymethacrylic nanoparticles (53) 67
Rolland, A.
Clinical pharmacokinetics of doxorubicin in hepatoma patients after a single intravenous injection of free or nanoparticle-bound anthracycline (54) 113
Rork, G.S., see Haslam, J.L. (56) 227
Roseman, T.J., see Kuu, W.-Y. (55) 77
Roth, H.J., see Müller, C.E. (57) 41
Röthlisberger, T., Testa, B., Van de Waterbeemd, H. and Carrupt, P.-A.
Hydration of substituted benzenes. Experimental studies and relationship with lipophilicity (51) 73
Rowe, R.C.
Binder–substrate interactions in granulation: a theoretical approach based on surface free energy and polarity (52) 149
Rowe, R.C.
Correlation between predicted binder spreading coefficients and measured granule and tablet properties in the granulation of paracetamol (58) 209
Rowe, R.C.
Interactions in coloured powders and tablet formulations: a theoretical approach based on solubility parameters (53) 47
Rowe, R.C.
Polar/non-polar interactions in the granulation of organic substrates with polymer binding agents (56) 117
Rowe, R.C.
Surface free energy and polarity effects in the granulation of a model system (53) 75
Rowe, R.C., see Barry, M.D. (53) 139
Rowe, R.C., see Roberts, R.J. (52) 213
Roy, M.L., see Pikal, M.J. (60) 203
Rozier, A., Mazuel, C., Grove, J. and Plazonnet, B.
Gelrite®: A novel, ion-activated, in-situ gelling polymer for ophthalmic vehicles. Effect on bioavailability of timolol (57) 163
Rubinstein, A., see Liaw, J. (59) 105
Rytting, J.H., see Wong, O. (52) 191

Saab, A.N. and Sloan, K.B.
The effect of aminomethyl (N-Mannich base) derivatization on the ability of S^6-pivaloyloxymethyl-6-mercaptopurine prodrug to deliver 6-mercaptopurine through hairless mouse skin (57) 253
Saettone, M.F., Chetoni, P., Torracca, M.T., Burgalassi, S. and Giannaccini, B.
Evaluation of muco-adhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid (51) 203
Sahlin, J.J., see Peppas, N.A. (57) 169
Saito, Y., see Imai, T. (53) 7
Sakane, T., Tanaka, C., Yamamoto, A., Hashida, M., Sezaki, H., Ueda, H. and Takagi, H.
The effect of polysorbate 80 on brain uptake and analgesic effect of D-kyotorphin (57) 77
Sakane, T., see Yamamoto, A. (51) 137
Saleh, A.M., El-Khordagui, L.K., Robb, D.A. and Florence, A.T.
Effect of some drugs and additives on the cross-linking of bovine serum albumin by glutaraldehyde (57) 205
Sanchika, K., see Katsu, T. (53) 61
Sande, S.A. and Karlsen, J.
Curve fitting of dissolution data by personal computer (55) 193
Sandouk, P., see Dumortier, G. (59) 1

Saneyoshi, M., see Kawaguchi, T. (58) R1
Sasaki, H., Kojima, M., Mori, Y., Nakamura, J. and Shibasaki, J.
Enhancing effect of pyrrolidone derivatives on transdermal drug delivery. II. Effect of application concentration and pre-treatment of enhancer (60) 177
Sasaki, H., Takahashi, T., Mori, Y., Nakamura, J. and Shibasaki, J.
Transdermal delivery of 5-fluorouracil and its alkylcarbamoyl derivatives (60) 1
Sasaki, Y., see Sugito, K. (60) 89
Satoh, T., see Imai, T. (53) 7
Schacht, E., see Vermeersch, H. (60) 253
Schaumberg, K., see Jaroszewsi, J.W. (53) 265
Schaupp, K., see Johnson, O.L. (53) 237
Scheer, R., see März, F. (58) 155
Schoen, F.J., see Johnston, T.P. (52) 139
Schoen, F.J., see Johnston, T.P. (59) 95
Schoenhard, G.L., see Cook, C.S. (60) 125
Schulman, S.G., see Maruyama, T. (59) 137
Scieszka, J.F., Aeed, P.A., Welch, D.R. and Cho, M.J.
Neutrophil-mediated transfer of polar substances from liposomes to mammary tumor cells in vitro (53) 167
Scieszka, J.F., see Cho, M.J. (52) 79
Scott, M.G., see Harron, D.W.G. (57) 9
Seijo, B., see Torres, D. (59) 9
Seki, T., Kawaguchi, T., Sugibayashi, K., Juni, K. and Morimoto, Y.
Percutaneous absorption of azidothymidine in rats (57) 73
Seki, T., see Kawaguchi, T. (58) R1
Selleri, S., see Orzalesi, G. (52) 225
Seminoff, L.A., Gleeson, J.M., Zheng, J., Olsen, G.B., Holmberg, D., Mohammad, S.F., Wilson, D. and Kim, S.W.
A self-regulating insulin delivery system. II. In vivo characteristics of a synthetic glycosylated insulin (54) 251
Seminoff, L.A., Olsen, G.B. and Kim, S.W.
A self-regulating insulin delivery system. I. Characterization of a synthetic glycosylated insulin derivative (54) 241
Serafini, M.F., see Carelli, V. (55) 199
Sezaki, H., see Sakane, T. (57) 77
Sezaki, H., see Yamamoto, A. (51) 137
Shah, S., see Pikal, M.J. (60) 203
Shah, V.P., Elkins, J., Lam, S.-Y. and Skelly, J.P.
Determination of in vitro drug release from hydrocortisone creams (53) 53
Shalmi, M., see Mørk, N. (60) 163
Shanks, R.G., see Harron, D.W.G. (57) 9
Shanley, D.B., see Collins, A.E.M. (51) 103
Sharkawi, M., see El-Ridy, M. (56) 23
Sharma, H.L., see Harris, D. (56) 97
Shek, P.N., see Barber, R.F. (60) 219
Shibasaki, J., see Sasaki, H. (60) 1
Shibasaki, J., see Sasaki, H. (60) 177
Shibata, T., see Natsume, H. (58) 79
Shihab, F.A., see Ezzedeen, F.W. (59) 255
Shim, C.-K., Yun, S.-K., Lee, M.-H. and Kim, S.-K.
Effect of sodium taurodeoxycholate on distribution and elimination of amaranth in rats (56) 269
Shimamoto, T., see Iga, K. (57) 241
Shimamoto, T., see Okada, H. (54) 231
Shiu, G.K., see El-Arini, S.K. (55) 25
Short, M.D., see Zainudin, B.M.Z. (51) 67
Short, R.D., see Davies, M.C. (57) 183
Siddiqui, O., see Lelawongs, P. (56) 13
Siman-Tov, A., see Magdassi, S. (59) 69
Singla, A.K., Mediratta, D.K. and Pathak, K.
Bioavailability of indomethacin from zinc-indomethacin complex (60) 27
Sinko, C.M. and Amidon, G.L.
Plasticizer-induced changes in the mechanical rate of response of film coatings: an approach to quantitating plasticizer effectiveness (55) 247
Sjökvist, E., Nyström, C. and Aldén, M.
Physicochemical aspects of drug release. IX. Investigation of some factors that impair dissolution of drugs from solid particulate dispersion systems (54) 161
Skelly, J.P., see El-Arini, S.K. (55) 25
Skelly, J.P., see Shah, V.P. (53) 53
Slack, J.A., see Baker, N.D. (52) 231
Slattery, J.T., see Lau, S.W.J. (54) 171
Slavik, M., see Monnot, E.A. (60) 41
Sloan, K.B., see Saab, A.N. (57) 253
Slop, D., see Bottenberg, P. (58) 203
Smart, J.D. and Kellaway, I.W.
Pharmaceutical factors influencing the rate of gastrointestinal transit in an animal model (53) 79
Smets, P., see Fortier, M. (52) 27
Smirnov, V.N., see Kosykh, V.A. (57) 223
Smith, A., Lampard, J.F., Carruthers, K.M. and Regan, P.
The filling of molten ibuprofen into hard gelatin capsules (59) 115
Spadaro, A., see Giammona, G. (57) 55
Spiro, S.G., see Zainudin, B.M.Z. (51) 67
Spittler, J., see Marchal-Heussler, L. (58) 115
Sprockel, O.L. and Prapaitrakul, W.
A comparison of microencapsulation by various emulsion techniques (58) 123
Srinivasan, V. and Higuchi, W.I.
A model for iontophoresis incorporating the effect of convective solvent flow (60) 133
Stanford, J.B., see Parkinson, H. (51) 189
Stark, E., see Kendall, A.T. (57) 217
Steffansen, B. and Bundgaard, H.
Erythromycin prodrugs: kinetics of hydrolysis of erythromycin and various erythromycin 2′-esters in aqueous solution and human plasma (56) 159
Stella, V.J., see Al-Razzak, L.A. (60) 53
Stella, V.J., see Prankerd, R.J. (52) 71
Stevens, H.N.E., see Farraj, N.F. (52) 11
Stevens, H.N.E., see Farraj, N.F. (52) 19
Stevens, J., see Taylor, K.M.G. (58) 49
Stevens, J., see Taylor, K.M.G. (58) 57
Stobaugh, J.F., see Monnot, E.A. (60) 41
Stohs, S.J., see Ezzedeen, F.W. (59) 255
Storm, G., see Bekers, O. (56) 103
Strickley, R.G., see Gu, L. (60) 99

Stupar, M., see Vulovic, N. (55) 123
Su, T.-J., see Hu, O.Y.-P. (53) 85
Suenaga, A., Bekers, O., Beijnen, J.H., Underberg, W.J.M., Tanimoto, T., Koizumi, K. and Otagiri, M.
The effect of heptakis (2,6-di-*O*-methyl)-γ-cyclodextrin on mitomycin C stability in aqueous solution (59) 121
Sugden, J.K., see Kendall, A.T. (57) 217
Sugden, J.K., see Parkinson, H. (51) 189
Sugden, K., see Hessell, P.G. (52) 159
Sugibayashi, K., see Morimoto, Y. (54) 27
Sugibayashi, K., see Natsume, H. (58) 79
Sugibayashi, K., see Seki, T. (57) 73
Sugibayashi, K., see Urushizaki, F. (58) 135
Sugimoto, I., see Matsuda, Y. (54) 211
Sugito, K., Ogata, H., Goto, H., Noguchi, M., Kogure, T., Takano, M., Maruyama, Y. and Sasaki, Y.
Gastrointestinal transit of non-disintegrating solid formulations in humans (60) 89
Suleiman, M.S., Najib, N.M., Hassan, M.A. and Abdel-Hamid, M.E.
Kinetics of the acid-catalyzed hydrolysis of famotidine (54) 65
Suleiman, M.S., see Hassan, M.A. (58) 19
Suleiman, M.S., see Najib, N.M. (51) 225
Suleiman, M.S., see Najib, N.M. (57) 197
Suleiman, M.S., see Tabba, H.D. (54) 57
Sutinen, R., Bilbao-Revoredo, O., Urtti, A. and Paronen, P.
Effect of sodium chloride on the mechanical and osmotic properties of silicone matrices (57) 155
Sutinen, R., Kovanen, A., Urtti, A. and Paronen, P.
Diffusion kinetics of alkyl *p*-aminobenzoates in silicone polymers and their release from silicone reservoir devices (57) 149
Sutter, B.K., see Lippold, B.H. (54) 15
Symillides, M., see Macheras, P. (52) 249
Szpunar, G.J., see Chiang, C.-M. (55) 229

Tabba, H.D., Abdel-Hamid, M.E., Suleiman, M.S., Al-Arab, M.M., Hasan, M.M., Abu-Lafi, S. and Najib, N.M.
Synthesis, identification and preliminary evaluation of esters and amide derivatives of diflunisal (54) 57
Tahseen, Y.H., see Ezzedeen, F.W. (59) 255
Takagi, H., see Sakane, T. (57) 77
Takagi, K., see Hasegawa, T. (58) 129
Takahashi, T., see Sasaki, H. (60) 1
Takano, M., see Sugito, K. (60) 89
Talsma, H., see Ozer, A.Y. (55) 185
Tammilehto, S. and Torniainen, K.
Photochemical stability of dothiepin in aqueous solutions (52) 123
Tammilehto, S., see Andersin, R. (56) 175
Tanaka, C., see Sakane, T. (57) 77
Tanaka, T., see Kaneo, Y. (57) 263
Tanimoto, T., see Suenaga, A. (59) 121
Tasset, C., Goethals, F., Préat, V. and Roland, M.
Effect of polyoxyethyleneglycol (24) cholesterol on the solubility, toxicity and activity of amphotericin B (58) 41
Taşyürek, M., see Gürsoy, A. (52) 101
Tatsumi, E., see Matsuda, Y. (60) 11
Tavakoli-Saberi, M.R. and Audus, K.L.
Physicochemical factors affecting β-adrenergic antagonist permeation across cultured hamster pouch buccal epithelium (56) 135
Tawashi, R., see El-Ridy, M. (56) 23
Taylor, D.C., see Harris, D. (56) 97
Taylor, G., see Taylor, K.M.G. (58) 49
Taylor, G., see Taylor, K.M.G. (58) 57
Taylor, K.M.G., Taylor, G., Kellaway, I.W. and Stevens, J.
Drug entrapment and release from multilamellar and reverse-phase evaporation liposomes (58) 49
Taylor, K.M.G., Taylor, G., Kellaway, I.W. and Stevens, J.
The stability of liposomes to nebulisation (58) 57
Taylor, R.B., Moody, R.R., Ochekpe, N.A., Low, A.S. and Harper, M.I.A.
A chemical stability study of proguanil hydrochloride (60) 185
Temple, D.J., see Karim, E.F.I.A. (52) 155
Teraoka, R., see Matsuda, Y. (54) 211
Testa, B., see Gryllaki, M. (51) 95
Testa, B., see Röthlisberger, T. (51) 73
Thoma, K. and Zimmer, T.
Retardation of weakly basic drugs with diffusion tablets (58) 197
Thomas, N.W., Butterworth, P. and Gould, P.L.
The effect of polyethylene glycol 1540 and Witepsol H12 suppositories on the store of rectal mucus in the rat (53) 261
Thomas, N.W., see Richardson, J.L. (56) 29
Thomas, N.W., see Richardson, J.L. (56) R1
Thornton, D., see Chen, T.K. (59) 211
Tiemessen, H.L.G.M., Boddé, H.E., Mollee, H. and Junginger, H.E.
A human stratum corneum–silicone membrane sandwich to simulate drug transport under occlusion (53) 119
Tiemessen, H.L.G.M., Boddé, H.E. and Junginger, H.E.
A silicone membrane sandwich method to measure drug transport through isolated human stratum corneum having a fixed water content (56) 87
Timoney, R.F., see Quigley, J.M. (58) 107
Toguchi, H., see Iga, K. (57) 241
Toguchi, H., see Okada, H. (54) 231
Tolfree, S.E.J., see Zainudin, B.M.Z. (51) 67
Tønnesen, H.H. and Grislingaas, A.-L.
Photochemical stability of biologically active compounds.. II. Photochemical decomposition of mefloquine in water (60) 157
Tønnesen, H.H.
Studies on curcumin and curcuminoids. XV. Catalytic effect of demethoxy- and bisdemethoxycurcumin on the peroxidation of linoleic acid by 15-lipoxygenase (51) 179
Tønnesen, H.H.
Studies on curcumin and curcuminoids. XVI. Effect of curcumin analogs on hyaluronic acid degradation in vitro (51) 259

Topp, E.M., see Joshi, H.N. (51) 19
Torniainen, K., see Tammilehto, S. (52) 123
Torracca, M.T., see Saettone, M.F. (51) 203
Torrado, J.J., Illum, L. and Davis, S.S.
Particle size and size distribution of albumin microspheres produced by heat and chemical stabilization (51) 85
Torres, D., Seijo, B., García-Encina, G., Alonso, M.J. and Vila-Jato, J.L.
Microencapsulation of ion-exchange resins by interfacial nylon polymerization (59) 9
Tsunekawa, Y., see Hasegawa, T. (56) 235
Tsuzuki, N., see Wong, O. (52) 191
Tu, Y.-H., Allen, Jr., L.V. and Wang, D.-P.
Stability of loperamide hydrochloride in aqueous solutions as determined by high performance liquid chromatography (51) 157
Turkistani, A.A.A., Gaber, M., Al-Meshal, M.A., Al-Shora, H.I. and Gouda, M.W.
Effect of sucralfate on procainamide absorption (59) R1

Ueda, H., see Sakane, T. (57) 77
Uekama, K., see Arima, H. (57) 107
Ulutin, Ş., see Gürsoy, A. (52) 101
Underberg, W.J.M., see Bekers, O. (52) 239
Underberg, W.J.M., see Bekers, O. (56) 103
Underberg, W.J.M., see Suenaga, A. (59) 121
Upadrashta, S.M., see Wurster, D.E. (55) 221
Urtti, A., see Sutinen, R. (57) 149
Urtti, A., see Sutinen, R. (57) 155
Urushizaki, F., Yamaguchi, H., Nakamura, K., Numajiri, S., Sugibayashi, K. and Morimoto, Y.
Swelling and mechanical properties of poly(vinyl alcohol) hydrogels (58) 135
Usteri, M. and Leuenberger, H.
Agglomeration of binary mixtures in a high-speed mixer (55) 135
Utsumi, E., see Yamamoto, A. (51) 137

Vadiei, K., Lopez-Berestein, G., Perez-Soler, R. and Luke, D.R.
In vitro evaluation of liposomal cyclosporine (57) 133
Vadiei, K., Perez-Soler, R., Lopez-Berestein, G. and Luke, D.R.
Pharmacokinetic and pharmacodynamic evaluation of liposomal cyclosporine (57) 125
Valls, O., see Hernández, J. (57) 211
Vandelli, M.A., see Forni, F. (60) 83
Van den Mooter, G., see Cachet, T. (55) 59
Van den Mooter, G., see Vinckier, C. (55) 67
Van de Waterbeemd, H., see Gryllaki, M. (51) 95
Van de Waterbeemd, H., see Röthlisberger, T. (51) 73
Van Doorne, H., see Bootsma, H.P.R. (51) 213
Van Doorne, H., see Bos, C.E. (55) 175
Van Ooteghem, M., see Ludwig, A. (54) 95
Van Scoik, K.G. and Carstensen, J.T.
Nucleation phenomena in amorphous sucrose systems (58) 185
Velissaratou, A.S. and Papaioannou, G.
In vitro release of chlorpheniramine maleate from ointment bases (52) 83
Venkatraghavan, V., see Bodor, N. (53) 195
Vergnaud, J.M., see Bidah, D. (58) 215
Vergnaud, J.M., see Chafi, N. (52) 203
Vermeersch, H., Remon, J.P., Permentier, D. and Schacht, E.
In vitro antitrichomonal activity of water-soluble prodrug esters of metronidazole (60) 253
Verstraeten, A.E., see Vincké, B.J. (54) 181
Vianello, S., see Pavanetto, F. (51) 55
Victorov, A.V., see Kosykh, V.A. (57) 223
Vila-Jato, J.L., see Torres, D. (59) 9
Vincent-Ballereau, F., Fisch, A. and Malkin, J.E.
Prevention of transmission of AIDS and hepatitis viruses in health care workers: evaluation of waste containers for injection, blood sampling and incision materials after use (58) 25
Vincké, B.J., Verstraeten, A.E., El Eini, D.I.D. and McCarthy, T.M.
Extended stability of 5-fluorouracil and methotrexate solutions in PVC containers (54) 181
Vinckier, C., Hauchecorne, R., Cachet, T., Van den Mooter, G. and Hoogmartens, J.
A new mechanism for the decomposition of erythromycin A in acidic aqueous solutions (55) 67
Vinckier, C., see Cachet, T. (55) 59
Visavarungroj, N., Herman, J. and Remon, J.P.
Crosslinked starch as binding agent. I. Conventional wet granulation (59) 73
Visavarungroj, N., see Herman, J. (55) 143
Volgushev, S.A., see Kosykh, V.A. (57) 223
Vromans, H., see Leuenberger, H. (52) 91
Vulovic, N., Primorac, M., Stupar, M. and Ford, J.L.
Some studies into the properties of indomethacin suspensions intended for ophthalmic use (55) 123

Wagner, D.L., Nesbitt, J.D., Conklin, J.D. and Hailey, F.J.
Absorption of orally, intraduodenally, and intraileally administered nitrofurantoin in man (57) 177
Wakusawa, S., see Hasegawa, T. (58) 129
Wan, L.S.C. and Prasad, K.P.P.
Uptake of water into tablets with low-substituted carboxymethyl cellulose sodium as disintegrant (55) 115
Wang, D.-P., see Tu, Y.-H. (51) 157
Wang, L.-H. and Chowhan, Z.T.
Drug-excipient interactions resulting from powder mixing. V. Role of sodium lauryl sulfate (60) 61
Wang, P.Y.
Lipids as excipient in sustained release insulin implants (54) 223
Washington, C. and Koosha, F.
Drug release from microparticulates; deconvolution of measurement errors (59) 79
Washington, C., Chawla, A., Christy, N. and Davis, S.S.
The electrokinetic properties of phospholipid-stabilized fat emulsions (54) 191

Washington, C.
Drug release from microdisperse systems: a critical review (58) 1
Washington, C.
Evaluation of non-sink dialysis methods for the measurement of drug release from colloids: effects of drug partition (56) 71
Washington, C.
The electrokinetic properties of phospholipid-stabilized fat emulsions. II. Droplet mobility in mixed electrolytes (58) 13
Washington, C., see Illum, L. (54) 41
Washington, C., see Johnson, O.L. (53) 237
Washington, C., see Johnson, O.L. (59) 131
Washington, N., Wilson, C.G., Greaves, J.L., Norman, S., Peach, J.M. and Pugh, K.
A gamma scintigraphic study of gastric coating by Expidet, tablet and liquid formulations (57) 17
Washington, N., see Davis, S.S. (60) 191
Watts, J.F., see Davies, M.C. (57) 183
Wearley, L.L. and Chien, Y.W.
Iontophoretic transdermal permeation of verapamil (III): Effect of binding and concentration gradient on reversibility of skin permeation rate (59) 87
Weiner, N., see Addicks, W.J. (56) 243
Weiner, N.D., see Chiang, C.-M. (55) 229
Weiner, N.D., see Williams, N.A. (51) 241
Welch, D.R., see Scieszka, J.F. (53) 167
Welshman, I.R., see Antal, E.J. (54) 33
Wennergren, B., Lindberg, J., Nicklasson, M., Nilsson, G., Nyberg, G., Ahlgren, R., Persson, C. and Palm, B.
A collaborative in vitro dissolution study: comparing the flow-through method with the USP paddle method using USP prednisone calibrator tablets (53) 35
West, P., see Illum, L. (54) 41
Weström, B.R., see Lundin, S. (59) 263
Whitaker, M., see Zainudin, B.M.Z. (51) 67
Wilding, I.R., see Davies, M.C. (57) 183
Wilkins, K.M., Hanlon, G.W., Martin, G.P. and Marriott, C.
The role of adhesion in the migration of bacteria along intrauterine contraceptive device polymer monofilaments (58) 165
Wilkins, K.M., Martin, G.P., Hanlon, G.W. and Marriott, C.
The influence of critical surface tension and microrugosity on the adhesion of bacteria to polymer monofilaments (57) 1
Williams, A.C. and Barry, B.W.
Essential oils as novel human skin penetration enhancers (57) R7
Williams, A.C. and Barry, B.W.
Urea analogues in propylene glycol as penetration enhancers in human skin (36) 43
Williams, N.A. and Weiner, N.D.
Interaction of recombinant leukocyte A interferon with lipid monolayers (51) 241
Wilson, C.G., see Davis, S.S. (60) 191
Wilson, C.G., see Washington, N. (57) 17
Wilson, D., see Seminoff, L.A. (54) 251
Wingstrand, K., Abrahamsson, B. and Edgar, B.
Bioavailability from felodipine extended-release tablets with different dissolution properties (60) 151
Winwood, D., see Bodor, N. (53) 195
Wolff, M., see Green, P.G. (55) 265
Wong, K.T., see Nixon, J.R. (58) 31
Wong, L.W. and Pilpel, N.
The effect of particle shape on the mechanical properties of powders (59) 145
Wong, O., Tsuzuki, N., Nghiem, B., Kuehnhoff, J., Itoh, T., Masaki, K., Huntington, J., Konishi, R., Rytting, J.H. and Higuchi, T.
Unsaturated cyclic ureas as new non-toxic biodegradable transdermal penetration enhancers. II. Evaluation study (52) 191
Wood, R.W., see Kuu, W.-Y. (55) 77
Woolfson, A.D., McCafferty, D.F., McGowan, K.E. and Boston, V.
Non-invasive monitoring of percutaneous local anaesthesia using laser–Doppler velocimetry (51) 183
Woolfson, A.D., see Karim, E.F.I.A. (52) 155
Wright, J., see Illum, L. (52) 221
Wright III, C.E., see Antal, E.J. (54) 33
Wurster, D.E. and Upadrashta, S.M.
Equilibrium binding studies of the 1,8-dihydroxy-9,10-anthraquinone–bovine serum albumin interaction (55) 221

Xiang, T.-x. and Anderson, B.D.
Inclusion complexes of purine nucleosides with cyclodextrins. II. Investigation of inclusion complex geometry and cavity microenvironment (59) 45
Xiang, T.-x., see Darrington, R.T. (59) 35

Yamaguchi, H., see Urushizaki, F. (58) 135
Yamamoto, A., Utsumi, E., Kawaratani, T., Sakane, T., Hashida, M. and Sezaki, H.
Effect of immunomodulator on drug absorption from the gastrointestinal tract: The mechanism whereby levamisole enhanced the intestinal absorption of sulfanilamide in the rat (51) 137
Yamamoto, A., see Sakane, T. (57) 77
Yang, S.T. and Ghebre-Sellassie, I.
The effect of product bed temperature on the microstructure of Aquacoat-based controlled-release coatings (60) 109
Yasuda, T., see Kitamura, S. (59) 217
Yata, N., see Murakami, T. (54) 259
York, P., see Marshall, P.V. (55) 257
Young, S.A. and Buckton, G.
Particle growth in aqueous suspensions: the influence of surface energy and polarity (60) 235
Yun, S.-K., see Shim, C.-K. (56) 269

Zainudin, B.M.Z., Tolfree, S.E.J., Biddiscombe, M., Whitaker, M., Short, M.D. and Spiro, S.G.
An alternative to direct labelling of pressurised bronchodilator aerosol (51) 67

Zajic, L. and Buckton, G.
The use of surface energy values to predict optimum binder selection for granulations (59) 155
Zalisz, R., see Fortier, M. (52) 27
Zheng, J., see Seminoff, L.A. (54) 251
Zimmer, T., see Thoma, K. (58) 197
Zipp, G.L. and Rodriguez-Hornedo, N.
Determination of crystal growth kinetics from desupersaturation measurements (51) 147
Zmaily, E., see Jalal, I. (52) 63
Zuber, M., see Dumortier, G. (59) 1

International Journal of Pharmaceutics, (1991) 21–33
© 1991 Elsevier Science Publishers B.V. 0378-5173/91/$03.50

Subject Index

Absorption, (51) 213; (53) 227; (54) 171; (57) 177; (59) 255; (60) 151
Absorption enhancer, (56) 29
Absorption enhancers, (57) 49
Absorption-partition relationship, (57) 189
Absorption promoter, (56) 181
Absorption promoters, (53) 227
Absorption rate constant, (55) 165
Acetaminophen, (51) 129; (54) 199; (57) 117
p-Acetoxyacetanilide, (51) 115; (51) 129
Acid-base catalysis, (51) 157
α_1-Acid glycoprotein, (54) 1; (59) 137
Acidic decomposition, (55) 59; (55) 67
Acidity constant, (52) 129
Acid stability, (54) 65
Acrylate-methacrylate copolymer coating, (58) 89
Acrylic hydrogel, (53) 209
Acrylic polymer, (53) 99
Activation energy, (56) 135
Activity test, (51) 203
Acute infection, (53) 129
Acyclovir, (57) 229
Adhesion, (53) 253
Adhesive action, (55) 115
Adipic acid, (57) 117
β-Adrenergic antagonist, (56) 135
Adriamycin content, (59) 57
Adsorbent, (53) 175
Adsorption, (53) 175; (55) 209
Aerosol, (51) 39
Affecting factor, (56) 235
Agglomerated cellulose powder, (57) 139
Aging, (55) 47
Agitation, (51) 213
AIDS, (58) R1; (59) 35; (60) 53
Air permeability, (56) 143
Albumin, (54) 1
Albumin concentration, (56) 235
Albumin microsphere, (51) 85; (54) 27; (54) 71; (58) 79
Alexidine, (55) 209
Alginic acid disintegrant, (56) 207
Alkaline hydrolysis, (52) 55
Alkylcarbamoyl derivative, (60) 1
Alkyl *p*-aminobenzoate, (57) 149
Amaranth, (56) 269
Amethocaine, (51) 183
Amide, (54) 57
Amiloride, (51) 169
Amino acid, (55) 99
7-Aminomethyl-6-mercaptopurine, (57) 253
Aminophylline, (51) 245
2-Aminopyridine, (53) 257
Amodiaquine, (56) 213
Amorphous cyclodextrin, (59) 225
Amorphous form, (53) 7
Amorphous state, (58) 185
Amphotericin B, (54) 41; (58) 41
Amphoteric substance, (52) 129
Angiotensin-converting enzyme, (60) 99
Anhydrous theophylline, (55) 143
Animal model, (60) 125
Antacid, (53) 175
Antagonist, MK571, (59) 281
Anthralin, (55) 221
Antibiotic, (58) 103
Anticancer drug, (55) 185
Antigen, CALLA, (59) 27
Antiglaucoma agent, β-adrenergic blocker, (53) 189
Anti-inflammatory activity, (52) 101; (57) 55
Antimalarial, (60) 157
Antineoplastic, (60) 41
Antineoplastic drug, (54) 181
Antiseptic, (55) 209
Antitrichomonal activity, (60) 253
Antiulcerogenic activity, (60) 27
Apparent permeability coefficient, (56) 135
Aquacoat, (60) 109
Aqueous colloidal polymer dispersion, (59) 197
Aqueous ethyl cellulose dispersion, (54) 15
Aromatic amine, (57) 189
Arrhenius expression, (51) 77
Arrhenius plot, (56) 135
Aspirin, (55) 47
Assay, (51) 161; (51) 263
Atropine, (55) 105
Autoradiography, (56) 75
Azide, (52) 231
Azidothymidine, (57) 73
Azlocillin, (58) 103
Azlocillin sodium, (58) 103
Azomethine cleavage, (52) 71
Azone, (52) 47; (52) 191; (53) 13; (55) 17; (56) 1; (56) 181; (57) 29

Bacterial adhesion, (57) 1; (58) 165; (59) 205
Bacterial immunomodulator, (52) 27

BALB/c mouse, (53) 129; (57) 23
Basal insulin dose, (54) 223
Benzenesulfonamide, (56) 273
Benzocaine, (59) 165
Benzocaine emulsion-gel film, (59) 165
Benzodiazepine, (56) 175
Betaxolol chlorhydrate, (58) 115
Bile salt, (59) 263
Binder–substrate interaction, (52) 149
Binding agent, (59) 73
Binding characteristics, (59) 137
Binding isotherm, (55) 221
Bioadhesion, (51) 203; (53) 1; (53) 209; (56) 97; (57) 17
Bioavailability, (53) 85; (54) 65; (54) 171; (56) 97; (59) 225; (60) 27; (60) 125; (60) 151
Bioavailability of naproxen, (53) 157
Biocompatibility, (58) 79
Biodegradability, (52) 191; (58) 79
Biodegradable drug delivery system, (51) 1
Biodegradable polymer, (59) 173
Bioequivalence, (54) 33
Bioinequivalence, (54) 33
Biological activity, (54) 241; (54) 251
Biological response, (54) 71
Bioprosthetic heart valve, (59) 95
Bioprosthetic heart valve calcification, (52) 139
4-Biphenylacetic acid, (52) 115; (57) 55; (59) 19
Bisbiguanide, (55) 209
Bleomycin, (55) 31
Blood, (60) 35
Blood-brain barrier, (57) 77
Blood clearance, (54) 41
Blood flow, (51) 137
B10 mouse, (53) 129
Bonding mechanism, (60) 197
Bovine immunoglobulin, (59) 263
Bovine serum albumin, (55) 221; (57) 205; (59) 263
Brain perfusion, (57) 77
Branched polymer, (52) 203
Brij 96, (57) 87
Brittleness, (54) 79
Buccal, (52) 159; (53) 227
Bupranolol, (55) 265

Calcification, (59) 95
Calcium chelation, (52) 79
Calcium fenoprofen, (60) 243
Candida albicans, (58) 41
Cannulated dog, (59) 105
Capsule, (53) 257
Capsule disintegration, (60) 61
Capsule dissolution, (60) 61
Carageenan, (52) 221
Carbamazepine, (53) 25
Carbonic anhydrase inhibition, (56) 273
Carbopol, (56) 97
Carbopol 934P, (53) 79
Carboxyfluorescein, (57) 211
S-Carboxymethyl-L-cysteine, (52) 155
Case-II transport, (57) 169
Catalytic effect, (51) 179; (51) 259
Cationic surfactant, (57) 189
CD, (59) 45
Cefixime trihydrate, (56) 125; (59) 217
Cell separation, (59) 27
Cellulose ether, (52) 265
Cetrimide, (53) 175
Characterization, (60) 243
Chemical conversion, (60) 1
Chemical stability, (53) 25; (56) 103; (56) 125
Chemoembolization, (54) 27
Chemoprophylaxis, (56) 23
Chinese, (53) 85
Chlorambucil, (57) 63
Chlorhexidine, (55) 209
Chloroadenine,2-, (60) 53
Chloro-2′,3′-dideoxyadenosine,2-, (60) 53
Chloroquine, (52) 179; (56) 213
Chlorpheniramine maleate concentration, (52) 83
Cholesterol monolayer, (57) 211
Cholesterol synthesis, (57) 223
Chronic infection, (53) 129; (57) 23
Cimetidine, (54) 89
Cisplatin (CDDP), (57) 241
Citrate, (52) 79; (56) 37
Clofazimine, (54) 155; (58) 107
Clonidine hydrochloride, (52) 37
Cloud point, (59) 131
CNBr activation method, (57) 263
Coalescence, (60) 109
Coated glass sphere, (52) 265
Coevaporate, (55) 157
Colloidal dispersion, (60) 171
Colloidal gold particle, (53) 209
Colloidal silicon dioxide, (54) 161
Colonic transit, (52) 1
Colorimetric determination, (57) 235
Coloured powder, (53) 47
Compact, (57) 95
Compacted disc, (57) 117
Compaction, (57) 95
Comparative bioavailability, (54) 33
Compendial standard, (51) 55
Competitive binding, (55) 221
Complexation, (52) 11; (52) 239; (57) 63; (58) 221
Complexation reaction, (55) 99
Compressed tablet, (57) 139
Compressed tablets, (56) 143
Compressibility, (56) 249
Compression, (57) 95
Computer program, (55) 193
Computer simulation, (51) 9
Concentration, (56) 13
Concentration dependence, (60) 177

Concentration exponent, (54) 51
Concentration profile, (56) 197; (59) 87
Conjunctiva, (53) 219
Constant of ionization, (57) 229
Contact angle, (58) 31; (59) 155; (60) 235
Contact angle measurement, (56) 227
Container effect, (60) 41
Contamination, (51) 55
Continuous flow-through bead bed apparatus, (55) 217
Controlled delivery, (59) 173
Controlled drug delivery, (56) 227
Controlled drug release, (58) 49; (60) 229
Controlled gastrointestinal passage, (56) 111
Controlled hydration, (56) 87
Controlled release, (51) 103; (51) 245; (52) 63; (52) 109; (52) 139; (52) 203; (53) 99; (55) 31; (56) 51; (56) 65; (56) 187; (56) 227; (57) 149; (57) 155; (58) 73; (59) 95; (59) 197; (60) 219
Controlled-release formulation, (60) 125
Controlled release formulation, (60) 191
Controlled release pellet, (52) 37
Controlled-release system, (59) 165
Coordination number, (52) 91
Copoly(lactic/glycolic acid), (54) 231
Cornea, (55) 237
Correlation, (51) 63
Cosolvent, (51) 195; (58) 177
Co-solvent solubility-stability relationship, (59) 271
Co-trimoxazole, (59) 255
Cough-cold liquid formulation, (53) 91
Coumarin anticoagulant, (59) 137
Creep compliance, (55) 247
Critical stress intensity factor, (52) 213
Cromolyn sodium, (53) 219
Cross-linked poly(vinyl alcohol), (58) 63
Crosslinked starch, (59) 73
Cross-linking, (57) 205
Crushing strength, (52) 91
Crystal anisotropy, (51) 129
Crystal defect, (51) 129
Crystal engineering, (57) 117; (60) 243
Crystal form, (60) 11
Crystal habit, (51) 129
Crystallinity, (53) 25; (56) 125; (60) 243
Crystallisation solvent, (55) 257
Crystallization, (51) 147; (55) 229; (58) 185
Crystal modification, (53) 25
Crystal/solvent interaction, (55) 257
Crystal structure, (55) 257
Crystal transition, (55) 143
Cultured hamster pouch buccal epithelium, (56) 135
Cultured rat hepatocyte, (53) 67
Curcumin, (57) 173; (58) 237
Curcumin analog, (51) 179; (51) 259
Curve fitting, (55) 193
Cutaneous metabolism, (55) 1
Cyclic-AMP phosphodiesterase, (58) 129
Cyclic urea, (52) 191
Cyclodextrin, (52) 11; (52) 115; (52) 239
β-Cyclodextrin, (51) 213; (54) 175; (56) 249; (58) 19; (58) 221; (59) 45; (59) 231
γ-Cyclodextrin, (59) 121
Cyclosporine, (57) 125; (57) 133
Cytotoxicity, (60) 53
Cytotoxics, (54) 181

Damping, (57) 95
Decomposition, (52) 179
Deconvolution, (59) 79
Deconvolution method, (59) 105
Decreased toxicity, (58) 41
Defect, (57) 117
Degradation, (52) 19; (52) 239
Degradation kinetics, (52) 123; (54) 65; (54) 211
Degradation product, (59) 217
Dehydration, (59) 217
Deoxyacyclovir, (57) 229
Deposition pattern, (51) 67
Derivative spectrophotometry, (51) 161; (51) 263
Derivative spectroscopy, (53) 257
Derivative UV spectrophotometry, (51) 169
Derivatized insulin, (54) 241; (54) 251
Dermal delivery, (55) 1; (55) 91
Dermatological patch, (60) 139
Detection and determination, (52) 225
Dexamethasone, (59) 225
Dexamethasone phosphate, (59) 225
Dextran conjugate, (51) 233
Dextran conjugate of glutathione, (57) 263
Dextran indomethacin ester prodrug, (52) 55
Dextran–naproxen glycolic acid ester conjugate, (51) 233
Dextran prodrug, (53) 157
Dextromethorphan hydrobromide, (53) 91
Diabetes, (54) 251
Diabetes mellitus, (54) 223
Dialysis, (56) 71
Dialysis rate constant, (55) 165
Diametral compression, (52) 213
2,4-Diaminopyrimidine, (52) 231
Diazemuls, (60) 35
Diazepam, (51) 213; (54) 103; (54) 171; (60) 35
Dibutyryl cyclic adenosine monophosphate, (51) 137
2′,3′-Dideoxyadenosine, (59) 35
Dideoxy-2′,3′-didehydrothymidine, 2′,3′, (58) R1
Dideoxyribose, 2′,3′-, (60) 53
Diet, (52) 155
Differential scanning calorimetry, (52) 115; (54) 161; (55) 129; (59) 19
Diffusion, (52) 203; (56) 71; (56) 135; (56) 197; (56) 243; (57) 169; (58) 1; (59) 79; (60) 229
Diffusion cell, (52) 83; (55) 91
Diffusion coefficient, (57) 197
Diffusion potential, (55) 237
Diffusion tablet, (58) 197

Diffusion-type mechanism, (60) 83
Diflunisal, (57) 197
Diflunisal–polyethylene glycol solid dispersion, (51) 225
Diflunisal prodrug, (54) 57
Digoxin, (53) 181
Dihydroergotamine, (56) 181
Dihydrohalide salt, (59) 211
1,8-Dihydroxy-9,10-anthraquinone, (55) 221
Diketopiperazine, (60) 99
Dilute solution properties, (58) 73
Dilute solution property, (56) 187
Dimethylformamide/water co-solvent, (59) 271
Dimethylsulfoxide, (53) 13
Dimethyl sulfoxide, (59) 211
Dipalmitoylphosphatidylcholine monolayer, (57) 211
Discoloration, (56) 125; (59) 217
Disease state, (54) 1
Disintegrant efficiency, (57) 139
Disintegrant mechanism, (57) 139
Disintegration, (51) 63; (51) 77; (55) 115
Disintegration force, (51) 63
Disintegration properties, (53) 35
Dispersed solute, (56) 197
Dissolution, (51) 213; (51) 225; (51) 245; (52) 11; (52) 19; (54) 123; (55) 217; (56) 151; (58) 1; (58) 221; (59) 79; (59) 255; (60) 151; (60) 229
Dissolution behavior, (53) 7
Dissolution profile, (52) 109
Dissolution rate, (51) 9; (51) 129; (52) 63; (54) 161; (56) 249; (57) 107; (58) 19; (59) 115
Dissolution testing, (53) 35; (55) 193
Distribution coefficient, (56) 135
Distribution volume, (56) 269
Disulfide cleavage, (57) 41
Dithiothreitol, (52) 231
Δ log P, (51) 95
DMSO, (55) 129
1-Dodecylazacycloheptan-2-one (Azone), (51) 47; (53) 61
Dodecyltrimethylammonium bromide, (57) 189
Dog, (59) 225
Dosage form, (52) 203
Dosage route, (57) 177
Dose-dependent pharmacokinetics, (54) 199
Dosulepin, (52) 123
Dothiepin, (52) 123
Down-regulation, (54) 259
Doxorubicin targeting, (53) 67
Doxylamine succinate, (53) 91
Drug absorption, (53) 145
Drug binding, (59) 87
Drug-carrier, (52) 183; (54) 113
Drug carrier, (53) 167; (58) 49
Drug delivery, (56) 71
Drug delivery system, (58) 49
Drug design, (52) 231
Drug development, (51) 179
Drug-excipient interaction, (60) 61
Drug incorporation method, (58) 63
Drug particle, (52) 265
Drug permeation, (53) 119; (56) 87
Drug release, (51) 1; (55) 47; (55) 53; (56) 71; (56) 261; (58) 1; (58) 89; (58) 215; (59) 1; (59) 79
Drug release kinetics, (60) 83
Drug release rate, (55) 143
Drug targeting, (59) 27; (59) 57
Drug transport, (56) 75
Drying rate, (60) 203
DSC, (59) 281
Dual-isotope scintigraphy, (60) 89
D-value, (54) 51
D-value, (56) 169
D value, (60) 147
Dynamics, (57) 9

E. coli, (59) 205
Edge-opening, (52) 213
Effective particle size, (52) 173
Effect of food, (53) 145
Efflux, (51) 39
Egg albumin, (53) 7
Egg lecithin, (54) 41
Elastic modulus, (57) 95
Elastic recovery, (59) 145
Electrical resistance, (55) 237
Electrolyte effect, (58) 229
Electron microscopy, (56) 75
Electro-osmosis, (60) 133
Emulsion, (59) 69
Emulsion nonsolvent addition, (58) 123
Emulsion-solvent evaporation, (58) 123
Emulsion stability, (53) 237; (54) 191; (58) 13; (59) 131
Encapsulation, (55) 53
Endocytosis, (53) 67
Energy-dispersive X-ray spectroscopy, (60) 109
Enhancer, (51) 47
Enprofylline, (56) 235
Enteric coating, (60) 171
Entropy of fusion, (51) 115
Enzymatic hydrolysis, (51) 27; (56) 159; (58) 143; (60) 163
Enzyme inhibitor, (58) 129; (60) 99
Ephedrine hydrochloride, (58) 89
Epidermal growth factor receptor, (54) 259
Epilepsy, (54) 171
Erythrocyte, (51) 175
Erythromycin, (56) 159
Erythromycin A, (55) 59; (55) 67
Erythromycin 2′-ester, (56) 159
Essential oil, (57) R7
Ester, (51) 27; (54) 57
Ester prodrug, (58) R1
Estradiol, (57) 29
Ethanehydroxydiphosphonate, (52) 139
Ethanehydroxy diphosphonate, (59) 95
Ethanol, (55) 17; (58) 93

Ethyl acetate, (55) 17; (58) 93
Ethyl alcohol, (54) 51
Ethyl 4-biphenylyl acetate, (57) 107
Ethyl cellulose, (56) 187; (56) 261; (58) 73
Ethylcellulose model film, (58) 31
Ethylene glycol, (57) 87
Eudragit, (53) 99; (60) 229
Eudragit RL, (55) 157
Eudragit RS, (55) 157
E value, (60) 147
È value, (60) 147
Excipient, (51) 263
Excipient-dispersion interaction, (58) 229
Experimental design, (51) 85
Expidet, (57) 17
Extended-release tablets, (60) 151
Extended stability, (54) 181

Factorial design, (51) 85; (56) 169
Famotidine, (58) 19
Fasted state, (59) 105
Fat emulsion, (53) 237; (54) 41; (54) 191; (58) 13
Felodipine, (60) 151
Fenton reaction, (57) 173
Ferric ion reduction, (57) 173
Ferroin complex, (57) 235
Film, (51) 1
Film casting, (59) 197
Film-coated tablet, (52) 109
Film coating, (51) 19; (55) 247; (57) 183
First order, (52) 63
Fissure penetration, (58) 203
Flow-through dissolution method, (53) 35
Fluid-bed coating, (60) 109
Fluidized bed coating, (54) 15
Fluid-phase marker, (53) 167
Fluorescence, (59) 137
Fluorescence quenching, (55) 221
Fluoride gel, (58) 203
Fluorocarbon, (59) 131
5-Fluorouracil, (36) 43; (54) 181; (55) 31; (55) 185; (57) 29
Fluorouracil, 5-, (57) R7
5-Fluorouracil, (60) 1; (60) 41
Flux, (55) 229
Food, (56) 151
Food–drug interaction, (55) 25
Food effect, (54) 123; (60) 125
Foodstuff, (51) 245
Formulation, (54) 79
Fragmentation, (59) 145
Free fatty acid, (56) 235
Free-radical scavenger, (58) 237
Free volume, (55) 247
Freeze drying, (56) 75; (60) 203
Freeze-thaw cycle, (58) 135
Furosemide, (53) 99; (60) 11; (60) 163

Gamma scintigraphy, (54) 41
Gas chromatography, (52) 225; (56) 175
Gastric emptying, (53) 79; (53) 107; (57) 17; (60) 89
Gastrointestinal motility, (59) 105
Gastrointestinal transit, (52) 1; (53) 79; (53) 107; (53) 145; (56) 97; (60) 191
Gel, (53) 139
Gelatin, (55) 31
Gelatin capsule, (54) 79
Gelatin microsphere, (54) 71
Gellan gum, (57) 163
Gelrite, (57) 163
Gelucire, (58) 215
Gentamicin, (53) 85; (56) 29
Glass bottle, (54) 143
Glass capillary GC assay, (52) 123
Glassy materials, (60) 203
Glaucoma, (58) 115
Glaucomatous rabbit, (58) 115
GLC assay, (52) 37
Glucose, (58) 177
Glutaraldehyde, (57) 205
Glutathione release kinetics, (57) 263
Glycerin, (57) 87
Glycosylated insulin, (54) 241; (54) 251
Glyoxylic acid, (52) 255
Golden syrian hamster, (53) 129
Gradient interpenetrating network, (55) 199
Granulation, (52) 149; (53) 75; (55) 135; (56) 117; (58) 209; (59) 155
Granule, (58) 209
Granule quality, (59) 73
Grinding effect, (56) 125
Griseofulvin, (54) 161
Growth rate, (51) 147
Guaiphenesin, (54) 15
Guinea pig tracheal smooth muscle, (58) 129

Habit, (57) 117
Habit modification, (55) 257
Hairless mouse, (56) 1
Hairless mouse skin, (52) 191
Hamster cheek pouch, (51) 47
Hamster pouch buccal epithelium, (56) 135
Health care worker, (58) 25
Heat, (56) 213
Heat of solution, (60) 243
Hemolysis, (53) 61; (58) 41
Heparin, (53) 237
Hepatitis B virus, (58) 25
Hepatocyte, (54) 259; (57) 223
Hepatosplenic schistosomiasis, (53) 249
Heptakis (2,6-di-*O*-methyl)-γ-cyclodextrin, (59) 121
Heptakis (2,3,6-tri-*O*-methyl)-γ-cyclodextrin, (59) 121
High-performance liquid chromatography, (51) 157; (52) 155; (52) 239; (53) 91; (54) 57; (55) 59; (56) 37
High performance liquid chromatography, (52) 225; (56) 103

High-speed mixer, (55) 135
Higuchi model, (53) 99
Higuchi square root, (52) 63
Histology, (53) 261
Hixson–Crowell cube root, (52) 63
HPLC, (54) 89; (58) 103; (59) 225; (60) 185
HPLC analysis, (54) 199
Human, (52) 155
Human buccal epithelial cell, (53) 253
Human epidermal growth factor, (54) 259
Human epidermal growth factor treatment, (54) 259
Human immunodeficiency virus, (58) 25
Human serum albumin, (59) 137
Human skin, (53) 13; (53) 43; (57) 29; (58) 93
Human urinary epithelial cell, (59) 205
Hyaluronic acid, (51) 203
Hyaluronic acid degradation, (51) 259
Hydrate, (51) 195
Hydration, (51) 73; (53) 119; (55) 129; (56) 87
Hydrochlorothiazide, (51) 169; (56) 97; (57) 9
Hydrochlorothiazide-amiloride combination tablet, (51) 169
Hydrocortisone, (53) 43
Hydrocortisone cream, (53) 53
Hydrocortisone 21-octanoate, (51) 39
Hydrogel, (58) 135; (59) 173
Hydrogen bonding, (51) 95
Hydrolysis, (52) 255; (59) 35; (60) 53
Hydrolysis kinetics, (51) 27; (52) 71
Hydrophilic matrix, (56) 51; (56) 65
Hydrophobicity, (58) 129
N-Hydroxyalkylation, (52) 255
Hydroxyethylcellulose, (57) 163
Hydroxyethyl starch conjugate, (51) 233
Hydroxyl radical, (51) 189; (51) 259; (57) 173; (57) 217; (58) 237
2-Hydroxypropyl-β-cyclodextrin, (57) 63; (59) 35; (59) 231
Hydroxypropyl methyl cellulose, (51) 19
Hydroxypropylmethylcellulose, (59) 155
Hyperthermia (HT), (57) 241

Ibuprofen, (59) 115
Identification, (54) 57
Ileocecal junction, (60) 89
Immobilized non-uniform drug distribution, (55) 199
Immunological response, (54) 251
Immunomicrosphere, (59) 27
Immunomodulating compound, (52) 27
Impregnation loading technique, (55) 199
Improved release kinetics, (55) 199
Impurity, (52) 225
Impurity in drug, (53) 257
Inclusion, (54) 175
Inclusion complex, (51) 213; (56) 249; (59) 45; (59) 121; (59) 225; (59) 231
Inclusion complexation, (57) 107; (58) 19
Incorporation of non-interacting bilayer drug, (55) 185
Increment, (51) 137
Indentation hardness, (57) R1
Indomethacin, (52) 191; (55) 17; (55) 53; (55) R1; (55) 123; (55) 157; (55) 217; (60) 27; (60) 191; (60) 229
Indomethacin nanocapsule, (52) 101
Inflammation targeting, (52) 221
Infrared, (51) 225
Infrared spectroscopy, (60) 11
Infusion, (54) 231
Inhibition of motility, (53) 241
Injectable doxorubicin-loaded nanoparticle, (54) 113
Injectable microsphere, (54) 231
Insert, (59) 1
In situ bioadhesion testing, (52) 265
In-situ gelling vehicle, (57) 163
In situ precipitation, (53) 13
Insulin, (53) 227; (57) 49
Insulin delivery, (54) 241
Insulin implant, (54) 223
Insulin separation, (54) 241
Interaction, (51) 225; (53) 7; (53) 47; (54) 123; (56) 117
Interaction constant, (56) 187; (58) 73
Interfacial phenomenon, (51) 77
Interfacial polymerization, (59) 9
Interference, (51) 161
Internal specific surface area, (52) 91
Intestinal absorption, (51) 137
Intestinal distribution in vivo in mice, (55) 39
Intra-arterial administration, (54) 27
Intracellular drug-carrier, (53) 67
Intramuscular administration, (54) 33
Intrauterine device, (58) 165
Intravenous admixture, (60) 41
Intravenous formulation, (57) 133
Intrinsic dissolution rate, (57) 117
Intrinsic viscosity, (56) 187; (58) 73
Inulin, (57) 77
In vitro control, (55) 147
In vitro dissolution, (55) 25
In vitro model, (54) 123
In vitro release, (52) 83; (53) 53; (55) 147; (57) 107
In vitro sustained release, (55) 157
In vivo, (54) 259
In vivo drug disposition, (55) 105
Ion-exchange resin, (59) 9
Ionic drug interaction, (56) 269
Ionic strength, (56) 13
Ionization constant of dextran, (52) 55
Iontophoresis, (56) 13; (59) 87; (60) 133
Ion transport, (55) 237
Irradiation, (52) 179
Irradiation intensity, (54) 211
Isobutylcyanoacrylate, (52) 101
Isobutylcyanoacrylate nanoparticle, (58) 115
Isoelectric point, (55) 237
Isoniazid, (57) 235
Isotherm, (54) 79

Karl-Fischer method, (51) 73
Keratin binding, (60) 1
Keratinized oral mucosa, (51) 47
Khellin, (57) 223
Kinetic constant, (51) 77
Kinetics, (51) 157; (54) 57; (55) 59; (56) 125; (57) 217; (58) 215
Kinetics of alkaline hydrolysis, (51) 233
Kinetics of in vitro release, (54) 71
D-Kyotorphin, (57) 77

Label, (51) 67
Lactate dehydrogenase leakage from isolated hepatocytes, (58) 41
Lactose, (51) 213
Lactose compact, (52) 91
Lamellar structure, (53) 139
Large volume parenteral solution, (54) 143
Lasalocid, (54) 41
Laser–Doppler velocimetry, (51) 183
Laser light scattering, (52) 173
Latex, (59) 197
Latex film, (60) 109
LD_{50}, (58) 41
LDL catabolism, (57) 223
Leakage, (55) 185
Lecithin, (59) 69
Leishmania donovani, (53) 129; (57) 23
Length of the curve, (52) 249
Length-to-width ratio, (51) 115
Leukocyte A interferon, (51) 241
Leukotriene D_4-specific antagonist, (59) 281
Leuprolide acetate, (54) 231
Levamisole, (51) 137
Levich equation, (55) 77
Levonorgestrel, (58) 93
Light, (56) 37
Light scattering, (52) 165; (57) 87
Linear free energy, (51) 129
Linkage structure, (57) 263
Linoleic acid, (56) 1
Linoleic acid peroxidation, (51) 179
Lipid bilayer, (53) 61
Lipid excipient, (54) 223
Lipid monolayer, (51) 241
Lipophilicity, (51) 73; (56) 273
Lipophilic/liposomal prodrugs, (57) 41
Lipophilic prodrug, (60) 1
Liposomal entrapment, (58) 49; (58) 57
Liposome, (51) 39; (53) 129; (55) 105; (55) 185; (56) 23; (57) 23; (57) 125; (57) 133; (57) 211; (58) 49; (58) 57; (60) 219
Liposome encapsulation, (56) 103
Liquid, (57) 17
Liver deposition, (54) 41
Liver uptake, (54) 251
Loperamide, (51) 157
Lorazepam, (54) 171
Low-substituted carboxymethylcellulose sodium, (55) 115
LPP theory, (57) 29
Lubricant, (60) 61
Lyophilization, (60) 203
Lysophosphatidylcholine, (57) 49

Macromolecular carrier, (57) 55
Macromolecular ester prodrug, (51) 233
Macromolecular prodrug, (57) 263
Macrophage, (52) 183
Magnesium stearate, (60) 61
Magnetic albumin microsphere, (59) 57
Magnetic field characteristics, (59) 57
Magnetic immunomicrosphere, (59) 27
Mannich base, (57) 253
D-Mannose, (59) 205
Marangoni effect, (55) R1
Mathematical model, (55) 193; (56) 111; (56) 243
Matrix system, (52) 203
Mean particle size, (52) 91
Mechanical properties, (57) 155
Mechanism, (55) 67
Mechanism formation, (55) R1
Mechanism of action of bisbiguanides, (55) 209
Medroxyprogesterone acetate, (54) 33
Mefloquine, (60) 157
Melphalan, (57) 63
Melt-filled capsule, (59) 115
Melting point, (55) 53
Membrane, (52) 115; (59) 19
Membrane diffusion, (57) 149
Membrane fluidity, (53) 61
Membrane leakage, (57) 211
Membrane monitoring, (58) 155
Membrane permeability, (53) 61; (57) 241
Mepyramine maleate, (53) 175
6-Mercaptopurine, (57) 41
Mercuric Chloride, (53) 13
Mercuric oxycyanide, (54) 51
Metabolism, (51) 175; (52) 155
Methacrylate polymer, (57) 183
Methotrexate, (54) 181; (59) 27
Methotrexate dialkyl ester, (59) 271
d-2-(6-Methoxy-2-naphthyl)propionic acid, (57) 55
Methyl cellulose, (51) 19
Methylcellulose, (55) 115
Methylcellulose disintegrant, (56) 207
(+)-*S*-Methyl-L-cysteine sulphoxide, (52) 155
1-Methyl-3-propylxanthine, (56) 235
Metronidazole, (57) 217; (58) 143; (60) 253
Micellar solubilization, (55) 165
Microautoradiographic study, (55) 39
Microbial growth, (58) 155
Microbial retention rate, (58) 155
Microbiological stability, (55) 175
Microcalorimetry, (51) 245; (56) 151
Microcapsule, (54) 15; (58) 31; (60) 83
Microcrystalline cellulose, (52) 213; (57) 139; (59) 155

Microdetermination, (54) 89
Microemulsion, (52) 165
Microemulsions, (57) 87
Microencapsulation, (55) 47; (58) 123; (59) 9
Micrograph, (52) 191
Microparticle, (56) 71; (58) 1; (59) 79; (59) 173
Microrugosity, (57) 1
Microsphere, (51) 1; (52) 183; (52) 221; (53) 99; (55) 31
Microwave drying, (51) 19
Midazolam, (56) 175
Milk, (56) 151
Minimum film forming temperature, (54) 15
Mini-tablet, (52) 109
Mitomycin, (52) 239
Mitomycin C, (54) 27; (55) 31; (58) 79
Mitomycin C degradation, (59) 121
Mixed micelle, (60) 35
Modeling, (57) 169
Model system, (53) 75
Modified drug release, (52) 249
Modified emulsion-solvent evaporation, (58) 123
Modified starch, (56) 51; (56) 65
Moexipril, (60) 99
Moisture adsorption on storage, (56) 143
Moisture transfer, (54) 79
Molecular weight distribution, (57) 263
Monoclonal antibody, (59) 27
Monofilament, (57) 1; (58) 165
Monohydrohalide salt, (59) 211
Morphine, (59) 1
Mucin, (53) 1
Mucin–gold conjugate, (53) 209
Mucoadhesion, (53) 79; (53) 209; (57) 17
Mucosa adhesion, (53) 79
Mucus, (53) 1; (59) 105
Mucus secretion, (53) 261
Multiparameter fitting, (55) 67
Multiparticular formulation, (53) 145
Multiple linear regression, (51) 115; (51) 129
Myristic acid, (56) 111

Nalidixic acid, (55) 91
Nalidixic acid ester, (55) 91
Nanocapsule, (55) R1
Nanoparticle, (58) 1
Nanoparticle toxicity, (53) 67
Naproxen ester conjugate, (53) 157
Naproxen–polysaccharide conjugate, (51) 233
Narcotic analgesic, (56) 1
Nasal administration, (54) 171
Nasal delivery, (57) 49
Nebulisation, (58) 57
Nebuliser, (58) 57
Needlestick, (58) 25
Nephrosis, (59) 231
Nephrotoxicity, (57) 125
Neutrophil (PMN), (53) 167
New non-toxic penetration enhancer, (52) 191
Nifedipine, (54) 211
Niflumic acid, (52) 129
Nitrofurantoin, (55) 257; (56) 111; (57) 177
Nitroglycerin, (53) 119; (56) 87
NMR, (59) 45
NMR spectroscopy, (52) 239
^{1}H-NMR spectroscopy, (51) 73
Nondestructive testing, (57) 95
Nondisintegrating formulation, (60) 89
Non-disintegrating tablet, (52) 1
Non-ionic surfactant, (53) 241; (57) 77
Non-ionic surfactant vesicle, (57) 23
Non-patient volunteer, (52) 159
Non-steroidal anti-inflammatory drug, (57) 55
Non-stoichiometric hydrate, (51) 129
Normalized solid fraction, (57) R1
Noscapine, (58) 197
No-sink release, (56) 197
Nucleation, (58) 185
Nucleoside, (60) 53
Nutritive mixture, (55) 99
Nylon microcapsule, (59) 9

Occlusion simulation, (53) 119
Occupancy time, (52) 249
Occupational risk, (58) 25
n-Octanol, (58) 107
Octanol-water partition coefficient, (59) 245
Ocular application, (60) 219
Ocular bioavailability, (57) 163
Ocular disposition, (53) 219
Ocular drug delivery, (55) 105
Ocular matrix, (51) 203
Ocular retention, (51) 203
Ointment base composition, (52) 83
Oleaginous suppository base, (57) 107
Oleic acid, (55) 265; (57) 73
One-month release, (54) 231
Ophthalmic drug delivery system, (58) 115
Ophthalmic semisolid vehicle, (51) 203
Ophthalmic suspension, (55) 123
Opticrom, (53) 219
Oral, (52) 159
Oral absorption, (51) 9
Oral administration, (54) 33; (54) 65
Oral administration in pig, (53) 157
Oral controlled drug delivery, (53) 209
Oral dosage form, (52) 109
Organic solvent system, (56) 187; (58) 73
Osmotic additive, (57) 149
Osmotic permeability, (56) 261
Osmotic pressure, (57) 241
Osmotic pump, (56) 227
Osmotic pumping, (56) 261
Oxalic acid dihydrate, (51) 147
Oxine, (52) 129

Oxprenolol, (57) 9
Oxygen transport, (59) 131

Palmitic acid, (54) 223
Paracetamol, (53) 249; (58) 123; (58) 177
Parenteral container/solution compatibility, (59) 245
Parenteral delivery, (59) 173
Parenteral nutrition, (55) 99
Parenteral use, (54) 103
Partial molar volume, (51) 95
Particle, (51) 67
Particle charge, (58) 229
Particle shape, (59) 145
Particle shape analysis, (55) 257
Particle size, (51) 85; (52) 19; (54) 33; (55) 123; (55) 185; (60) 89
Particle size distribution, (51) 9
Particulate matter, (51) 55
Partition, (56) 71
Partition coefficient, (54) 155; (57) 229; (58) 107; (58) 129
Partition coefficients, (60) 163
Partitioning, (51) 39
Partitioning thermodynamics, (58) 107
Partition method, (57) 229
Passive drug targeting, (54) 113
Patient with hepatocellular carcinoma, (54) 113
Penetration enhancer, (36) 43; (52) 47; (53) 13; (53) 61; (53) 227; (55) 265; (57) R7; (58) 93; (60) 139; (60) 177
Penetration enhancers, (57) 29
D-Penicillamine, (57) 41
Peptide, (56) 13; (57) 49; (60) 99
Peptide transport, (59) 263
Percolation theory, (55) 135
Percutaneous absorption, (36) 43; (53) 119; (56) 87; (57) 29; (57) 73; (60) 139; (60) 177
Percutaneous local anaesthesia, (51) 183
Percutaneous penetration, (53) 43
Percutaneous permeation, (60) 1
Perfluorocarbon, (59) 69
Periodontal disease, (51) 103
Permeability, (54) 15; (55) 229
Permeation, (58) 31
Permeation enhancer, (56) 1
Permselectivity, (55) 237
Peroral dosage form, (56) 111
Phagocytosis, (52) 183
Phagocytosis of liposomes by PMNs, (53) 167
Pharmaceutical, (59) 211
Pharmaceutical adjuvant, (57) 205
Pharmacokinetic, (52) 27
Pharmacokinetic modelling, (53) 181
Pharmacokinetics, (51) 47; (52) 37; (53) 85; (53) 249; (54) 33; (54) 71; (54) 89; (54) 199; (54) 251; (54) 259; (57) 9; (57) 125; (57) 177; (59) 225
Pharmacokinetics of doxorubicin in hepatoma patient, (54) 113
Phase diagrams, (57) 87
Phase transition, (57) 241; (58) 185
Phase transition system, (57) 163
pH, (56) 13
pH dependence, (52) 63; (54) 155
pH-dependency, (56) 235
pH effect, (54) 15; (57) 197; (60) 41
pH-solubility relationship, (59) 271
pH-stability relationship, (59) 271
o-Phenanthroline-Fe(III) mixture, (57) 235
Phenol, (56) 169; (60) 147
Phenolsulfonphthalein, (60) 177
Phosphate, (56) 37
Phosphatidylcholine, (52) 115; (59) 19
Phospholipid, (54) 191; (58) 13
Phospholipid interaction, (55) 209
Phospholipid release, (53) 61
Photochemical decomposition kinetics, (56) 175
Photochemical reaction, (56) 213
Photochemical stability, (52) 123; (60) 157
Photodegradation, (54) 211
Photolysis, (57) 217
Photostability, (54) 211
Physical stability, (53) 25
Physicochemical characteristics, (58) 221
Physico-chemical properties, (57) 229
Picotamide, (52) 225
Pilocarpine, (51) 203; (54) 71
Piroxicam, (53) 257
S^6-Pivaloyloxymethyl-6-mercaptopurine, (57) 253
S^6-Pivaloyloxymethyl-6-mercaptopurine, 9-aminomethyl derivative, (57) 253
pK_a, (60) 53
Plasma, (52) 27
Plasma concentration, (54) 89; (57) 73
Plasma level, (52) 159; (57) 177
Plasma protein binding, (54) 1; (60) 35
Plasma ratio, (60) 35
Plastic adsorption, (60) 41
Plastic deformation, (59) 145
Plasticizer, (54) 15; (60) 109
Plasticizing efficiency, (55) 247
Platelet aggregation, (52) 101
Polarity, (52) 149; (53) 47; (53) 75; (56) 117
Poloxamer, (59) 131
Poloxamine 908, (52) 221; (54) 41
Polyacrylic acid, (51) 203; (53) 79
Poly(acrylic acid), (56) 97
Polyanhydride polymer, (52) 203
Polycarbophil, (52) 265
Polycyanoacrylate nanoparticle, (55) 39
Poly(DL-lactide), (51) 1
Poly-(D,L-lactide) polymer, (55) R1
Polyethylene, (59) 245
Polyethylene glycol, (53) 261; (54) 161
Poly(ethylene glycol), (57) 197; (58) 221
Polyhydroxybutyric acid, (51) 103
Polymer, (52) 109; (53) 219; (56) 117
Polymer binder, (58) 209

Polymeric film, (59) 197
Polymeric matrix, (56) 197
Polymeric prodrug, (57) 55
Polymer matrix, (55) 199
Polymer-water partitioning, (59) 245
Polymethacrylic nanosphere, (53) 67; (54) 113
Polymorphism, (59) 281; (60) 11
α,β-Poly(*N*-hydroxyethyl)-DL-aspartamide, (57) 55; (59) 19
Polyoxyethyleneglycol (24) cholesterol, (58) 41
Polypeptide, (59) 173; (60) 133
Poly(vinyl alcohol), (58) 135
Polyvinylpyrrolidone, (59) 155
Poorly water-soluble drug, (53) 7
Porosity, (57) 95
Porous membrane, (59) 173
Potassium sorbate, (55) 175
Potato starch, (56) 207
Powder, (52) 19; (57) 95
Powder dissolution, (60) 243
Powder flowability, (56) 249
Powder mixing, (60) 61
Powder, yield value, (59) 145
Power consumption measurement, (55) 135
Power law expression, (60) 83
Precipitation, (51) 147
Prednisone, (53) 35
Pre-post closure, (59) 263
Preservative adsorption, (58) 229
Preservative efficacy, (54) 51; (56) 169; (60) 147
Pressure pack, (51) 39
Pressurised aerosol, (51) 67
Pre-treatment, (60) 177
Prevention, (58) 25
Primary culture, (56) 135
Procaine hydrochloride, (51) 189
Prodrug, (51) 27; (52) 255; (55) 1; (55) 91; (56) 159; (58) 143
Prodrugs, (60) 163; (60) 253
Progabide, (52) 11; (52) 19
Progesterone delivery system, (55) 199
Proguanil, (60) 185
Propranolol, (53) 189; (56) R1
Propranolol controlled-release, (55) 25
Propylene glycol, (36) 43; (52) 47; (53) 13; (54) 51; (57) 29; (57) 87
Protamine, (53) 253; (59) 205
Protein, (59) 173
Protein binding, (56) 235
Protein drug delivery, (53) 227
Proxyphylline release, (58) 63
Pseudoephedrine hydrochloride, (53) 91
Pseudolatex, (60) 171
Pseudomonas aeruginosa, (53) 253
Pupil dilation, (55) 105
Purine nucleoside, (59) 45
2-Pyridylalkanol, (51) 95
Pyroglutamyl aminopeptidase, (52) 255
Pyroglutamyl peptide, (52) 255
Pyrrolidone derivative, (60) 177
Quality control, (51) 55
Quantitative evaluation, (56) 217
Quantitative structure–activity relationship, (56) 273

Rabbit, (51) 203; (53) 219; (54) 71
Radially edge-cracked tablet, (52) 213
Radiolabeling, (57) 1
Radiotracer, (53) 219
Rapid freezing, (56) 75
Rat, (53) 261; (54) 89; (54) 231; (56) 29; (56) R1
pH-Rate profile, (51) 157
Rat stomach or jejunum, (52) 265
Raw material, (54) 143
Receptor fluid, (53) 43
Red fluorescein, (52) 129
Redox reaction, (55) 99
Reduction, (52) 231; (59) 211
Reflectivity, (56) 261
Relative hardness, (57) R1
Relative humidity, (54) 79; (54) 131
Relaxant effect, (58) 129
Relaxation, (57) 169
Relaxed complex elastic modulus, (57) R1
Release, (55) 217; (57) 241; (58) 79
Release kinetics, (58) 31
Release of indomethacin, (52) 191
Release of inflammatory mediator, (52) 183
Release rate, (52) 83; (53) 99
Renal excretion studies, (56) 111
Reservoir device, (57) 149
Residence time, (60) 89
Retardation, (58) 197
Retardation spectrum, (55) 247
Reticuloendothelial system, (54) 41
Retinoic acid, (54) 175
Reversed-phase high-performance liquid chromatography, (54) 113
Reversed-phase HPLC, (56) 273
Reverse osmosis, (58) 155
Reverse osmosis cartridge, (58) 155
Reversible kinetics, (52) 71
Rheological properties, (59) 115
Rodent skin, (58) 93
Rotating disk, (55) 77
Rotating paddle method, (55) 217
RU 41740, (52) 27
Rubber stopper, (54) 143

Salbutamol, (51) 39; (51) 67
Salbutamol sulfate, (60) 83
Salicylic acid, (51) 47; (52) 203
Saliva concentration, (54) 199
Saran Wrap, (60) 139
Scanning electron microscope, (56) 125
Scanning electron microscopy, (60) 109
Schistosomiasis, (56) 23
γ-Scintigraphy, (52) 1; (52) 221; (53) 107
Seal coat, (60) 109

Secondary drying, (60) 203
Selenium, (55) 99
Self-diffusion system, (59) 173
Self similarity, (55) 135
Semi-solid matrix, (55) 53
Serum albumin, human, (57) 211
Shellac, (60) 171
Silicone, (57) 149
Silicone matrix, (57) 155
Silicone rubber, (52) 139; (55) 199
Simultaneous determination, (51) 63
Site-specific chemical delivery system, (53) 189
Skin absorption, (55) 265
Skin accumulation, (60) 177
Skin metabolism, (55) 1
Skin penetration, (55) 91
Skin permeation, (56) 1
Skin permeation enhancer, (55) 17
Slow-release formulation, (57) 9
Small angle X-ray scattering, (53) 139
Small intestinal transit, (60) 89
Small volume parenteral, (51) 55
Snake skin, (52) 191
Sodium ampicillin, (55) 77
Sodium carboxy methyl cellulose, (54) 161
Sodium carboxymethylcellulose, (57) 139
Sodium chloride, (56) 37; (57) 155
Sodium cromoglycate, (57) 205; (58) 49; (58) 57
Sodium deoxycholate, (52) 11
Sodium lauryl sulfate, (60) 61
Sodium metabisulphite, (54) 51
Sodium methylhydroxybenzoate, (55) 175
Sodium salicylate, (55) 77; (57) 205; (58) 215
Sodium stibogluconate, (53) 129; (57) 23
Solid dispersion, (53) 7; (55) 157; (58) 221
Solid oral dosage form, (51) 213
Solid particulate dispersion, (54) 161
Solid state, (51) 225
Solubility, (51) 195; (51) 225; (52) 11; (54) 175; (57) 63; (58) 143; (58) 177; (59) 281; (60) 11; (60) 41; (60) 53; (60) 163
Solubility measurement, (52) 129
Solubility parameter, (53) 47
Soluble starch conjugate, (51) 233
Solution, (51) 225
Solvent casting, (51) 1
Solvent-dependent lipophilicity, (51) 95
Solvent effect, (60) 99
Solvent evaporation method, (51) 1
Solvent flow, (60) 133
Sonication, (51) 189; (57) 217
Sonic energy, (51) 189
Sorbitol, (58) 177
Sorption–desorption moisture transfer model, (54) 79
Specific binding, (54) 259
Spectral interference, (51) 263
Speed of compression, (57) R1
Spherical crystallization, (53) 99
Spirogermanium, (60) 41
Spray-drying, (51) 213; (56) 249
Spray-drying technique, (60) 83
Spreading coefficient, (58) 209; (60) 235
Stability, (51) 157; (52) 11; (52) 71; (52) 101; (55) 99; (55) 123; (55) 185; (56) 37; (56) 159; (56) 175; (57) 63; (58) 57; (58) 143; (59) 217; (60) 41; (60) 53; (60) 99; (60) 185; (60) 253
Stability constant, (57) 63
Stabilization, (59) 121
Standard addition, (51) 161
Steroidogenesis, (54) 231
Sterol complexation, (58) 41
Stratum corneum, (52) 47; (53) 119; (55) 129; (56) 75; (56) 87
Stratum corneum–silicone membrane sandwich, (53) 119; (56) 87
Streaming potential, (55) 237
Strength and disintegration of tablets, (56) 207
Structure–activity relationship, (53) 241
Submicronized emulsion, (54) 103
Sucrose, (58) 177; (58) 185
Sugar, (58) 177
Sulfamethoxazole, (59) 255
Sulfanilamide, (51) 137
Sulfonamide, (51) 27
N-Sulfonyl imidate ester, (51) 27
Sulphadiazine, (52) 129
Sulphaguanidine tablet, (56) 207
Sunlight, (56) 213
Superoxide scavenger, (58) 237
Suppository, (53) 257; (53) 261; (55) 217
Surface-active agent, (58) 203
Surface chemical analysis, (57) 183
Surface energy, (59) 155; (60) 235
Surface free energy, (52) 149; (53) 75; (60) 197
Surface tension, (53) 1; (57) 1; (58) 203
Surface topography, (56) 249
Surface wetting, (56) 227
Surfactant, (55) 165
Suspension, (59) 255; (60) 235
Suspension formulation, (54) 33
Suspensions, (51) 263
Suspension stability, (58) 229
Sustained release, (54) 223
Sustained release dosage form, (52) 249
Sustained release preparation, (55) 199
Sustained release system, (59) 165
Swelling, (51) 77; (55) 115; (57) 155; (58) 135
Synthesis, (54) 57
Synthetic antacid, (52) 173
Synthetic membrane, (53) 53
Syrup, (51) 263
Systemic absorption, (59) 1
Systemic clearance, (56) 269

Tablet, (51) 63; (53) 47; (55) 175; (57) 17; (58) 209; (60) 185
Tablet film coating, (58) 89
Tablets, (60) 197

Tablet size, (53) 107
Tablet strength, (54) 131
Targeted drug delivery system, (56) 217
Tartar emetic, (56) 23
Taurodeoxycholate, (56) 269
Tauromustine, (56) 37
Tear fluid, (60) 219
Technetium-99m, (51) 67
Teflon, (51) 67
Temperature, (56) 37
Temperature effect, (60) 41
Tensile strength, (51) 19; (56) 143; (59) 145
Terpene, (57) R7
Testosterone, (56) 197
Tetracycline, (56) 151
Tetracycline hydrochloride, (51) 103
Tetradecyltrimethylammonium bromide, (57) 189
Tetrahymena elliotti, (53) 241
Theo-dur tablet, (59) 105
Theophylline, (51) 195; (52) 63; (52) 109; (59) 105; (60) 125
Theophylline controlled release, (54) 123
Theophylline monohydrate, (55) 143
Thermal analysis, (51) 225; (52) 47; (55) 257; (56) 125; (60) 11
Thermodynamics, (55) 221; (58) 177; (60) 229
Thermosensitive LUV liposome, (57) 241
Thiamine, (57) 41
Thin application, (55) 229; (56) 243
Thin-layer chromatography, (52) 225
Thiol, (52) 231
Thiouracil, (57) 41
Thyroid, (51) 175
Thyroidectomized rat, (51) 175
Thyroxine, (51) 175
Tight junction, (52) 79
Timefurone, (57) 223
Time–temperature superposition, (55) 247
Timolol maleate, (57) 163
T-lymphocyte proliferation, (57) 133
Tolbutamide, (58) 221
Topical, (55) 229; (56) 243
Topical delivery, (55) 1
Topical drug delivery, (60) 219
Topographical characterization, (55) 25
Total parenteral nutrition, (53) 237; (54) 143; (54) 191; (58) 13
Toxicity, (59) 231
Trace element, (54) 143; (55) 99
Transdermal administration, (57) R7
Transdermal delivery, (55) 1; (55) 265; (56) 181
Transdermal drug delivery, (60) 177
Transdermal therapeutic system, (55) 147
Transepithelial electrical resistance, (52) 79
Transference number, (56) 13
Transit delaying excipient, (56) 111
Transmission electron microscopy, (52) 101; (53) 13
Triamcinolone acetonide, (60) 139
Triamterene, (57) 9
N-Trifluoroacetyldoxorubicin-14-valerate (AD-32), (56) 103
Trimethoprin, (59) 255
2,2,4-Trimethylpentane, (54) 155
Trinitrine in vitro release, (55) 147
TRITON, (53) 241
Tropical storage condition, (55) 175
Tropicamide, (51) 203
Tubing effect, (60) 41
Tumor cell interaction, (53) 167
Tween 80, (52) 11

Ultrastructure, (54) 33
Ultrastructure preservation, (56) 75
Ultraviolet, (52) 179
Ultraviolet irradiation, (56) 213
Unilamellar liposome, (57) 211
Unsymmetrical disulfides, (57) 41
Urea, (36) 43
Urea analogue, (36) 43
Ureidopenicillin, (58) 103
Urinary excretion, (57) 177
USP paddle dissolution method, (53) 35
UV irradiation, (54) 211
UV spectrophotometry, (52) 239
UV-spectrophotometry, (53) 257

Vaginal administration, (56) 29; (56) R1
Vaginal histology, (56) 29; (56) R1
Valium, (60) 35
Van der Waals force, (60) 197
Variable diffusion coefficient, (55) 77
Vasopressin, (59) 263
Vehicle, (55) 229; (56) 243
Verapamil, (53) 145
Verapamil hydrochloride, (59) 87
Viscoelastic behavior, (58) 135
Viscoelasticity, (57) 95
Viscosity, (53) 219; (58) 203
Viscosity–concentration profile, (55) 77
Viscous modulus, (57) 95
Visualization, (53) 13
VLDL secretion, (57) 223
Volume fraction, (58) 31
Volume reduction behaviour, (54) 131

Water adsorption, (54) 131
Water content, (51) 115
Water, for injection, (58) 155
Water penetration, (55) 115
Water, pure, (58) 155
Water–solid interaction, (54) 131
Water-soluble β-cyclodextrin, (57) 107
Water-swellable matrix, (58) 63
Water uptake, (51) 63
Water vapor permeability, (51) 19
Wavelength dependence, (54) 211
Wet granulation, (59) 73
Witepsol H12, (53) 261
Writhing test, (57) 77

Xanthine derivative, (58) 129
Xenobiotic, (57) 189
X-ray diffraction, (56) 125; (59) 217; (60) 11
X-Ray microanalysis, (56) 75
X-ray photoelectron spectroscopy, (57) 183
X-ray powder diffraction, (54) 161; (59) 281

Young's modulus, (51) 19

Zero-order release, (57) 169
Zeta potential, (53) 237; (58) 13; (58) 229; (59) 69
Zinc-indomethacin complex, (60) 27
ζ potential, (54) 191

MANUSCRIPTS should be submitted **in quadruplicate** in English and be accompanied by a list of **6–8 key words**. All data that would help referees to evaluate the paper should also be supplied.

Full length papers
should be typewritten with double spacing on one side of the sheet only,
should be divided into **Summary** (including **key words**), Introduction, Materials and Methods, Results and Discussion,
should be accompanied by a separate sheet bearing Title, Author's names and their affiliations.
should not **normally** exceed 10 printed pages (18 typescript pages) in length.

Rapid communications should not exceed 4 printed pages (9 typescript pages) and should not be divided into sections i.e. Introduction etc. They preferably should have a 20–50 word Summary and a full reference list should be provided. Preferably **no figures** should be included; otherwise a delay in publication time will occur.

Descriptions/reviews of computer programs should include in the manuscript information on hardware compatibility and software availability (including costs, ordering address, etc.). All manuscripts must be accompanied by a manual describing software validation; operating instructions (in greater detail than in the manuscript) and illustrations of input and output data sets. In order that reviewers can appropriately evaluate the package, three copies of the manual and software (diskettes, tapes, etc.) should accompany submission. Software and manuals will be returned only upon request by the authors.

Tables should be compiled on separate sheets with a short descriptive title, a legend and/or footnotes identified by a, b, c, etc.

Figures
Line drawings (including graphs) should be drawn in black ink on white paper. Lettering should be in proportion to the figure to allow for reduction to page format.
Half-tone figures should be sharp, high-contrast original prints on glossy paper.
The magnification of micrographs should be indicated by **a scale bar in the figure**.
If figures are not to be reduced their format should not exceed 16 × 20 cm. All legends should be typed double spaced on separate sheets.

References

Should be assembled alphabetically on a separate sheet. In the text they should be referred to by name and year (Harvard System). More than one paper from the same author in the same year must be identified by the letters a, b, c, etc. placed after the year of publication. In the text, when referring to a work by more than two authors, the name of the first author should be given followed by et al. Literature references must consist of names and initials of all authors, title of paper referred to, abbreviated title of periodicals and the volume, year and first **and last** page numbers of the paper. Periodicals, books and multi-author books should accord with the following examples:

Kaplan, S.A., Weinfeld, R.E. and Lee, T.L., Semiautomated spectrophotofluorometric determination of trimethoprim in biological fluids. J. Pharm. Sci., 62 (1973) 1865–1870.
D'Arcy, P.F. and Griffin, J.P., Iatrogenic Diseases, Oxford University Press, London, 1972, p. 11.
Johnson, C.A., International problems in the control of medicines. In Deasy, P.B. and Timoney, R.F. (Eds.), The Quality Control of Medicines, Elsevier, Amsterdam, 1976, pp. 83–95.

Abbreviations of journal titles should follow the system used by the ISDS List of Serial Title Word Abbreviations, 1985 (available from 20 rue Bachaumont, 75002 Paris, France – ISBN 2-904938-02-8), but beginning each word with a capital

Proofreading will be undertaken by the Publisher. *Correspondence and queries relating to proofs* should be directed to the publishers: IJP, Elsevier Science Publishers B.V., P.O. Box 1527, 1014 AG Amsterdam, The Netherlands. Telephone: (20) 5803465. Proofs will not be sent out unless specifically requested by the author(s) when the paper is submitted and so indicated on the title page. No alteration of substance to the text, tables or legends will be accepted.

Page Charge There will be no page charge.

Reprints Fifty reprints of each paper will be provided free of charge. Additional copies may be ordered at prices shown on the reprint order form which will be sent to the author.

Subscriptions
1991: Volumes 67–77 (11 volumes in 33 issues). Volume 67 is published in advance in order to decrease publication time. It remains part of the 1991 subscription year. Dfl. 3740.00 (US$ 2101.00) including postage, packaging and handling.
The Dutch guilder price is definitive. The US$ price is subject to exchange rate fluctuations and is therefore only given as a guide

Journals are sent by surface delivery to all countries, except the following countries where SAL air delivery (Surface Airlifted Mail) is ensured: U.S.A., Canada, Japan, Australia, New Zealand, P.R. China, India, Israel, South Africa, Malaysia, Singapore, South Korea, Taiwan, Pakistan, Hong Kong, Brazil, Argentina, Mexico and Thailand. Airmail rates for other countries are available on request.

Subscription orders can be entered only by calendar year (January–December) and should be sent to: **Elsevier Science Publishers B.V., Journals Department, P.O. Box 211, 1000 AE Amsterdam, The Netherlands, Telex 18582 ESPA NL**, or to your usual subscription agent. Claims for missing issues should be made within three months of publication, otherwise they cannot be honored free of charge.

In the U.S.A. and Canada: All questions arising **after acceptance** of a manuscript by the editor, especially those relating to proofs, publication and reprints, should be directed to the publishers, **Elsevier Science Publishers B.V. P.O. Box 1527, 1000 BM Amsterdam, The Netherlands**. For further information and personal subscriptions, contact: **Elsevier Science Publishing Co., Inc., Attn.: Journal Information Center, 655 Avenue of the Americas, New York, NY 10010, U.S.A. Tel.: (212) 633-3750; Telefax: (212) 633-3990; Telex: 420-643 AEP UI.**

Advertising. Apply to W.J. van Cattenburch (Advertising Manager), P.O. Box 211, 1000 AE Amsterdam, The Netherlands. (Tel. (20) 5803714.)

This journal is printed on acid-free paper.

INTERNATIONAL JOURNAL OF PHARMACEUTICS

CONTENTS

Announcement from the Publisher v

Author Index 1

Subject Index 21

© 1991 Elsevier Science Publishers B.V. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher, Elsevier Science Publishers B.V., P.O. Box 1527, 1000 BM Amsterdam, The Netherlands.

Submission of a paper to this journal entails the author's irrevocable and exclusive authorization of the publisher to collect any sums or considerations for copying or reproduction payable by third parties (as mentioned in article 17 paragraph 2 of the Dutch Copyright Act of 1912 and in the Royal Decree of June 20, 1974 (S. 351) pursuant to article 16b of the Dutch Copyright Act of 1912) and/or to act in or out of Court in connection therewith.

Special regulations for readers in the U.S.A. This journal has been registered with the copyright Clearance Center, Inc. Consent is given for copying of articles for personal or internal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per-copy fee stated in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The appropriate fee should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 27 Congress Street, Salem, MA 01970, U.S.A. If no code appears in an article, the author has not given broad consent to copy and permission to copy must be obtained directly from the author. All articles published prior to 1980 may be copied for a per-copy fee of US $2.25, also payable through the Center. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotion purposes, or for creating new collective works. Special written permission must be obtained from the publisher for such copying.

Special regulations for authors. Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the publisher. This transfer will ensure the widest possible dissemination of information.

Cited in: Current Contents (Life Sciences; Clinical Practice); International Pharmaceutical Abstracts; Biological Abstracts; Chemical Abstracts; Excerpta Medica EMBASE; PASCAL M; Science Citation Index

Printed in The Netherlands

ISSN 0378-4173

international journal of pharmaceutics

cumulative author and subject indexes
volumes 61–70

published twice monthly

elsevier

INTERNATIONAL JOURNAL OF PHARMACEUTICS

AIMS AND SCOPE

The INTERNATIONAL JOURNAL OF PHARMACEUTICS provides a medium for the publication of research results dealing with all aspects of Pharmaceutics including physical, chemical, analytical, biological and engineering studies related to drug delivery in its broadest sense. Such areas include:

1. Drug delivery systems
2. Physical pharmacy
3. Biopharmaceutics
4. Pharmacodynamics and pharmacokinetics
5. Membrane function and transport
6. Biotechnology
7. Drug and prodrug design
8. Radiopharmaceuticals
9. Sterility and sterilization
10. Quality control of pharmaceuticals
11. Pharmaceutical analysis
12. Drug stability
13. Pharmaceutical technology
14. Descriptions/reviews of computer programs relating to the above areas
15. Application of cell and molecular biology in drug delivery

EDITORIAL POLICY

The over-riding criteria for publication are originality, high scientific quality and interest to a multidisciplinary audience. Papers not sufficiently substantiated by experimental detail will not be published. Any technical queries will be referred back to the author, although the Editors reserve the right to make alterations in the text without altering the technical content.
Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur with the submission and that a copy of the final manuscript has been approved by all authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out. If accepted, the manuscript shall not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors and Publisher.

EDITORS IN CHIEF

For: Europe, Africa, Near East

P.F. D'ARCY
School of Pharmacy,
University of London,
29/39 Brunswick Square,
London WC1N 1AX,
U.K.

For: The Americas and Australia

W.I. HIGUCHI
Department of
Pharmaceutics,
College of Pharmacy
University of Utah,
Salt Lake City,
UT 84112,
U.S.A.

J.H. RYTTING
(Associate Editor)
Pharmaceutical
Chemistry Dept.,
School of Pharmacy,
University of Kansas,
Lawrence, KS 66045,
U.S.A.

For: Japan

T. NAGAI
Department of
Pharmaceutics, Faculty of
Pharmaceutical Sciences,
Hoshi University,
Ebara 2-4-41,
Shinagawa-ku,
Tokyo 142, Japan.

EDITORIAL BOARD

G. Amidon (Ann Arbor, MI)
B.D. Anderson (Salt Lake City, UT)
G.S. Banker (Minneapolis, MN)
H. Boxenbaum (Cincinnati, OH)
H. Bundgaard (Copenhagen)
J.T. Carstensen (Madison, WI)
D.J.A. Crommelin (Utrecht)
S.S. Davis (Nottingham)
A.T. Florence (London)
J.L. Fox (Salt Lake City, UT)
H.L. Fung (Amherst, NY)
D. Ganderton (London)
J. Hadgraft (Cardiff)
M. Hanano (Tokyo)
E.N. Hiestand (Kalamazoo, MI)
N.F.H. Ho (Kalamazoo, MI)
T.M. Jones (Beckenham)
K. Knutson (Salt Lake City, UT)
G. Levy (Amherst, NY)
A. Li Wan Po (Belfast)
J.A. Mollica (Wilmington, DE)
J.M. Newton (London)
I.H. Pitman (Parkville)
G. Poste (Philadelphia, PA)
B.J. Poulsen (Palo Alto, CA)
A.J. Repta (Lawrence, KS)
J.R. Robinson (Madison, WI)
T.J. Roseman (Round Lake, IL)
R.C. Rowe (Macclesfield)
M.F. Saettone (Pisa)
H. Sezaki (Kyoto)
J.E. Shaw (Palo Alto, CA)
E. Shefter (Boulder, CO)
D.D. Shen (Seattle, WA)
J. Sjögren (Mölnlycke)
R.S. Summers (Pretoria)
D.J. Temple (Cardiff)
B. Testa (Lausanne)
K. Thoma (Munich)
R.F. Timoney (Dublin)
E. Tomlinson (Alameda, CA)
J.L. Vila Jato (Santiago de Compostela)
G. Zografi (Madison, WI)

INSTRUCTIONS TO AUTHORS

Submission of a paper to the International Journal of Pharmaceutics implies: (1) that it is not being submitted for publication elsewhere; (2) the transfer of the Copyright from the Author to the Publisher. Manuscripts submitted under multiple authorship are reviewed on the assumption that all listed authors concur with the submission and that a copy of the final manuscript has been approved by all authors and tacitly or explicitly by the responsible authorities in the laboratories where the work was carried out If accepted, the manuscript shall not be published elsewhere in the same form, in either the same or another language, without the consent of the Editors and Publisher.
Papers and original figures should be submitted plus **three copies** and accompanied by a letter of transmittal to one of the Editors in Chief. When the paper is to be published as a Rapid Communication, this should be clearly indicated to the Editor in Chief.

TYPES OF PAPERS

(1) Full length papers.
(2) Rapid communications not exceeding 1500 words or equivalent space.
(3) Notes (formerly Short Communications) limited to 1500 words or equivalent, including figures/tables.
(4) Descriptions/reviews of computer programs useful to pharmaceutical scientists.
(5) Suggestions for Review Articles will be considered by the Editors-in-Chief.

INTERNATIONAL JOURNAL OF PHARMACEUTICS

CUMULATIVE AUTHOR AND SUBJECT INDEXES
VOLUMES 61–70

INTERNATIONAL JOURNAL OF PHARMACEUTICS

Editors in Chief

P.F. D'ARCY (London, U.K.), W.I. HIGUCHI (Salt Lake City, UT, U.S.A.)
and T. NAGAI (Tokyo, Japan)
(Associate Editor: J.H. RYTTING, Lawrence, KS, U.S.A.)

Editorial Board

G. AMIDON (Ann Arbor, MI, U.S.A.)
B.D. ANDERSON (Salt Lake City, UT, U.S.A.)
G.S. BANKER (Minneapolis, MN, U.S.A.)
H. BOXENBAUM (Cincinnati, OH, U.S.A.)
H. BUNDGAARD (Copenhagen, Denmark)
J.T. CARSTENSEN (Madison, WI, U.S.A.)
D.J.A. CROMMELIN (Utrecht, The Netherlands)
S.S. DAVIS (Nottingham, U.K.)
A.T. FLORENCE (London, U.K.)
J.L. FOX (Salt Lake City, UT, U.S.A.)
H.L. FUNG (Amherst, NY, U.S.A.)
D. GANDERTON (London, U.K.)
J. HADGRAFT (Cardiff, U.K.)
M. HANANO (Tokyo, Japan)
E.N. HIESTAND (Kalamazoo, MI, U.S.A.)
N.F.H. HO (Kalamazoo, MI, U.S.A.)
T.M. JONES (Beckenham, U.K.)
K. KNUTSON (Salt Lake City, UT, U.S.A.)
G. LEVY (Amherst, NY, U.S.A.)
A. LI WAN PO (Belfast, U.K.)
J.A. MOLLICA (Wilmington, DE, U.S.A.)
J.M. NEWTON (London, U.K.)
I.H. PITMAN (Parkville, Australia)
G. POSTE (Philadelphia, PA, U.S.A.)
B.J. POULSEN (Palo Alto, CA, U.S.A.)
A.J. REPTA (Lawrence, KS, U.S.A.)
J.R. ROBINSON (Madison, WI, U.S.A.)
T.J. ROSEMAN (Round Lake, IL, U.S.A.)
R.C. ROWE (Macclesfield, U.K.)
M.F. SAETTONE (Pisa, Italy)
H. SEZAKI (Kyoto, Japan)
J.E. SHAW (Palo Alto, CA, U.S.A.)
E. SHEFTER (Boulder, CO, U.S.A.)
D.D. SHEN (Seattle, WA, U.S.A.)
J. SJÖGREN (Mölnlycke, Sweden)
R.S. SUMMERS (Pretoria, South Africa)
B. TESTA (Lausanne, Switzerland)
D.J. TEMPLE (Cardiff, U.K.)
K. THOMA (Munich, F.R.G.)
R.F. TIMONEY (Dublin, Ireland)
E. TOMLINSON (Alameda, CA, U.S.A.)
J.L. VILA JATO (Santiago de Compostela, Spain)
G. ZOGRAFI (Madison, WI, U.S.A.)

AUTHOR AND SUBJECT INDEXES
VOLUMES 61–70

ELSEVIER SCIENCE PUBLISHERS B.V. – AMSTERDAM

© 1991, Elsevier Science Publishers B.V.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the Publisher, Elsevier Science Publishers B.V., P.O. Box 1527, 1000 BM Amsterdam, The Netherlands.
No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances in the medical sciences, the Publisher recommends that independent verification of diagnoses and drug dosages should be made.
Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Special regulations for authors. Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the Publisher. This transfer will ensure the widest possible dissemination of information.
Submission of a paper to this journal entails the author's irrevocable and exclusive authorization of the Publisher to collect any sums or considerations for copying or reproduction payable by third parties (as mentioned in Article 17, Paragraph 2 of the Dutch Copyright Act of 1912, and in the Royal Decree of June 20, 1974 (S. 351) pursuant to Article 16b of the Dutch Copyright Act of 1912) and/or to act in or out of Court in connection therewith.
Special regulations for readers in the U.S.A. This journal has been registered with the Copyright Clearance Center, Inc. Consent is given for copying of articles for personal or internal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per-copy fee stated in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The appropriate fee should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 27 Congress Street, Salem, MA 01970, U.S.A. If no code appears in an article the author has not given broad consent to copy and permission to copy must be obtained directly from the author. All articles published prior to 1980 may be copied for a per-copy fee of US$ 2.25, also payable through the Center. This consent does not extend to other kinds of copying such as for general distribution, resale, advertising and promotion purposes, or for creating new collective works. Special written permission must be obtained from the Publisher for such copying.

Printed in the Netherlands

Printed in the Netherlands

This journal is printed on acid-free paper.

Announcement from the Publisher

ELSEVIER SCIENCE PUBLISHERS

encourages the submission of electronic manuscripts

The preferred storage medium is a $5\frac{1}{4}$ or $3\frac{1}{2}$ inch disk in MS-DOS or MS-DOS compatible format, although other systems, e.g. Macintosh, are acceptable.

Your disk and (exactly matching) printed version (printout, hardcopy) should be submitted together to the accepting editor. In case of revision, the same procedure should be followed such that, on acceptance of the article, the file on disk and the printout are identical. Both will then be forwarded by the editor to Elsevier.

Please follow the general instructions on style/arrangement and, in particular, the reference style of this journal as given in 'Instructions to Authors'.

Illustrations and tables will be handled conventionally.

Please label the disk with your name, the software & hardware used and the name of the file to be processed.

Contact the Publisher for further information.

ELSEVIER SCIENCE PUBLISHERS B.V.
P.O. Box 1527, 1000 BM Amsterdam
The Netherlands
Fax: (+31-20) 5803454

3/91

International Journal of Pharmaceutics, (1991) 1–18
© 1991 Elsevier Science Publishers B.V. 0378-5173/91/$03.50

Author Index

Abrahamsson, B., see Sandberg, A. (68) 167
Ackermann, C., see Siebert, J.G.H. (61) 157
Ackermann, C., see Siebert, J.G.H. (65) 29
Ackermann, C., see Siebert, J.G.H. (66) 157
Adams, K.A., see Shenouda, L.S. (61) 127
Adjei, A., Doyle, R., Pratt, M., Finley, R. and Johnson, E.
Bioavailability of leuprolide following intratracheal administration to beagle dogs (61) 135
Ahlgren, R., see Nicklasson, M. (69) 255
Ahlneck, C. and Zografi, G.
The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state (62) 87
Akerele, J.O., see Okhamafe, A.O. (68) 11
Akiyama, K., see Yamashita, C. (70) 225
Al-Angary, A.A., Khidr, S.H., Mahrous, G.M. and Gouda, M.W.
In-vitro dissolution and in-vivo absorption of marketed sustained release theophylline preparations (65) R5
Al-Angary, A.A., see Al-Meshal, M.A. (64) 155
Al-Angary, A.A., see El-Sayed, Y.M. (64) 109
Al-Gohary, O.M.N.
An in vitro study of the interaction between mebeverine hydrochloride and magnesium trisilicate powder (67) 89
Al-Hmoud, H., Efentakis, M. and Choulis, N.H.
A controlled release matrix using a mixture of hydrophilic and hydrophobic polymers (68) R1
Al-Hmoud, H., see Efentakis, M. (70) 153
Al-Meshal, M.A., El-Sayed, Y.M., Al-Angary, A.A., Lutfi, K.M. and Gouda, M.W.
Interruption of the enterohepatic circulation of indomethacin by cholestyramine in rabbits (64) 155
Al-Meshal, M.A., see El-Sayed, Y.M. (64) 109
Albers, D.D., see Tu, Y.-H. (61) 119
Aldén, M., see Sjökvist, E. (69) 53
Alderborn, G., see Eriksson, M. (63) 189
Alderborn, G., see Wikberg, M. (62) 229
Alderborn, G., see Wikberg, M. (63) 23
Alderborn, G., see Wikberg, M. (69) 239
Allen, Jr., L.V., see Tu, Y.-H. (61) 119
Allsopp, M.A., Sewell, G.J., Rowland, C.G., Riley, C.M. and Schowen, R.L.
The degradation of carboplatin in aqueous solutions containing chloride or other selected nucleophiles (69) 197
Alonso, M.J., Losa, C., Calvo, P. and Vila-Jato, J.L.
Approaches to improve the association of amikacin sulphate to poly(alkylcyanoacrylate) nanoparticles (68) 69
Alonso, M.J., see Egea, M.A. (67) 103
Alpar, H.O., Bason, A.M., Hickman, J.A., Richards, F.M. and Field, W.N.
Estimation by FACS of the delivery of liposome encapsulated macromolecules into myeloid cells (62) 133
Alsina, M.A., Solé, N., Mestres, C., Busquets, M.A., Haro, I. and García Antón, J.M.
Physicochemical interaction of opioid peptides with phospholipids and membranes (70) 111
Alsina, M.A., see Egea, M.A. (67) 103
Altorfer, H., see Werner, I.A. (63) 155
Amagai, Y., see Watanabe, Y. (64) 147
Amidon, G.L., see Skelly, J.P. (63) 83
Anderberg, E.K. and Nyström, C.
Physicochemical aspects of drug release. X. Investigation of the applicability of the cube root law for characterization of the dissolution rate of fine particulate materials (62) 143
Andersen, C., see Christrup, L.L. (66) 169
Andry, M.-C., see Lévy, M.-C. (62) 27
Andry, M.-C., see Lévy, M.-C. (69) R1
Angberg, M., Nyström, C. and Castensson, S.
Evaluation of heat-conduction microcalorimetry in pharmaceutical stability studies. (II) Methods to evaluate the microcalorimetric response (61) 67
Anie, S.J., Fell, J.T. and Waigh, R.D.
Visualisation of a fluorinated pharmaceutical formulation in the anaesthetised rat using ^{19}F- and ^{1}H-NMR imaging (69) 181
Arafat, T., see Sallam, E. (67) 247
Aramaki, Y., see Hara, T. (67) 123
Armstrong, D.J., see Mitchell, K. (66) 233
Artursson, P., see Fahlvik, A.K. (65) 249
Artursson, P., see Lundin, S. (64) 181
Asano, M., Fukuzaki, H., Yoshida, M., Kumakura, M., Mashimo, T., Yuasa, H., Imai, K., Yamanaka, H., Kawaharada, U. and Suzuki, K.
In vivo controlled release of a luteinizing hormone-releasing hormone agonist from poly(DL-lactic acid) formulations of varying degradation pattern (67) 67
Asano, M., see Imasaka, K. (68) 87
Ashby, L.J., see De Morais, S.M. (66) 107
Athersuch, A., see Washington, C. (64) 217
Attwood, D., Collett, J.H. and O'Connor, C.A.
Influence of gamma irradiation on the rheological properties of gels of the poloxamine, Synperonic T908 (70) 147
Attwood, D., Collett, J.H. and O'Connor, C.A.
The effect of gamma irradiation on the surface, rheological and micellar behaviour of the block copolymer, Tetronic 908 (65) 201
Austin, P., see Collier, P.J. (66) 201

Avgerinos, A. and Malamataris, S.
Bioavailability of controlled release indomethacin microspheres and pellets (63) 77
Avgerinos, A., Noormohammadi, A. and Hutt, A.J.
Disposition of ibuprofen enantiomers following the oral administration of a novel controlled release formulation to healthy volunteers (68) 97
Avgerinos, A., see Malamataris, S. (62) 105
Avgoustakis, K. and Nixon, J.R.
Biodegradable controlled release tablets. 1: Preparative variables affecting the properties of poly(lactide-co-glycolide) copolymers as matrix forming material (70) 77
Awad, R., see Sallam, E. (67) 247

Baghal, T., see Sallam, E. (67) 247
Bains, D., Boutell, S.L. and Newton, J.M.
The influence of moisture content on the preparation of spherical granules of barium sulphate and microcrystalline cellulose (69) 233
Baker, N.D., Griffin, R.J. and Irwin, W.J.
The percutaneous absorption of *m*-azidopyrimethamine: A soft antifolate for topical use (65) 115
Barber, R.F., see Jurima-Romet, M. (63) 227
Barnwell, S.G., see White, D.G. (69) 169
Barr, W.H., see Skelly, J.P. (63) 83
Barry, B.W., see Kadir, R. (70) 87
Bartel, R.L., see Shah, P.K. (68) 285
Barthélémy, C., see Santi, P. (68) 43
Barzegar-Jalali, M.
A model for linearizing drug dissolution data (63) R9
Barzegar-Jalali, M.
Determination of absolute drug bioavailability without intravenous administration (65) R1
Bason, A.M., see Alpar, H.O. (62) 133
Bassam, F., York, P., Rowe, R.C. and Roberts, R.J.
Young's modulus of powders used as pharmaceutical excipients (64) 55
Bassam, F., see York, P. (66) 143
Bassani, V., Casadebaig, J., Jacob, M., Menut, C., Lechat, I. and Lamaty, G.
Preparation of a low-alcohol extract of *Rosmarinus officinalis* using a reverse osmosis membrane (63) 57
Basu, K. and Mitra, A.K.
Effects of 3-hydrazone modification on the metabolism and protein binding of progesterone (65) 109
Bechgaard, E., see Gizurarson, S. (65) 243
Beckett, A.H., see Hadzija, B.W. (67) 185
Beezer, A.E., see Blair, T.C. (63) 251
Beezer, A.E., see De Morais, S.M. (66) 107
Beijnen, J.H., see Bekers, O. (68) 271
Beijnen, J.H., see Van der Houwen, O.A.G.J. (67) 155
Bekers, O., Beijnen, J.H., Kempers, Y.A.G., Bult, A. and Underberg, W.J.M.
Effects of cyclodextrins on *N*-trifluoroacetyldoxorubicin-14-valerate (AD-32) stability and solubility in aqueous media (68) 271
Bekers, O., see Van der Houwen, O.A.G.J. (67) 155
Ben-Yossef, R., see Touitou, E. (70) 159
Benet, L.Z., see Skelly, J.P. (63) 83
Benita, S., see Levy, M.Y. (66) 29
Benita, S., see Pathak, Y.V. (65) 169
Benoit, J.P., see Dubernet, C. (64) 99
Bermejo, M.V., Pérez-Varona, A.T., Segura-Bono, M.J., Martín-Villodre, A., Plá-Delfina, J.M. and Garrigues, T.M.
Compared effects of synthetic and natural bile acid surfactants on xenobiotic absorption. I. Studies with polysorbate and taurocholate in rat colon (69) 221
Bermejo, M.V., see Garrigues, T.M. (64) 127
Bernà, L., see Roca, M. (69) 189
Bettinetti, G.P., see Giordano, F. (62) 153
Beugre, T., see Bonhomme, L. (65) R9
Bhatnagar, S., see Vyas, S.P. (69) 5
Binns, J.S., see Davies, M.C. (66) 223
Bisrat, M., Nyström, C. and Edman, P.
Influence of dissolution rate of sparingly soluble drugs on corneal permeability in vitro (63) 49
Björk, E. and Edman, P.
Characterization of degradable starch microspheres as a nasal delivery system for drugs (62) 187
Blair, T.C., Buckton, G., Beezer, A.E. and Bloomfield, S.F.
The interaction of various types of microcrystalline cellulose and starch with water (63) 251
Bloomfield, S.F., see Blair, T.C. (63) 251
Bluhm, D.P., Summers, R.S., Lowes, M.M.J. and Dürrheim, H.H.
Influence of container on vitamin A stability in TPN admixtures (68) 281
Bluhm, D.P., Summers, R.S., Lowes, M.M.J. and Dürrheim, H.H.
Lipid emulsion content and vitamin A stability in TPN admixtures (68) 277
Bodmeier, R. and Paeratakul, O.
Process and formulation variables affecting the drug release from chlorpheniramine maleate-loaded beads coated with commercial and self-prepared aqueous ethyl cellulose pseudolatexes (70) 59
Bodor, N., see Brewster, M.E. (68) 215
Bodor, N., see Estes, K.S. (65) 101
Bogdanov, B., see Panzova, B. (65) 35
Bogdanov, B., see Panzova, B. (70) 187
Bolhuis, G.K., see Riepma, K.A. (66) 47
Bolton, R., see De Morais, S.M. (66) 107
Bonhomme, L., Duleba, B., Beugre, T. and Fredj, G.
HPLC determination of the stability of retinoic acid in gel formulation (65) R9
Bonn, R., see Hadgraft, J. (64) 187
Borchardt, R.T., see Shah, P.K. (63) 281
Borchardt, R.T., see Shah, P.K. (68) 285
Borg, K., see Hjärtstam, J. (61) 101
Borgå, B., see Nicklasson, M. (69) 255
Bos, C.E., Vromans, H. and Lerk, C.F.
Lubricant sensitivity in relation to bulk density for granulations based on starch or cellulose (67) 39
Botha, S.A., see Van Tonder, E.C. (63) 35

Bourgeois, D., see Davies, M.C. (66) 223
Boutell, S.L., see Bains, D. (69) 233
Bouzon, J., see Laghoueg-Derriche, N. (67) 163
Brannon-Peppas, L. and Peppas, N.A.
Time-dependent response of ionic polymer networks to pH and ionic strength changes (70) 53
Braquet, P., see Dowty, M.E. (68) 231
Brasseur, N., Brault, D. and Couvreur, P.
Adsorption of hematoporphyrin onto polyalkylcyanoacrylate nanoparticles: carrier capacity and drug release (70) 129
Brault, D., see Brasseur, N. (70) 129
Breäs, R., see Poelma, F.G.J. (64) 161
Brewster, M.E., Deyrup, M., Seyda, K. and Bodor, N.
Synthesis, characterization and in vitro evaluation of various sulfonamide chemical delivery systems (68) 215
Brewster, M.E., see Estes, K.S. (65) 101
Britten, J.R., see Pilpel, N. (70) 241
Bronaugh, R.L., see Storm, J.E. (65) 265
Buckton, G. and Efentakis, M.
The use of thermodynamic activation parameters and compensation analysis to model drug release from hydrophobic matrices (62) 157
Buckton, G.
The role of compensation analysis in the study of wettability, solubility, disintegration and dissolution (66) 175
Buckton, G., see Blair, T.C. (63) 251
Buckton, G., see Efentakis, M. (70) 153
Bult, A., see Bekers, O. (68) 271
Bult, A., see Van der Houwen, O.A.G.J. (67) 155
Bundgaard, H. and Mørk, N.
Kinetics of the decarboxylation of foscarnet in acidic aqueous solution and its implication in its oral absorption (63) 213
Bundgaard, H., Jensen, E., Falch, E. and Pedersen, S.B.
Allopurinol prodrugs. V. Water-soluble *N*-substituted (aminomethyl)benzoyloxymethyl allopurinol derivatives for parenteral or rectal delivery (64) 75
Bundgaard, H., see Jensen, E. (70) 137
Bundgaard, H., see Kahns, A.H. (62) 193
Bundgaard, H., see Møss, J. (66) 183
Bundgaard, H., see Møss, J. (66) 39
Burgot, G. and Burgot, J.L.
Water/*n*-octanol thermodynamic parameters of some phenothiazines (62) R5
Burgot, G., Serrand, P. and Burgot, J.-L.
Thermodynamics of partitioning in the *n*-octanol/water system of some β-blockers (63) 73
Burgot, J.-L., see Burgot, G. (63) 73
Burgot, J.L., see Burgot, G. (62) R5
Busquets, M.A., see Alsina, M.A. (70) 111
Butula, I., see Maysinger, D. (63) 149
Buur, A., see Møss, J. (66) 183

Caira, M.R., see Van Tonder, E.C. (63) 35
Calabrese, G., see Dal Pozzo, A. (70) 219
Calvo, M.B., Pedraz, J.L., Vicente, M.T. and Domínguez-Gil, A.
Pharmacokinetics of cefazoline and dibenzylamine administered in a sustained drug delivery system to healthy volunteers (67) 259
Calvo, P., see Alonso, M.J. (68) 69
Cappel, M.J. and Kreuter, J.
Effect of nonionic surfactants on transdermal drug delivery: I. Polysorbates (69) 143
Cappel, M.J. and Kreuter, J.
Effect of nonionic surfactants on transdermal drug delivery:. II. Poloxamer and poloxamine surfactants (69) 155
Cappel, M.J., see Tsai, J.-C. (68) 127
Carlin, A.S., see Storm, J.E. (65) 265
Carlisi, B., see Giammona, G. (64) 239
Carr, L., see Patel, J.P. (65) 195
Carrió, I., see Roca, M. (69) 189
Carstensen, H., Müller, B.W. and Müller, R.H.
Adsorption of ethoxylated surfactants on nanoparticles. I. Characterization by hydrophobic interaction chromatography (67) 29
Carstensen, J.T., see Ertel, K.D. (61) 9
Carter, J.E., see Skelly, J.P. (63) 83
Casadebaig, J., see Bassani, V. (63) 57
Castelli, F., Giammona, G., Raudino, A. and Puglisi, G.
Macromolecular prodrugs interaction with mixed lipid membrane. A calorimetric study of naproxen linked to polyaspartamide interacting with phosphatidylcholine and phosphatidylcholine-phosphatidic acid vesicles (70) 43
Castensson, S., see Angberg, M. (61) 67
Catellani, P.L., see Santi, P. (68) 43
Cavallaro, G., see Giammona, G. (64) 239
Čepelak, I., see Juretić, D. (61) 219
Chafi, N., Monthéard, J.P. and Vergnaud, J.M.
Release of 2-aminothiazole from polymer carriers (67) 265
Chambers, L.A., see Walker, M. (70) 167
Chan, H.-K. and Gonda, I.
Methotrexate: Existence of different types of solid (68) 179
Chandler, S.G., Illum, L. and Thomas, N.W.
Nasal absorption in the rat. I: A method to demonstrate the histological effects of nasal formulations (70) 19
Chandraprakash, K.S., Udupa, N., Umadevi, P. and Pillai, G.K.
Pharmacokinetic evaluation of surfactant vesicle-entrapped methotrexate in tumor-bearing mice (61) R1
Chang, H.W., see Yoon, E.J. (67) 177
Chang, P., see Law, S.L. (70) 1
Chang, R.-K. and Rudnic, E.M.
The effect of various polymeric coating systems on the dissolution and tableting properties of potassium chloride microcapsules (70) 261
Chang, Y., see Chaudhuri, B. (65) 57
Chaudhuri, B., Chang, Y. and Karara, A.H.
Polyether polyurethane delivery systems. II: Effect of coadministration of pentostatin with N^6-(Δ^2-isopentenyl)adenosine (65) 57
Chauhan, U.P.S., see Jaggi, M. (69) 77
Chee, S.-M., see Davidson, A.G. (63) 29
Chien, Y.W., see Lelawongs, P. (61) 179
Choi, S.-H., see Gonsho, A. (65) 183

Choulis, N.H., see Al-Hmoud, H. (68) R1
Christrup, L.L., Davis, S.S., Frier, M., Melia, C.D., Rasmussen, S.N., Washington, N., Wilding, I.R. and Andersen, C.
Deposition of a model substance, ^{99m}Tc E-HIDA, in the oral cavity after administration of lozenges, chewing gum and sublingual tablets (66) 169
Chukuka, C.S., see Okhamafe, A.O. (68) 11
Chung, S.M., Yoon, E.J., Kim, S.H., Lee, M.G., Lee, H., Park, M.K. and Kim, C.-K.
Pharmacokinetics of 5-fluorouracil after intravenous infusion of 5-fluorouracil-acetic acid-human serum albumin conjugates to rabbits (68) 61
Church, S.P., see Davies, M.C. (66) 223
Climent, E., see Garrigues, T.M. (64) 127
Collett, J.H., see Attwood, D. (65) 201
Collett, J.H., see Attwood, D. (70) 147
Collier, P.J., Austin, P. and Gilbert, P.
Uptake and distribution of some isothiazolone biocides into *Escherichia coli* ATCC 8739 and *Schizosaccharomyces pombe* NCYC 1354 (66) 201
Collins, J.V., see Leigh, T.R. (67) 275
Colombo, P., Conte, U., Gazzaniga, A., Maggi, L., Sangalli, M.E., Peppas, N.A. and La Manna, A.
Drug release modulation by physical restrictions of matrix swelling (63) 43
Colombo, P., see Santi, P. (68) 43
Concheiro, A., see Pérez-Marcos, B. (67) 113
Conte, U., see Colombo, P. (63) 43
Cordes, G., see Hadgraft, J. (64) 187
Couvreur, P., see Brasseur, N. (70) 129
Couvreur, P., see Seijo, B. (62) 1
Crooks, P.A., see Tawfiq, F.A. (64) 45
Cserháti, T., Olajos, S. and Szögyi, M.
Physicochemical interaction of some benzodiazepine derivatives with amino acids and phospholipids (61) 189

Dal Pozzo, A., Liggeri, E., Delucca, C. and Calabrese, G.
Prediction of skin permeation of highly lipophilic compounds; in vitro model with a modified receptor phase (70) 219
Da Silva, H., see Gregoriadis, G. (65) 235
Davidson, A.G. and Smail, G.A.
Isolation and characterisation of an acid-catalyzed intermediate hydrolysis product of nitrazepam (69) 1
Davidson, A.G., Chee, S.-M., Millar, F.M. and Watson, D.
Isolation and identification of an alkali-catalyzed hydrolysis product of nitrazepam (63) 29
Davidson, R., see Dennis, A.B. (65) 85
Davies, M.C., Binns, J.S., Melia, C.D., Hendra, P.J., Bourgeois, D., Church, S.P. and Stephenson, P.J.
FT Raman spectroscopy of drugs in polymers (66) 223
Davies, M.C., Wilding, I.R., Short, R.D., Melia, C.D. and Rowe, R.C.
The in-situ chemical analysis of polymer film coatings using static secondary ion mass spectrometry (SSIMS) (62) 97
Davis, S.S., Robertson, C. and Wilding, I.R.
Gastrointestinal transit of a multiparticulate tablet formulation in patients with active ulcerative colitis (68) 199
Davis, S.S., see Christrup, L.L. (66) 169
Davis, S.S., see Illum, L. (63) 207
Davis, S.S., see Johnson, O.L. (63) 65
Davis, S.S., see Khosla, R. (62) R9
Davis, S.S., see Moghimi, S.M. (68) 121
Davis, S.S., see Saunders, J. (68) 265
De Boer, A.H., see Riepma, K.A. (66) 47
Delucca, C., see Dal Pozzo, A. (70) 219
Demeester, J., see Jurima-Romet, M. (63) 227
De Morais, S.M., Beezer, A.E., Ashby, L.J. and Bolton, R.
Biologically based QSARs: study of cardanol derivatives on interaction with *Saccharomyces cerevisiae* (66) 107
De Muynck, C., see De Vroe, C. (65) 49
De Muynck, C., see Vandenbossche, G.M.R. (67) 195
Dennis, A.B., Farr, S.J., Kellaway, I.W., Taylor, G. and Davidson, R.
In vivo evaluation of rapid release and sustained release Gelucire capsule formulations (65) 85
De Pablos Pons, F., see González, A.G. (67) R1
De Villiers, C., see Munday, D.L. (69) 123
De Vroe, C., De Muynck, C., Remon, J.P. and Samsom, M.
A study on the stability of three antineoplastic drugs and on their sorption by i.v. delivery systems and end-line filters (65) 49
Deyrup, M., see Brewster, M.E. (68) 215
De Zeeuw, R.A., see Wiechers, J.W. (65) 77
De Zeeuw, R.A., see Wiechers, J.W. (66) 53
Dimitriou, A., see Malamataris, S. (68) 51
Dittert, L., see Tawfiq, F.A. (64) 45
Dittrich, C., see Mader, R.M. (68) 151
Domínguez-Gil, A., see Calvo, M.B. (67) 259
Donato, I., see Giammona, G. (64) 239
Dorle, A.K., see Sheorey, D.S. (68) 19
Dowty, M.E. and Braquet, P.
Effect of extracellular pH on cytoplasmic pH and mechanism of pH regulation in cultured bovine corneal endothelium: Possible importance in drug transport studies (68) 231
Doyle, R., see Adjei, A. (61) 135
Drenth, B.F.H., see Wiechers, J.W. (65) 77
Drenth, B.F.H., see Wiechers, J.W. (66) 53
Dubernet, C., Rouland, J.C. and Benoit, J.P.
Comparative study of two ethylcellulose forms (raw material and microspheres) carried out through thermal analysis (64) 99
Duchêne, D., see Lin, S.-Z. (69) 211
Duffield, J.R., see Hall, S.B. (70) 251
Duleba, B., see Bonhomme, L. (65) R9
Durr, M., see Grove, J. (66) 23
Dürrheim, H.H., see Bluhm, D.P. (68) 277
Dürrheim, H.H., see Bluhm, D.P. (68) 281

Edman, P., see Bisrat, M. (63) 49
Edman, P., see Björk, E. (62) 187
Edman, P., see Fahlvik, A.K. (65) 249

Eerikäinen, S., see Laakso, R. (67) 79
Efentakis, M., Al-Hmoud, H., Buckton, G. and Rajan, Z.
The influence of surfactants on drug release from a hydrophobic matrix (70) 153
Efentakis, M., see Al-Hmoud, H. (68) R1
Efentakis, M., see Buckton, G. (62) 157
Egea, M.A., Valls, O., Alsina, M.A., Garcia, M.L., Losa, C., Vila-Jato, J.L. and Alonso, M.J.
Interaction of amikacin loaded nanoparticles with phosphatidylcholine monolayers as membrane models (67) 103
Eissens, A.C., see Frijlink, H.W. (64) 195
El-Faham, T.H., see Ibrahim, S.A. (61) 1
El-Sayed, Y.M., Al-Meshal, M.A., Al-Angary, A.A., Lutfi, K.M. and Gouda, M.W.
Accelerated clearance of intravenous indomethacin by oral activated charcoal in rabbits (64) 109
El-Sayed, Y.M., see Al-Meshal, M.A. (64) 155
Eley, J.G., Halbert, G.W. and Florence, A.T.
Incorporation of prednimustine into low density lipoprotein: activity against P388 cells in tissue culture (65) 219
Eley, J.G., Halbert, G.W. and Florence, A.T.
The incorporation of estramustine into low density lipoprotein and its activity in tissue culture (63) 121
Elliott, P.N.C., see Mitchell, K. (66) 233
ElShaboury, M.H.
Physical properties and dissolution profiles of tablets directly compressed with β-cyclodextrin (63) 95
Enever, R.P., see Shahjahan, M. (70) 9
Eriksson, M., Nyström, C. and Alderborn, G.
Evaluation of a permeametry technique for surface area measurements of coarse particulate materials (63) 189
Ertel, K.D. and Carstensen, J.T.
Examination of a modified Arrhenius relationship for pharmaceutical stability prediction (61) 9
Esezobo, S., see Pilpel, N. (70) 241
Espinar, F.J.O., Igea, S.A., Méndez, J.B. and Jato, J.L.V.
Reduction in the ulcerogenicity of naproxen by complexation with β-cyclodextrin (70) 35
Estelrich, J., see Montero, M.T. (62) 21
Estes, K.S., Brewster, M.E., Webb, A.I. and Bodor, N.
A non-surfactant formulation for alfaxalone based on an amorphous cyclodextrin: Activity studies in rats and dogs (65) 101
Estorch, M., see Roca, M. (69) 189

Fabin, B., see Touitou, E. (70) 159
Fagerness, P.E., see Snider, B.G. (66) 63
Fahlvik, A.K., Artursson, P. and Edman, P.
Magnetic starch microspheres: Interactions of a microsphere MR contrast medium with macrophages in vitro (65) 249
Falch, E., see Bundgaard, H. (64) 75
Farooq, A., see Jha, P. (63) 143
Farr, S.J., see Dennis, A.B. (65) 85
Farraj, N.F., see Illum, L. (63) 207
Fassihi, A.R., see Munday, D.L. (69) 123
Fattal, E., see Seijo, B. (62) 1
Fell, J.T., see Anie, S.J. (69) 181
Fernández-Arévalo, M., see Rabasco, A.M. (67) 201
Ferry, J., see Tsai, J.-C. (68) 127
Field, W.N., see Alpar, H.O. (62) 133
Finley, R., see Adjei, A. (61) 135
Finne, U., Väisänen, V. and Urtti, A.
Modification of ocular and systemic absorption of timolol from ocular inserts by a buffering agent and a vasoconstrictor (65) 19
Finne, U., see Urtti, A. (61) 241
Florence, A.T., see Eley, J.G. (63) 121
Florence, A.T., see Eley, J.G. (65) 219
Florence, A.T., see Gregoriadis, G. (65) 235
Florence, A.T., see Omotosho, J.A. (61) 51
Florence, A.T., see Ping, Q. (61) 79
Flynn, G.L., see Hou, S.Y.E. (66) 79
Flynn, G.L., see Tsai, J.-C. (68) 127
Ford, J.L., see Mitchell, K. (66) 233
Fredj, G., see Bonhomme, L. (65) R9
Friðriksdóttir, H., see Loftsson, T. (62) 243
Frier, M., see Christrup, L.L. (66) 169
Frijlink, H.W., Eissens, A.C., Schoonen, A.J.M. and Lerk, C.F.
The effects of cyclodextrins on drug absorption. II. In vivo observations (64) 195
Fukuzaki, H., see Asano, M. (67) 67
Fukuzaki, H., see Imasaka, K. (68) 87
Fürst, W., Neubert, R., Jurkschat, T. and Lücke, L.
Prodrug approach of orotic acid using an absorption model (61) 43

Gabrijelčič, V., Šentjurc, M. and Kristl, J.
Evaluation of liposomes as drug carriers into the skin by one-dimensional EPR imaging (62) 75
Gallarate, M., see Gasco, M.R. (69) 193
Ganderton, D., see Leigh, T.R. (67) 275
Ganderton, D., see Malamataris, S. (70) 69
Gangal, S.V., see Jaggi, M. (69) 77
Garcia, M.L., see Egea, M.A. (67) 103
García Antón, J.M., see Alsina, M.A. (70) 111
Garr, J.S.M. and Rubinstein, M.H.
Direct compression characteristics of xylitol (64) 223
Garren, K.W. and Pyter, R.A.
Aqueous solubility properties of a dibasic peptide-like compound (63) 167
Garrigues, T.M., Pérez-Varona, A.T., Climent, E., Bermejo, M.V., Martín-Villodre, A. and Plá-Delfina, J.M.
Gastric absorption of acidic xenobiotics in the rat: Biophysical interpretation of an apparently atypical behaviour (64) 127
Garrigues, T.M., see Bermejo, M.V. (69) 221
Gasco, M.R., Gallarate, M. and Pattarino, F.
In vitro permeation of azelaic acid from viscosized microemulsions (69) 193
Gasco, M.R., Pattarino, F. and Lattanzi, F.
Long-acting delivery systems for peptides: reduced plasma testosterone levels in male rats after a single injection (62) 119

Gaskin, P.W., see Hall, S.B. (70) 251
Gaspar, R., Préat, V. and Roland, M.
Nanoparticles of polyisohexylcyanoacrylate (PIHCA) as carriers of primaquine: formulation, physico-chemical characterization and acute toxicity (68) 111
Gazzaniga, A., see Colombo, P. (63) 43
Gazzaniga, A., see Giordano, F. (62) 153
Gerber, J.J., Van der Watt, J.G. and Lötter, A.P.
Physical characterisation of three pseudopolymorphs of cyclopenthiazide (69) 265
Ghanem, A.-H., see Liu, P. (64) 7
Ghogare, A.B., see Sadana, G.S. (70) 195
Giammona, G., Carlisi, B., Cavallaro, G., Donato, I., Pinio, F. and Liveri, V.T.
Calorimetric investigation of the interaction between α,β-poly(*N*-hydroxyethyl)-DL-aspartamide and surfactants (64) 239
Giammona, G., see Castelli, F. (70) 43
Gibbons, W.A., see Toth, I. (68) 191
Gilbert, P., see Collier, P.J. (66) 201
Gilligan, C.A., see Li Wan Po, A. (66) 111
Ginés, J.M., see Rabasco, A.M. (67) 201
Giordano, F., Gazzaniga, A., Bettinetti, G.P. and La Manna, A.
The influence of water content on the binding capacity of β-cyclodextrin (62) 153
Gizurarson, S., Marriott, C., Martin, G.P. and Bechgaard, E.
The influence of insulin and some excipients used in nasal insulin preparations on mucociliary clearance (65) 243
Glazer, M., see Karehill, P.G. (64) 35
Gogoi, P.J., see Vyas, S.P. (69) 5
Goidas, P., see Malamataris, S. (68) 51
Gómez-Amoza, J.L., see Pérez-Marcos, B. (67) 113
Gonda, I., see Chan, H.-K. (68) 179
Gonsho, A., Imanidis, G., Vogt, P., Kern, E.R., Tsuge, H., Su, M.-H., Choi, S.-H. and Higuchi, W.I.
Controlled (trans)dermal delivery of an antiviral agent (acyclovir). I: An in vivo animal model for efficacy evaluation in cutaneous HSV-1 infections (65) 183
González, A.G. and De Pablos Pons, F.
Evaluation of acidity constants for sparingly soluble compounds from fluorescence measurements (67) R1
Good, W.R., see Liu, P. (64) 7
Gorgin, M.K., see Tu, Y.-H. (61) 119
Gorman, S.P., Jones, D.S. and Loftus, A.M.
The synergistic effect of direct and indirect ultrasonic energy and chlorhexidine gluconate on spores of *Bacillus subtilis* (65) 127
Gorman, S.P., see Jones, D.S. (64) R1
Gouda, M.W., see Al-Angary, A.A. (65) R5
Gouda, M.W., see Al-Meshal, M.A. (64) 155
Gouda, M.W., see El-Sayed, Y.M. (64) 109
Graf, E., see März, F. (61) 57
Gratteri, P., see Santoni, G. (64) 235
Gregoriadis, G., Da Silva, H. and Florence, A.T.
A procedure for the efficient entrapment of drugs in dehydration-rehydration liposomes (DRVs) (65) 235
Griffin, R.J., see Baker, N.D. (65) 115
Grove, J., Durr, M., Quint, M.-P. and Plazonnet, B.
The effect of vehicle viscosity on the ocular bioavailability of L-653,328 (66) 23
Gulati, M., see Singh, S. (68) 105
Gupta, R.L., see Singh, S. (68) 105
Gutiérrez, C., see Pérez-Marcos, B. (67) 113
Guyot-Hermann, A.-M., see Santi, P. (68) 43

Hackemüller, D., see Lippold, B.C. (61) 205
Hadgraft, J., Wolff, M., Bonn, R. and Cordes, G.
Development of biphasic transdermal nitroglycerin delivery systems (64) 187
Hadgraft, J., see Lewis, D. (65) 211
Hadgraft, J., see Marques, H.M.C. (63) 259
Hadgraft, J., see Marques, H.M.C. (63) 267
Hadgraft, J., see Walker, M. (70) 167
Hadzija, B.W., Obeng, E.K., Ruddy, S.B., Noormohammadi, A. and Beckett, A.H.
Bioavailability of a controlled release indomethacin formulation in healthy subjects (67) 185
Halbert, G.W., see Eley, J.G. (63) 121
Halbert, G.W., see Eley, J.G. (65) 219
Hall, S.B., Gaskin, P.W., Duffield, J.R. and Williams, D.R.
An interfacial equilibria model for the electrokinetic properties of a fat emulsion (70) 251
Hamed, M.Y., Mostafa, E.M. and Tous, S.S.
Antifertility effect of orally formulated melatonin tablets in mice (69) 93
Hara, M., see Maitani, Y. (64) 139
Hara, T., Ishihara, H., Aramaki, Y. and Tsuchiya, S.
Characteristics of the binding of asialofetuin-labeled liposomes to isolated rat hepatocytes (67) 123
Haro, I., see Alsina, M.A. (70) 111
Hashida, M., see Nishida, K. (65) 7
Haslam, J.L., see Merfeld, A.E. (69) 63
Hassan, M.A., Najib, N.M. and Suleiman, M.S.
Characterization of glibenclamide glassy state (67) 131
Hayward, D.S. and Jenke, D.R.
Interactions between polymer containers and parenteral solutions: Correlating equilibrium polymer-water interaction constants with solute partition coefficients (66) 87
Helm, V.J. and Müller, B.W.
Stability of the synthetic pentapeptide thymopentin in aqueous solution: Effect of pH and buffer on degradation (70) 29
Hendra, P.J., see Davies, M.C. (66) 223
Hendriksen, B.A. and Williams, J.D.
Characterization of calcium fenoprofen. 2. Dissolution from formulated tablets and compressed rotating discs (69) 175
Herbots, H., see Provost, C. (62) 217
Herder, R.E., see Wiechers, J.W. (65) 77
Herman, J. and Remon, J.P.
Modified starches as hydrophilic matrices for controlled oral delivery. III. Evaluation of sustained-release theophylline formulations based on thermal modified starch matrices in dogs (63) 201

Hermens, W.A.J.J., see Schipper, N.G.M. (64) 61
Hettler, D., see Lévy, M.-C. (69) R1
Heya, T., Okada, H., Tanigawara, Y., Ogawa, Y. and Toguchi, H.
Effects of counteranion of TRH and loading amount on control of TRH release from copoly(dl-lactic/glycolic acid) microspheres prepared by an in-water drying method (69) 69
Hickman, J.A., see Alpar, H.O. (62) 133
Hidalgo, I.J., see Shah, P.K. (63) 281
Hiestand, E.N. and Smith, D.P.
Tablet bond. II. Experimental check of model (67) 231
Hiestand, E.N.
Tablet bond. I. A theoretical model (67) 217
Higuchi, W.I., see Gonsho, A. (65) 183
Higuchi, W.I., see Liu, P. (64) 7
Higuchi, W.I., see Sims, S.M. (69) 109
Hirate, J., Zhu, C., Horikoshi, I. and Nagase, S.
Disposition of warfarin in analbuminemic rats (65) 149
Hjärtstam, J., Borg, K. and Lindstedt, B.
The effect of tensile stress on permeability of free films of ethyl cellulose containing hydroxypropyl methylcellulose (61) 101
Hjärtstam, J., see Lindstedt, B. (67) 21
Hogan, J.E., see Mitchell, K. (66) 233
Holgado, M.A., see Rabasco, A.M. (67) 201
Holland, S.J. and Warrack, J.K.
Low-temperature scanning electron microscopy of the phase inversion process in a cream formulation (65) 225
Hollingsbee, D.A., see Walker, M. (70) 167
Horikoshi, I., see Hirate, J. (65) 149
Hou, S.Y.E. and Flynn, G.L.
Phase volume and partitioning effects on drug delivery from topical emulsions (66) 79
Hughes, R.A., see Toth, I. (68) 191
Hussain, A., see Tawfiq, F.A. (64) 45
Hussain, M.S.H., York, P. and Timmins, P.
Influence of commercial and high purity magnesium stearates on sodium chloride and paracetamol DC granules during tabletting (70) 103
Hutchinson, L.E.F., see O'Mullane, J.E. (63) 177
Hutt, A.J., see Avgerinos, A. (68) 97

Ibrahim, H., see Sallam, E. (67) 247
Ibrahim, S.A., El-Faham, T.H., Tous, S.S. and Mostafa, E.M.
Formulation, release characteristics and evaluation of ibuprofen suppositories (61) 1
Igea, S.A., see Espinar, F.J.O. (70) 35
Igwilo, C.I., see Pilpel, N. (68) 157
Ilievska, M., see Panzova, B. (70) 187
Illum, L., Farraj, N.F., Davis, S.S., Johansen, B.R. and O'Hagan, D.T.
Investigation of the nasal absorption of biosynthetic human growth hormone in sheep—use of a bioadhesive microsphere delivery system (63) 207
Illum, L., see Chandler, S.G. (70) 19
Illum, L., see Moghimi, S.M. (68) 121
Imai, K., see Asano, M. (67) 67
Imai, T., Shiraishi, S., Saitô, H. and Otagiri, M.
Interaction of indomethacin with low molecular weight chitosan, and improvements of some pharmaceutical properties of indomethacin by low molecular weight chitosans (67) 11
Imanidis, G., see Gonsho, A. (65) 183
Imasaka, K., Yoshida, M., Fukuzaki, H., Asano, M., Kumakura, M., Mashimo, T., Yamanaka, H. and Nagai, T.
A new biodegradable implant consisting of waxy-type poly(ϵ-caprolactone-co-δ-valerolactone) and estramustine (68) 87
Irwin, W.J., Sanderson, F.D. and Li Wan Po, A.
Percutaneous absorption of ibuprofen and naproxen: Effect of amide enhancers on transport through rat skin (66) 243
Irwin, W.J., Sanderson, F.D. and Li Wan Po, A.
Percutaneous absorption of ibuprofen: Vehicle effects on transport through rat skin (66) 193
Irwin, W.J., see Baker, N.D. (65) 115
Iseki, K., see Kohri, N. (68) 255
Ishida, E., see Tsunematsu, H. (68) 77
Ishihara, H., see Hara, T. (67) 123
Ismailos, G., see Parissi-Poulou, M. (62) R13
Isowa, K., see Quan, D. (68) 239
Issopoulos, P.B.
Analytical investigations of isonicotinic acid hydrazide (isoniazid). VI. Sensitive colorimetric determination of micro amounts of isoniazid using an indirect redox method (70) 201
Issopoulos, P.B.
Colorimetric determination of dihydralazine sulfate using paramolybdate anion as an oxidizing agent (61) 261
Ito, R., Machida, Y., Sannan, T. and Nagai, T.
Magnetic granules: a novel system for specific drug delivery to esophageal mucosa in oral administration (61) 109
Iwuagwu, M.A. and Jideonwo, A.
Preliminary investigations into the in-vitro interaction of folic acid with magnesium trisilicate and edible clay (65) 63

Jacob, M., see Bassani, V. (63) 57
Jacobsen, L., see Nicklasson, M. (69) 255
Jaggi, M., Khar, R.K., Chauhan, U.P.S. and Gangal, S.V.
Liposomes as carriers of ^{99m}Tc glucoheptonate for liver imaging (69) 77
Jain, N.B., see Wesdyk, R. (65) 69
Jain, N.K., see Vyas, S.P. (69) 5
Jalšenjak, I., see Juretić, D. (61) 219
Jalšenjak, I., see Maysinger, D. (63) 149
Jalšenjak, V., see Juretić, D. (61) 219
Jato, J.L.V., see Espinar, F.J.O. (70) 35
Jenke, D.R., see Hayward, D.S. (66) 87
Jensen, E. and Bundgaard, H.
Aminomethylbenzoate esters of chloramphenicol as a novel prodrug type for parenteral administration (70) 137
Jensen, E., see Bundgaard, H. (64) 75
Jha, P., Murugesan, K. and Farooq, A.

Particle size and release of norethindrone acetate through silastic tubing: an in vitro and in vivo study (63) 143
Jideonwo, A., see Iwuagwu, M.A. (65) 63
Johansen, B.R., see Illum, L. (63) 207
Johnson, E., see Adjei, A. (61) 135
Johnson, O.L., Washington, C. and Davis, S.S.
Long-term stability studies of fluorocarbon oxygen transport emulsions (63) 65
Jones, D.S., McCafferty, D.F., Woolfson, A.D. and Gorman, S.P.
A study of the stability of taurolidine in plasma and protein-free serum (64) R1
Jones, D.S., see Gorman, S.P. (65) 127
Jonkman, J.H.G., see Wiechers, J.W. (66) 53
Joshi, Y.M., see Wesdyk, R. (65) 69
Junginger, H.E., see Lehr, C.-M. (70) 235
Juretić, D., Čepelak, I., Jalšenjak, V., Žanić-Grubišić, T., Lipovac, K. and Jalšenjak, I.
Effect of microencapsulated acetylsalicylic acid on glycosylation of human serum proteins in vitro (61) 219
Jurima-Romet, M., Barber, R.F., Demeester, J. and Shek, P.N.
Distribution studies of liposome-encapsulated glutathione administered to the lung (63) 227
Jurkschat, T., see Fürst, W. (61) 43

Kadir, F., Zuidema, J., Pijpers, A., Vulto, A. and Verheijden, J.H.M.
Drug lipophilicity and release pattern of some β-blocking agents after intra-adipose injection in pigs (64) 171
Kadir, R. and Barry, B.W.
α-Bisabolol, a possible safe penetration enhancer for dermal and transdermal therapeutics (70) 87
Kahns, A.H. and Bundgaard, H.
Prodrugs as drug delivery systems. 107. Synthesis and chemical and enzymatic hydrolysis kinetics of various mono- and diester prodrugs of *N*-acetylcysteine (62) 193
Kaluzny, B.D., see Snider, B.G. (66) 63
Kaneniwa, N., see Otsuka, M. (62) 65
Kanfer, I., see Stubbs, C. (63) 113
Karara, A.H., see Chaudhuri, B. (65) 57
Karba, R., see Mrhar, A. (62) 15
Karehill, P.G. and Nyström, C.
Studies on direct compression of tablets. XXI. Investigation of bonding mechanisms of some directly compressed materials by strength characterization in media with different dielectric constants (relative permittivity) (61) 251
Karehill, P.G. and Nyström, C.
Studies on direct compression of tablets. XXII. Investigation of strength increase upon ageing and bonding mechanisms for some plastically deforming materials (64) 27
Karehill, P.G., Glazer, M. and Nyström, C.
Studies on direct compression of tablets. XXIII. The importance of surface roughness for the compactability of some directly compressible materials with different bonding and volume reduction properties (64) 35
Kaufman, M.J.
Rate and equilibrium constants for acid-catalyzed lactone hydrolysis of HMG-CoA reductase inhibitors (66) 97
Kawaharada, U., see Asano, M. (67) 67
Kellaway, I.W., see Dennis, A.B. (65) 85
Kellaway, I.W., see Marques, H.M.C. (63) 259
Kellaway, I.W., see Marques, H.M.C. (63) 267
Kempers, Y.A.G., see Bekers, O. (68) 271
Kerč, J., Srčič, S., Mohar, M. and Šmid-Korbar, J.
Some physicochemical properties of glassy felodipine (68) 25
Kern, E.R., see Gonsho, A. (65) 183
Khar, R.K., see Jaggi, M. (69) 77
Khidr, S.H., see Al-Angary, A.A. (65) R5
Khosla, R. and Davis, S.S.
The effect of tablet size on the gastric emptying of non-disintegrating tablets (62) R9
Killion, Jr, R.B. and Stella, V.J.
The nucleophilicity of dextrose, sucrose, sorbitol, and mannitol with *p*-nitrophenyl esters in aqueous solution (66) 149
Kim, C.-K., see Chung, S.M. (68) 61
Kim, C.K., see Yoon, E.J. (67) 177
Kim, S.H., see Chung, S.M. (68) 61
Kimura, T., see Kurosaki, Y. (67) 1
Kinget, R., see Provost, C. (62) 217
Kiwada, H., see Yamashita, C. (70) 225
Klimek, R., see Thoma, K. (67) 169
Kogoshi, T., see Watanabe, Y. (64) 147
Kohli, D.V., see Tripathi, M. (67) 207
Kohri, N., Yatabe, H., Iseki, K. and Miyazaki, K.
A new type of a pH-independent controlled release tablet (68) 255
Kreuter, J., see Cappel, M.J. (69) 143
Kreuter, J., see Cappel, M.J. (69) 155
Kreuter, J., see Tröster, S.D. (61) 85
Kristl, J., see Gabrijelčič, V. (62) 75
Ktistis, G.
A viscosity study on oil-in-water microemulsions (61) 213
Kumakura, M., see Asano, M. (67) 67
Kumakura, M., see Imasaka, K. (68) 87
Kunchandy, E. and Rao, M.N.A.
Generation of superoxide anion and hydrogen peroxide by (+)-cyanidanol-3 (65) 261
Kurihara-Bergstrom, T., see Liu, P. (64) 7
Kurosaki, Y., Nagahara, N., Tanizawa, T., Nishimura, H., Nakayama, T. and Kimura, T.
Use of lipid disperse systems in transdermal drug delivery: Comparative study of flufenamic acid permeation among rat abdominal skin, silicon rubber membrane and stratum corneum sheet isolated from hamster cheek pouch (67) 1
Kussendrager, K.D., see Riepma, K.A. (66) 47
Kynoch, D.J., see Washington, C. (64) 217

Laakso, R. and Eerikäinen, S.
Effects of core components on indomethacin release from film-coated granules (67) 79
Laghoueg-Derriche, N. and Vergnaud, J.M.
Modelling the process of drying of dosage forms made of drug dispersed in a polymer (67) 51
Laghoueg-Derriche, N., Bouzon, J. and Vergnaud, J.M.

Effect of temperature of the drying process of dosage forms prepared by a humidity technique (67) 163
Laine, E., see Niemi, L. (68) 205
La Manna, A., see Colombo, P. (63) 43
La Manna, A., see Giordano, F. (62) 153
Lamaty, G., see Bassani, V. (63) 57
Lattanzi, F., see Gasco, M.R. (62) 119
Law, S.L., Chang, P. and Lin, C.H.
Characteristics of mitoxantrone loading on liposomes (70) 1
Law, T.K., see Ping, Q. (61) 79
Lechat, I., see Bassani, V. (63) 57
Lee, G., see Schückler, F. (70) 173
Lee, H., see Chung, S.M. (68) 61
Lee, H., see Yoon, E.J. (67) 177
Lee, M.G., see Chung, S.M. (68) 61
Lee, M.G., see Yoon, E.J. (67) 177
Lehr, C.-M., Poelma, F.G.J., Junginger, H.E. and Tukker, J.J.
An estimate of turnover time of intestinal mucus gel layer in the rat in situ loop (70) 235
Leigh, T.R., Nazir, T., Wiggins, J., Ganderton, D. and Collins, J.V.
Performance characteristics of the DeVilbiss Ultraneb 99 ultrasonic nebuliser with reference to use in sputum induction (67) 275
Lelawongs, P., Liu, J.-C. and Chien, Y.W.
Transdermal iontophoretic delivery of arginine-vasopressin. (II): Evaluation of electrical and operational factors (61) 179
Lerk, C.F., see Bos, C.E. (67) 39
Lerk, C.F., see Frijlink, H.W. (64) 195
Lerk, C.F., see Riepma, K.A. (66) 47
Levi-Schaffer, F., see Touitou, E. (70) 159
Lévy, M.-C. and Andry, M.-C.
Microcapsules prepared through interfacial cross-linking of starch derivatives (62) 27
Lévy, M.-C., Hettler, D., Andry, M.-C. and Rambourg, P.
Polyhydroxamic serum albumin microcapsules: preparation and chelating properties (69) R1
Levy, M.Y. and Benita, S.
Drug release from submicronized o/w emulsion: A new in vitro kinetic evaluation model (66) 29
Lewis, D. and Hadgraft, J.
Mixed monolayers of dipalmitoylphosphatidylcholine with Azone or oleic acid at the air-water interface (65) 211
Liaw, J., see Rojanasakul, Y. (66) 131
Lichtenberger, R. and Merkle, H.P.
Intrinsic diffusion coefficients of drugs in pressure-sensitive adhesive polymer masses (64) 117
Liggeri, E., see Dal Pozzo, A. (70) 219
Lin, C.H., see Law, S.L. (70) 1
Lin, S.-Z., Wouessidjewe, D., Poelman, M.-C. and Duchêne, D.
Indomethacin and cyclodextrin complexes (69) 211
Lindberg, J., see Nicklasson, M. (69) 255
Lindstedt, B., Sjöberg, M. and Hjärtstam, J.
Osmotic pumping release from KCl tablets coated with porous and non-porous ethylcellulose (67) 21
Lindstedt, B., see Hjärtstam, J. (61) 101
Lipovac, K., see Juretić, D. (61) 219
Lippold, B.C. and Hackemüller, D.
The influence of skin moisturizers on drug penetration in vivo (61) 205
Liu, J.-C., see Lelawongs, P. (61) 179
Liu, P., Higuchi, W.I., Ghanem, A.-H., Kurihara-Bergstrom, T. and Good, W.R.
Quantitation of simultaneous diffusion and metabolism of β-estradiol in hairless mouse skin: Enzyme distribution and intrinsic diffusion/metabolism parameters (64) 7
Liveri, V.T., see Giammona, G. (64) 239
Li Wan Po, A., see Irwin, W.J. (66) 193
Li Wan Po, A., see Irwin, W.J. (66) 243
Li Wan Po, A., see Mhando, J.R. (62) 249
Li Wan Po, A., see Zhou, X.H. (62) 259
Li Wan Po, A., see Zhou, X.H. (69) 29
Li Wan Po, A., see Zhou, X.H. (70) 271
Li Wan Po, A., Wong, L.P. and Gilligan, C.A.
Characterisation of commercially available theophylline sustained- or controlled-release systems: in-vitro drug release profiles (66) 111
Loftsson, T. and Friðriksdóttir, H.
Degradation of lomustine (CCNU) in aqueous solutions (62) 243
Loftsson, T. and Ólafsdóttir, B.J.
Cyclodextrin-accelerated degradation of β-lactam antibiotics in aqueous solutions (67) R5
Loftsson, T. and Ólafsdóttir, B.J.
The effect of 2-hydroxypropyl-β-cyclodextrin on the simultaneous dissolution and degradation of chlorambucil (66) 289
Loftus, A.M., see Gorman, S.P. (65) 127
Lombardo, E., see Santoni, G. (64) 235
Losa, C., see Alonso, M.J. (68) 69
Losa, C., see Egea, M.A. (67) 103
Loth, H.
Vehicular influence on transdermal drug penetration (68) 1
Lötter, A.P., see Gerber, J.J. (69) 265
Lötter, A.P., see Van Tonder, E.C. (63) 35
Louden, J.D. and Rowe, R.C.
A quantitative examination of the structure of emulsions prepared using cetostearyl alcohol and cetrimide using Fourier transform infrared microscopy (63) 219
Lowes, M.M.J., see Bluhm, D.P. (68) 277
Lowes, M.M.J., see Bluhm, D.P. (68) 281
Lücke, L., see Fürst, W. (61) 43
Lucks, J.S., Müller, B.W. and Müller, R.H.
Polymeric and emulsion carriers—interaction with antiflocculants and ionic surfactants (63) 183
Ludwig, A., Unlü, N. and Van Ooteghem, M.
Evaluation of viscous ophthalmic vehicles containing carbomer by slit-lamp fluorophotometry in humans (61) 15
Lugt, C.B., see Titulaer, H.A.C. (69) 83
Lundin, S. and Artursson, P.
Absorption of a vasopressin analogue, 1-deamino-8-D-arginine-vasopressin (dDAVP), in a human intestinal epithelial cell line, CaCO-2 (64) 181

Lutfi, K.M., see Al-Meshal, M.A. (64) 155
Lutfi, K.M., see El-Sayed, Y.M. (64) 109
Luyt, A.S., see Siebert, J.G.H. (61) 157
Luyt, A.S., see Siebert, J.G.H. (65) 29
Luyt, A.S., see Siebert, J.G.H. (66) 157

Ma, L., Ramachandran, C. and Weiner, N.D.
Partitioning of an homologous series of alkyl *p*-aminobenzoates into multilamellar liposomes: effect of liposome composition (70) 209
Macheras, P., see Parissi-Poulou, M. (62) R13
Machida, Y., see Ito, R. (61) 109
Machida, Y., see Maitani, Y. (64) 139
Machida, Y., see Takahashi, T. (61) 35
Mader, R.M., Rizovski, B., Steger, G.G., Moser, K., Rainer, H. and Dittrich, C.
Permeability of latex membranes to anti-cancer drugs (68) 151
Maggi, L., see Colombo, P. (63) 43
Magnusson, A.-B., see Nicklasson, M. (69) 255
Mahrous, G.M., see Al-Angary, A.A. (65) R5
Maitani, Y., Nakagaki, M. and Nagai, T.
Surface potential of liposomes with entrapped insulin (64) 89
Maitani, Y., Uchida, N., Nakagaki, M. and Nagai, T.
Effect of bile salts on the nasal mucosa: Membrane potential measurement (69) 21
Maitani, Y., Uchida, N., Taniguchi, M., Yamazaki, S., Hara, M., Takayama, K., Machida, Y. and Nagai, T.
The inactivation process of fibroblast interferon-β in the preparation stage and in rabbit nasal absorption of mixed and freeze-dried powder dosage forms (64) 139
Malamataris, S. and Avgerinos, A.
Controlled release indomethacin microspheres prepared by using an emulsion solvent-diffusion technique (62) 105
Malamataris, S. and Ganderton, D.
Sustained release from matrix system comprising hydrophobic and hydrophilic (gel-forming) parts (70) 69
Malamataris, S., Goidas, P. and Dimitriou, A.
Moisture sorption and tensile strength of some tableted direct compression excipients (68) 51
Malamataris, S., see Avgerinos, A. (63) 77
Malamataris, S., see Pilpel, N. (68) 157
Mälkki, L. and Tammilehto, S.
Decomposition of salbutamol in aqueous solutions. I. The effect of pH, temperature and drug concentration (63) 17
Marques, H.M.C., Hadgraft, J. and Kellaway, I.W.
Studies of cyclodextrin inclusion complexes. I. The salbutamol-cyclodextrin complex as studied by phase solubility and DSC (63) 259
Marques, H.M.C., Hadgraft, J., Kellaway, I.W. and Pugh, W.J.
Studies of cyclodextrin inclusion complexes. II. Molecular modelling and ^{1}H-NMR evidence for the salbutamol-β-cyclodextrin complex (63) 267
Marriott, C., see Gizurarson, S. (65) 243
Marsh, K., see Patel, J.P. (65) 195
Marshall, P.V. and York, P.
The compaction properties of nitrofurantoin samples crystallised from different solvents (67) 59
Martin, G.P., see Gizurarson, S. (65) 243
Martín-Villodre, A., see Bermejo, M.V. (69) 221
Martín-Villodre, A., see Garrigues, T.M. (64) 127
Martínez-Pacheco, R., see Pérez-Marcos, B. (67) 113
März, F., Scheer, R. and Graf, E.
Use of a laser diffraction particle counter to monitor integrity of reverse osmosis membranes and its inefficiency to detect bacteria in product water (61) 57
Mascagni, P., see Toth, I. (68) 191
Mashimo, T., see Asano, M. (67) 67
Mashimo, T., see Imasaka, K. (68) 87
Matsumoto, M., see Watanabe, Y. (64) 147
Matsuo, H., see Yamashita, C. (70) 225
Mayer, J.M., see Wernly-Chung, G.N. (63) 129
Maysinger, D., Zorc, B., Butula, I. and Jalšenjak, I.
Preparation and in vivo effect of microencapsulated cholinotoxin (63) 149
McCafferty, D.F., see Jones, D.S. (64) R1
McCafferty, D.F., see Woolfson, A.D. (62) 9
McGowan, K.E., see Woolfson, A.D. (62) 9
McKeown, R.H., see Prankerd, R.J. (62) 37
Melia, C.D., see Christrup, L.L. (66) 169
Melia, C.D., see Davies, M.C. (62) 97
Melia, C.D., see Davies, M.C. (66) 223
Méndez, J.B., see Espinar, F.J.O. (70) 35
Menut, C., see Bassani, V. (63) 57
Merfeld, A.E., Haslam, J.L. and Rork, G.S.
An in vitro drug release rate method for lipoidal materials (69) 63
Merkle, H.P., see Lichtenberger, R. (64) 117
Merkus, F.W.H.M., see Schipper, N.G.M. (64) 61
Mestres, C., see Alsina, M.A. (70) 111
Mhando, J.R. and Li Wan Po, A.
Controlled release of local anaesthetic agents from liquid–solid emulsion gels (62) 249
Miettunen, R., see Sutinen, R. (62) 113
Miglani, B.D., see Mukherji, G. (65) 1
Millar, F.M., see Davidson, A.G. (63) 29
Miller, S.C., see Wu, H.-L.S. (66) 213
Mitchell, K., Ford, J.L., Armstrong, D.J., Elliott, P.N.C., Rostron, C. and Hogan, J.E.
The influence of additives on the cloud point, disintegration and dissolution of hydroxypropylmethylcellulose gels and matrix tablets (66) 233
Mitra, A.K., see Basu, K. (65) 109
Mitra, A.K., see Schilling, R.J. (62) 53
Mitsuzono, T., see Quan, D. (68) 239
Miyazaki, K., see Kohri, N. (68) 255
Moës, A.J., see Timmermans, J. (62) 207
Moghimi, S.M., Porter, C.J.H., Illum, L. and Davis, S.S.
The effect of poloxamer-407 on liposome stability and targeting to bone marrow: comparison with polystyrene microspheres (68) 121
Mohar, M., see Kerč, J. (68) 25
Moneghini, M., Rubessa, F., Rupena, P. and Zingone, G.

Analysis of chlorcyclizine and related compounds by liquid chromatography for stability studies (63) R1
Moneghini, M., see Mrhar, A. (62) 15
Monés, J., see Roca, M. (69) 189
Montelius, K., see Sjödin, L. (63) 135
Montero, M.T., Estelrich, J. and Valls, O.
Binding of non-steroidal anti-inflammatory drugs to human serum albumin (62) 21
Monthéard, J.P., see Chafi, N. (67) 265
Moore, D.E.
Kinetic treatment of photochemical reactions (63) R5
Moore, D.E., see Tønnesen, H.H. (70) 95
Mora, J., see Roca, M. (69) 189
Mørk, N., see Bundgaard, H. (63) 213
Morris, K., see Wesdyk, R. (65) 69
Moser, K., see Mader, R.M. (68) 151
Møss, J. and Bundgaard, H.
Prodrugs of peptides. 7. Transdermal delivery of thyrotropin-releasing hormone (TRH) via prodrugs (66) 39
Møss, J., Buur, A. and Bundgaard, H.
Prodrugs of peptides. 8. In vitro study of intestinal metabolism and penetration of thyrotropin-releasing hormone (TRH) and its prodrugs (66) 183
Mostafa, E.M., see Hamed, M.Y. (69) 93
Mostafa, E.M., see Ibrahim, S.A. (61) 1
Mrhar, A., Rubessa, F., Karba, R., Moneghini, M. and Primosic, S.
Pharmacokinetic evaluation of sustained release formulations of theophylline by analog hybrid simulation (62) 15
Mukherji, G., Murthy, R.S.R. and Miglani, B.D.
Preparation and evaluation of cellulose nanospheres containing 5-fluorouracil (65) 1
Müller, B.W., see Carstensen, H. (67) 29
Müller, B.W., see Helm, V.J. (70) 29
Müller, B.W., see Lucks, J.S. (63) 183
Müller, R.H., see Carstensen, H. (67) 29
Müller, R.H., see Lucks, J.S. (63) 183
Müller, U., see Tröster, S.D. (61) 85
Mummaneni, V. and Vasavada, R.C.
Solubilization and dissolution of famotidine from solid glass dispersions of xylitol (66) 71
Munday, D.L., Fassihi, A.R. and De Villiers, C.
Bioavailability study of a theophylline oral controlled release capsule containing film coated mini-tablets in beagle dogs (69) 123
Munday, M.R., see Toth, I. (68) 191
Mura, P., see Santoni, G. (64) 235
Muranishi, S., see Takada, K. (65) 159
Muranushi, N., see Oguma, T. (63) 101
Murphy, C.A., see Toth, I. (68) 191
Murthy, R.S.R., see Mukherji, G. (65) 1
Murugesan, K., see Jha, P. (63) 143

Nada, A.H.
Influence of caffeine on the renal effects and solubility of ketoprofen (70) 191
Nagahara, N., see Kurosaki, Y. (67) 1
Nagai, T., see Imasaka, K. (68) 87
Nagai, T., see Ito, R. (61) 109
Nagai, T., see Maitani, Y. (64) 139
Nagai, T., see Maitani, Y. (64) 89
Nagai, T., see Maitani, Y. (69) 21
Nagai, T., see Quan, D. (68) 239
Nagai, T., see Takahashi, T. (61) 35
Nagai, T., see Takayama, K. (61) 225
Nagase, S., see Hirate, J. (65) 149
Najib, N.M. and Suleiman, M.S.
Determination of some parameters influencing the dissolution rate of famotidine (61) 173
Najib, N.M., see Hassan, M.A. (67) 131
Nakagaki, M., see Maitani, Y. (64) 89
Nakagaki, M., see Maitani, Y. (69) 21
Nakai, Y., see Oguchi, T. (61) 27
Nakane, S., see Nishida, K. (65) 7
Nakashima, M., see Oguma, T. (63) 101
Nakayama, T., see Kurosaki, Y. (67) 1
Nazir, T., see Leigh, T.R. (67) 275
Nederman, T., see Sjödin, L. (63) 135
Nequist, G., see Patel, J.P. (65) 195
Neubert, R., see Fürst, W. (61) 43
Newman, A., see Wesdyk, R. (65) 69
Newton, J.M., see Bains, D. (69) 233
Newton, J.M., see Tan, S.B. (61) 145
Newton, J.M., see Tan, S.B. (63) 275
Newton, J.M., see Tan, S.B. (64) 227
Newton, J.M., see Tan, S.B. (66) 207
Newton, J.M., see Tan, S.B. (66) 273
Newton, J.M., see Tan, S.B. (66) 283
Niazy, E.M.
Influence of oleic acid and other permeation promoters on transdermal delivery of dihydroergotamine through rabbit skin (67) 97
Nicklasson, M., Orbe, A., Lindberg, J., Borgå, B., Magnusson, A.-B., Nilsson, G., Ahlgren, R. and Jacobsen, L.
A collaborative study of the in vitro dissolution of phenacetin crystals comparing the flow through method with the USP Paddle method (69) 255
Niemi, L. and Laine, E.
Effect of water content on the microstructure of an o/w cream (68) 205
Nilsson, G., see Nicklasson, M. (69) 255
Nishida, K., Tonegawa, C., Nakane, S., Takakura, Y., Hashida, M. and Sezaki, H.
Effect of electric charge on the hepatic uptake of macromolecules in the rat liver (65) 7
Nishimura, H., see Kurosaki, Y. (67) 1
Nixon, J.R., see Avgoustakis, K. (70) 77
Nobile, L., see Raggi, M.A. (61) 199
Noormohammadi, A., see Avgerinos, A. (68) 97
Noormohammadi, A., see Hadzija, B.W. (67) 185
Nuutinen, J., see Vidgren, M. (64) 1
Nyström, C., see Anderberg, E.K. (62) 143
Nyström, C., see Angberg, M. (61) 67
Nyström, C., see Bisrat, M. (63) 49

Nyström, C., see Eriksson, M. (63) 189
Nyström, C., see Karehill, P.G. (61) 251
Nyström, C., see Karehill, P.G. (64) 27
Nyström, C., see Karehill, P.G. (64) 35
Nyström, C., see Sjökvist, E. (67) 139
Nyström, C., see Sjökvist, E. (69) 53
Nyström, C., see Westerberg, M. (69) 129

Obata, Y., see Takayama, K. (61) 225
Obeng, E.K., see Hadzija, B.W. (67) 185
O'Connor, C.A., see Attwood, D. (65) 201
O'Connor, C.A., see Attwood, D. (70) 147
Ogawa, Y., see Heya, T. (69) 69
Oguchi, T., Okada, M., Yonemochi, E., Yamamoto, K. and Nakai, Y.
Freeze-drying of drug-additive binary systems. III. Crystallization of α-cyclodextrin inclusion complex in freezing process (61) 27
Oguma, T., Shimamura, K., Ushio, Y., Yamada, H., Takahashi, K., Muranushi, N., Yoshikawa, T., Nakashima, M. and Uematsu, T.
Pharmacokinetic analysis of discontinuous absorption process of ceftibuten in humans (63) 101
O'Hagan, D.T., see Illum, L. (63) 207
Okabe, H., see Takayama, K. (61) 225
Okada, H., see Heya, T. (69) 69
Okada, M., see Oguchi, T. (61) 27
Okhamafe, A.O., Akerele, J.O. and Chukuka, C.S.
Pharmacokinetic interactions of norfloxacin with some metallic medicinal agents (68) 11
Okor, R.S.
Retard release from a flocculated emulsion system (65) 133
Ólafsdóttir, B.J., see Loftsson, T. (66) 289
Ólafsdóttir, B.J., see Loftsson, T. (67) R5
Olajos, S., see Cserháti, T. (61) 189
Omotosho, J.A., Florence, A.T. and Whateley, T.L.
Absorption and lymphatic uptake of 5-fluorouracil in the rat following oral administration of w/o/w multiple emulsions (61) 51
Omotosho, J.A.
The effect of acacia, gelatin and polyvinylpyrrolidone on chloroquine transport from multiple w/o/w emulsions (62) 81
O'Mullane, J.E., Petrak, K., Hutchinson, L.E.F. and Tomlinson, E.
The effect of adsorbed coats of Poloxamers 237 and 338 on the in vitro aggregation and in vivo distribution of polystyrene latex (PSL) particles (63) 177
Onyekweli, A.O., see Pilpel, N. (70) 241
Orbe, A., see Nicklasson, M. (69) 255
Otagiri, M., see Imai, T. (67) 11
Othman, S.
Multicomponent derivative spectroscopic analysis of sulfamethoxazole and trimethoprim (63) 173
Otsuka, M. and Kaneniwa, N.
Effect of grinding on the crystallinity and chemical stability in the solid state of cephalothin sodium (62) 65
Paddock, S.W., see Rojanasakul, Y. (61) 163
Paeratakul, O., see Bodmeier, R. (70) 59
Palmer, A.J., see Sewell, G.J. (70) 119
Panzova, B. and Bogdanov, B.
Physicochemical basis for the microbicidal action of disinfection solutions. I. Polyvinylpyrrolidinone-iodine (65) 35
Panzova, B., Ilievska, M., Trendovska, G. and Bogdanov, B.
Simultaneous determination of polythiazide and prazosin in tablets by second-order derivative UV spectroscopy (70) 187
Parissi-Poulou, M., Ismailos, G. and Macheras, P.
Modified HPLC analysis of diltiazem in plasma for pharmacokinetic studies (62) R13
Park, M.K., see Chung, S.M. (68) 61
Park, M.K., see Yoon, E.J. (67) 177
Parker, M.D., York, P. and Rowe, R.C.
Binder-substrate interactions in wet granulation. 1: The effect of binder characteristics (64) 207
Paronen, P., see Sutinen, R. (62) 113
Paronen, P., see Vidgren, M. (64) 1
Patel, J.P., Marsh, K., Carr, L. and Nequist, G.
Factorial designs in ophthalmic formulation development of Enalkiren (65) 195
Pathak, Y.V., Rubinstein, A. and Benita, S.
Enhanced stability of physostigmine salicylate in submicron o/w emulsion (65) 169
Pattarino, F., see Gasco, M.R. (62) 119
Pattarino, F., see Gasco, M.R. (69) 193
Pedersen, S.B., see Bundgaard, H. (64) 75
Pedraz, J.L., see Calvo, M.B. (67) 259
Peppas, N.A., see Brannon-Peppas, L. (70) 53
Peppas, N.A., see Colombo, P. (63) 43
Perboni, I., see Raggi, M.A. (61) 199
Pérez-Marcos, B., Gutiérrez, C., Gómez-Amoza, J.L., Martínez-Pacheco, R., Souto, C. and Concheiro, A.
Usefulness of certain varieties of Carbomer in the formulation of hydrophilic furosemide matrices (67) 113
Pérez-Varona, A.T., see Bermejo, M.V. (69) 221
Pérez-Varona, A.T., see Garrigues, T.M. (64) 127
Perlia, X., see Werner, I.A. (63) 155
Petrak, K., see O'Mullane, J.E. (63) 177
Pijpers, A., see Kadir, F. (64) 171
Pikal, M.J. and Shah, S.
The collapse temperature in freeze drying: Dependence on measurement methodology and rate of water removal from the glassy phase (62) 165
Pillai, G.K., see Chandraprakash, K.S. (61) R1
Pilpel, N., Britten, J.R., Onyekweli, A.O. and Esezobo, S.
Compression and tableting of pharmaceutical powders at elevated temperatures (70) 241
Pilpel, N., Igwilo, C.I. and Malamataris, S.
Effects of molecular coatings on the compression and tableting of some pharmaceutical powders (68) 157
Ping, Q., Law, T.K., Whateley, T.L. and Florence, A.T.
Aggregation and gelation of a polymerisable diacryloyl derivative of poloxamer 407 (61) 79
Pinio, F., see Giammona, G. (64) 239

Pinzauti, S., see Santoni, G. (64) 235
Pipkin, J.D., see Urtti, A. (61) 235
Pipkin, J.D., see Urtti, A. (61) 241
Plá-Delfina, J.M., see Bermejo, M.V. (69) 221
Plá-Delfina, J.M., see Garrigues, T.M. (64) 127
Plazonnet, B., see Grove, J. (66) 23
Poelma, F.G.J., Breäs, R. and Tukker, J.J.
Intestinal absorption of drugs. IV. The influence of taurocholate and L-cysteine on the barrier function of mucus (64) 161
Poelma, F.G.J., see Lehr, C.-M. (70) 235
Poelman, M.-C., see Lin, S.-Z. (69) 211
Porter, C.J.H., see Moghimi, S.M. (68) 121
Pråhl, M., see Sjödin, L. (63) 135
Prankerd, R.J. and McKeown, R.H.
Physico-chemical properties of barbituric acid derivatives. Part I. Solubility-temperature dependence for 5,5-disubstituted barbituric acids in aqueous solutions (62) 37
Pratt, M., see Adjei, A. (61) 135
Préat, V., see Gaspar, R. (68) 111
Primosic, S., see Mrhar, A. (62) 15
Provost, C., Herbots, H. and Kinget, R.
Transparent oil-water gels. Part II. A study of the gel structure in transparent oil-water gels by differential scanning calorimetry (62) 217
Pugh, W.J., see Marques, H.M.C. (63) 267
Puglisi, G., see Castelli, F. (70) 43
Puglisi, G., see Santagati, N.A. (65) 137
Pyter, R.A., see Garren, K.W. (63) 167

Quan, D., Takayama, K., Mitsuzono, T., Isowa, K. and Nagai, T.
Influence of novel percutaneous absorption enhancers, cyclohexanone and piperidone derivatives, on histopathology of rat skin (68) 239
Quint, M.-P., see Grove, J. (66) 23

Rabasco, A.M., Ginés, J.M., Fernández-Arévalo, M. and Holgado, M.A.
Dissolution rate of diazepam from polyethylene glycol 6000 solid dispersions (67) 201
Raggi, M.A., Nobile, L., Perboni, I. and Ramini, M.
Extractive colorimetric determination of iron(III) in pharmaceutical formulations by means of trifluoroacetylacetone (61) 199
Ragno, G., see Vetuschi, C. (65) 177
Rainer, H., see Mader, R.M. (68) 151
Rajan, Z., see Efentakis, M. (70) 153
Ramachandran, C., see Ma, L. (70) 209
Rambourg, P., see Lévy, M.-C. (69) R1
Ramini, M., see Raggi, M.A. (61) 199
Rao, M.N.A., see Kunchandy, E. (65) 261
Rasmussen, S.N., see Christrup, L.L. (66) 169
Rathbone, M.J.
Human buccal absorption. I. A method for estimating the transfer kinetics of drugs across the human buccal membrane (69) 103
Raudino, A., see Castelli, F. (70) 43
Remon, J.P., see De Vroe, C. (65) 49
Remon, J.P., see Herman, J. (63) 201
Remon, J.P., see Vandenbossche, G.M.R. (67) 195
Remon, J.P., see Visavarungroj, N. (62) 125
Remon, J.P., see Visavarungroj, N. (65) 43
Remon, J.P., see Visavarungroj, N. (69) 43
Repta, A.J., see Urtti, A. (61) 235
Repta, A.J., see Urtti, A. (61) 241
Richards, F.M., see Alpar, H.O. (62) 133
Riepma, K.A., Lerk, C.F., De Boer, A.H., Bolhuis, G.K. and Kussendrager, K.D.
Consolidation and compaction of powder mixtures. I. Binary mixtures of same particle size fractions of different types of crystalline lactose (66) 47
Riley, C.M., see Allsopp, M.A. (69) 197
Riley, C.M., see Ross, D.L. (63) 237
Ringard-Lefebvre, C., see Santi, P. (68) 43
Rizovski, B., see Mader, R.M. (68) 151
Roberts, R.J., see Bassam, F. (64) 55
Roberts, R.J., see York, P. (66) 143
Robertson, C., see Davis, S.S. (68) 199
Robins, R.H., see Snider, B.G. (66) 63
Robinson, J.R., see Rojanasakul, Y. (61) 163
Robinson, J.R., see Rojanasakul, Y. (63) 1
Robinson, J.R., see Rojanasakul, Y. (66) 131
Robinson, J.R., see Rojanasakul, Y. (68) 135
Robinson, J.R., see Skelly, J.P. (63) 83
Roblot-Treupel, L., see Seijo, B. (62) 1
Roca, M., Carrió, I., Monés, J., Mora, J., Estorch, M. and Bernà, L.
Labelling procedure of antacid preparations using ^{99m}Tc-pyrophosphate (69) 189
Rogers, J.A., see Vudathala, G.K. (69) 13
Rojanasakul, Y. and Robinson, J.R.
Electrophysiological and ultrastructural characterization of the cornea during in vitro perfusion (63) 1
Rojanasakul, Y. and Robinson, J.R.
The cytoskeleton of the cornea and its role in tight junction permeability (68) 135
Rojanasakul, Y., Liaw, J. and Robinson, J.R.
Mechanisms of action of some penetration enhancers in the cornea: Laser scanning confocal microscopic and electrophysiology studies (66) 131
Rojanasakul, Y., Paddock, S.W. and Robinson, J.R.
Confocal laser scanning microscopic examination of transport pathways and barriers of some peptides across the cornea (61) 163
Roland, M., see Gaspar, R. (68) 111
Romeyn, S.G., see Schipper, N.G.M. (64) 61
Rork, G., see Urtti, A. (61) 235
Rork, G., see Urtti, A. (61) 241
Rork, G.S., see Merfeld, A.E. (69) 63
Ross, D.L. and Riley, C.M.
Aqueous solubilities of some variously substituted quinolone antimicrobials (63) 237
Rostron, C., see Mitchell, K. (66) 233

Rouland, J.C., see Dubernet, C. (64) 99
Rowe, R.C., see Bassam, F. (64) 55
Rowe, R.C., see Davies, M.C. (62) 97
Rowe, R.C., see Louden, J.D. (63) 219
Rowe, R.C., see Parker, M.D. (64) 207
Rowe, R.C., see York, P. (66) 143
Rowland, C.G., see Allsopp, M.A. (69) 197
Rubessa, F., see Moneghini, M. (63) R1
Rubessa, F., see Mrhar, A. (62) 15
Rubino, J.T. and Thomas, E.
Influence of solvent composition on the solubilities and solid-state properties of the sodium salts of some drugs (65) 141
Rubinstein, A., see Pathak, Y.V. (65) 169
Rubinstein, M.H., see Garr, J.S.M. (64) 223
Ruddy, S.B., see Hadzija, B.W. (67) 185
Rudnic, E.M., see Chang, R.-K. (70) 261
Runge, T.A., see Snider, B.G. (66) 63
Rupena, P., see Moneghini, M. (63) R1

Sadana, G.S. and Ghogare, A.B.
Mechanistic studies on photolytic degradation of nifedipine by use of ^{1}H-NMR and ^{13}C-NMR spectroscopy (70) 195
Saitô, H., see Imai, T. (67) 11
Saket, M., see Sallam, E. (67) 247
Sallam, E., Ibrahim, H., Takieddin, M., Baghal, T., Saket, M., Awad, R. and Arafat, T.
Dissolution characteristics of interactive powder mixtures. 4. Effects of additives on the dissolution of griseofulvin from Emcompress carrier (67) 247
Samsom, M., see De Vroe, C. (65) 49
Sandberg, A., Abrahamsson, B. and Sjögren, J.
Influence of dissolution rate on the extent and rate of bioavailability of metoprolol (68) 167
Sanderson, F.D., see Irwin, W.J. (66) 193
Sanderson, F.D., see Irwin, W.J. (66) 243
Sangalli, M.E., see Colombo, P. (63) 43
Sannan, T., see Ito, R. (61) 109
Santagati, N.A., Villari, A., Spadaro, A. and Puglisi, G.
Simultaneous determination of antazoline and its degradation product by UV spectrophotometry (65) 137
Santi, P., Catellani, P.L., Colombo, P., Ringard-Lefebvre, C., Barthélémy, C. and Guyot-Hermann, A.-M.
Partition and transport of verapamil and nicotine through artificial membranes (68) 43
Santoni, G., Mura, P., Pinzauti, S., Lombardo, E. and Gratteri, P.
Simultaneous UV spectrophotometric determination of procaine hydrochloride and phenazone in an otic formulation (64) 235
Saunders, J., Davis, S.S., Wilson, C.G. and Smith, A.
Effect of uptake of albumin microspheres on cellular activity of mouse peritoneal macrophages (68) 265
Scheer, R., see März, F. (61) 57
Schilling, R.J. and Mitra, A.K.
Intestinal mucosal transport of insulin (62) 53
Schipper, N.G.M., Hermens, W.A.J.J., Romeyn, S.G., Verhoef, J. and Merkus, F.W.H.M.
Nasal absorption of 17-beta-estradiol and progesterone from a dimethyl-cyclodextrin inclusion formulation in rats (64) 61
Schoonen, A.J.M., see Frijlink, H.W. (64) 195
Schowen, R.L., see Allsopp, M.A. (69) 197
Schückler, F. and Lee, G.
The influence of Azone on monomolecular films of some stratum corneum lipids (70) 173
Segura-Bono, M.J., see Bermejo, M.V. (69) 221
Seijo, B., Fattal, E., Roblot-Treupel, L. and Couvreur, P.
Design of nanoparticles of less than 50 nm diameter: preparation, characterization and drug loading (62) 1
Sendo, T., see Urtti, A. (61) 241
Šentjurc, M., see Gabrijelčič, V. (62) 75
Serrand, P., see Burgot, G. (63) 73
Sewell, G.J., Palmer, A.J. and Tidy, P.J.
Characterisation of a frozen storage-microwave thawing system for intravenous infusions (70) 119
Sewell, G.J., see Allsopp, M.A. (69) 197
Seyda, K., see Brewster, M.E. (68) 215
Sezaki, H., see Nishida, K. (65) 7
Shaco-Ezra, N., see Touitou, E. (70) 159
Shah, P.K., Bartel, R.L. and Borchardt, R.T.
Permeability characteristics of cultured mouse keratinocytes compared to hairless mouse skin (68) 285
Shah, P.K., Hidalgo, I.J. and Borchardt, R.T.
A simple diffusion device to study transport across cells cultured on microporous membranes (63) 281
Shah, S., see Pikal, M.J. (62) 165
Shah, V.P., see Skelly, J.P. (63) 83
Shahjahan, M. and Enever, R.P.
Solubilities of nitrofurazone and ultraviolet light absorbers in polyethylene glycols and nonionic surfactants (70) 9
Shastri, A.S., see Sheorey, D.S. (68) 19
Shek, P.N., see Jurima-Romet, M. (63) 227
Shenouda, L.S., Adams, K.A. and Zoglio, M.A.
A controlled release delivery system using two hydrophilic polymers (61) 127
Sheorey, D.S., Shastri, A.S. and Dorle, A.K.
Effect of variables on the preparation of shellac microcapsules by solvent evaporation technique: Part 1 (68) 19
Shimamura, K., see Oguma, T. (63) 101
Shiraishi, S., see Imai, T. (67) 11
Shiu, G.K., see Su, S.Y. (67) 211
Short, R.D., see Davies, M.C. (62) 97
Siebert, J.G.H., Luyt, A.S. and Ackermann, C.
A new transmission electron microscopic (TEM) method to determine differences between cationic polymers in solution (61) 157
Siebert, J.G.H., Luyt, A.S. and Ackermann, C.
Factors affecting the permeation of urea and water through nude mouse skin in vitro: IV. Polymer carriers (65) 29
Siebert, J.G.H., Luyt, A.S. and Ackermann, C.
The effect of various polymer applications on the physical structure of nude mouse skin (66) 157
Simmons, J.E., see Storm, J.E. (65) 265
Simmons, J.E., see Su, S.Y. (67) 211
Sims, S.M., Higuchi, W.I. and Srinivasan, V.

Skin alteration and convective solvent flow effects during iontophoresis: I. Neutral solute transport across human skin (69) 109
Singh, S., Gulati, M. and Gupta, R.L.
Complexation behaviour of azathioprine with metal ions (68) 105
Sjöberg, M., see Lindstedt, B. (67) 21
Sjödin, L., Nederman, T., Pråhl, M. and Montelius, K.
Radioreceptor assay for formulations of salmon calcitonin (63) 135
Sjögren, J., see Sandberg, A. (68) 167
Sjökvist, E. and Nyström, C.
Physicochemical aspects of drug release. XI. Tableting properties of solid dispersions, using xylitol as carrier material (67) 139
Sjökvist, E., Nyström, C. and Aldén, M.
Physicochemical aspects of drug release. XIII. The effect of sodium dodecyl sulphate additions on the structure and dissolution of a drug in solid dispersions (69) 53
Skelly, J.P., Amidon, G.L., Barr, W.H., Benet, L.Z., Carter, J.E., Robinson, J.R., Shah, V.P. and Yacobi, A.
Report of the workshop on: in vitro and in vivo testing and correlation for oral controlled/modified release dosage forms (63) 83
Skelly, J.P., see Su, S.Y. (67) 211
Smail, G.A., see Davidson, A.G. (69) 1
Šmid-Korbar, J., see Kerč, J. (68) 25
Šmid-Korbar, J., see Vrečer, F. (68) 35
Smith, A., see Saunders, J. (68) 265
Smith, D.P., see Hiestand, E.N. (67) 231
Snider, B.G., Runge, T.A., Fagerness, P.E., Robins, R.H. and Kaluzny, B.D.
Identification of degradation products occurring in acidic solutions of a 21-aminosteroid (tirilazad) (66) 63
Soebagyo, S.S. and Stewart, P.J.
Factors influencing the homogeneity and drug redistribution of disintegrant-diazepam-carrier ternary mixtures (66) 263
Solé, N., see Alsina, M.A. (70) 111
Souto, C., see Pérez-Marcos, B. (67) 113
Spadaro, A., see Santagati, N.A. (65) 137
Srčič, S., see Kerč, J. (68) 25
Srčič, S., see Vrečer, F. (68) 35
Srinivasan, V., see Sims, S.M. (69) 109
Steger, G.G., see Mader, R.M. (68) 151
Stella, V.J., see Killion, Jr, R.B. (66) 149
Stella, V.J., see Umprayn, K. (66) 253
Stephenson, P.J., see Davies, M.C. (66) 223
Steward, Jr, D.L., see Streng, W.H. (61) 265
Stewart, P.J., see Soebagyo, S.S. (66) 263
Storm, J.E., Bronaugh, R.L., Carlin, A.S. and Simmons, J.E.
Cutaneous metabolism of nitroglycerin in viable rat skin in vitro (65) 265
Story, M.J., see White, D.G. (69) 169
Streng, W.H. and Steward, Jr, D.L.
Ionization constants of an amino acid as a function of temperature (61) 265
Stubbs, C. and Kanfer, I.
A stability-indicating high-performance liquid chromatographic assay of erythromycin estolate in pharmaceutical dosage forms (63) 113
Su, M.-H., see Gonsho, A. (65) 183
Su, S.Y., Shiu, G.K., Simmons, J.E. and Skelly, J.P.
Some considerations on the analytical method for dissolution of conjugated estrogen tablets (67) 211
Suleiman, M.S., see Hassan, M.A. (67) 131
Suleiman, M.S., see Najib, N.M. (61) 173
Summers, R.S., see Bluhm, D.P. (68) 277
Summers, R.S., see Bluhm, D.P. (68) 281
Sutinen, R., Urtti, A., Miettunen, R. and Paronen, P.
Water-activated and pH-controlled release of weak bases from silicone reservoir devices (62) 113
Suzuki, K., see Asano, M. (67) 67
Szögyi, M., see Cserháti, T. (61) 189

Takada, K., Yoshikawa, H. and Muranishi, S.
Pharmacokinetic analysis of plasma drug level data obtained from a transdermal therapeutic system with a complex absorption model (65) 159
Takahashi, K., see Oguma, T. (63) 101
Takahashi, T., Takayama, K., Machida, Y. and Nagai, T.
Characteristics of polyion complexes of chitosan with sodium alginate and sodium polyacrylate (61) 35
Takakura, Y., see Nishida, K. (65) 7
Takayama, K., Okabe, H., Obata, Y. and Nagai, T.
Formulation design of indomethacin gel ointment containing *d*-limonene using computer optimization methodology (61) 225
Takayama, K., see Maitani, Y. (64) 139
Takayama, K., see Quan, D. (68) 239
Takayama, K., see Takahashi, T. (61) 35
Takieddin, M., see Sallam, E. (67) 247
Tammilehto, S., see Mälkki, L. (63) 17
Tan, S.B. and Newton, J.M.
Capsule filling performance of powders with dosator nozzles of different wall texture (66) 207
Tan, S.B. and Newton, J.M.
Influence of capsule dosator wall texture and powder properties on the angle of wall friction and powder-wall adhesion (64) 227
Tan, S.B. and Newton, J.M.
Influence of compression setting ratio on capsule fill weight and weight variability (66) 273
Tan, S.B. and Newton, J.M.
Minimum compression stress requirements for arching and powder retention within a dosator nozzle during capsule filling (63) 275
Tan, S.B. and Newton, J.M.
Observed and expected powder plug densities obtained by a capsule dosator nozzle system (66) 283
Tan, S.B. and Newton, J.M.
Powder flowability as an indication of capsule filling performance (61) 145
Tanigawara, Y., see Heya, T. (69) 69

Taniguchi, M., see Maitani, Y. (64) 139
Tanizawa, T., see Kurosaki, Y. (67) 1
Tawfiq, F.A., Hussain, A., Dittert, L. and Crooks, P.A.
Kinetics of decomposition of *O*-acyl derivatives of salicylamide and related compounds (64) 45
Taylor, G., see Dennis, A.B. (65) 85
Tønnesen, H.H. and Moore, D.E.
Photochemical stability of biologically active compounds. III. Mefloquine as a photosensitizer (70) 95
Testa, B., see Wernly-Chung, G.N. (63) 129
Thoma, K. and Klimek, R.
Photostabilization of drugs in dosage forms without protection from packaging materials (67) 169
Thomas, E., see Rubino, J.T. (65) 141
Thomas, N.W., see Chandler, S.G. (70) 19
Tidy, P.J., see Sewell, G.J. (70) 119
Timmermans, J. and Moës, A.J.
How well do floating dosage forms float? (62) 207
Timmins, P., see Hussain, M.S.H. (70) 103
Titulaer, H.A.C., Zuidema, J. and Lugt, C.B.
Formulation and pharmacokinetics of artemisinin and its derivatives (69) 83
Toguchi, H., see Heya, T. (69) 69
Tomlinson, E., see O'Mullane, J.E. (63) 177
Tonegawa, C., see Nishida, K. (65) 7
Toth, I., Hughes, R.A., Munday, M.R., Murphy, C.A., Mascagni, P. and Gibbons, W.A.
Lipidic peptides. II. Synthesis, activity and transport of anti-inflammatory benzoquinolizine-lipidic peptide conjugates (68) 191
Touitou, E., Levi-Schaffer, F., Shaco-Ezra, N., Ben-Yossef, R. and Fabin, B.
Enhanced permeation of theophylline through the skin and its effect on fibroblast proliferation (70) 159
Tous, S.S., see Hamed, M.Y. (69) 93
Tous, S.S., see Ibrahim, S.A. (61) 1
Trendovska, G., see Panzova, B. (70) 187
Tripathi, M., Kohli, D.V. and Uppadhyay, R.K.
Effect of cholic and deoxycholic acid conjugates on solubility and dissolution of indomethacin and phenylbutazone (67) 207
Tröster, S.D., Müller, U. and Kreuter, J.
Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants (61) 85
Tsai, J.-C., Cappel, M.J., Weiner, N.D., Flynn, G.L. and Ferry, J.
Solvent effects on the harvesting of stratum corneum from hairless mouse skin through adhesive tape stripping in vitro (68) 127
Tsantili-Kakoulidou, A., see Wernly-Chung, G.N. (63) 129
Tsuchiya, S., see Hara, T. (67) 123
Tsuge, H., see Gonsho, A. (65) 183
Tsunematsu, H., Ishida, E., Yoshida, S. and Yamamoto, M.
Synthesis and enzymatic hydrolysis of aspirin-basic amino acid ethyl esters (68) 77
Tu, Y.-H., Wang, Y., Allen, Jr., L.V., Albers, D.D. and Gorgin, M.K.
Pharmacokinetics of metronidazole administered intravenously to male rats (61) 119
Tukker, J.J., see Lehr, C.-M. (70) 235
Tukker, J.J., see Poelma, F.G.J. (64) 161

Uchida, N., see Maitani, Y. (64) 139
Uchida, N., see Maitani, Y. (69) 21
Udupa, N., see Chandraprakash, K.S. (61) R1
Uematsu, T., see Oguma, T. (63) 101
Umadevi, P., see Chandraprakash, K.S. (61) R1
Umprayn, K., Waugh, W. and Stella, V.J.
Mechanism of degradation of the investigational cytotoxic agent, cyclodisone (NSC-348948) (66) 253
Underberg, W.J.M., see Bekers, O. (68) 271
Underberg, W.J.M., see Van der Houwen, O.A.G.J. (67) 155
Unlü, N., see Ludwig, A. (61) 15
Uppadhyay, R.K., see Tripathi, M. (67) 207
Urtti, A., Pipkin, J.D., Rork, G. and Repta, A.J.
Controlled drug delivery devices for experimental ocular studies with timolol. 1. In vitro release studies (61) 235
Urtti, A., Pipkin, J.D., Rork, G., Sendo, T., Finne, U. and Repta, A.J.
Controlled drug delivery devices for experimental ocular studies with timolol. 2. Ocular and systemic absorption in rabbits (61) 241
Urtti, A., see Finne, U. (65) 19
Urtti, A., see Sutinen, R. (62) 113
Ushio, Y., see Oguma, T. (63) 101

Vainio, P., see Vidgren, M. (64) 1
Väisänen, V., see Finne, U. (65) 19
Valls, O., see Egea, M.A. (67) 103
Valls, O., see Montero, M.T. (62) 21
Vandenbossche, G.M.R., Vanhaecke, E., De Muynck, C. and Remon, J.P.
Stability of topical erythromycin formulations (67) 195
Van der Houwen, O.A.G.J., Bekers, O., Beijnen, J.H., Bult, A. and Underberg, W.J.M.
A general approach to the interpretation of pH degradation profiles in the presence of ligands (67) 155
Van der Watt, J.G., see Gerber, J.J. (69) 265
Vanhaecke, E., see Vandenbossche, G.M.R. (67) 195
Van Ooteghem, M., see Ludwig, A. (61) 15
Van Tonder, E.C., Caira, M.R., Botha, S.A. and Lötter, A.P.
Polymorphism of doxylamine succinate and X-ray structural study of Form I and of doxylamine succinate 0.5 succinic acid (63) 35
Vasavada, R.C., see Mummaneni, V. (66) 71
Vergnaud, J.M., see Chafi, N. (67) 265
Vergnaud, J.M., see Laghoueg-Derriche, N. (67) 163
Vergnaud, J.M., see Laghoueg-Derriche, N. (67) 51
Verheijden, J.H.M., see Kadir, F. (64) 171
Verhoef, J., see Schipper, N.G.M. (64) 61
Vetuschi, C. and Ragno, G.
Fourth UV derivative spectrophotometry for the simultaneous assay of atenolol and chlorthalidone in pharmaceuticals (65) 177
Vicente, M.T., see Calvo, M.B. (67) 259

Vidgren, M., Paronen, P., Vidgren, P., Vainio, P. and Nuutinen, J.
Radiotracer evaluation of the deposition of drug particles inhaled from a new powder inhaler (64) 1
Vidgren, P., see Vidgren, M. (64) 1
Vila-Jato, J.L., see Alonso, M.J. (68) 69
Vila-Jato, J.L., see Egea, M.A. (67) 103
Villari, A., see Santagati, N.A. (65) 137
Visavarungroj, N. and Remon, J.P.
Crosslinked starch as a binding agent. II. Granulation in a high shear mixer (65) 43
Visavarungroj, N. and Remon, J.P.
Crosslinked starch as a disintegrating agent (62) 125
Visavarungroj, N. and Remon, J.P.
Crosslinked starch as binding agent. III. granulation of an insoluble filler (69) 43
Vogt, P., see Gonsho, A. (65) 183
Vrečer, F., Srčič, S. and Šmid-Korbar, J.
Investigation of piroxicam polymorphism (68) 35
Vromans, H., see Bos, C.E. (67) 39
Vudathala, G.K. and Rogers, J.A.
Effect of cholesterol on the aging of griseofulvin-phospholipid coprecipitates (69) 13
Vulto, A., see Kadir, F. (64) 171
Vyas, S.P., Bhatnagar, S., Gogoi, P.J. and Jain, N.K.
Preparation and characterization of HSA-propranolol microspheres for nasal administration (69) 5

Waigh, R.D., see Anie, S.J. (69) 181
Walker, M., Chambers, L.A., Hollingsbee, D.A. and Hadgraft, J.
Significance of vehicle thickness to skin penetration of Halcinonide (70) 167
Wang, Y., see Tu, Y.-H. (61) 119
Warrack, J.K., see Holland, S.J. (65) 225
Washington, C., Athersuch, A. and Kynoch, D.J.
The electrokinetic properties of phospholipid stabilized fat emulsions. IV. The effect of glucose and of pH (64) 217
Washington, C.
The electrokinetic properties of phospholipid-stabilized fat emulsions. III. Interdroplet potentials and stability ratios in monovalent electrolytes (64) 67
Washington, C.
The stability of intravenous fat emulsions in total parenteral nutrition mixtures (66) 1
Washington, C., see Johnson, O.L. (63) 65
Washington, N., see Christrup, L.L. (66) 169
Watanabe, Y., Kogoshi, T., Amagai, Y. and Matsumoto, M.
Preparation and evaluation of enteric granules of aspirin prepared by acylglycerols (64) 147
Watson, D., see Davidson, A.G. (63) 29
Waugh, W., see Umprayn, K. (66) 253
Webb, A.I., see Estes, K.S. (65) 101
Weiner, N.D., see Ma, L. (70) 209
Weiner, N.D., see Tsai, J.-C. (68) 127
Werner, I.A., Altorfer, H. and Perlia, X.
The effectiveness of various scavengers on the γ-irradiated, methanolic solution of medazepam (63) 155
Wernly-Chung, G.N., Mayer, J.M., Tsantili-Kakoulidou, A. and Testa, B.
Structure-reactivity relationships in the chemical hydrolysis of prodrug esters of nicotinic acid (63) 129
Wesdyk, R., Joshi, Y.M., Jain, N.B., Morris, K. and Newman, A.
The effect of size and mass on the film thickness of beads coated in fluidized bed equipment (65) 69
Westerberg, M. and Nyström, C.
Physicochemical aspects of drug release. XII. The effect of some carrier particle properties and lubricant admixture on drug dissolution from tableted ordered mixtures (69) 129
Whateley, T.L., see Omotosho, J.A. (61) 51
Whateley, T.L., see Ping, Q. (61) 79
White, D.G., Story, M.J. and Barnwell, S.G.
An experimental animal model for studying the effects of a novel lymphatic drug delivery system for propranolol (69) 169
Wiechers, J.W., Drenth, B.F.H., Jonkman, J.H.G. and De Zeeuw, R.A.
Percutaneous absorption of triamcinolone acetonide from creams with and without Azone® in humans in vivo (66) 53
Wiechers, J.W., Herder, R.E., Drenth, B.F.H. and De Zeeuw, R.A.
Percutaneous absorption, disposition, metabolism, and excretion of ^{14}C-labelled Cyoctol in humans after a single dermal application (65) 77
Wiggins, J., see Leigh, T.R. (67) 275
Wikberg, M. and Alderborn, G.
Compression characteristics of granulated materials. II. Evaluation of granule fragmentation during compression by tablet permeability and porosity measurements (62) 229
Wikberg, M. and Alderborn, G.
Compression characteristics of granulated materials. III. The relationship between air permeability and mechanical strength of tablets of some lactose granulations (63) 23
Wikberg, M. and Alderborn, G.
Compression characteristics of granulated materials. IV. The effect of granule porosity on the fragmentation propensity and the compactibility of some granulations (69) 239
Wilding, I.R., see Christrup, L.L. (66) 169
Wilding, I.R., see Davies, M.C. (62) 97
Wilding, I.R., see Davis, S.S. (68) 199
Williams, D.R., see Hall, S.B. (70) 251
Williams, J.D., see Hendriksen, B.A. (69) 175
Wilson, C.G., see Saunders, J. (68) 265
Wolff, M., see Hadgraft, J. (64) 187
Wong, L.P., see Li Wan Po, A. (66) 111
Woolfson, A.D., McCafferty, D.F. and McGowan, K.E.
The metabolism of amethocaine by porcine and human skin extracts: influence on percutaneous anaesthesia (62) 9
Woolfson, A.D., see Jones, D.S. (64) R1
Wouessidjewe, D., see Lin, S.-Z. (69) 211

Wu, H.-L.S. and Miller, S.C.
In vitro release of nicotinic acid alkyl esters from poloxamer vehicles (66) 213

Yacobi, A., see Skelly, J.P. (63) 83
Yamada, H., see Oguma, T. (63) 101
Yamamoto, K., see Oguchi, T. (61) 27
Yamamoto, M., see Tsunematsu, H. (68) 77
Yamanaka, H., see Asano, M. (67) 67
Yamanaka, H., see Imasaka, K. (68) 87
Yamashita, C., Matsuo, H., Akiyama, K. and Kiwada, H.
Enhancing effect of cetylmannoside on targeting of liposomes to Kupffer cells in rats (70) 225
Yamazaki, S., see Maitani, Y. (64) 139
Yatabe, H., see Kohri, N. (68) 255
Yonemochi, E., see Oguchi, T. (61) 27
Yoon, E.J., Chang, H.W., Lee, M.G., Lee, H., Park, M.K. and Kim, C.K.
Pharmacokinetics of methotrexate after intravenous infusion of methotrexate-rabbit serum albumin conjugate to rabbits (67) 177
Yoon, E.J., see Chung, S.M. (68) 61
York, P., Bassam, F., Rowe, R.C. and Roberts, R.J.
Fracture mechanics of microcrystalline cellulose powders (66) 143
York, P., see Bassam, F. (64) 55
York, P., see Hussain, M.S.H. (70) 103
York, P., see Marshall, P.V. (67) 59
York, P., see Parker, M.D. (64) 207
Yoshida, M., see Asano, M. (67) 67
Yoshida, M., see Imasaka, K. (68) 87
Yoshida, S., see Tsunematsu, H. (68) 77
Yoshikawa, H., see Takada, K. (65) 159
Yoshikawa, T., see Oguma, T. (63) 101
Yuasa, H., see Asano, M. (67) 67

Žanić-Grubišić, T., see Juretić, D. (61) 219
Zhou, X.H. and Li Wan Po, A.
Comparison of enzyme activities of tissues lining portals of absorption of drugs: Species differences (70) 271
Zhou, X.H. and Li Wan Po, A.
Comparison of enzymic activities of tissues lining portals of drug absorption, using the rat as a model (62) 259
Zhou, X.H. and Li Wan Po, A.
Effects of cholic acid and other enhancers on the bioavailability of insulin from a subcutaneous site (69) 29
Zhu, C., see Hirate, J. (65) 149
Zingone, G., see Moneghini, M. (63) R1
Zoglio, M.A., see Shenouda, L.S. (61) 127
Zografi, G., see Ahlneck, C. (62) 87
Zorc, B., see Maysinger, D. (63) 149
Zuidema, J., see Kadir, F. (64) 171
Zuidema, J., see Titulaer, H.A.C. (69) 83

International Journal of Pharmaceutics, (1991) 19–31
© 1991 Elsevier Science Publishers B.V. 0378-5173/91/$03.50

Subject Index

ABBOTT-64662, (65) 195
Absorbed nitrate, (65) 265
Absorption enhancement, (62) 53; (64) 61
Absorption enhancer, (68) 239; (69) 29; (70) 19
Absorption kinetics, (69) 103
Absorption model system, (61) 43
Absorption-redistribution, (69) 169
Accelerated clearance, (64) 155
Accelerated elimination, (64) 109
Accelerated stability, (61) 9
N-Acetylcysteine, (62) 193
Acetylsalicylic acid, (61) 67
Acetylsalicylic acid microcapsule, (61) 219
Acid-catalyzed hydrolysis, (69) 1
Acidity constant, (67) R1
Acquired immune deficiency syndrome, (68) 215
Acquired immunodeficiency syndrome, (67) 275
Acrylic polymer, (62) 105
Acryloyl derivative, (61) 79
Actin filament, (68) 135
Activated charcoal, (64) 109
Acyclovir, (65) 183
Acylglycerol, (64) 147
N-Acyloxymethyl derivative, (64) 75
Adaptive least squares, (61) 225
Additive effect, (67) 247
Adhesion, (66) 263
Adsorbate, (68) 69
Adsorbed water, (62) 65
Adsorption, (64) 89
Aggregation, (61) 79
Aging, (64) 27; (69) 13
Air-liquid interface, (68) 285
Air permeability, (63) 23; (69) 239
Albumin microsphere, (68) 265; (69) 5
Alfaxalone, (65) 101
Alkanol, (68) 285
n-Alkyl nicotinate, (66) 213
Alkyl *p*-aminobenzoate, (70) 209
Allopurinol, (64) 75
Althesin, (65) 101
Amethocaine, (62) 9
Amifloxacin, (63) 237
Amikacin-loaded nanoparticle, (67) 103
Amikacin sulfate, (68) 69
Amino acid-benzodiazepine interaction, (61) 189
N-(2-Aminoethyl)-2-(*N*-benzylanilino)acetamide, (65) 137
Aminopeptidase, (62) 259; (70) 271
Aminosteroid, (66) 63
Ampicillin, (62) 1
Analbuminemic rat, (65) 149
Analog-hybrid simulation, (62) 15
Angle of wall friction, (64) 227
Animal model, (65) 183
Anionic hydrogel, (70) 53
Anipamil, (64) 117
Annular shear cell, (64) 227
Antacid, (69) 189
Antazoline, (65) 137
Anti-cancer drug, (68) 151
Antifertility agent, (69) 93
Antiflocculant, (63) 183
Anti-inflammatory drug, (68) 191; (68) 265
Antiviral efficacy, (65) 183
Aquacoat, (70) 59
Aqueous pseudolatex, (70) 59
Aqueous solution, (67) 155; (70) 29
Arching, (63) 275
Arginine, (68) 77
Arrhenius equation, (61) 9
Arrhenius plot, (63) 17
Artemether, (69) 83
Artemisinin, (69) 83
Artesunate, (69) 83
Arylacetic acid derivative, (62) 21
Asialofetuin, (67) 123
Asialoglycoprotein receptor, (67) 123
Aspirin, (61) 67; (64) 147
Asthma therapy, (64) 1
Atenolol, (65) 177
Avicel® PH 101, (61) 251
Axial recovery, (67) 59
Axial tensile strength, (64) 35
Azathioprine, (68) 105
Azelaic acid, (69) 193
m-Azidopyrimethamine, (65) 115
Azone, (66) 53; (66) 79; (66) 243
Azone®, (68) 239
Aztreonam, (67) R5

Bacillus subtilis, (65) 127
Bacteria, detection, (61) 57
Bacterial spore, (65) 127
Barbiturate, (62) 37

Barium sulfate, (69) 233
Barrier function, (64) 161
Base-catalyzed hydrolysis, (63) 29
Benzisothiazolone, (66) 201
Benzodiazepine, (63) 155
Benzodiazepine derivative, (61) 189
Benzodiazepine stability, (63) 29; (69) 1
Bilayer fluidity, (61) 205
Bile salt, (69) 21; (69) 29; (69) 221
Binder-substrate interaction, (64) 207
Binding agent, (65) 43
Binding properties, (62) 153
Bioadhesive microspheres, (63) 207
Bioadhesive polymer, (61) 109
Bioassay, (63) 135
Bioavailability, (63) 77; (63) 201; (64) 139; (64) 171; (64) 195; (65) 85; (65) R5; (67) 185; (68) 167; (69) 123
Biocompatibility, (62) 187
Biodegradable implanted tablet, (70) 77
Biodegradable polyester, (68) 87
Biodegradable polymer, (67) 67
Biodistribution, (69) 77
Biophysical model, (64) 7
Biscarboxyethylcarboxyfluorescein, (68) 231
Block copolymer, (65) 201; (70) 147
β-Blocker, (63) 73
β-Blocking agent, (64) 171
Blood clearance, (69) 77
Body distribution, (61) 85
Boltzmann superposition, (70) 53
Bonding mechanism, (61) 251; (64) 27; (64) 35
Bovine serum albumin, (70) 219
Brittleness, (64) 55
Brittle separation, (67) 217; (67) 231
Buccal absorption, (69) 103
Buccal cavity, (69) 103
Buccal membrane, (69) 103
Buffer, (70) 29
Buffering additive, (62) 113
Bulk density, (67) 39
Buoyancy, (62) 207
Buretrol®, (68) 281
Butibufen sodium, (62) 21

Caco-2 cell, (63) 281
Caffeine, (65) 115
Caffeine effect, (70) 191
Calcitonin, (63) 135
Calcium fenoprofen, (69) 175
Calorimetry, (61) 67; (64) 239
Capillary action, (68) 1
Capsule filling, (61) 145; (63) 275; (66) 207; (66) 283
Capsule fill weight, (66) 273
Capsule fill weight variability, (66) 273
Capsules, (64) 227
Carbomer, (61) 15; (67) 113
Carboplatin, (69) 197
Carboxymethyl cellulose, (68) R1
Carboxymethylstarch, (62) 27
Carboxypeptidase B, (68) 77
Cardanol derivative, (66) 107
Carrier capacity, (70) 129
Cationic polymer, (61) 157
Cefazoline, (67) 259
Ceftibuten, (63) 101
Cell culture, (63) 135; (64) 181
Cell surface, (62) 133
Cellulose ester, (62) 97
Cellulose ether, (62) 97
Centrifugal rotating mixer, (64) 147
Cephalothin sodium, (62) 65
Cetostearyl alcohol, (63) 219; (68) 205
Cetrimide, (63) 219
Cetylmannoside, (70) 225
Cetyltrimethylammonium bromide, (64) 239
Characterization, (69) 175; (69) 211; (70) 119
Charge density, (69) 21
Charging kinetics, (63) 1
Chelating microcapsules, (69) R1
Chemical analysis, in situ, (62) 97
Chemical hydrolysis, (63) 129
Chemical stability, (62) 65; (68) 271
Chitosan, (61) 35
Chlorambucil, (66) 289
Chloramphenicol, (70) 137
Chlorcyclizine hydrochloride, (63) R1
Chlorhexidine, (65) 127
Chloride effect, (69) 197
Chloroform solvate, (69) 13
Chlorpheniramine maleate, (70) 59
Chlorthalidone, (65) 177
Cholesterol, (69) 13; (70) 111; (70) 209
Cholesterol esterase, (70) 271
Cholestyramine, (64) 155
Choline acetyltransferase, (63) 149
Cholinotoxin, (63) 149
Ciprofloxacin, (63) 237
Cisplatin, (69) 197
Citric acid, (68) 255
Clearance, (65) 149; (70) 225
Clinical study, (66) 53
Clonidine, (65) 159
Cloud point, (66) 233
Coarse particulate material, (63) 189
Coated system, (63) 43
Coating, (63) 43
Cocoa butter, (61) 1
Collaborative study, (69) 255
Collapse temperature, (62) 165
Colonic absorption, (69) 221
Colorimetry, (61) 261; (70) 201
Compact, (67) 217; (67) 231
Compactibility, (69) 239
Compaction, (62) 153; (66) 47

Compaction force, (64) 223
Compaction properties, (67) 59
Compact strength, (61) 251
Compartment model, (63) 101
Compensation, (62) 157
Compensation analysis, (66) 175
Complex, (64) 195
Complexation, (67) 11
Complexation reaction, (61) 199
Compressed tablet, (67) 139; (69) 129
Compression, (68) 157; (70) 241
Compression force, (67) 113
Compression isotherm, (70) 111
Compression setting, (66) 273
Compression speed, (64) 223
Compression stress, (63) 275
Computer graphics, (63) 267
Computer optimization, (61) 225
Concentration profile, (68) 1
Confocal microscopy, (61) 163; (66) 131
Conjugated estrogen tablet, (67) 211
Consolidation, (66) 47
Contact angle measurement, (61) 85
Container compatibility, (66) 87
Contraceptive delivery system, (63) 143
Controlled drug delivery, (67) 265; (69) 63
Controlled drug release, (61) 241
Controlled release, (61) 235; (62) 105; (62) 113; (62) 249; (65) 183
Controlled-release, (66) 111
Controlled release, (67) 51; (67) 185; (68) R1; (68) 255; (69) 123; (70) 69; (70) 147; (70) 153
Controlled release formulation, (68) 97
Controlled/Sustained drug release, (62) 157
Convective solvent flow, (69) 109
Copoly(dl-lactic/glycolic acid), (69) 69
Coprecipitate, (69) 13
Cornea, (61) 163; (66) 131; (68) 135
Corneal permeability, (63) 49
Corticosteroid, (70) 167
Cosolvency, (65) 141
Cream formulation, (65) 225
Critical stress intensity factor, (66) 143
Crosslinked starch, (62) 125; (65) 43; (69) 43
Crushing strength, (62) 153
Cryoprotectant, (64) 139
Cryo-scanning electron microscopy, (65) 225
Crystal defect, (62) 87
Crystal engineering, (69) 175
Crystal growth, (68) 179
Crystal hydrate, (65) 141
Crystalline solid-state properties, (67) 59
Crystallization, (61) 27; (68) 25; (68) 35
Cube root law, (61) 127; (62) 143
Cultured bovine corneal endothelium, (68) 231
Cultured mouse keratinocyte, (68) 285
Curing, (70) 59
Current density, (61) 179
Curve fitting, (65) 159
Cutaneous metabolism, (65) 265
Cyclodextrin, (64) 195; (65) 101; (66) 289; (67) R5; (68) 271
Cyclodextrin, amorphous, (65) 101
α-Cyclodextrin, (61) 27
β-Cyclodextrin, (63) 95; (63) 267; (69) 211; (70) 35
Cyclodextrin, α-, (63) 259
Cyclodextrin, β-, (62) 153; (63) 259
Cyclodextrin derivative, (62) 243
Cyclodextrin, γ-, (63) 259
Cyclodisone, (66) 253
Cyclohexanone, (68) 239
Cyclopenthiazide, (69) 265
Cyoctol, (65) 77
Cysteine, L-, (64) 161
Cytochalasin B, (66) 131; (68) 135
Cytoplasmic pH, (68) 231
Cytoskeleton, (68) 135
Cytotoxicity, (66) 253

L-Dan cell, (63) 121
Decarboxylation, (63) 213
Decomposition, (62) 65
Decomposition kinetics, (63) 17; (64) 45
Degradation, (65) 137; (66) 63; (66) 253; (66) 289; (69) 197
Degradation in aqueous solution, (62) 243
Degradation kinetics, (66) 97; (67) 155
Dehydration-rehydration vesicle, (65) 235
Delivery, (62) 133
Delivery systems, (66) 223
Deposition pattern, (64) 1
Derivative spectrophotometry, (65) 177
Detergent dialysis, (69) 77
Dextrose, (66) 149
Dialysis diffusion technique, (66) 29
Diazepam, (63) 95; (64) 195; (66) 29; (67) 201
Dibasic compounds, (63) 167
Dibenzylamine, (67) 259
Dicalcium phosphate dihydrate, (69) 43
Dielectric constant, (61) 251
Dienone-phenol rearrangement, (66) 63
Differential scanning calorimetry, (62) 217; (68) 25; (69) 53; (70) 87
Diffusion, (61) 127; (62) 75; (64) 7; (68) 285
Diffusion boundary layer, (62) 143
Diffusion cell, (66) 39
Diffusion coefficient, (61) 173; (66) 213; (68) 43
Diffusion device, (63) 281
Diffusion-erosion, (70) 69
Diffusion-evaporation process, (67) 51
Difloxacin, (63) 237
Digitonin, (66) 131
Dihydralazine sulfate, (61) 261
Dihydroergotamine, (67) 97
Diltiazem, (62) R13
Dimethylamide, (66) 243

Dimethyl-β-cyclodextrin, (64) 61
Dimyristoylphosphatidylcholine, (69) 13
Dioleoylphosphatidylcholine, (70) 1
Di-*O*-methyl-β-cyclodextrin derivative, (63) 259
Dipalmitoylphosphatidylcholine-benzodiazepine interaction, (61) 189; (70) 209
Dipentum granulation, (69) 239
Direct compression, (63) 95; (64) 27; (64) 35
Direct compression excipient, (68) 51
Discontinuous absorption, (63) 101
Disinfection activity, (65) 35
Disintegrant, (66) 263
Disintegrating agent, (62) 125
Disintegration, (66) 175
Disintegration time, (67) 139
Disodium cromoglycate, (64) 1
Disposition, (65) 77; (65) 149; (70) 225
Dissociation constant, (61) 173
Dissolution, (62) 157; (65) R5; (66) 71; (66) 175; (66) 233; (66) 289; (67) 131; (67) 207; (67) 211; (67) 247; (70) 153
Dissolution profile, (63) 95
Dissolution rate, (63) 49; (67) 139; (67) 201; (68) 25; (69) 53; (69) 129
Dissolution test, (64) 147
Dissolution testing, (62) 143; (69) 63; (69) 255
Distribution coefficient, (70) 209
Distribution volume, (65) 149
DLVO theory, (64) 67
Dosage form, (66) 169; (67) 51; (67) 169; (68) 199
Dosage form analysis, (63) 113
Dosator nozzle, (63) 275; (64) 227; (66) 207; (66) 273; (66) 283
Dose application, (70) 167
Dose dumping, (66) 111
Dose thickness, (70) 167
Double-layer tablet, (64) 35
Doxylamine succinate 0.5 succinic acid, (63) 35
Drug, (67) 169
Drug absorption, (64) 181; (64) 195
Drug adsorption, (70) 129
Drug analysis, (65) 177
Drug binding, (62) 21
Drug carrier, (67) 103; (70) 225
Drug delivery, (61) 51; (61) 109; (62) 259; (63) 121; (69) 29; (69) 169
Drug delivery device, (61) 235
Drug delivery system, (62) 249; (63) 43; (67) 67; (67) 259; (68) 87; (68) 215
Drug determination, (62) R13
Drug disposition, (68) 97
Drug distribution, (65) 1
Drug entrapment, (65) 235
Drug-excipient interaction, (62) 87
Drug lipophilicity, (64) 171
Drug/polymer association, (68) 69
Drug-polymer device, (67) 51
Drug release, (65) 19; (66) 29; (67) 67; (68) 215; (69) 129; (70) 129
Drug release modelling, (66) 111
Drugs, (66) 223
Drug solubility, (68) 1
Drug stability, (67) 195
Drug targeting, (61) 85; (63) 121; (68) 111
Drying process, (67) 51
DSC, (62) 217; (63) 35; (63) 259; (68) 35; (70) 43
Ductile extension, (67) 217; (67) 231
Ductility, (64) 55
Dyphylline, (61) 127

Edible clay, (65) 63
EDTA, (61) 15; (66) 131; (68) 135
Elastic deformation, (67) 59
Elastic modulus, (67) 217; (67) 231
Elastic recovery, (64) 223
Electrical resistance, (68) 135
Electric charge, (65) 7
Electrolyte, (64) 67
Electron microscopy, (63) 1
Electro-osmosis, (69) 109
Elevated temperature, (70) 241
Emcompress carrier, (67) 247
Emulsion, (63) 219; (64) 217; (65) 133; (66) 1; (66) 79
Emulsion film, (62) 249
Emulsion gel, (62) 249
Emulsion globule structure, (65) 133
Emulsion solvent-diffusion technique, (62) 105
Emulsion stability, (63) 65; (65) 225; (70) 251
Enalkiren, (65) 195
Endothermic adsorption, (67) 89
Enhanced absorption rate, (67) 11
Enhanced dissolution, (67) 11
Enhanced permeation, (70) 159
Enhancement factor, (66) 53
Enhancer, (65) 115
Enoxacin, (63) 237
Enteric binding, (64) 155
Enteric granule, (64) 147
Enterohepatic cycling, (64) 109
Enzymatic degradation, (64) 181; (66) 183
Enzymatic hydrolysis, (62) 193; (68) 77; (70) 137
Enzyme activity, (63) 149
Enzyme distribution, (64) 7
Enzyme inhibitor, (65) 57; (66) 97
Enzymic activity, (62) 259
Epidermal membrane, (70) 167
EPR, one-dimensional imaging, (62) 75
Equilibrium solubility, (67) 131
Erosion, (61) 127
Erythromycin, (63) 113; (67) 195
Erythromycin estolate, (63) 113
Esophageal cancer, (61) 109
Ester, (62) 193
Ester prodrug, (61) 43
β-Estradiol, (64) 7
17-β-Estradiol, (64) 61

Estramustine, (63) 121; (68) 87
Etching, (65) 225
Ethyl cellulose, (61) 101
Ethylcellulose, (64) 99
Ethyl cellulose, (65) 1
Ethylcellulose, (67) 21
Ethyl cellulose, (70) 59
Eudragit, (62) 157
Eudragit RL, (67) 265
Eudragit RL 100, (70) 153
Eudragit RS 100, (68) R1
Everted gut sac, (62) 53
Excised pig cornea, (63) 49
Excretion, (65) 77
Expected deviation, (66) 283
Extended release, (68) 167
Extractive colorimetric analysis, (61) 199
Extrusion/spheronization, (69) 233

Factorial design, (65) 195
Famotidine, (61) 173
Famotidine:xylitol solid dispersion, (66) 71
Fat distribution, (64) 171
Fat emulsion, (63) 183; (64) 67; (68) 277; (70) 251
Fe(III) assay, (61) 199
Felodipine, (62) 143; (68) 25
Ferric trifluoroacetylacetonate complex, (61) 199
Ferrite, (61) 109
[Ferrous(2,2′-dipyridyl)$_3$]$^{2+}$ chelate complex, (70) 201
Fibroblast, (70) 159
Filler, (67) 79
Film-coated granule, (67) 79
Film coating, (69) 123; (70) 59
Film thickness, (65) 69
Filter absorption/adsorption, (67) 211
Fine particulate powder, (62) 143
Fleroxacin, (63) 237
Floating dosage form, (62) 207
Floating force kinetics, (62) 207
Flocculated emulsion system, (65) 133
Flocculation, (64) 67
Flow cell, (69) 255
Flow cytometry, (62) 133
Flow-through method, (69) 255
Flufenamic acid, (67) 1
Fluid-bed coating, (65) 69
Fluidity, (65) 35
Fluorescence, (70) 95
Fluorimetric titration, (67) R1
Fluorine, (69) 181
Fluorocarbon, (63) 65
Fluoroquinolone, (63) 237
Fluorouracil, 5-, (61) 51; (65) 1
5-Fluorouracil, (68) 61; (70) 87
5-Fluorouracil acetic acid, (68) 61
5-Fluorouracil-acetic acid-human serum albumin conjugate, (68) 61
Flurbiprofen, (62) 21; (70) 153

Folic acid, (65) 63
Formulation, (67) 195; (69) 83
Foscarnet, (63) 213
Fourier transform, (66) 223
Fourier transform infrared microscopy, (63) 219
Four-point beam bending, (64) 55; (66) 143
Fracture mechanics, (66) 143
Fragmentation, (69) 129
Fragmentation tendency, (67) 139
Freeze-drying, (61) 27
Freeze drying, (62) 165
Freeze-drying, (70) 35
Frequency, (61) 179
Friability, (67) 139
Frog palate, (65) 243
Frozen storage, (70) 119
Furosemide, (67) 113
Fusogen, (62) 133

Gafquat polymer, (61) 157
Galactocerebroside, (70) 1
Gallopamil, (64) 117
Gamma irradiation, (65) 201; (70) 147
Gamma scintigraphy, (62) R9; (65) 85
Gamma-scintigraphy, (66) 169
Gamma scintigraphy, (68) 199
Ganglioside, (70) 111
Gastric absorption, (64) 127
Gastric emptying, (62) R9; (63) 101; (69) 189
Gastric liquid, (67) 265
Gastric scintigraphy, (69) 189
Gastrointestinal absorption, (66) 97
Gastrointestinal tract, (69) 181
Gastrointestinal transit, (68) 199
Gastrointestinal ulcer, (70) 35
Gel, (65) R9
Gelatin, (62) 27
Gelation, (61) 79; (65) 201; (66) 213
Gel ointment, (61) 225
Gel structure, (62) 217
Gelucire, (65) 85
Glass container, (68) 281
Glass transition, (62) 87; (62) 165; (68) 25
Glass transition aging, (64) 99
Glassy state, (67) 131; (68) 25
Glibenclamide, (67) 131
Glutathione, (63) 227
Glyceryl monostearate, (64) 147
Glyceryl trilaurate, (64) 147
Granulation, (62) 229; (64) 207; (67) 39
Granule fragmentation, (62) 229; (63) 23; (69) 239
Granule porosity, (69) 239
Granule properties, (62) 229
Granule quality, (65) 43
Grinding, (62) 65
Griseofulvin, (62) 143; (63) 49; (67) 139; (67) 247; (69) 13; (69) 53
p-Guanidino-L-phenylalanine, (68) 77

Hairless mouse skin, (64) 7; (68) 285; (69) 143; (69) 155
Hairless mouse skin permeation, (69) 193
Halcinonide, (70) 167
Hamster cheek pouch, (67) 1
Hardness, (67) 217; (67) 231
H_1-blocker, (63) R1
Heat of dissolution, (61) 173
Hematoporphyrin, (70) 129
Hepatic first-pass effect, (69) 169
Hepatic uptake, (65) 7
Hepatocyte, (67) 123
Herpes simplex virus-1, (65) 183
Hexose, (70) 235
High shear mixer, (65) 43
Histamine release, (68) 191
Histopathology, (68) 239
HLB, (66) 213
HMG-CoA reductase, (66) 97
Hormone analog, (62) 119
HPLC, (61) 119; (62) R13; (63) 113; (68) 271
HPLC analysis, (63) R1; (67) 211
HPLC assay, (63) 17; (65) R9
Human, (65) 77; (67) 185; (67) 259
Human growth hormone, (63) 207
Human serum albumin, (62) 21; (62) 27; (69) R1
Human skin, (69) 109
Hydration, (61) 205; (62) 37
3-Hydrazone derivative, (65) 109
Hydrocortisone, (66) 79
Hydrodynamically balanced system, (62) 207
Hydrodynamic layer, (61) 173
Hydrolysis, (61) 67
Hydrophilic matrix, (62) 207; (67) 113
Hydrophobic compound, (70) 219
Hydrophobic-hydrophilic (gel-forming) system, (70) 69
Hydroxamic acid, (69) R1
p-Hydroxybenzoic acid butyl derivative, (69) 103
Hydroxyethyl cellulose, (66) 23
Hydroxyethylstarch, (62) 27
Hydroxypropyl β-cyclodextrin, (69) 211
Hydroxypropyl methylcellulose, (61) 101
Hydroxypropylmethylcellulose, (61) 127; (66) 233
Hygroscopicity, (62) 65

Ibufenac, (62) 21
Ibuprofen, (61) 1; (62) 21; (66) 193; (66) 243
Ibuprofen disposition, (68) 97
Ibuprofen enantiomer, (68) 97
Identification, (66) 63
IM-9 Lymphoblast, (63) 135
Implantable device, (68) 87
Implantation, (69) 93
Inactivation, (64) 139
Inclusion complex, (65) 101; (69) 211; (70) 35
Inclusion complexation, (63) 259; (63) 267
Inclusion compound, (61) 27
Indomethacin, (61) 225; (62) 157; (64) 109; (64) 155; (67) 11; (67) 79; (67) 185; (67) 207; (69) 211
Indomethacin-controlled release, (63) 77
Indomethacin microsphere, (62) 105
Infrared spectroscopy, (67) 131; (68) 35
Inhalation dosage form, (64) 1
Injectable microsphere, (69) 69
Inorganic filler, (64) 55
In-situ model, (70) 235
Insoluble substance, (67) R1
Insulin, (61) 163; (62) 53; (62) 187; (64) 89; (65) 243
Insulin absorption, (69) 29
Interaction, (66) 47; (67) 11; (68) 11
Interactive powder mixture, (67) 247
Interactive system, (66) 263
Interfacial complex film, (62) 81
Interfacial cross-linking process, (62) 27; (69) R1
Interferon-β, (64) 139
Interparticle potential, (64) 67; (64) 217
Intestinal absorption, (64) 161; (66) 183
Intestinal loop, (70) 235
Intestinal mucosal transport, (62) 53
Intestine, (64) 181
Intra-adipose injection, (64) 171
Intragastric degradation, (63) 213
Intramolecular rearrangement, (64) 45
Intranasal administration, (70) 19
Intratracheal instillation, (63) 227
Intravenous infusion, (70) 119
Intravenous nutrition, (70) 251
Intrinsic diffusion coefficient, (64) 117
Intrinsic dissolution, (69) 265
Intrinsic dissolution rate, (69) 175
Intrinsic parameters, (64) 7
In vitro absorption, (68) 43
In vitro evaluation, (69) 5
In vitro interaction, (65) 63; (67) 89
In vitro/in vivo correlation, (68) 167
In vitro metabolism, (65) 109
In vitro model, (70) 219
In vivo analysis, (62) R13
In vivo evaluation, (69) 5
In vivo-in vitro correlation, (64) 187
In-water drying method, (69) 69
Ionic interaction, (69) 69
Ionic strength effect, (66) 111
Ionization constant, (63) 237
Iontophoresis, (61) 179; (69) 109
IR, (63) 35
Iron, (69) R1
Iron-containing pharmaceutical, (61) 199
Iron(III), (61) 199
Iron oxide, (65) 249
Iron toxicity, (65) 249
γ-Irradiation sterilization, (63) 155
Isobutylcyanoacrylate, (62) 1
Isohexylcyanoacryate, (62) 1
Isolated rat hepatocyte, (65) 7
Isolated rat liver microsomes, (65) 109
Isolated stratum corneum, (67) 1

Isoniazid, (70) 201
N^6-(Δ^2-Isopentenyl)adenosine, (65) 57
Isosorbide dinitrate, (65) 159
Isothiazolone biocide, (66) 201

JR polymer, (61) 157

Kaposi's sarcoma, (65) R9
Kathon, (66) 201
Keratin, (61) 205
Ketoprofen, (65) 85
Ketoprofen-caffeine interaction, (70) 191
Ketoprofen solubility, (70) 191
Kinetics, (61) 67; (66) 253; (69) 197
Kneading, (69) 211
Kupffer cell, (70) 225

L-653,328, (66) 23
Lactone hydrolysis, (66) 97
Lactose, (61) 251; (66) 47
Lactose granulation, (63) 23; (69) 239
Lamellar structure, (68) 205
Laminate permeation, (64) 117
Langmuir trough, (65) 211
Laser scattering, (61) 57
Latex coating, (70) 261
Latex membrane, (68) 151
Laureth-9, (70) 19
LC analysis, (63) 237
L1210 cell culture, (65) 57
Leaching polymer, (67) 21
Lecithin, (65) 211
Leuprolide, bioavailability from lung, (61) 135
Leuprolide, intratracheal delivery, (61) 135
LFER, (66) 107
LH-RH, (62) 119
Ligand influence, (67) 155
Lignocaine, (62) 249
d-Limonene, (61) 225
Lipid composition, (70) 1
Lipid disperse system, (67) 1
Lipid extraction, (69) 63
Lipidic amino acid, (68) 191
Lipidic peptide, (68) 191
Lipid structure, (68) 1
Lipophilic drug, (64) 161
Lipophilicity, (64) 75; (64) 127
Liposome, (62) 1; (62) 75; (62) 133; (63) 227; (65) 235; (67) 123; (69) 77; (70) 1; (70) 225
Loading efficiency, (70) 1
Local chemotherapy, (61) 109
Lomefloxacin, (63) 237
Lomustine, (62) 243
Long-acting delivery, (62) 119
Low-alcohol extract, (63) 57
Low density lipoprotein, (63) 121
Low molecular weight chitosan, (67) 11
Lubricant grade effect, (70) 103
Lubricant sensitivity, (67) 39
Lubrication, (69) 129; (70) 103
Lymph, (69) 169
Lymphatic uptake, (61) 51
Lyophilization, (62) 165
Lysophosphatidylcholine, (63) 207

Macromolecular carrier, (64) 239
Macromolecule, (62) 133
Macrophage, (65) 249; (68) 265
Magnesium stearate, (70) 103
Magnesium trisilicate, (65) 63; (67) 89
Magnetic granule, (61) 109
Malaria, (69) 83
Male rat, (67) 67
Mannitol, (66) 149
Matrix tablets, (70) 69
Mean yield pressure, (64) 223
Mebeverine hydrochloride, (67) 89
Mechanochemistry, (62) 65
Medazepam, (63) 155
Mefloquine, (70) 95
Melatonin, (69) 93
Melt cooling, (68) 35
Melting, (70) 241
Membrane, (70) 43
Membrane capacitance, (63) 1
Membrane diffusion, (66) 29
Membrane fluidity, (70) 209
Membrane fusion, (62) 133
Membrane impedance, (63) 1
Membrane potential, (63) 1; (69) 21
Membrane resistance, (63) 1
6-Mercaptopurine, (68) 105
Metabolism, (62) 9; (64) 7
Metal complex, (68) 105
Metallic compound, (68) 11
Methanol, (69) 143; (69) 155
Methaoxedrine, (65) 19
Methotrexate, (61) R1; (67) 177; (68) 179; (68) 265
Methotrexate-rabbit serum albumin conjugate, (67) 177
Methyl cellulose, (65) 1
Metoprolol, (68) 167
Metronidazole, (61) 119
Mevalonic acid, (66) 97
Mice, (69) 93
Micelle, (65) 201
Microcalorimetry, (61) 67; (63) 251; (66) 107
Microcapsule, (68) 19
Microcrystalline cellulose, (63) 251; (64) 55; (64) 207; (69) 233
Microcrystalline cellulose powder, (66) 143
Microdetermination, (70) 201
Microelectrophoresis, (64) 89
Microemulsion, (61) 213
Microemulsion, w/o, (62) 119
Microencapsulation, (62) 27

Micro-enema, (64) 195
Microfine cellulose, (67) 39
Microfluidization, (65) 235
Microporous coated osmotic pump, (69) 63
Microporous membrane, (63) 281; (68) 285
Microscopy surface area, (63) 189
Microsphere, (65) 249
Microsphere-pellet, (63) 77
Microspheres, (62) 187; (64) 99
Microstructure, (65) 225; (68) 205
Microwave thawing, (70) 119
Minimal essential medium, (65) 265
Mitoxantrone, (70) 1
Mixed emulsifier, (68) 205
Mixed micelle, (62) 53
Modeling drug release, (62) 249
Model macromolecule, (65) 7
Mode of action, (66) 243
Modified starch, (63) 201
Moisture, (62) 153
Moisture content, (69) 233
Moisture sorption, (62) 87
Moisture sorption-analysis, (68) 51
Moisturizer, (61) 205
Molecular coating, (68) 157
Molecular mobility, (62) 87
Molecular ratio, (63) 267
Moment analysis, (65) 7
Monolayer, (65) 211; (70) 111
Monolayer penetration kinetics, (67) 103
Monomer carrier, (67) 265
Moulded tablet, (69) 93
Mouse skin, (65) 29
MR contrast medium, (65) 249
Mucin, (70) 235
Mucoadhesion, (70) 235
Mucociliary clearance, (65) 243
Mucus, (64) 161
Mucus gel layer, (70) 235
Multilamellar liposome, (64) 89; (70) 209
Multi-particulate system, (65) 69
Multiple emulsion, (61) 51
Multiple w/o/w emulsion, (62) 81

Na^+/H^+ exchanger, (68) 231
Nalidixic acid, (63) 237
Naloxone, (70) 111
Nanoparticle, (61) 85; (62) 1
Nanoparticles, (68) 69; (68) 111
Nanoparticle stability, (67) 103
Nanosphere-entrapped drug, (65) 1
Naproxen, (64) 195; (66) 243; (70) 35; (70) 43
Nasal absorption, (64) 61
Nasal administration, (62) 187; (64) 139; (65) 243; (69) 5
Nasal delivery, (63) 207
Nasal histology, (70) 19
Nasal mucosa, (69) 21
Native starch, (67) 39
Nernst-Planck theory, (69) 109
Net compaction energy, (64) 223
Neutralization, (69) 211
Nicotine, (68) 43
Nicotinic acid ester, (63) 129
Nifedipine, (70) 195
Niosomes, (61) R1
Nitrazepam, (63) 29; (69) 1
Nitrofurantoin, (67) 59
Nitrofurazone, (70) 9
Nitroglycerin, (64) 187; (65) 159; (65) 265
p-Nitrophenyl ester, (66) 149
NMF, (61) 205
^{13}C-NMR, (63) 129
^{13}C-NMR, (70) 195
^{1}H-NMR, (70) 195
NMR,^{1}H-, (63) 267
NMR imaging, (69) 181
Nonionic emulsifying agent, (62) 217
Nonionic surfactant, (70) 9
Non-phagocytic cell, (62) 133
Norethindrone acetate, (63) 143
Norfloxacin, (63) 237; (68) 11
Notched beam specimen, (66) 143
NSAIDs, (62) 21
Nucleophilicity, (66) 149
Nucleophilic substitution, (69) 197

Observed deviation, (66) 283
Octanol, (69) 143; (69) 155
n-Octanol, (62) R5; (63) 73
Octylphenoxypolyethoxyethanol, (64) 239
Ocular absorption, (61) 241; (65) 19
Ocular bioavailability, (66) 23
Ocular drug delivery, (61) 235; (61) 241
Ocular retention, (61) 15
Ofloxacin, (63) 237
Ointment base, (68) 1
Oleic acid, (65) 115; (67) 97; (70) 159
Ophthalmic formulation, (65) 195
Oral absorption, (68) 191
Oral cavity, (66) 169; (69) 103
Oral dosage form, (69) 123
Oral mucosal membrane, (69) 103
Oral route, (61) 51
Ordered mixture, (69) 129
Orotic acid, (61) 43
Osmolality, (65) 35
Osmotic pumping, (61) 101; (67) 21
Ostwald ripening, (63) 65
Otic product, (64) 235
Outward migration, (65) 77
Ovulation, (69) 93
o/w cream, (68) 205
Oxazepam, (69) 129
Oxidative degradation, (64) 99

Papaverine hydrochloride, (68) 255
Parabolic-type degradation, (67) 67
Paracetamol DC granules, (70) 103
Paramolybdate anion, (61) 261
Parenteral delivery, (64) 75
Parenteral nutrition, (64) 217; (66) 1
Particle, (67) 217; (67) 231
Particle characterization, (63) 189
Particle counting, (61) 57
Particle interaction, (66) 263
Particle size, (63) 49; (64) 227
Particle size distribution, (62) 143
Particle size effect, (66) 273
Particulate properties, (67) 59
Partition, (68) 43
Partitioning, (62) R5; (63) 73; (66) 79
P388 cell, (63) 121
Penetration, (66) 183
Penetration deceleration, (61) 205
Penetration enhancement, (66) 53; (68) 1
Penetration enhancer, (61) 205; (66) 131; (66) 243; (67) 97; (69) 143; (69) 155; (70) 87
Penetration kinetics, (70) 111
Penetration mechanism, (68) 1
Pentostatin, (65) 57
Peptide, (61) 179; (70) 111
Peptide absorption, (69) 29
Peptide bioavailability, (61) 135
Peptide delivery, (61) 163; (62) 259; (70) 271
Peptide, lung absorption, (61) 135
Peptides, (63) 167
Percutaneous absorption, (61) 225; (65) 77; (65) 115; (65) 211; (66) 53; (66) 157; (66) 193; (66) 243; (67) 97; (68) 239; (70) 87
Percutaneous anesthesia, (62) 9
Percutaneous permeation, (67) 1
Perfluorocarbon, (69) 181
Perfluorodecalin, (63) 65
Performance monitoring, (70) 119
Perfused skin, (65) 265
Permeability, (61) 101; (65) 29; (68) 43; (68) 151; (70) 167
Permeametry surface area, (63) 189
Permselectivity, (61) 163
Pharmaceutical aerosols, (61) 135
Pharmaceutical analysis, (61) 261
Pharmaceutical excipient, (63) 275
Pharmaceutical formulation, (69) 181
Pharmacokinetic parameters, (64) 109; (64) 155
Pharmacokinetics, (61) 43; (61) 119; (61) 241; (62) 15; (63) 77; (65) 159; (67) 177; (67) 259; (68) 11; (68) 61; (69) 83; (70) 225
Phase angle, (63) 1
Phase inversion, (65) 225
Phase volume, (66) 79
Phenacetin, (69) 255
Phenazone, (64) 235
Phenobarbitone, (63) 95
Phenothiazine, (62) R5
Phenoxymethylpenicillin, (67) R5
Phenylalkylcarboxylic acid, (64) 127
Phenylbutazone, (67) 207
pH, (62) 113
pH effect, (66) 111; (66) 193; (69) 197
Extracellular pH, (68) 231
pH-independent dissolution, (64) 147
pH-independent release, (68) 255
Network, pH change, (70) 53
pH-rate profile, (63) 17; (70) 29
Phosphate-buffered saline, (65) 265
Phosphatidic acid, (70) 43
Phosphatidylcholine, (70) 43
Phospholipid, (65) 169; (69) 13; (70) 111
Phospholipid vesicle, (62) 75
Phosphonoformate, (63) 213
Phosphorescence, (70) 95
Photodecomposition, (70) 195
Photodegradation, (67) 169; (68) 277
Photon correlation spectroscopy, (67) 103
Photooxidation, (70) 95
Photosensitizer, (70) 129
Photosensitizing potential, (70) 95
Physical stability, (68) 179
Physostigmine salicylate, (65) 169
Pig model, (69) 169
Piperidone, (68) 239
Piroxicam, (68) 35
pK_a, (61) 173
Plasma, (61) 119; (64) R1
Plasma protein binding, (65) 149
Plastic deformation, (67) 59; (70) 241
Plasto-elastic properties, (68) 157
Platinum(II) complex, (69) 197
Pneumocystis carinii pneumonia, (67) 275
Poloxamer, (65) 169; (66) 213
Poloxamer, polymerisable, (61) 79
Poloxamer surfactant, (69) 155
Poloxamine surfactant, (69) 155
Polyalkylcyanoacrylate, (68) 69
Polyalkylcyanoacrylate nanoparticle, (67) 103
Polyalkylcyanoacrylate nanoparticles, (70) 129
Polyaspartamide, (70) 43
Poly(DL-lactic acid), (67) 67
Polyether polyurethane, (65) 57
Poly(ethylene glycol), (61) 1
Polyethylene glycol 6000, (67) 201; (69) 53; (70) 9
Poly(ethyloxazoline), (61) 127
Polyion complex, (61) 35
Polyisohexylcyanoacrylate, (68) 111
Poly(lactic acid) microcapsules, (63) 149
Poly(lactide-co-glycolide) copolymer, (70) 77
Polylysine, (61) 163
Polymer binder, (64) 207
Polymer carrier, (65) 29; (66) 157; (67) 265
Polymer coiling tendency, (61) 157

Polymer film coating, (62) 97
Polymeric delivery system, (65) 57
Polymerization, (68) 69
Polymer matrix, (65) 19
Polymer-water partitioning, (66) 87
Poly(methacrylate) copolymer, (62) 97
Poly(methyl methacrylate), (61) 85
Polymorphic form, (63) 35
Polymorphism, (62) 37; (68) 35; (69) 265
α,β-Poly(*N*-hydroxyethyl)-DL-aspartamide, (64) 239
Polypropylene film, (69) 63
Polysorbate, (69) 143
Polystyrene particles, (63) 183
Polythiazide, (70) 187
Polyvinyl alcohol, (66) 23
Poly(vinyl methyl ether-maleic anhydride), (65) 19
Polyvinylpyrrolidinone-iodine, (65) 35
Polyvinyl pyrrolidone, (68) 255
Polyvinylpyrrolidone, (69) 93
Pore formation, (67) 21
Porosity, (63) 189
Potassium chloride, (70) 261
Powder, (64) 55; (66) 207; (68) 157; (70) 241
Powder dissolution, (69) 265
Powder dosage form, (64) 139
Powder flowability, (61) 145
Powder mixture, (66) 47
Powder plug density, (66) 283
Powder retention, (63) 275
Powders, (64) 227
Powder-wall adhesion, (64) 227
Prazosin, (70) 187
Precorneal kinetics, (61) 15
Prednisolone, (63) 95; (68) 265
Prednisolone acetate, (63) 49
Preparative variables, (70) 77
Preservation, (66) 201
Pressure-sensitive adhesive, (64) 117
Primaquine, (68) 111
Procaine hydrochloride, (64) 235
Prodrug, (62) 193; (63) 129; (64) 75; (66) 23; (66) 39; (66) 183; (68) 77; (70) 137
Prodrug delivery, (62) 259; (70) 271
Progesterone, (64) 61; (65) 109
Prolonged release, (69) 69
Propranolol, (62) 113; (69) 5; (69) 169
Propranolol HCl, (68) R1
Propranolol hydrochloride, (66) 233
Propylene glycol, (66) 193
Prostate gland, (61) 119
Protection, (63) 155
Protein binding, (65) 109
Protein-free serum, (64) R1
Protein glycosylation, (61) 219
Proxel, (66) 201
Pseudolatex coating, (70) 261
Pseudopolymorphism (hydrate), (68) 179
Psoriasis, (65) 115; (70) 159
Pulmonary absorption, (61) 135
Pulmonary delivery, (63) 227
Pulmonary distribution, (63) 227
Pulsatile application, (61) 179
Pulse current, (61) 179
PVC bag, (68) 281

Qinghaosu, (69) 83
QSAR, (66) 107
Quality control, (65) 177
Quantum yield, (70) 95
Quinolone, (63) 237
Quinolone, 4-, (68) 11

Radial and axial tensile strength, (67) 139
Radical, (63) 155
Radiolabeling, (69) 189
Radiopharmaceutical, (69) 189
Radioreceptor assay, (61) 241; (63) 135
Radius of curvature, (67) 217; (67) 231
Raman, (66) 223
Rapid release, (65) 85
Rat, (62) 187; (63) 135; (70) 19; (70) 35
Rat abdominal skin, (67) 1
Rat liver perfusion, (65) 7
Rat lung, (63) 227
Rat prostate, (67) 67; (68) 87
Rats, (64) 61
Rat skin, (66) 193
Reaction mechanism, (69) 197; (70) 191
Rectal absorption, (64) 75
Redox potential, (65) 35
Release rate, (61) 235; (69) 63
Renin inhibitors, (63) 167
Reservoir device, (62) 113
Resultant-weight measurement, (62) 207
Retard release, (65) 133
Retinoic acid, (65) R9
Reverse dialysis, (66) 29
Reverse osmosis, (61) 57
Reverse osmosis membrane, (63) 57
Reverse osmosis membrane, monitoring, (61) 57
Reynolds number, (63) 189
Rheological properties, (64) 161
Rheology, (70) 147
Rosmarinus officinalis, (63) 57
Rotating disc, (69) 175

Saffan, (65) 101
Salbutamol, (63) 259; (63) 267
Salbutamol (sulfate), (63) 17
Salicylamide *O*-acyl derivative, (64) 45
Salicylate, (62) 27
Saliva, (68) 11
Sarcoma-180 transplantable tumor, (61) R1
Scanning electron microscopy, (66) 157; (68) 25

Scavenger, (63) 155
Scintigraphy, (69) 77
Second-derivative UV spectroscopy, (70) 187
Segregation, (65) 69
Seminal vesicle, (61) 119
Semi-solid, (67) 195
Sheep, (63) 207
Shellac, (68) 19
Silastic implant, (63) 143
Silastic®, (67) 1
Silicone, (62) 113
Silicone tubing, (61) 235; (61) 241
Simulation, (68) 255
Simultaneous determination, (64) 235; (65) 137; (65) 177; (70) 187
Skin, (62) 9; (62) 75; (65) 183; (66) 53
Skin absorption, (64) 187
Skin penetration, (66) 39
Skin penetration enhancer, (65) 211
Skin permeation, (66) 79; (70) 219
Slit-lamp fluorophotometry, (61) 15
Sodium alginate, (61) 35
Sodium chloride, (61) 251
Sodium chloride granules, (70) 103
Sodium deoxycholate, (66) 131
Sodium dodecyl sulfate, (64) 239; (69) 53
Sodium polyacrylate, (61) 35
Sodium salt, (65) 141
Soft drug, (65) 115
Solid dispersion, (67) 139; (67) 201; (69) 53
Solid dosage form, (67) 265
Solid solution, (69) 53
Solid-state, (62) 65
Solid-state degradation, (62) 87
Solid-state properties, (65) 141
Solid-state transition, (62) 87
Solid type, (68) 179
Solubility, (63) 101; (63) 167; (63) 237; (63) 259; (65) 141; (66) 71; (66) 175; (67) 207; (68) 271; (69) 265; (70) 9; (70) 137
Solubility–temperature dependence, (62) 37
Solubilization, (65) 141; (66) 213
Solvate, (69) 265
Solvent effect, (68) 127
Solvent evaporation, (64) 99; (68) 19
Solvent-water partition coefficient, (66) 87
Sorbitol, (66) 149
Sorption, (63) 251
Sotalol, (62) 113
Species differences, (70) 271
Spectrofluorophotometry, (68) 231
Spherical granule, (69) 233
Spironolactone, (63) 95
Sporicidal, (65) 127
Spray-drying, (69) 211
Sputum induction, (67) 275
Stability, (61) 67; (62) 193; (62) 243; (63) R1; (63) 113; (63) 183; (63) 213; (64) 67; (64) 75; (64) R1; (64) 217; (65) 137; (65) 169; (66) 1; (66) 71; (67) R5; (67) 177; (70) 29; (70) 137
Stability constant, (63) 259; (68) 105
Stability prediction, (61) 9
Stability profile, (67) 155
Stability study, (63) 35
Stability testing, (61) 9
Stabilization, (67) 169
Staphylococcus aureus, (65) 35
Starch, (63) 251; (64) 55
Static secondary ion mass spectrometry, (62) 97
Steady state, (67) 185
Stereochemistry, (68) 97
Steroid anesthetic, (65) 101
Stoichiometry, (61) 27; (68) 105
Strain index, (67) 217; (67) 231
Stratum corneum, (61) 205; (65) 211; (68) 1; (68) 127
Strength increase, (64) 27
Structure-reactivity relationship, (63) 129
S-type degradation, (67) 67
Subcutaneous injection, (69) 29
Submicron emulsion, (66) 29
Submicronized emulsion, (65) 169
Sucrose, (66) 149
Sugar, (64) 55
Sulfadiazine, (68) 19
Sulfonamide, (68) 215
Suppository, (61) 1
Surface characterization, (67) 247
Surface energy, (67) 217; (67) 231
Surface potential, (64) 89
Surface roughness, (64) 35
Surface tension, (65) 35
Surface texture, (64) 227
Surfactant, (64) 239; (65) 243; (70) 153
Surfactant coating, (61) 85
Sustained release, (62) 81; (65) 85; (65) R5
Sustained-release, (66) 111
Sustained release, (67) 113; (70) 59; (70) 69
Sustained release dosage form, (62) 15
Sustained-release dosage form, (63) 201
Sustained release system, (63) 143
Swelling, (63) 43; (70) 53
Synergism, (65) 127
Synperonic T908, (65) 201
Synthetic surfactant, (69) 221
Systemic absorption, (61) 241; (65) 19

Tablet, (67) 113; (68) 255
Tablet dissolution, (69) 175
Tableting, (68) 157; (70) 241; (70) 261
Tableting index, (68) 51
Tablet permeability, (62) 229
Tablet porosity, (62) 229
Tablets, (62) 153; (64) 27; (65) 177
Tablet size, (62) R9
Tablet specific surface area, (66) 47

Tablet strength, (63) 23; (69) 239
Tablet strength reduction ratio, (69) 239
Tablet surface area, (62) 229; (63) 23
Tabletting, (70) 103
Tangential filtration, (63) 57
Tape stripping, (65) 77; (68) 127
Targeting, (61) 109; (67) 123; (70) 225
Taurinamide, (64) R1
Taurocholate, (64) 161
Taurolidine, (64) R1
Taurultam, (64) R1
^{99m}Tc-GHA, (69) 77
^{99m}Tc-pyrophosphate, (69) 189
Temafloxacin, (63) 237
Temperature effect, (69) 197
Tensile strength, (64) 223; (67) 59; (67) 217; (67) 231; (68) 51; (68) 157; (70) 241
Tensile stress, (61) 101
Ternary mixture, (66) 263
Testosterone, (63) 281
Theophylline, (62) 15; (63) 201; (65) R5; (66) 111; (69) 123; (70) 159
Theory, (67) 155
Thermal analysis, (64) 99; (66) 71; (67) 131; (68) 179
Thermal gelation, (70) 147
Thermal gelation temperature, (66) 233
Thermodynamic activity, (69) 143; (69) 155
Thermodynamics, (62) 37; (62) R5; (62) 157; (63) 73; (63) 251; (66) 175
Thermometric titration, (62) R5; (63) 73
Thermomicroscopy, (63) 35
Thioester, (62) 193
Thymopentin, (70) 29
Thyrotropin releasing hormone, (69) 69
Tight junction, (68) 135
Timolol, (61) 235; (61) 241; (65) 19
Tissue distribution, (67) 177; (68) 61
Tissue esterase, (62) 259
Tissue integrity, (63) 1
Tissue viability, (63) 1
Topical application, (68) 127
Topical delivery, (70) 167
Torque rheometry, (64) 207
Total parenteral nutrition, (64) 67
Toxoplasmosis, (68) 215
TPN, (64) 217; (66) 1; (68) 277; (68) 281
Transacylation, (64) 45
Transcutol, (70) 159
Transdermal delivery, (64) 187; (65) 183; (66) 39
Transdermal drug delivery, (65) 211; (69) 143; (69) 155
Transdermal patch, (64) 117
Transdermal penetration, (65) 265
Transdermal therapeutic system, (65) 159
Transition state, (61) 67
Transmembrane drug delivery, (68) 191
Transmission electron microscopy, (66) 157
Transparent oil-water gel, (62) 217
Transport number, (69) 21
Transport pathway, (61) 163
$t^{1/2}$ release, (61) 127
TRH, (66) 39; (66) 183
Triamcinolone acetonide, (66) 53; (70) 87
N-Trifluoroacetyldoxorubicin-14-valerate (AD-32), (68) 271
Turnover time, (70) 235

Ulcerative colitis, (68) 199
Ultrasonic energy, (65) 127
Ultrasonic nebuliser, (67) 275
Ultraviolet light absorber, (70) 9
Ultraviolet spectrophotometry, (65) 137
Ultraviolet spectroscopy, (64) 235
Unstirred water layer, (63) 281
Urea, (65) 29; (66) 157
Urine, (68) 11
Urine volume, (70) 191
USP Basket method, (69) 255
USP Paddle method, (69) 255
Ussing chamber, (66) 183
Uvinul D-50, (70) 9
Uvinul N-35, (70) 9

Vacuum, (61) 251
Vacuum microbalance, (63) 251
Vasopressin, (61) 179; (64) 181
Vehicle effect, (66) 193
Verapamil, (68) 43
Verapamil analog, (64) 117
Visceral leishmaniasis, (68) 111
Viscoelasticity, (67) 217; (67) 231
Viscosity, (61) 213; (65) 35; (66) 23
Viscosized microemulsion, (69) 193
Viscous eye drop, (61) 15
Vitamin A, (68) 277; (68) 281
Volume reduction, (64) 35

Warfarin, (65) 149
Water, (63) 251; (65) 29; (66) 157
Water adsorption, (62) 153
Water content, (68) 205
Water desorption, (62) 153
Water evaporation, (68) 205
Water mobility, (62) 165
Water sorption, (62) 87; (64) 99
Waxy-type polymer, (68) 87
Wet granulation, (69) 43
Wet granulation process, (65) 43
Wettability, (70) 69
Wetting, (66) 175; (70) 153

Xenobiotic, (64) 127
X-ray analysis, (68) 25
X-ray crystallography, (63) 35
X-ray diffraction, (67) 131

X-ray powder diffraction, (69) 53
Xylitol, (64) 223; (67) 139

Young's modulus, (64) 55

Zero-order absorption, (65) 159
Zero order release, (61) 127
Zeta potential, (63) 183; (67) 123; (70) 251
Z value, (70) 9

QSAR: Rational Approaches to the Design of Bioactive Compounds

Proceedings of the VIII European Symposium on Quantitative Structure-Activity Relationships, Sorrento (Napoli), Italy, 9-13 September 1990

edited by **C. Silipo** *and* **A. Vittoria**, Dipartimento di Chimica Farmaceutica e Tossicologica, Universitàgli Studie di Napoli, Napoli, Italy

PHARMACOCHEMISTRY LIBRARY Volume 16

1991 xvi + 576 pages
Price: US 237.00 / Dfl. 415.00
ISBN 0-444-88839-X

Quantitative structure-activity relationships constitute a subject which has seen enormous growth in the past decade. Techniques which have been developed and used widely outside of medicinal chemistry are now used by those working with QSAR. These techniques employ powerful computers, molecular graphics systems and sophisticated software. Although QSAR techniques have been developed to optimize activities of known sets of analogs, recent methodologies suggest that these techniques can be useful in the modeling of new chemical entities.

The contributions in this state-of-the-art volume cover a wide range of disciplines, tools and ideas which will be of interest to medicinal chemists, pharmacologists and biologists. The book gives an update of progress in the science of the quantitative approaches of the interface between chemistry, physical chemistry and biology-pharmacology. The use of molecular graphics, computational and conformational methods in drug research is extensively covered.

Contents: Due to limitations of space only a random selection of papers is mentioned here. Preface (C. Silipo and A. Vittoria). Opening Address (P. Pratesi). Section I. QSAR: General Aspects (9 papers). New Perspectives in QSAR (C. Hansch). QSAR Analysis of Dose and Property Dependent Activity Classes of Homologous Drugs (K.-J. Schaper, A.K. Saxena). Section II. Parametrization in QSAR: Hydrophobic and Other Descriptors (23 papers). Chromatographic Rm Values as Lipophilicity Index (G.L. Biagi, et al.). The Strange Story of the Methylene Fragment Value (P.J. Taylor). Drug Design H-Bonding Scale (O.A. Raevsky, et al.). The Nature of Molar Refractivity (J.C. Dearden, et al.). Section III. Computational Methods in QSAR (17 papers). Exp-Drug, A New Computer Program for Experimental Design in Drug Design (E. Marengo, M. Conterno). Drug Design Artificial Intelligence System (A.M. Sapegin, et al.). Selection of Informative Structures for QSAR Studies (S. Clementi, et al.). Section IV. Computer Assisted Molecular Modeling and Receptor Mapping (21 papers). Ligands of the Central Benzodiazepine Receptors: Computer-Aided Characterization of Their Specific Interactions (B. Brandau, et al.). Computer-Assisted Analysis of the Possible Binding Sites of H1-Antagonists (E.E. Polymeropoulos, et al.). Structure Activity Relationship of Musk Compounds (D.J.A. De Ridder, H. Schenk). Section V. Peptide Drug Design (4 papers). Computer Calculation of Peptide Hydrophobicity (A.J. Leo). Chemometric Investigation in Peptide QSAR (S. Clementi, et al.). Section VI. QSAR Application in Medicinal Chemistry: Concepts and Methodologies (26 papers). QSAR and Modeling of Enzyme Inhibitors, Anticonvulsants and Amphiphilic Drugs Interacting with Membranes (J.K. Seydel, et al.). 3D-QSAR: Further Studies on Inhibitors of Angiotensin-Converting Enzyme (S.A. DePriest, et al.). QSAR and Conformational Analysis of Antidepressant Diphenyl Sulfide Derivatives (M. Kucha t al.). Molecular Modeling-Based Design of Novel, Selective, Potent D1 Dopamine Agonists (Y.C. Martin, et al.). Section VII. Correlation Analysis in Toxicology, Pharmacokinetics and Environmental Sciences (16 papers). A Strategy for Ranking Chemical Hazards. An Update (M.L. Tosato). QSAR and Biological Parametrization in Toxicology (M. Tich COMPACT: A Form of Discriminant Analysis for the Identification of Potential Carcinogens (D.F.V. Lewis, et al.). Reliability Control of Alcohol Metabolism Prediction Law (C. Mercier, et al.).

In the USA & Canada
Elsevier Science Publishing Co., Inc.
P.O. Box 882
Madison Square Station
New York, NY 10159
Fax: (New York) 212-633-3990
Tel: (New York) 212-989 5800
Telex: 420643

In the rest of the world
Elsevier Science Publishers
P.O. Box 181
1000 AD Amsterdam
The Netherlands
Fax: 31-20-5803 249
Tel.: 31-20-5803 911
Telex: 18582 espa nl

ELSEVIER SCIENCE PUBLISHERS

The Dutch guilder price is definitive. US$ prices are subject to exchange rate fluctuations. Prices are excl. B.T.W. for Dutch customers



journal of controlled release

Official Journal of the Controlled Release Society

The ***journal of controlled release*** is an international journal dealing with the science and technology of the controlled release of active agents. The term '*controlled release*' is used in its broadest sense to include control over rate of release using - either singly or in combination - diffusion, chemical reactions, dissolution, osmosis or mechanical devices, as well as control over the site of action of the active agent using pro-drugs or carriers such as water-soluble polymers, microcapsules or liposomes. Although the major emphasis of the journal is controlled release, relevant work dealing with toxicology, pharmacokinetics and biocompatibility is also included. The journal is intended to serve a wide range of specialists and to bring together high quality papers dealing with various aspects of controlled release of therapeutic agents for human and animal use, as well as those dealing with insect and other pest management, fertilizers, weed control, and marine antifouling applications. In addition to original papers, technical reviews and short communications, the journal includes book reviews, reports of meetings, descriptions of new controlled release products, announcements pertaining to activities of the Controlled Release Society, and other announcements. Rapid communication notes are short papers which are reviewed with high priority and are published in the earliest possible issue.

Abstracted/Indexed in:
Biosciences Information Science, Chemical Abstracts, Current Contents, Excerpta Medica, International Pharmaceutical Abstracts, Polymer Contents.

Editors:

Jan Feijen
Faculty of Chemical Technology, University of Twente, Enschede, The Netherlands.

Jorge Heller
Controlled Release and Biomedical Polymer Sciences Department, SRI International, Menlo Park, CA, U.S.A.

Associate Editor: David Friend
Controlled Release and Biomedical Polymer Sciences Department, SRI International, Menlo Park, CA, U.S.A.

1991 Subscription Information:
Volumes 14-17 in 12 issues
Price: US$ 681.25/Dfl. 1260.00
ISSN 0168-3659

Please send your orders and requests for a complimentary copy and/or further information to one of the following addresses:

Elsevier Science Publishers
P.O. Box 181, 1000 AD Amsterdam,
The Netherlands.
Fax: (020) 5803-249.

Elsevier Science Publishing Co. Inc.
Journal Information Center, P.O. Box 882,
Madison Square Station, New York,
NY 10159, U.S.A.
Tel: (212) 633-3750. Fax: (212) 633-3990.

Prices include postage and handling charges. The Dfl. price is definitive; US$ price is subject to exchange rate fluctuations. Prices are excl. of BTW for Dutch residents.

ELSEVIER SCIENCE PUBLISHERS

MANUSCRIPTS should be submitted **in quadruplicate** in English and be accompanied by a list of **6–8 key words**. All data that would help referees to evaluate the paper should also be supplied.

Full length papers
should be typewritten with double spacing on one side of the sheet only,
should be divided into **Summary** (including **key words**), Introduction, Materials and Methods, Results and Discussion,
should be accompanied by a separate sheet bearing Title, Author's names and their affiliations.
should not **normally** exceed 10 printed pages (18 typescript pages) in length.

Rapid communications should not exceed 4 printed pages (9 typescript pages) and should not be divided into sections i.e. Introduction etc. They preferably should have a 20–50 word Summary and a full reference list should be provided. Preferably **no figures** should be included; otherwise a delay in publication time will occur.

Descriptions/reviews of computer programs should include in the manuscript information on hardware compatibility and software availability (including costs, ordering address, etc.). All manuscripts must be accompanied by a manual describing software validation; operating instructions (in greater detail than in the manuscript) and illustrations of input and output data sets. In order that reviewers can appropriately evaluate the package, three copies of the manual and software (diskettes, tapes, etc.) should accompany submission. Software and manuals will be returned only upon request by the authors.

Tables should be compiled on separate sheets with a short descriptive title, a legend and/or footnotes identified by a, b, c, etc.

Figures
Line drawings (including graphs) should be drawn in black ink on white paper. Lettering should be in proportion to the figure to allow for reduction to page format.
Half-tone figures should be sharp, high-contrast original prints on glossy paper.
The magnification of micrographs should be indicated by **a scale bar in the figure**.
If figures are not to be reduced their format should not exceed 16 × 20 cm. All legends should be typed double spaced on separate sheets.

References

Should be assembled alphabetically on a separate sheet. In the text they should be referred to by name and year (Harvard System). More than one paper from the same author in the same year must be identified by the letters a, b, c, etc. placed after the year of publication. In the text, when referring to a work by more than two authors, the name of the first author should be given followed by et al. Literature references must consist of names and initials of all authors, title of paper referred to, abbreviated title of periodicals and the volume, year and first **and last** page numbers of the paper. Periodicals, books and multi-author books should accord with the following examples:

Kaplan, S.A., Weinfeld, R.E. and Lee, T.L., Semiautomated spectrophotofluorometric determination of trimethoprim in biological fluids. J. Pharm. Sci., 62 (1973) 1865–1870.
D'Arcy, P.F. and Griffin, J.P., Iatrogenic Diseases, Oxford University Press, London, 1972, p. 11.
Johnson, C.A., International problems in the control of medicines. In Deasy, P.B. and Timoney, R.F. (Eds.), The Quality Control of Medicines, Elsevier, Amsterdam, 1976, pp. 83–95.

Abbreviations of journal titles should follow the system used by the ISDS List of Serial Title Word Abbreviations, 1985 (available from 20 rue Bachaumont, 75002 Paris, France – ISBN 2-904938-02-8), but beginning each word with a capital

Proofreading will be undertaken by the Publisher. *Correspondence and queries relating to proofs* should be directed to the publishers: IJP, Elsevier Science Publishers B.V., P.O. Box 1527, 1014 AG Amsterdam, The Netherlands. Telephone: (20) 5803465. Proofs will not be sent out unless specifically requested by the author(s) when the paper is submitted and so indicated on the title page. No alteration of substance to the text, tables or legends will be accepted.

Page Charge There will be no page charge.

Reprints Fifty reprints of each paper will be provided free of charge. Additional copies may be ordered at prices shown on the reprint order form which will be sent to the author.

Subscriptions
1991: Volumes 67–77 (11 volumes in 33 issues). Volume 67 is published in advance in order to decrease publication time. It remains part of the 1991 subscription year. Dfl. 3740.00 (US$ 2101.00) including postage, packaging and handling.
The Dutch guilder price is definitive. The U.S. dollar price is subject to exchange-rate fluctuations and is given only as a guide.

Subscriptions are accepted on a prepaid basis only, unless different terms have been previously agreed upon. Personal subscription rates and conditions, if applicable, are available upon request from the Publisher.

Subscription orders can be entered only by calendar year (Jan.–Dec.) and should be sent to Elsevier Science Publishers, Journal Department, P.O. Box 211, 1000 AE Amsterdam, The Netherlands, telephone 31.20.5803642, fax 31.20.5803598, or to your usual subscription agent.

Postage and handling charges include surface delivery except to the following countries where air delivery via SAL (Surface Air Lift) mail is ensured:

Argentina, Australia, Brazil, Canada, Hong Kong, India, Israel, Japan *, Malaysia, Mexico, New Zealand, Pakistan, P.R. China, Singapore, South Africa, South Korea, Taiwan, Thailand, U.S.A.

* For Japan air delivery (SAL) requires 50% additional charge of the normal postage and handling charge. For all other countries airmail rates are available upon request.

Claims for missing issues must be made within three months of our publication (mailing) date, otherwise such claims cannot be honoured free of charge.

In the U.S.A. and Canada: All questions arising **after acceptance** of a manuscript by the editor, especially those relating to proofs, publication and reprints, should be directed to the publishers, **Elsevier Science Publishers B.V. P.O. Box 1527, 1000 BM Amsterdam, The Netherlands**. For further information and personal subscriptions, contact: **Elsevier Science Publishing Co., Inc., Attn.: Journal Information Center, 655 Avenue of the Americas, New York, NY 10010, U.S.A. Tel.: (212) 633-3750; Telefax: (212) 633-3990; Telex: 420-643 AEP UI.**

This journal is in the ADONIS Service, whereby copies of individual articles, as identified by an ADONIS number, can be printed out from CD-ROM on request. The ADONIS number is printed on the first page of each article. An explanatory leaflet can be obtained by writing to ADONIS B.V., P.O. Box 839, 1000 AV Amsterdam, The Netherlands.

Advertising. Apply to W.J. van Cattenburch (Advertising Manager), P.O. Box 211, 1000 AE Amsterdam, The Netherlands. (Tel. (20) 5803714.)

This journal is printed on acid-free paper.

INTERNATIONAL JOURNAL OF PHARMACEUTICS

CONTENTS

Announcement from the Publisher	v
Author Index	1
Subject Index	19

© 1991 Elsevier Science Publishers B.V. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior written permission of the publisher, Elsevier Science Publishers B.V., P.O. Box 1527, 1000 BM Amsterdam, The Netherlands.

Submission of a paper to this journal entails the author's irrevocable and exclusive authorization of the publisher to collect any sums or considerations for copying or reproduction payable by third parties (as mentioned in article 17 paragraph 2 of the Dutch Copyright Act of 1912 and in the Royal Decree of June 20, 1974 (S. 351) pursuant to article 16b of the Dutch Copyright Act of 1912) and/or to act in or out of Court in connection therewith.

Special regulations for readers in the U.S.A. This journal has been registered with the copyright Clearance Center, Inc. Consent is given for copying of articles for personal or internal use, or for the personal use of specific clients. This consent is given on the condition that the copier pays through the Center the per-copy fee stated in the code on the first page of each article for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The appropriate fee should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 27 Congress Street, Salem, MA 01970, U.S.A. If no code appears in an article, the author has not given broad consent to copy and permission to copy must be obtained directly from the author. All articles published prior to 1980 may be copied for a per-copy fee of US $2.25, also payable through the Center. This consent does not extend to other kinds of copying, such as for general distribution, resale, advertising and promotion purposes, or for creating new collective works. Special written permission must be obtained from the publisher for such copying.

Special regulations for authors. Upon acceptance of an article by the journal, the author(s) will be asked to transfer copyright of the article to the publisher. This transfer will ensure the widest possible dissemination of information.

Cited in: Current Contents (Life Sciences; Clinical Practice); International Pharmaceutical Abstracts; Biological Abstracts; Chemical Abstracts; Excerpta Medica EMBASE; PASCAL M; Science Citation Index

Printed in The Netherlands